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The pursuit and discovery of new antibiotics that prevent bacterial spread 
and growth in new ways without causing drug-resistance has met limited 
success since the early 1960s. In May 2006, scientists at Merck disclosed their 
finding of platensimycin, a broad-spectrum antibiotic extracted from a 
Streptomyces platensis broth that originated from a soil sample in South Africa. 
This natural product exerts potent Gram-positive antibacterial activity with no 
cross-resistance by selectively inhibiting Type II fatty acid biosynthesis 
through targeting the fatty acid condensing enzyme FabF. The confluence of 
interesting biological activity and structural complexity has made 
platensimycin an attractive target for chemical synthesis (Chapter 1).  
Whilst encountering several dead ends and detours in our earlier carbonyl 
ylide cycloaddition strategies to the unprecedented tetracyclic core of 
platensimycin (Chapters 2 and 3), we eventually succeeded a new and high-
yielding enantioselective formal synthesis of this natural product (Chapters 4 
and 5) from commercially available eugenol in 16 steps and 18% overall yield. 
The culmination of our synthesis efforts advanced three key methods: (1) a 
new Bi(OTf)3-LiClO4 combination to catalyze a Marson-type, Friedel-Crafts 
cyclization of an unactivated lactol with complete stereo- and regiocontrol; (2) 
a facile TBAF-promoted intramolecular alkylative dearomatization without 
undue silyl activation; and (3) a chemo-, regio-, and diastereoselective 
conjugate reduction of a cyclic dienone, inspired by iminium-based 
organocatalysis to reverse substrate steric control, and transfer hydrogenation 
with Hantzsch esters.     
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The unusual aromatic domain of platensimycin was synthesized from 2-
nitroresorcinol by a unique and concise four-step sequence, with an overall 
57% yield, through the development of a new Lieben-haloform condition to 
directly convert aryl methyl ketones to the aryl methyl esters in a practical 
fashion (Chapter 5). Upon installation of the propionate side-arm via a Michael 
addition approach, the amide coupling of the C-17
 
tetracyclic enone acid with 
the anilide unit was achieved by treatment with HATU, and a final hydrolysis 
subsequently completed the total synthesis of platensimycin. The exploration 
of C2-symmetrical amine-based organocatalysts to further improve the desired 
chemo- and stereoselectivity of the conjugate reduction step is currently 
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TASF tris(dimethylamino)sulfonium difluorotrimethylsilicate 
TBAF tetrabutylammonium fluoride 
TBAHS tetrabutylammonium hydrogen sulfate 
TBAI tetrabutylammonium iodide 
xxix 
 
TBATFA tetrabutylammonium trifluoroacetate 
TBS tert-butyldimethylsilyl 
TCA trichloroacetic acid 
TFA trifluoroacetic acid 
TfOH trifluoromethanesulfonic acid 
THF tetrahydrofuran 
TLC thin-layer chromatography 
TMS trimethylsilyl 
TMSE (trimethylsilyl)ethyl 
TMSOK potassium silanoate 
TRIP 3,3’-bis(2,4,6-triisopropylphenyl)-1,1’-binaphthyl-2,2’-diyl 
hydrogen phosphate 
TsCl para-toluenesulfonyl chloride 
UV ultraviolet 
v/v volume per volume 
wrt with respect to 
















1.1 Background of Antibacterial Resistance  
The discovery of penicillin (1-1, Figure 1.1) by Alexander Fleming in 1928 
represents a milestone in the modern era of antibiotics discovery.[1] Penicillins 
continue to help millions around the world to fight off deadly infections, and 
inspired the development of various types of antibiotics against different 
pathogens. However, the effectiveness of available antibiotics has diminished 
steadily due to the continuously emerging antimicrobial resistance, as bacteria 
have evolved mechanisms according to Darwinian selection principles to foil 
the treatments with antibiotics.[2] Antimicrobial resistance is a global public 
health concern today and modern medicine has met limited success controlling 
its spread.  
Hospitals worldwide have been plagued with several potent multiply-drug 
resistant strains of Gram-positive bacteria pathogens, so-called super-bugs,[3] 
and among them are methicillin-resistant Staphylococcus aureus (MRSA), 
vancomycin-intermediate Staphylococcus aureus (VISA), and vancomycin-
resistant enterococci (VRE). First accepted in 1961, infection due to MRSA is 
fast-becoming a worrisome issue.[4,5] For example, in many Asian countries 
today, 70-80% of isolates of S. aureus are MRSA. Hospitals have to turn to 
more costly and much potent antibiotics, such as vancomycin (1-2) and Zyvox 
(linezolid 1-3) as alternatives (Figure 1.1). Regarded as the gold standard of 
care and the antibiotic of last resort, vancomycin is also gradually losing its 





Figure 1.1. Structures of penicillin (1-1), vancomycin (1-2), and linezolid (1-3). 
 
Treatment of infection due to microbes with multiple drug-resistances has 
therefore become a daunting task. According to CDC (Centers for Disease 
Control and Prevention) statistics, nearly 2 million patients in the U.S. have 
hospital-acquired infection each year and approximately 90,000 of them die as 
a result of their infection.[6] This situation will only worsen with the fact that 
only two new chemical classes of antibiotics have been discovered and 
introduced to the clinic since the early 1960s, namely linezolid (an 
oxazolidinone, Figure 1.1) and daptomycin (a lipopeptide). Most classes of 
antibiotics were discovered in the 1940s and 1950s, and newer versions are 
simply variations of their predecessors based on similar modes of actions.[7,8] 
Most antibiotics used today generally work on specific bacterial biochemical 
processes, such as blocking the synthesis of the cell wall, deformation of the 
cell membrane, and inhibition of their DNA replication or protein production 





Table 1.1. Classification of commercially available antibiotics. 
Pharmacological Target Representative Antibiotics 
Cell wall synthesis 
pathway 
β-Lactams (penicillin) and Glycopeptides 
(vancomycin) 
Protein synthesis pathway Macrolides (erythromycin), Linezolid and Tetracycline 
Nucleic acid synthesis Fluoroquinolones (levofloxacin) and Rifampin 
Metabolic pathway Sulfonamides (sulfamethoxazole) 
Cell membrane Polymyxins and Daptomycin 
 
The search for novel targets for antibiotics activity has been an uphill 
challenge that has eluded scientists for years. Consequentially, the big 
pharmaceutical companies are beginning to dishearten, and gradually dropping 
out from the purportedly financially unrewarding antibiotics research.[9] With 
the market reaching a stalemate, the limited modes of action targeted by 
commercially available antibiotics could have engendered the increasing 
antimicrobial resistance over the short time frame. By undergoing random 
mutation and natural selection, bacteria figure out the ways to evade antibiotics 
with the acquisition of new genetic coding to develop into super-bugs, such 
that one day resistance to every antibiotic is not an “if” but a “when”.[10] 
Henceforth, the discovery of a new class of antibiotic, possessing a differing 
antibacterial action, is critically needed in this enduring battle. Turning back to 
nature to rediscover natural products in search for novel therapeutic agents 
could still hold great promises in the drug discovery process.[11] 
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1.2 Discovery of Platensimycin  
 
 
Figure 1.2. Structure of (-)-platensimycin (1-4). 
 
In 2006, a multi-national team of Merck scientists led by Wang, Soisson and 
Singh from Rahway, New Jersey reported the discovery of a new and potent 
antibiotic, (-)-platensimycin (1-4) isolated from a Streptomyces platensis strain 
MA7327 that originated from a soil sample in South Africa (Figure 1.2).[12] 
250,000 natural product extracts were screened in search of the next-generation 
antibacterial agents targeting the bacterial fatty acid synthesis (FAS) pathway. 
Fatty acids are important components of cell membranes and cell envelopes in 
organisms. The biosynthetic pathways for FAS are, however, significantly 
different between mammals and bacteria which makes it an attractive target for 
antibiotic discovery.[13]  
The type I FAS (FASI) found in eukaryotic organisms, such as mammals 
and fungi, synthesizes fatty acids with one multi-functional enzyme. In 
contrast, the type II FAS (FASII) is discovered in prokaryotes like plants, 
parasites and bacteria (Figure 1.4) that involves several enzymes working 
specifically at different stages of the complex pathway. Currently, only a few 
available drugs that target FASII have been used in clinic, such as isoniazid[14] 
and triclosan[15] which are inhibitors of the fatty acid biosynthesis (Fab) 
reductase enzyme I. Two other antibiotics thiolactomycin (1-5) and cerulenin 
(1-6) were also known to act by this mechanism (Figure 1.3), but were 
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Figure 1.3. Structures of thiolactomycin (1-5) and cerulenin (1-6). 
 
Platensimycin was discovered through a newly invented target-based whole-
cell screening strategy using antisense differential sensitivity assay technology 
to screen the natural product broths against Fab enzymes,[17,18] followed which 
a FASII gel elongation assay was applied for target confirmation.[19] The 
structure of platensimycin was confirmed by X-ray crystallographic analysis of 
a 6’-bromo derivative.[17] The natural product consists of an unusual, polar 2,4-
dihydroxy-3-amino benzoic acid domain and an architecturally complex 
hydrophobic tetracyclic ketolide fragment joined by a propionamide chain. 
There are six chiral centers on the hydrophobic core and three of them are 
quaternary chiral centers.  
In-vitro studies and independent in-vivo assays with a non-resistant model S. 
aureus infection in mice have shown that platensimycin exhibited strong and 
broad-spectrum Gram-positive antibacterial activity.[12] Owing to its unique 
mode of action against FASII, platensimycin demonstrated no cross-resistance 
to an array of major antibiotic-resistant bacteria, including the most pathogenic 
MRSA (MIC = 0.5 µg ml-1), VISA (MIC = 0.5 µg ml-1), VRE (MIC = 0.1 µg 
ml-1), linezolid- and macrolide-resistant pathogens. Platensimycin also showed 
no toxicity when placed in contact with mammalian cells and during in-vivo 
testing with the mouse models. 
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1.3 Unique Mode of Antibacterial Action  
Platensimycin selectively targets the highly conserved elongation 
condensing enzyme, β-ketoacyl-(acyl-carrier-protein (ACP)) synthase I (FabF), 
essential in FASII. As mentioned earlier, the bacterial fatty acid biosynthesis is 
a complicated process in which multiple enzymes are involved. As shown in 
Figure 1.4,[5,13c,20] the cysteine residue in the FabF active site reacts with the 
growing fatty acid delivered by ACP during the elongation step. This triggers 
the closed FabF enzyme to adopt an open conformation and affords the acyl-
enzyme intermediate, which then allow the malonyl-ACP substrate to bind to 
it. Subsequent decarboxylation, followed by Claisen condensation occurs 
within the enzyme, and liberates the elongated product, β-ketoacyl-ACP. This 
product will then be converted to the new two-carbon homologated fatty acid 
through a sequential reduction-elimination-reduction series catalyzed by 
different enzymes. Binding assays revealed that platensimycin binds to the 
“malonyl binding” sub-site of the acyl-enzyme intermediate, preventing the 
entry of the malonyl-ACP substrate, and therefore inhibits the bacterial fatty 







Figure 1.4. Catalytic cycle of FabF in bacterial fatty acid biosynthesis (FASII) 
pathway.  
 
Further X-ray crystallographic studies of the binding site using a mutated 
FabF enzyme extracted from an Escherichia coli strain ecFabF(C163Q) to 
mimic the open conformation of the acyl-enzyme intermediate was 
performed.[12] Wang and co-workers revealed that strong binding interactions 
exist between platensimycin and the catalytic pocket of the enzyme; in 
particular, the 2-hydroxybenzoic acid unit potentially mimics the acid moiety 
of malonyl-ACP whereby it interacts with His 303 and His 340 (Figure 1.5A). 
Another energetically favorable and important interaction observed is the edge-
to-face pi stacking between Phe400 and the aromatic ring of the benzoic acid 
9 
 
sitting partially in the binding domain of the acyl-enzyme intermediate (Figure 
1.5B).  
It was also determined that the enone on the ketolide domain does not play 
an important role in platensimycin’s biological activity.[17] The lipophilic 
domain positions in the mouth of the enzyme, outside the active site, through 
van der Waals interaction with the protein backbone and hydrogen bonding 
with Ala309 and Thr270 which have also contributed to binding specificity. 
Synthetic analog work carried out by Nicolaou and co-workers showed that 
decreasing the complexity in the cage region of the core ketolide fragment 
reduced antibacterial potency.[21] Notably, the binding site is made up of 17 
highly conserved amino acids residues with 4 of them (His340-His303-Cys163 
and Phe400, Figure 1.5B) being critical catalytic sites where chemical reactions 
associated with the enzyme are performed.[12] By these virtues, drug resistance 




Figure 1.5. A. Crystallographic studies of platensimycin and ecFabF(C163Q): (a) blue 
represents binding at the malonyl sub-site; (b) red represents interactions at the mouth 
of the active site; (c) purple represents the area of the molecule exposed to solvent; 
and (d) dotted (dark) blue line indicates ionic interaction. B. Interactions between the 




1.4 Biosynthesis of Platensimycin  
By understanding the biosynthetic pathways leading to the biosynthesis of 
platensimycin, the Merck researchers could improve the production of the 
natural product from the original 2-4 mg/L to 56 mg/L through fermentation of 
S. platensis.[22,23] Feeding experiments with labeled precursors revealed that 
platensimycin’s lipophilic C-17 tetracyclic enone acid is actually derived from 
the non-mevalonate terpenoid pathway[24] with structural reminiscence of the 
ent-kaurene class of natural products found in plants and fungi.[23,25]  
In a simplified representation of the proposed biosynthesis (Figure 1.6), 
initial condensation of the terpenoid building blocks – isopentyl diphosphate 1-
7 and dimethylallyl diphosphate 1-8, both synthesized by the non-mevalonate 
pathway, affords the diterpenoid (C-20) precursor geranyl geranyl diphosphate 
1-9. The polyene compound would undergo a series of enzymatic-catalyzed 
cationic rearrangements with diterpene synthases[26] to cyclize into the skeletal 
framework of homoplatensic precursor 1-10 and ent-kaurene 1-11. Extensive 
oxidation of the carbon backbone then provides homoplatensic acid 1-13 and 
homoplatensimide 1-12. Oxidative cleavage of the α,β-unsaturated amide or 
acid results in the loss of the terminal three carbons producing the C-17 
platensic acid 1-14 precursor to platensimycin.  
All three compounds are natural congeners of platensimycin that have also 
been isolated from the fermentation broth of S. platensis which provided 
further evidence of their biogenetic relationship.[22,27] While the exact 
substitution pattern of the aromatic domain has not yet been observed in 
nature,[25] the isotopic enrichment patterns observed from the feeding 
experiments have suggested a 4 + 3 carbon unit biosynthesis similar to that of 
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known 3-amino-4-hydroxybenzamide 1-16[28] which involves participation of 
the tricarboxylic acid (or Krebs) cycle and the glycolytic pathway. Finally, an 
N-acyltransferase-catalyzed biosynthetic coupling of the platensic acid with the 
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Figure 1.6. Biosynthesis of platensimycin (1-4). 
 
The strong antibacterial potency against a wide range of Gram-positive 
pathogens coupled with its unique mechanism of action for the key condensing 
enzyme FabF, platensimycin clearly represents a new class of architectural 
unprecedented antibiotics with the first novel target in antibiotics research 
since the early 1960s. Platensimycin, however, demonstrated reduced efficacy 
when administered by conventional delivery routes, as a result continuous 
infusion and high doses were required. This behavior could probably be 
attributed to its poor pharmacokinetic properties[29] which can potentially be 
overcome by structural modifications of the natural product in the hope of 
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generating more promising analogs as leads to a new generation of antibiotics.  
Interestingly, the inhibition of FASII as strategy to combat Gram-positive 
bacteria has recently been challenged on the basis of experiments by Brinster et 
al. who showed that bacterial survival does not depend crucially on their own 
production of fatty acids since they can potentially tap on exogenous fatty acids 
directly from the serum of their human host.[30] This argument on whether 
FASII is a suitable antibacterial target for Gram-positive pathogens, however, 
remains an on-going debate in the microbiology community.[31] More recently, 
Singh and Wu et al. from the Merck Research Laboratories discovered that 
platensimycin is also a potent and selective inhibitor of the mammalian fatty 
acid synthase against fatty acid synthesis and oxidation, but not sterol 
synthesis.[32]  
Platensimycin demonstrated superior activity over currently available FASI 
inhibitors cerulenin (1-6) and C75, in further virtue to its preferential 
concentration in the liver in-vivo (in mouse models). Chronic treatment with 
platensimycin resulted in a reduction of the liver triglyceride levels and 
improved insulin sensitivity through suppression of the hepatic glucose 
production. The interesting results from this new study open up possibilities of 
developing platensimycin as a therapeutic agent for the treatment of 
diabetes,[33] liver steatosis, and related metabolic disorders. Indeed, the 
discovery of platensimycin marks one of the finest work in 2006 in the field of 





1.5 Nicolaou’s Syntheses of Platensimycin  
Shortly after its disclosure, platensimycin (1) has become the focus of 
intense synthetic activity across the chemical community in recognition of its 
interesting biological profile as well as its intriguing and structurally 
challenging tetracyclic ketolide core. To date, this potent broad-spectrum 
antibiotic has succumbed to over 21 total, formal and analog syntheses,[34-
38,53,54,57-61]
 most of which were recently reviewed.[39] Hailed as the fastest 
synthesis in the west, the Nicolaou group reported the first total synthesis of 
platensimycin (±)-1-4 in racemic form,[34] just four months after disclosure of 
the initial report.[12] In their retrosynthetic analysis of the natural product, the 
first disconnection was inarguably made at the amide bond to afford two sub-
targets: tetracyclic enone acid (platensic acid) 1-14 and aromatic aniline 1-17.  
As shown in Scheme 1.1, the group’s preparation of 1-14 began with enone 
1-19 which was readily synthesized in four steps from commercially available 
3-ethoxy-2-cyclohexenone 1-18 according to the known procedure by Hayashi 
et al.[40] Their key step was a Ru(II)-catalyzed Trost cycloisomerization to 
convert 1-19 to the spirocycle 1-20 as an inconsequential 1:1 mixture of 
diastereomers. A stoichiometric Saegusa oxidation of 1-20, followed by acidic 
hydrolysis of the TBS enol ether, furnished the bis-enone 1-21 anticipated for 
their second key cyclization step. Kagan reagent samarium(II) iodide, with 
HFIP in THF/HMPA, was utilized to couple the aldehyde functionality onto 
one side of the bis-enone through a ketyl radical-mediated conjugate addition 
to deliver the tricycle 1-22 as a 2:1 mixture of diastereomers at C10. TFA-
promoted intramolecular etherification completed the cage-like core 1-23 from 
1-22, which became the target (aka Nicolaou’s intermediate) of a number of 
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formal syntheses (Tables 1-2 – 1-4). Steric-controlled double alkylation of 1-23 
with iodomethane and allyl iodide afforded the cage structure 1-24 as a single 
diastereomer. Olefin metathesis between 1-24 and vinyl pinacol boronate 1-25 
with Grubbs II catalyst, followed by a mild oxidation of the resulting borate by 
trimethylamine N-oxide circumvented their initial nontrivial oxidation 
sequence to give aldehyde 1-26 in good yield. Further oxidation under Pinnick 
conditions then provided the desired platensic acid 1-14.                  
 
Scheme 1.1. Nicolaou’s racemic synthesis of platensic acid 1-14.  
 
The synthesis of the aromatic domain commenced from commercially 
available 2-nitroresorcinol 1-27 (Scheme 1.2). Protection of 1-27 as the bis-
MOM ether, followed by reduction of the nitro functionality, and protection of 
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the resulting aniline with a Boc group afforded compound 1-28. Initial in situ 
silylation of the carbamate, followed by lithiation of the aromatic ring with 
another equivalent of nBuLi, and quenching with Mander’s reagent methyl 
cyanoformate installed the requsite carboxylate group regioselectively. 
Thermolysis of the Boc group under microwave radiation then provided the 
other sub-target aniline 1-17. Finally, the amide coupling of 1-14 and 1-17 was 
achieved by treatment with HATU and Et3N, followed by a global deprotection 
completed the total synthesis of (±)-platensimycin (1-4). 
 
 
Scheme 1.2. Nicolaou’s completion of (±)-platensimycin. 
  
Soon after his reports on the racemic synthesis of platensimycin,[34,36b] 
Nicolaou and co-workers completed the asymmetric synthesis of (-)-
platensimycin[35] through two synthetic approaches to access aldehydes 1-29 
(Scheme 1.3) and 1-21 (Scheme 1.4) enantioselectively, thus allowing the 
realization of their key SmI2-mediated radical cyclization in constructing the 
tricyclic framework. The first approach (Scheme 1.3) relied on the analogous 
Trost cycloisomerization using Zhang’s Rh(I)-catalyzed enantioselective 
cyclization conditions[41] with the acetylenic ester 1-30, prepared from the 
previously reported enone 1-19. While other acetylene derivatives failed, 
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treatment of 1-30 with [{Rh(cod)Cl}2] and chiral ligand (S)-BINAP in the 
presence of AgSbF6 delivered the desired spirocycle 1-31 in 91% yield and 
more than 95% ee.  
Barton-McCombie decarboxylation was pursued to remove the additional 
carboxylate group and Barton ester 1-32 could be synthesized from 1-30 in 3 
steps. Under the treatment of visible light and nBu3SnH, vinylic radical 1-33 
was generated which unexpectedly underwent a 1,3-hydrogen atom shift to 
form the allylic radical 1-34. Hydrogen atom capture at the less hindered 
primary end of the allylic system eventually gave the endocyclic olefin 1-35. 
Acidic hydrolysis of the acetal group revealed aldehyde 1-29, which was then 
subjected to the same SmI2 cyclization conditions as used in their previous 
racemic efforts[34], giving rise to the desired axial alcohol 1-36 in 39% yield as 
a single diastereomer. Notably, the subtle double bond migration between 1-29 
and 1-21 has remarkably led to the excellent stereoselectivity observed in this 
transformation. Closure of the final ring via etherification with TFA 
uneventfully furnished the enantioenriched tetracyclic enone 1-23, constituting 
a formal synthesis. The previously described synthetic sequence[34] could be 
applied to further elaborate 1-23 into (-)-platensimycin (1-4).         





Scheme 1.3. Nicolaou’s formal synthesis of (-)-platensimycin via an enantionselective 
enyne cycloisomerization. 
 
In a concerted effort, chiral aldehyde 1-21 was prepared via another route 
using an auxiliary-based approach with Myers’ asymmetric alkylation method 
of the pseudoephedrines (Scheme 1.4).[35] Amide 1-37, derived from 3-
bromopropionaldehyde acetal[42] and (S,S)-pseudoephedrine, was alkylated 
with benzyl bromide 1-38 via dianion chemistry to afford amide 1-39 with 85% 
de, which a single recrystallization gave essentially diastereomerically pure 
material. Cleavage of the chiral auxiliary group with MeLi, and enol triflate (1-
40) formation with Comins’ reagent (1-41) were achieved uneventfully.  
The phenolic allylsilane 1-42 was formed through a sequential Kumada 
coupling of 1-40 with Peterson reagent TMSCH2MgCl to introduce the 
allylsilane moiety, followed by alkaline cleavage of the TBS group. The crucial 
oxidative cyclodearomatization reaction of 1-42 was promoted by hypervalent 
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iodine(III) chemistry, and iodosobenzene diacetate (PIDA) in trifluoroethanol 
was found to be most reliable in driving the cyclization to deliver the desired 
spirocycle 1-43. Finally, deprotection of the 1,3-dioxolane group gave the 
common intermediate aldehyde 1-21 as an enantiomerically enriched form 
whose conversion to (-)-1-4 could be achieved by the previously established 
sequence.[34]                 
 
Scheme 1.4. Nicolaou’s formal synthesis of (-)-platensimycin via Myers’ asymmetric 
alkylation and an oxidative dearomatization.  
 
The Nicolaou group went even further to develop an asymmetric enyne 
cycloisomerization reaction using terminal alkynes as substrates,[36f,g] in the 
pursuit of improving the overall efficiency of their previously described 
enantioselective cycloisomerization-based approach (Scheme 1.3) where a 
multistep decarboxylation sequence was necessitated from the employment of 
the internal alkyne 1-30.[35] They first examined the reaction with a number of 
chiral Rh-based complexes with various terminal enynes. Preformed rhodium 
catalyst [Rh((S)-BINAP)]SbF6 demonstrated superior reactivity and 
enantioselectivity as well as good functional-group tolerability over other 
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catalytic systems including Zhang’s in-situ generated catalyst (from 
[{Rh(cod)Cl}2], (S)-BINAP, and AgSbF6) for internal alkynes.[41] This newly-
developed technology was thereby applied to a more streamline and highly 
efficient formal synthesis of platensimycin (-)-1-4 (Scheme 1.5). Beginning 
from the known enone 1-19, IBX·MPO oxidation of its TMS silyl enol ether 
afforded the bis(enone) hydroxyl enyne 1-44 after acidic hydrolysis of the TBS 
group. Asymmetric cycloisomerization of 1-44 with [Rh((S)-BINAP)]SbF6 
underwent smoothly to afford the common spiro aldehyde 1-21 in 86% yield, 
and an improved ee of greater than 99% was obtained.           
 
 
Scheme 1.5. Nicolaou’s formal synthesis of (-)-platensimycin via an enantioselective 
enyne cycloisomerization for terminal alkynes.  
 
1.6 Total & Formal Syntheses of Platensimycin – Key Strategic Steps  
An examination of the present literature collating the key and unique 
strategic steps each group has employed in the total/formal syntheses of (±)- 
and (-)-platensimycin has been summed up in Tables 1-2 – 1-4. It is pretty 
amazing that a compact molecule like platensimycin could be synthesized by 
such diverse methods with efforts focused mainly on the core ketolide structure 
(1-23). Radical-based cyclization has been a popular game plan adopted by 
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several groups, especially the Nicolaou group as described (entries 1-5), to 
assemble the complex carbocyclic motif(s) (Table 1.2).  
In a chiral pool approach using (R)-(-)-carvone, Chen and Nicolaou (entry 
6)[36c] made use of Kagan’s reagent to again generate the ketyl radical from 
aldehyde 1-51 and cyclized into an exocyclic enone to construct the 
cyclohexanol ring 1-52. Although the reaction was highly stereoselective, the 
undesired chiral center at C9 was predominantly formed, and epimerization of 
this stereocenter was necessitated to complete the synthesis. The equilibration 
process was only found successful upon inversion of the C5 hydroxyl group via 
Mitsunobu conditions, and subjecting the tricycle 1-53 to KOH in MeOH at 50 
°C provided 1-54 and 1-55 in 1.1:1 dr at C9. A stereoselective L-selectride-
mediated reduction of the ketone in tricycle 1-55, followed by acid-promoted 
etherification of the resulting alcohol thereby furnished the desired tetracyclic 
core 1-56.  
Table 1.2. Radical-based approaches to the tetracyclic enone 1-23 of platensimycin.   
 
Group Steps to 1-23a 
Starting 



































































































































































































 Longest linear sequence to 1-23 unless otherwise stated (overall yield). 
 
The Snider group (entry 7)[36a] employed a similar radical-based Michael-
type cyclization strategy as the Nicolaou group (entry 5), using vinyl bromide 
as the radical precursor, to prepare Marinovic dione 1-61 from the cis-bicyclic 
diketone 1-59. 1-59 was synthesized from 5-methoxy-1-tetralone (1-57) via a 
Birch reductive alkylation process to generate a diastereomeric mixture of cis- 
and trans-decalins, which upon acid-catalyzed equilibration afforded greater 
quantities of the desired cis-isomer. A stereoselective reduction of the carbonyl 
at C10 in dione 1-61, followed by etherification of the resulting axial alcohol 
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into its double bond, were realized in Snider’s high-yielding (±)-formal 
synthesis of platensimycin.  
In Matsuo’s (±)-approach (entry 8),[36d] an interesting transannular radical 
cyclization across C12-C15 was adopted as end-game efforts to assemble the 
tetracyclic core of platensimycin from the monothioacetal 1-69. A 
diastereoselective Diels-Alder reaction between Danishefsky diene 1-63 and 
the α,β-unsaturated cyclohexenone 1-62 established the desired all-syn 
configuration necessary for the ensuing catalytic oxypalladation with alcohol 
1-66. Finally, benzenethiol addition to the mixture of endo- and exo- alkenyl 
moieties 1-67/68 then delivered the key intermediate 1-69.  
In another synthesis, Lee and co-workers (entry 9)[36e] were quick to 
assemble the tricyclic core 1-71 through a radical-based conjugate addition 
method whose diastereoselectivity at C9 was found to be temperature-
dependent. The key step in their synthesis relied on a remarkable oxygen-
controlled regioselective C-H insertion of alkylidene carbene 1-73 in pursuit of 
the final cyclohexenone ring. The high selectivity observed in the insertion of 
the C8-Ha bond of the structurally constrained pyran 1-72 was attributed by the 
strong deactivating effects the electron-withdrawing oxygen exerted, 
inductively, on the other equatorial C10-Hb bond. Subsequent oxidative 
opening of the cyclopentene 1-74 and re-closure via an intramolecular aldol 






Table 1.3. Enantioselective approaches to the tetracyclic enone 1-23 of platensimycin.   
 
Group Steps to 1-23a 
Starting 






















































































































































 Longest linear sequence to 1-23 unless otherwise stated (overall yield). 
 
Beside chiral pool-based syntheses, several enantioselective approaches 
have been reported in the literature toward (-)-1-23 (Table 1.3). The Nicolaou 
group, as earlier mentioned, was the first to achieve an asymmetric synthesis of 
platensimycin through an enantioselective enyne cycloisomerization (Table 
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1.2, entries 2 and 4) and Myers’ asymmetric alkylation technology (Table 1.2, 
entry 3).[35,36f-g] The Yamamoto group (entry 10)[37a] commenced their efficient 
synthesis of (-)-1-23 with the group’s developed methodology on Brønsted acid 
assisted chiral Lewis acid (BLA) catalyzed highly enantio- and regioselective 
Diels-Alder reaction[43] between methyl cyclopentadiene 1-75 and methyl 
acrylate 1-76 to give the [4+2] cycloadduct 1-79 in 99% ee. 1-79 was then 
transformed to the bicyclic ketone 1-80 using the group’s one-pot procedure – 
an initial N-nitrosoaldol reaction with nitrosobenzene followed by oxidative 
decarboxylation upon treatment with lithium hydroxide.[44] Another unique 
transformation which added elegance to the synthesis was the conversion of 1-
80 to the bicyclic lactone 1-81 presumably through a Baeyer-Villiger oxidation 
with tandem hydrolysis which promoted a re-lactonization into the olefin at 
C15. A resulting double bond migration and dehydration completed the 
cascade process. After a series of nontrivial manipulations, the group 
accomplished the anticpated intramolecular Robinson annulation of aldehyde 
1-82 with L-proline to mediate the initial stereoselective intramolecular 
Michael addition, followed by sodium hydroxide treatment to finish the aldol 
dehydration, and delivered 1-23 with its C9-epimer 1-83 in 5:1 dr. 
The Corey group (entry 11)[37b] has also developed a highly enantioselective 
synthesis of (-)-1-23 through two key methods: (1) a rhodium-BINAP 
catalyzed asymmetric 1,4-addition of potassium 2-propenyl trifluoroborate 1-
85 into the cyclic enone 1-84 to afford the chiral ketone 1-86 in excellent yield 
and 94% ee; and (2) a rhodium-DIOP catalyzed diastereoselective 
hydrogenation of bis-enone 1-90 under high pressure conditions to produce the 
tetrahydro ketone 1-91 with the desired stereocenter at C9 almost exclusively. 
Re-installation of the α,β-unsaturation to furnish 1-23 was achieved 
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regioselectively with the IBX sequence developed by Nicolaou and co-
workers.[46]  
Mulzer and Pfaltz (entry 12)[37c] have developed an asymmetric version of 
Mulzer’s original protecting-group free synthesis of (±)-1-23 (Table 1.4, entry 
16)[38c] through two chiral entry points, including (1) a stereoselective synthesis 
of Mander’s tricycle 1-116 via a highly enantioselective hydrogenation of α,β-
unsaturated ester 1-92 using Pfaltz’s specialized iridium(I)/P,N-ligand catalyst 
(Ir-cat); and (2) Ir-cat-catalyzed diastereoselective hydrogenation of bis-enone 
1-90 under 50 bar pressures over 65 h to deliver the desired tetrahydro ketone 
1-91 and its undesired C9-epimer 1-94 in 40:1 dr. This is a remarkable 
improvement in selectivity compared to the original 1.3:1 dr achieved with 
Crabtree catalyst on 1-90, having only a slight preference for the desired 
isomer 1-91.[38c] Finally, selective monooxidation of 1-91 with iodic acid-
dimethyl sulfoxide complex furnished 1-23 in 60% yield.  
The Canesi group (entry 13)[37d] used Evans oxazolidinone chemistry to 
establish the desired chirality at C12 with 95% ee, while the stereochemistry at 
the quaternary center in tetrahydrofuran 1-95 was inconsequential. The key 
step in their synthesis was an application of the group’s methodology in 
oxidative Prins-pinacol rearrangement with phenols activated by hypervalent 
iodine reagents which transformed 1-95 to the hydroperoxyketal 1-96 after 
hydrogen peroxide quenched. An interesting Schreiber-Fenton 
fragmentation[47] of 1-96 with FeSO4/Cu(OAc)2 then afforded the acetate 1-97 
which is associated with Nicolaou’s aldehydes 1-21 and 1-29 via a sequential 
hydrolysis and PCC oxidation.  
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Nakada and co-workers (entry 14)[37e] embarked on a 29-step endeavor to 
synthesize the asymmetric version of Snider’s intermediate 1-108 in 6% overall 
yield. The desired stereochemistry across the C8-C9 ring junction in decaline 
1-100 was introduced through a copper-catalyzed intramolecular 
cyclopropanation of the α-diazo-β-keto sulfone 1-98 using CuOTf and the 
bisoxazoline ligand 1-99 to produce the desymmetrized cyclopropane 
intermediate 1-100 in 95% ee. A notable step in Nakada’s sequence is the 
tosylic acid-mediated intramolecular aldol-Michael addition with enol ether 1-
103 to give the tricycle 1-104 in 96% yield – a unique Michael system among 
the otherwise popular radical-based 1,4-cyclization methods utilized by various 
groups. 
Table 1.4. Total and formal syntheses of (±)/(-)-platensimycin.  
 
Group Steps to 1-23a 
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 Longest linear sequence to 1-23 unless otherwise stated (overall yield). 
 
The second total synthesis of (-)-platensimycin till date was accomplished 
by the Ghosh group who achieved the tetracyclic core using an intramolecular 
Diels-Alder strategy (Table 1.4, entry 15).[38a,b] (S)-(+)-Carvone was used to 
prepare the chiral bicyclic ketone 1-109 with the desired stereocenters in a 
multistep approach. Due to the marginal steric difference between either sides 
of the ketone, the group has to employ an asymmetric HWE olefination using 
chiral phosphonoacetate reagent 1-110 to introduce the desired E-selectivity in 
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the allyl alcohol 1-111, which would in turn determine the duly orientation of 
the diene required for the crucial Diels-Alder reaction.  
The best results were obtained with the inclusion of a α-methoxy substituent 
to accelerate the normal Diels-Alder reaction under sealed tube conditions with 
BHT as the radical inhibitor. Only the E-enol ether of 1-112 underwent the key 
intramolecular Diels-Alder process to afford the tetracyclic core 1-113, and 
generated the C4-quaternary center concomitantly with the correct 
stereochemistry. The unreacted Z-enol ether of 1-112, due to increased steric 
interaction between the methoxy group and the ring methylene at transition 
state, could be isomerized with mercury salts in the presence of triethylamine 
to produce a 1:1 ratio of E/Z enol ethers, and recycled into the Diels-Alder 
reaction to obtain greater quantities of 1-113. Further homologation and 
elaboration of 1-113 furnished platensic acid 1-14 in 30 steps with 2% overall 
yield.  
Aniline 1-114 was chosen as the coupling partner in Ghosh’s total synthesis 
of (-)-platensimycin which was first utilized by Nicolaou and co-workers in 
their synthesis of another potent antibiotic platencin.[49] 1-114 was prepared 
from Giannis’ methyl ester 1-147[50] in a two-step procedure, including an ester 
exchange with 2-trimethylsilylethanol 1-148 and catalytic hydrogenation over 
Pd-C (Scheme 1.6). Finally, HATU coupling between 1-114 and 1-14, 

























































Scheme 1.6. A. Synthesis of aniline 1-114 from Giannis’ methyl ester. B. Giannis’ 
concise synthesis of the aromatic sub-unit (1-151) of platensimycin.[50] 
 
The core ketolide fragment (1-23) of platensimycin has been diversely 
assembled through a few common carbocyclic frameworks, namely Nicolaou’s 
[6,5]-spirocycles, decalinone derivatives, Yamamoto’s and Ghosh’s [5,5]-
bicycles, and Corey’s and Mulzer’s anisole-derived tetralones. The seven-
membered oxabicyclo[3.2.1] carbon skeletons have also been utilized by 
several groups, and their reported syntheses are intriguing (Table 1.4, entries 
18, 19 and 21). Njardarson and co-workers employed a copper-catalyzed ring 
expansion protocol developed by the group[51] to convert the vinyl epoxide 1-
125 into the dihydrofuran 1-126 in good to excellent yields (entry 18).[38e] The 
seven-membered ring in 1-125 was assembled by an interesting Molander’s 
trifluoroborate Suzuki-type cross-coupling of 2-bromo-anisaldehye 1-122, 
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followed by a thermodynamically-favored intramolecular aldol condensation in 
1-124.  
The Wang group has developed the first Lewis acid-catalyzed type II 
intramolecular [3+2] cycloaddition of cyclopropane 1,1-diesters with carbonyls 
and imines.[38f] They demonstrated the potential of this strategy in a formal 
synthesis of (±)-platensimycin with the construction of diester 1-130 from 
Sc(OTf)3-catalyzed [3+2] cycloaddition of cyclopropane 1-129 (entry 19). 
Subsequent Krapcho decarboxylation of 1-130 delivered the desired endo-
isomer 1-131 almost exclusively which could be further converted into the 
tetracyclic bis-enone intermediate 1-90 through 1-132 using the sequence 
reported by the Njardarson group.[38e]  
Finally, the Wright group (entry 21)[38h] pursued their key 
oxabicyclo[3.2.1]octadiene intermediate through a highly efficient formal 
[4+3] cyclocondensation of the substituted furan 1-137 with 
tetrabromocyclopropene 1-138, which upon hydrolysis with aqueous silver 
nitrate provided a 4:1 mixture of dibromoenones 1-141 and 1-142, in favor of 
the desired regio-isomer. Woodward-Wilds modified-Robinson annulation 
reaction[52] through trione 1-143, with accompanying thermal deformylation, 
constructed the cyclohexenone ring in enone 1-144. The completion of the 
tetracyclic core (1-146) was achieved with an intramolecular γ-alkylation of the 
tosylate 1-145 – a similar approach to the alkylative cyclodearomatization 
event in Corey’s (Table 1.3, entry 11)[37b] and Njardarson’s (entry 18)[38e] end-
game strategy. 
The Eun Lee group (entry 17)[38d] accomplished a high-yielding and elegant 
formal synthesis of (-)-platensimycin using (S)-propylene oxide in a chiral pool 
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approach. They exploited a carbonyl ylide cycloaddition strategy to assemble 
the tricyclic core 1-118 in a single step catalyzed by Rh2(OAc)4, and this 
particular transformation is discussed in greater details in the subsequent 
chapters. A notable challenge in their synthesis was the installation of the 
requisite C9 stereochemistry (1-121) which they achieved in moderate 
selectivity (~2.5:1 dr) through 1,4-hydrosilylation of enone 1-120 with 
Wilkinson’s Rh(I)-catalyst.  
The Magnus group (entry 20)[38g] dimethylated Mulzer’s intermediate 1-116 
at positions C4 and C15, afterwhich an interesting autoxidation of the alcohol 
1-134 under ambient conditions provided the desired C10 axial alcohol 1-135 
as a single stereoisomer. The correct C9-H configuration in diol 1-136 was 
delivered by conjugate hydride reduction with LiAlH2(OEt)2 directed by the 
C10 (axial) hydroxyl group. Subsequent etherification of 1-136 in DMSO 
under microwave conditions furnished the C4-methylated derivative of (±)-1-
23 in 65% yield.                           
1.7 Platensimycin analogs 
While a number of approaches have been reported for the formal and total 
syntheses of platensimycin, a few groups have also published their efforts on 
the design and synthesis of different analogs of this important natural product 
(Figure 1.7). Kaliappan and co-worker reported an early enantioselective 
synthesis of the oxatetracyclic core 1-152 possessing an extra methyl group at 
C9 of the lipophilic domain of natural platensimycin for the sole purpose of 
studying its chemistry.[53] The Corey group also reported an enantiocontrolled 
total synthesis of a near-structural mimic 1-153 of platensimycin by replacing 
one of the methylene bridges with oxygen and the excision of the other 
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methylene bridge.[54] They tested the antibiotic activities of 1-153 but the 
biological profile was not published. Merck has spent considerable efforts 
synthesizing through mainly chemical modifications of the natural product, and 
biological evaluation of a range of platensimycin analogs.[22,29,55] They have 
also isolated a series of natural congeners of the molecule.[22,56] None of those 
compounds were, however, found to be more active than natural platensimycin, 
thus suggesting that the presence of each and every functional group is crucial 
for the antibacterial activity of platensimycin.  
The Nicolaou group has also reported the design, synthesis, and biological 
evaluation of various platensimycin analogs with varying degrees of molecular 
complexity in order to understand the role of each structural domain within the 
molecule.[21] Nicolaou and co-workers have prepared (1) 
adamantaplatensimycin 1-154 in which the adamantyl moiety would represent 
the isosteric cage,[57] and (2) carbaplatensimycin 1-155 to investigate the 
importance of the etheral oxygen as a hydrogen bond acceptor.[58] Both 
synthetic analogs demonstrated slightly lower antibiotic potency against 
MRSA compared with platensimycin. Other simpler analogs prepared by the 
group[21,36g] and Sintim’s oxazinidinyl platensimycin 1-156[59] were also proved 
less active. Eun Lee and co-workers reported the synthesis of isoplatensimycin 
1-157, the undesired regioisomer from their intramolecular carbonyl ylide 
cycloaddition strategy toward platensimycin synthesis.[38d,60] The seemingly 
subtle structural modification causes a dramatic decrease in the antibacterial 
activity. Recently, the group has also prepared two other analogs 7-
phenylplatensimycin 1-158 and 11-methyl-7-phenylplatensimycin 1-159 which 
were found to be more potent than platensimycin against MRSA and MSSA 


















































































Figure 1.7. Some synthetic analogs of (-)-platensimycin. 
 
1.8 Conclusion 
Platensimycin (-)-1-4 is a potent, broad spectrum antibiotic whose 
architectural complexity and important antibiotic activity with a novel mode of 
action against the bacterial fatty acid biosynthesis pathway has generated great 
interest in the scientific community. Although an unfavorable pharmacokinetic 
profile has limited its potential for further clinical development in antibiotics 
research, the biological interest in this natural product is still ongoing and has 
certainly spurred the exploration of numerous synthetic analogs of 
platensimycin. Since its disclosure in 2006, platensimycin has been a very 
popular target for chemical synthesis, and diverse approaches have been 
continually published in the literature.  
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The achievement of a stereospecific route with convenient access to the C8-
C9 ring junction stereochemistry of the tetracyclic enone moiety has been a 
constant challenge to the synthetic chemists. The flexibility of the synthetic 
approach for developing potential analogs that may prove superior to the 
natural product, with special regard to its pharmacological properties, is of 
great interest to the researchers. With these challenges in mind, we embarked 
on the pursuit of a total synthesis of platensimycin (-)-1-4 focusing on the 
structurally important core ketolide fragment 1-23. Our efforts toward this goal 












A Dirhodium(II)-Catalyzed Carbonyl 




2.1 First-Generation Retrosynthetic Analysis of (±)-Platensimycin   
Our first-generation racemic synthesis towards the methylated core ketolide 
fragment 2-1 of platensimycin (1-4) is outlined below, in retrosynthetic format 
(Scheme 2.1). The final stages in the synthesis envisioned an intramolecular 
pinacol coupling with (either concerted or stepwise) deoxygenation of diketone 
2-3 to provide the highly substituted cyclohexenone 2-2. Regioselective allylic 
oxidation[62] of 2-2 followed by olefin transposition through sequential 
reduction and IBX-mediated oxidation[46] processes were envisaged to liberate 
2-1.  
At the beginning of our total synthesis program, the groups of 
Nicolaou,[34,36b] Snider[36a] and Kaliappan[53] consecutively published their 
independent efforts in the total and formal syntheses of platensimycin, in which 
the compact core was readily assembled by radical-based methods on similar 
Michael-type systems, and those protocols were non-tandem operations. To 
complete the cage-like structure, a common trifluoroacetic acid-promoted 
intramolecular etherification into an exocyclic olefin was employed in their 
syntheses. Late-stage intramolecular etherification has thus become an 
important synthetic tool to access the tetrahydrofuran moiety in subsequent 
platensimycin syntheses.[39]  
Hereof, we would explore a different (first-generation) synthesis route in 
which we reckoned that an amalgamation of radical- and metal-catalyzed-
based cyclization cascades could be developed as a competitive strategy to 





Scheme 2.1. Retrosynthetic analysis of (±)-platensimycin (1-4). 
 
We thus anticipated that the diketone 2-3 could arise from the α,β-
unsaturated ketone 2-4 through a 5-exo-trig radical-based ring closure into the 
exo-methylene, with phenyl sulfide as the internal radical precursor. A radical-
based Michael-type addition cascade with methyl vinyl ketone 2-5 would 
continue to elaborate the tricyclic core. The origins of 2-4 were then traced to 
keto-ester 2-6 by standard functional-group manipulations including an 
Eschenmoser methylenation. Finally, the oxabicyclo[3.2.1]octane framework 
in 2-6 was conceived to be accessible through a dirhodium(II)-catalyzed 
carbonyl ylide cyclization and cycloaddition cascade whose disconnections 
thereby afforded the levulinic acid-derived α-diazoketone 2-7 and methyl 
propiolate 2-8.  
This metal-catalyzed diazo decomposition-promoted anionic cascade 
applied in the syntheses of complex oxapolycyclic systems, containing variably 
substituted di- or tetrahydrofuran rings, has been extensively studied by groups 
of Padwa[63] and Hodgson[64] in the past decade. The tandem carbonyl ylide 
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cycloaddition strategy has therefrom been a powerful tool for the syntheses of a 
growing number of natural products (Figure 2.1) such as zaragozic acid (2-
9)[65a], nemorensic acids (2-11)[65b], colchicines (2-12)[65c], pseudolaric acid (2-
10)[65d] and polygalolides (2-13)[65e]. Eventually, we plan to make this carbonyl 
ylide approach stereoselective either through investigating the reaction with 
Hashimoto-inspired chiral dirhodium(II) carboxylate catalysts[66] or by 
exploring the synthesis with chiral auxiliary-based methods[67]. 
 
 
Figure 2.1. Some totally synthetic natural products prepared via the carbonyl ylide 
cycloaddition approach. 
 
2.2 Carbonyl Ylide Cycloaddition Strategy to the Oxabicyclo[3.2.1] 
Carbon Skeleton  
The synthesis commenced with the diazotization of commercially available 
levulinic acid (2.14) through diazomethane substitution (Scheme 2.2). 
Preparation of laboratory-scale diazomethane from Diazald 2-18 (synthesized 
from p-toluenesulfonyl chloride and methylamine)[68] was a first in our group 
and has been nontrivial to generate up to 0.2 mol of the dry reagent (two 
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batches in series of ~0.1 mol scale each). After considerable attempts with 
various conditions, levulinic acid treated to an etheral solution of diazomethane 
was converted to the α-diazoketone 2-7 via mixed anhydride activation in 80% 
yield. After flash column purification of the acid-sensitive 2-7, the anticipated 
catalytic carbonyl ylide cyclization cycloaddition with methyl propiolate (2-8) 
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 Scheme 2.2. Synthesis of a key oxabicyclo[3.2.1]octane intermediate. 
 
Initially, the reactions with Rh2(OAc)4 as catalyst in either CH2Cl2, Et2O or 
toluene solvent were low yielding between 20-30% and demonstrated almost 
no regioselectivity. When benzene was used, however, the desired 
regioselectivity was gratifyingly attained through electronic effects from 
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matching MO coefficients between the pair of dipole and dipolarophile (2-8), 
as illustrated, in the carbonyl ylides 2-95 and 2-96. A separable mixture of 1,3-
dipolar cycloadduct 2-15 and its regioisomer 2-16 were obtained in 82% yield 
with an improved 4:1 regioselectivity, in favor of the desired isomer 2-15. All 
attempts to prepare the pentafluorophenyl ester of propargylic acid for 
increasing the regio-preference in the carbonyl ylide cycloaddition via steric 
and electronic controls were unsuccessful.    
Catalytic hydrogenation over Pd-C of the α,β-unsaturated ester 2-15 at 
ambient pressures proceeded uneventfully with complete stereocontrol over H-
addition from the exo-face of the bicyclic system to furnish Me ester 2-6 in 
90% yield. Hydrogenation of 2-15 proceeded to completion in EtOAc after 12 
h, while the process was sluggish in MeOH. Basic hydrolysis of 2-6 with LiOH 
then afforded keto-acid 2-17 in 77% yield. No α-epimerization of the Me ester 
was observed when the hydrolysis was kept within 2 h.  
Poor selectivity was, however, observed in our attempts to reduce the 
carboxylic acid preferentially in the presence of the ketone functionality (2-19, 
Table 2.1). Reduction with BH3·THF at -78 °C only recovered the starting 
material 2-17 (entry 1). At elevated temperatures, however, there was no 
selectivity; traces of 2-17 with partially reduced byproducts and diol 2-20 from 
over-reduction could be observed (entry 2). Initial exposure of 2-17 to 
trimethyl borate as an acid activating reagent, followed by treatment with 
BH3·THF at 0 °C [69] was met with limited success (entry 3). When the acid 
was first converted to an acyl chloride, followed by selective reduction with 
NaBH4, the reaction was disappointingly low yielding and a complex mixture 
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of byproducts was obtained (entry 4). Consequently, both carbonyl groups 
were reduced using an excess of BH3·THF to afford diol 2-20 in 90% yield 
(entry 5). DIBAL-H mediated reduction of 2-6 directly to 2-20 was comparable 
with a yield of 72% versus the former 69% over two steps (entry 6).  
Table 2.1. Selective reduction of the carboxylic acid in 2-17.   
 
entry conditions yield (%)a remarks 
1 BH3·THF (1.4 eq.), THF,         
-78 °C, 2.5 h 
- No reduction. 2-17 was 
recovered. 
2 BH3·THF (1.6 eq.), THF,         
-20 °C to rt, 12 h 
42 2-20 was afforded. Traces of 2-
17 and byproducts obtained. 
3 i. B(OMe)3 (4 eq.), THF,       
10 °C, 10 mins; then 
ii. BH3·THF (3 eq.), THF,       
0 °C to rt, 12 h [69] 
68 2-20 was afforded. No 2-17 
recovered. Some byproducts. 
4 i. (COCl)2 (2 eq.), DMF (1 
drop), CH2Cl2, 0 °C, 1 h; then 
ii. BH3·THF (3 eq.), THF,       
-10 °C to rt, 12 h 
traceb Complex mixture. Impure 2-19 
obtained after flash column. 
5 BH3·THF (2.5 eq.), THF, 0 °C 
to rt, 16 h 
90 Clean reaction. 
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6c  DIBAL-H (5 eq.), CH2Cl2,      
-78 °C to -20 °C, 8 h 
72 Some byproducts observed. 
 
a
 Isolated yield of 2-20. b Isolated yield of 2-19. c Me ester 2-6 was directly used for reduction. 
 
Thereafter, selective mono-tosylation of the diol (2-20) with TsCl and Et3N, 
followed by Dess-Martin oxidation of the secondary alcohol afforded ketone 2-
21 in 67% yield over two steps (Scheme 2.3). Nucleophilic substitution with 
thiophenol in DMSO and K2CO3 then transformed the keto tosylate (2-21) to 
keto phenyl sulfide 2-22 in 70% yield (Scheme 3).  
The ensuing Eschenmoser methenylation of 2-22 was nontrivial. After 
examination of the literature, a modified procedure of Danishefsky’s synthesis 
of Gelsemine[70] enabled us to obtain the α,β-unsaturated ketone 2-4 with a 
modest yield of 51% over two steps. Ketone 2-22 was first converted to the 
silyl enol ether using LiHMDS and TESCl at -78 °C before treatment of the 
crude mixture with Eschenmoser’s salt overnight. Finally, and surprisingly, 
treatment with 3M NaOH solution at ambient temperature spontaneously 
resulted in a possible steric-driven elimination of the dimethylamino group, 
without the duly formation of a better leaving quaternary ammonium salt, to 
furnish the required α-exo-methylene (2-4).  
With 2-4 in hand, the stage was set to assemble the tricyclic core and 
construct the C8 quaternary center in diketone 2-3 through the anticipated 
radical-based cascade operation (Scheme 2.4). The sequential radical formation 
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on C7 upon C8-C13 closure would be conceivably trapped and alkylated by the 
methyl vinyl ketone 2-5. Due to safety constraints, azobisisobutryonitrile 
(AIBN) was not available to our lab, thus commercially available 1,1’-azo-bis-
1-cyclohexanenitrile (ACN) was used as the free radical initiator[71] instead for 





































Scheme 2.3. Preparation of the α,β-unsaturated ketone 2-4. 
 
2.3 Radical-Based Cyclization and 1,4-Addition Cascade to the 
Oxatricyclic Core   
When 2-4 was gently refluxed with the radical trap 2-5 in the presence of 
nBuSn3H and ACN in toluene, a complex mixture was afforded with no starting 
ketone 2-4 recovered (Scheme 2.4). To initially avoid complications from the 
highly possible polymerization of methyl vinyl ketone, ethyl acrylate (2-23), a 
milder Michael acceptor, was selected as the alternative intermolecular radical 
trap to first model study the feasibility of our strategy. Unfortunately, no ring 
closure event occurred although starting material 2-4 was completely 
consumed under similar conditions with 2-5. Unreacted ethyl acrylate remained 
in large excess as observed by TLC.  
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We proposed that the α,β-unsaturated carbonyl system may have disfavored 
addition to the α-position of the exo-methylene. A reversal of the olefin LUMO 
coefficient seemed necessary to improve the reactivity of this cyclization, for 
which the allyl Bn ether 2-25 was recognized as an appropriate intermediate. 2-
4 was reduced with DIBAL-H and protected with BnBr, using NaH and 
catalytic TBAI, to afford an inseparable diastereomeric mixture of 2-25. The 
intended radical cascade was then repeated with 2-25 and 2-23, with the other 
reagents (nBu3SnH and ACN) added across longer hours using a syringe pump. 
A complex mixture was again observed on TLC and no desirable product 
formation was suggested by ESI-MS. 
 
 
Scheme 2.4. Key radical-based cyclization and 1,4-addition cascade with 2-4 and 2-
25. 
 
In Naito’s approach to the pyrrolidine ring in (-)-α-kainic acid (2-31, 
Scheme 2.5B), the group succeeded in performing a one-pot C-C cyclization 
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and elimination cascade promoted by phenylsulfanyl radicals prepared from 
benzenethiol and AIBN.[72] Inspired by their strategy, α,β-unsaturated ketone 
2-4 was examined with modified Naito’s conditions using benzenethiol, ACN, 
and an additional equivalent of nBu3SnH to generate radical at C13 to attempt a 
possible C8-C13 diradical formation through a concomitant sulfanyl radical-
promoted conjugate addition into the enone (Scheme 2.5A). Our efforts to 
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Scheme 2.5. A. Diradical cyclization of 2-4 promoted by phenylsulfanyl radicals. B. 
Naito’s phenylsulfanyl radical addition-cyclization-elimination approach to (-)-α-
kainic acid (2-31). 
 
2.4 Future Plans for the Assembly of the Oxatricyclic Compact Core   
The formation of the C8-C13 bond via radical approaches has been 
synthetically challenging attributed by a number of possible factors, and the 
increased in torsional strain resulting from the tricyclic core assembly is 
probably one of them. The tertiary radical at C8, presumably generated through 
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phenylsulfanyl radical-promoted 1,4-addition, could be further stabilized by 
hyperconjugative effects and/or pi-conjugation with the α-carbonyl group, such 
that the species became unreactive towards an anticipated diradical cyclization.  
Unoptimized radical-based conditions are often unpredictable and that truly 
applies to our ambitious cyclization-addition tandem process. We proposed that 
the complex mixtures we have repeatedly observed under these reaction 
conditions could be the result from a preferential fragmentation of the oxa-
bicyclic framework (2-4) to generate an initial oxygen-stabilized radical-
containing intermediate 2-32 that further decomposed to various byproducts, 
e.g. 2-33–2-35 (Figure 2.2).  
 
 
Figure 2.2. Possible fragmentation pathways for the tetrahydrofuran moiety in 2-4. 
 
Thus, we could conceive an alternative cyclization using anionic-based 
methods to construct the cage-like core through possible key intermediates 
such as the β-keto aldehyde 2-36 and the α-allylated ketone 2-37 (Figure 
2.3A). Different bases would be screened for driving the anticipated alkylative 
cyclization. The side-arm on C8 would then facilitate construction of the 
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cyclohexenone moiety, after the crucial ring closure. Accordingly, groups of 
Njardarson[38e] and Wright[38h] were the only two groups till date to have 
assembled the tricyclic core unit in a formal synthesis of (±)-platensimycin via 
a final ring closure along C8-C13, using (1) TBAF-mediated alkylative 
cyclodearomatization of 1-128, and (2) tert-butoxide promoted cyclization in 
1-145 (Figure 2.3B).   
  
 
Figure 2.3. A. Proposed intermediates for an anionic-based cyclization approach to 
the oxatricyclic core.  B. Ring closure along C8-C13 achieved by the groups of 
Njardarson and Wright. 
  
With a continual interest in the carbonyl ylide cycloaddition strategy, we 
directed this cascade process to a second-generation asymmetric synthesis of 
the core ketolide structure of (-)-platensimycin. Revisiting our retrosynthetic 
blueprint for the oxabicyclo[3.2.1] carbon skeleton, the second-generation 
approach would boast a direct and expedient construction of the key 
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oxatricyclic compact core (2-38) in a single transformation step via Padwa’s 
dirhodium(II)-catalyzed cycloaddition cascade on a quaternary α-diazoketone 
precursor (2-39). The retrosynthetic analysis of this newly conceived route is 
outlined in Scheme 2.6.  
2.5 A Second-Generation Carbonyl Ylide Cycloaddition Approach to the 
Tetracyclic Enone (-)-1-23    
 
 
Scheme 2.6. Retrosynthetic analysis of the tetracyclic enone (-)-1-23 of (-)-
platensimycin. 
 
The core ketolide fragment 1-23, aka Nicolaou’s intermediate, could be 
accessed by a late-stage intramolecular aldol condensation of keto-aldehyde 1-
121 whose disconnection afforded the oxatricyclic ketone 2-38 through a 
stereoselective retro-1,4-reduction and retro-olefination reaction. Thus, ketone 
2-38 was expected to arise from the quaternary substituted α-diazoketone 2-39 
through the anticipated dirhodium(II)-catalyzed carbonyl ylide cyclization 
cycloaddition cascade with the allyl group as an internal dipolarphile.  
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This type of intramolecular carbonyl ylide cycloaddition (with 2-43) in the 
presence of Rh2(OAc)4 has earlier been shown by Padwa et al. to generate a 
mixture of cyclopropane 2-48, and two regioisomeric [3+2] cycloadducts 2-46 
and 2-47 through ylide conformations 2-44 and 2-48 respectively (Figure 
2.4).[73] The group found that the formation of cycloadduct 2-47 was favored 
when R = H, along with cyclopropane 2-48 (~1:1) and a small amount of the 
desired regioisomeric cycloadduct 2-46. Based on these findings by Padwa and 
coworkers, a reversal of this product distribution with suppression of the 
cyclopropanation reaction is thus necessary to ensure the success of our 
synthetic approach. Investigations into the dirhodium(II) ligand effects and the 
steric-electronic nature of the internal dipolarophile will be essential to our 
total synthesis of platensimycin.  
 
 
Figure 2.4. The Padwa group study on the intramolecular carbonyl ylide 
cycloaddition reaction with Rh2(OAc)4 for a 1,4-diketone substrate (2-43). 
  
Our priority was, however, to first examine the outcome and feasibility of 
this carbonyl ylide cycloaddition strategy with 2-39 since the latter differs 
sterically from Padwa’s substrate (2-43, R = H). Moving on with the 
retrosynthesis, the origins of the α-diazoketone 2-39 were then traced to the 
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bicyclic lactam 2-40 through a hydrolytic or reductive cleavage of Meyers’ 
amino acid-based chiral auxiliary. Meyers’ chemistry of the reported bicyclic 
lactam 2-41[74,75] through a sequential alkylation and acylation events was 
conceived to afford the desired α-quaternary center stereoselectively. Finally, 
2-41 could be readily prepared from the condensation of levulinic acid (2-14) 
and L-valinol (2-42).     
2.6 Pursuit of the Quaternary-Substituted Keto-Acid 2-60 via Meyers’ 
Bicyclic Lactam Auxiliary    
L-Valinol (2-42) was conveniently prepared by Meyers’ NaBH4/I2 reduction 
protocol with L-valine in 61% yield.[76] The lower than expected yield obtained 
was due to the loss of material during its purification by distillation. The 
synthesis of the oxatricyclic ketone 2-38 commenced with the condensation of 
levulinic acid (2-14) and L-valinol (2-42) under Dean-Stark conditions to 
furnish Meyers’ bicyclic lactam 2-41 in 95% yield (Scheme 2.7). To control 
the absolute stereochemistry of the requisite α-quaternary center in α-
diazoketone 2-39, the sequential order of alkylation and acylation events with 
2-41 is important.  
It was reported by Meyers et al. that alkylation of the bicyclic lactam 2-41 
(a pseudo-amide with a pyramidal N-center) is endo-selective, i.e. approach 
from the (concave) α-face is preferred, due to electronic pi-perturbation from 
the nitrogen’s lone pair with its lithium enolate, and possible N-lone pair 
stabilization of the developing σ* of the incoming alkyl electrophile.[77] 
Through a series of experiments and ab initio molecular orbital calculations, 
Meyers and coworkers showed that this type of alkylation does not follow the 
60 
 
originally-believed Cieplak effect[78] and the endo-face of 2-41 actually reveal 
a larger HOMO coefficient that favors the endo transition state by 1.26 
kcal/mol (Insert Figure 2-53).[79]  
 
 
Scheme 2.7. Stereochemical synthesis of the quaternary substituted Meyers’ lactam 2-
40. 
 
It was experimentally demonstrated by Meyers and Arrington that acylation 
is, however, exo-selective from the less hindered face of 2-41 i.e. approach 
from the convex β-face is preferred, although the rationale behind is still 
unclear.[80] Thus, lactam 2-41 was first subjected to the alkylation conditions 
with LDA and allyl bromide to afford a 3:1 dr in favor of the endo-allylated 
lactam 2-49 over its C8 epimer in 95% yield. Next, acylation of the 
61 
 
inconsequential mixture of C8-allylated lactams with LDA and ethyl 
chloroformate established the desired C8-stereochemistry with complete exo-
selectivity to furnish a single diastereomer of ethyl ester 2-51 in 89% yield. 
Chemoselective reduction of the ester moiety in 2-51 using NaBH4 under 
standard conditions (THF/H2O, rt) took 3 days for completion to furnish 
alcohol 2-52 in 70% yield. By using a combination of NaBH4-CuSO4 in 
EtOH,[81] the selective reduction of 2-51 was achieved in 3 h and 2-52 was 
afforded in 87% yield. However, it is noteworthy that undesired reduction of 
the olefin (referred 2-54) was observed as well, when the reaction was strongly 
refluxed for longer hours under higher copper-catalyst loadings. This 
byproduct could only be separated after the Bn-protection step to give 2-54.  
Initially, we planned to determine the absolute stereochemistry of the newly 
constructed α-quaternary center by growing crystals of the p-bromobenzoyl 
ester of alcohol 2-52 for X-ray analysis. However, only yellow viscous oil was 
obtained after several attempts of recrystallization. Thus, 1D-NOE studies 
(with reference to the L-valinol’s i-Pr group) were performed on the ester 2-55 
and verified the desired C8-configuration (Figure 2.5). Benzyl protection of 2-
52 then provided the Bn-protected lactam 2-40 in 97% yield.    
 
 
Figure 2.5. 1D-NOE studies of the p-bromobenzoyl ester 2-55 in verification of the 




After securing the desired stereocenter at C8, the next step to cleave 
Meyers’ auxiliary in 2-40 was nontrivial. Meyers et al. reported the conditions 
using 5% H2SO4 in alcohol solvents to hydrolyze bicyclic lactams directly to 
their keto esters derivatives,[74a] but our attempts with this method have been 
unsuccessful (Scheme 2.8). There was either no reaction after long hours of 
reflux in MeOH or the lactam degraded completely to a complex mixture when 
10% H2SO4 in EtOH was used.  
 
 
Scheme 2.8. Acidic hydrolysis of bicyclic lactam 2-40. 
 
Efforts to cleave the auxiliary reductively using Meyers’s alternative 
procedures were carried out in parallel (Scheme 2.9). This includes a two-step 
sequential reduction with Red-Al, followed by hydrolysis of the resulting 
carbinolamine (2-57) to provide the keto-aldehyde 2-58.[82] Although this 
method of Meyers’ auxiliary cleavage has been commonly applied, the broad 
spectrum of conditions reported varied among the lactams which necessitated 
optimization for 2-40. The TBS-version of 2-40 which we have prepared 
initially did not survive the reductive conditions.  
After some experimentation, Bn-protected lactam 2-40 was reduced by Red-
Al at -20 °C for as long as 48 h to afford the carbinolamine 2-57 quantitatively 
and nBu4H2PO4-mediated hydrolysis (mildly acidic) in aq. EtOH uneventfully 
furnished the keto-aldehyde 2-58 after stirring for 2 days. 1M aq. KH2PO4 
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solution was also found to be capable of hydrolyzing the carbinolamine 
effectively as a low cost reagent. 2-58 was eventually oxidized under Pinnick 
conditions to transform the keto-aldehyde to the keto-acid 2-60 which, 
unexpectedly, cyclized into its γ-ketone concomitantly.  
 
 
Scheme 2.9. Reductive cleavage of Meyers’ auxiliary and oxidation of the resulting 
keto-aldehyde 2-58. 
 
We rationalized that the facile cyclization had most probably occurred due 
to the Thorpe-Ingold effect[83] exerted by the neighbouring (C8) quaternary 
center, which resulted in a kinetically-driven 5-membered lactone hemiacetal 
2-59 formation in 75% yield over three steps. It was only in DMSO-d6 (a 
relatively neutral solvent) that we ever observed opening of the lactone 
hemiacetal 2-59 (via 1H and 13C NMR) to produce the originally desired keto-
acid 2-60.  
2.7 Efforts to Prepare the α-Diazo-Ketone Intermediate    
With the keto-acid 2-60 masked as the lactone hemiacetal 2-59, and in the 
presence of the sterically hindered C8 quaternary center, transformation to the 
α-diazoketone 2-39 only proved problematic. Considerable experimentation 
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were undertaken to reveal the keto-acid from the hemiacetal, and activate the 
acid for diazotization (Scheme 2.10); however, our efforts were met with 
disappointing results. Various modes of activation that have been explored 
with 2-59, include, preparation of the mixed anhydride (2-61–2-63), the acyl 
chloride (2-64) and the acyl sulfonate[84] (2-65–2-66) intermediates; following 
which they were treated with freshly distilled etheral solutions of diazomethane 
to drive the diazo substitution reaction.  
 
Scheme 2.10. Screening of activation conditions toward α-diazoketone 2-39 
formation. 
 
Unfortunately, it turned out that this one-pot or sequential process would 
either favored byproduct formation of the methyl ester 2-67 (resulted from an 
undesired methylation with CH2N2) or generate a complex mixture. Among 
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these methods, the mixed anhydride (2-61) formation with 2-59 using ethyl 
chloroformate and KOtBu, followed by treatment with CH2N2 afforded the 
desired α-diazoketone 2-39, albeit in 18% yield (at best) and the major 
byproduct isolated was 2-67. Hydrolysis of 2-67 with LiOH aqueous solution 
readily recovered 2-59 in excellent yields. We proceeded to subject 2-39 to 
catalytic Rh2(OAc)4 in benzene at room temperature initially which observed 
no carbonyl ylide cycloaddition. Attempt to heat the reaction, however, caused 
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Following the unsuccessful trials to transform 2-59, we conceived that the 
Bn-protected hydroxyl methyl arm could have adversely increased the sterics 
that favored hemiacetal cyclization, as well as hindered the diazo substitution 
reaction. To examine the steric influences brought about by protecting group 
manipulation on the formation of the keto-acid 2-60 and diazoketone 2-39, 
sterically less cumbersome C8 side-arms including the MOM-protected[85] (2-
68, Scheme 2.11A) and Me-protected (2-71, Scheme 2.11B) derivatives of the 
alcohol 2-52 were prepared. Meyers’ auxiliary cleavage of 2-68 and 2-71 under 
the same optimized reductive conditions, nonetheless, resulted in facile and 
uncontrolled cyclization to furnish the respective MOM- and Me-protected 
lactone hemiacetals 2-70 and 2-73.  
Subjected to similar methods of activation (Scheme 2.12), attempts to 
convert 2-70 and 2-73 into their α-diazoketone intermediates proved to be 
futile. This sequence of transformation was sluggish, and methyl ester (2-
82/83) formation was favored instead. Likewise, the mixed anhydride (2-74) 
method using KOtBu and ethyl chloroformate combination facilitated the 
formation of MOM-protected diazoketone 2-75, albeit in even lower yield of 





Scheme 2.12. Screening of activation conditions toward α-diazoketones 2-75/76 
formation. 
 
2.8 Other Methods to Prepare the α-Diazo-Ketone Intermediate    
At this juncture, we decided to circumvent formation of the lactone 
hemiacetal which have made the conversion to the diazoketone sluggish and 
difficult. Alternative preparations toward α-diazoketone 2-39 were considered 
to replace the standard diazo substitution method with CH2N2. Regitz-type 
diazo-transfer methods[86] would be nontrivial with our levulinic acid-type 
substrate since the other α-methyl ketone position, further away from the 





Scheme 2.13. Preparation of the β-keto ester 2-85. 
 
Henceforth, we proposed the formation of the β-keto ester 2-85 (Scheme 
2.13) which would facilitate the selective introduction of the diazo group at the 
activated methylene position (2-86) via Regitz diazo-transfer. The additional 
ester functionality could help to favor a type III carbonyl ylide-cycloaddition 
process[63a] for diazoketone 2-86, and the ester group could be readily 
decarboxylated in the later stage. Thus, keto-aldehyde 2-58 (briefly purified) 
was subjected to Roskamp conditions[87] using SnCl2 and ethyl diazoacetate (2-
84) but no reaction was observed. Yoshii’s conditions using TiCl4 for bulky 
aldehydes[88] was also attempted only to provide a complex mixture. 
Recently, Fukuyama and coworkers have disclosed the discovery of N,N’-
ditosylhydrazine [TsNHNHTs (2-87)] as a convenient reagent for the facile and 
high-yielding synthesis of diazoacetates from bromoacetates (Figure 2.6A).[89] 
In their report, they further applied their protocol with 2-bromoacetophenone to 
afford 2-diazoacetophenone in 94% yield. Although this is the only reported 
example of diazo-formation directly from α-halo ketones in the literature, we 
were nevertheless interested to explore Fukuyama’s new methodology on our 





Figure 2.6. A. Fukuyama’s preparation of 2-diazoacetophenone with their new 
TsNHNHTs reagent 2-87. B. A trial synthesis of 2-diazoacetophenone from 2-
chloroacetophenone with Fukuyama’s protocol.  
 
We anticipated that the α-halo-carbonyl functionality could be selectively 
introduced to our substrate through an organo-lithium addition, followed by 
nBu4H2PO4-mediated hydrolysis of the Bn-protected bicyclic lactam 2-40 
(Scheme 2.14). α-Chloro-diketone 2-89 was initially prepared and tested due to 
the immediate availability of the chloroiodomethane reagent in our laboratory. 
The bromo-derivative of 2-89 could be obtainable via a Finkelstein reaction 
with LiBr when necessary. A successful trial reaction with 2-
chloroacetophenone and TsNHNHTs (2-87) using Fukuyama’s conditions was 







Scheme 2.14. Preparation of α-chloro-diketone 2-89 from bicyclic lactam 2-40.  
 
Whilst organo-lithium species such as nBuLi and MeLi have been shown to 
react efficiently with the ketone-like lactam functionality[90], 
chloromethyllithium (prepared in-situ from chloroiodomethane and nBuLi) 
failed to react with the Bn-protected bicyclic lactam 2-40. An alternative route 
to prepare α-chloro-diketone 2-89 was necessitated beginning with lactone 
hemiacetal 2-59 (Scheme 2.15). The hemiacetal was first removed through 
NaBH4-mediated opening and reduction of the masked ketone. The resulting 
epimeric alcohol underwent lactonization during acidic work-up to afford 
lactone 2-90 in 76% yield. The treatment of 2-90 with chloromethyllithium at -
78 °C did not unduly open up the lactone and exposed the resulting α-
chloroketone towards further addition, but provided the chlorohydrin 
intermediate 2-91 instead in 62% yield.[91]  
After several attempts, a combination of PCC and NaOAc in CH2Cl2 was 
found to oxidize 2-91 (with ring opening) to the desired α-chloro-diketone 2-
89 in 78% yield. Thus, TsNHNHTs (2-87) was conveniently prepared in 74% 
yield from p-toluenesulfonyl hydrazide and p-toluenesulfonyl chloride 
according to the procedure reported by Fukuyama and coworkers (Figure 
2.6A).[89] With the reactant and reagent in hand, diazo substitution of the a-
chloro group was anticpated. The transformation of 2-89 to the α-diazoketone 
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2-39 was, however, sluggish to our disappointment. Although we observed 
partial formation of the α-N,N’-ditosylhydrazide (2-92) from 2-89, no 
spontaneous elimination of the sulfinic acids could occur to furnish the desired 
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Scheme 2.15. Synthesis of the α-chloro-diketone 2-89 and transformation to the α-
diazoketone 2-39 using Fukuyama’s TsNHNHTs reagent (2-87). 
 
2.9 Summary    
Our efforts to prepare the cage-like core in platensimycin 1-4 through a 
dirhodium(II)-catalyzed carbonyl ylide cycloaddition approach as synthetic 
strategy was unsuccessful thus far. Nontrivial laboratory scale preparation of 
the hazardous diazomethane reagent was optimized, and used in the 
preparation of the levulinic acid-derived α-diazoketone 2-7 via diazo 
substitution of a mixed anhydride species. Rh2(OAc)4-catalyzed one-pot 
carbonyl ylide cyclization and racemic cycloaddition between 2-7 and methyl 
propiolate (2-8) afforded a 4:1 regioselectivity with benzene as solvent in favor 
of the desired cycloadduct 2-15 over 2-16. After a series of uneventful 
functional group manipulations, the next essential cascade operation utilized a 
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radical-based cyclization of the α,β-unsaturated ketone 2-4, and tandem 
Michael-type addition with methyl vinyl ketone (2-8) as radical trap. This 
nontrivial process seemingly proved to be highly unfavorable towards the 
initial C8-C13 ring closure, and competing reactions were observed instead.  
Thus, we adopted a new game plan to stereoselectively construct the 
challenging C8 quaternary center in the initial stages of our second-generation 
synthesis, using Meyers’ bicyclic lactam chiral auxiliary technology. A single-
step intramolecular transformation of the α-diazoketone 2-39 into the 
oxatricyclic core 2-38 using Padwa’s dirhodium(II)-catalyzed carbonyl ylide 
cycloaddition methodology was conceived. Cleavage of the Meyers’ auxiliary 
unexpectedly afforded the 5-membered lactone hemiacetal 2-59 which 
disfavored the formation of the α-diazoketone 2-39 regardless of -Bn, -MOM 
or -Me protection on the C8 side-arm. The best result obtained, thus far, was 
through diazo substitution of the mixed anhydride (2-61) prepared with 2-59 
and ethyl chloroformate to provide 2-39 in 18% yield. The yield was, however, 
irreproducible and made the forward synthesis impractical.  
Considerable attempts to install the needed diazo functionality via different 
methods were also met with limited success. During our examination with 
Fukuyama’s procedure to prepare diazoacetates and diazoketones from their 
corresponding α-halo precursors, the resulting α-N,N’-ditosylhydrazide 2-92 
produced did not eliminate readily as anticipated to provide any desired 2-39. 
Continual efforts to pursue innovative methods to generate important carbonyl 
ylides as intramolecular [3+2] cycloaddition precursors for assembling the core 
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ketolide structure of platensimycin were carried out, and these are discussed in 






















General Procedures and Methods:  
Unless stated otherwise, all non-aqueous reactions were performed in flame-
dried round bottom flasks under an inert argon atmosphere with freshly 
distilled dry solvents under anhydrous conditions. Tetrahydrofuran (THF) was 
distilled over sodium/benzophenone. Diethyl ether (Et2O) was distilled over 
sodium wire. Dichloromethane (CH2Cl2), and 1,4-dioxane were distilled over 
CaH2. Methanol (MeOH) was distilled over magnesium activated by iodine 
crystals. Dry acetonitrile (CH3CN) and toluene were directly obtained from 
Glass Contour’s solvent dispensing system. Commercial reagents were 
purchased from Sigma Aldrich, Fluka, Merck, Alfa Aesar or Strem Chemicals, 
and used as received without further purification. (S)-TRIP was kindly donated 
by Professor List from Max-Planck-Institut für Kohlenforschung. 4Å 
molecular sieves were activated by heating in a furnace at 300 °C for 20 h 
before storing in a dry dessicator, which would be heated at 200 ºC under high 
vacuum for 15-20 min immediately prior to use.  
Yields refer to chromatographically and spectroscopically homogeneous 
materials, unless otherwise stated. Reaction progress was monitored by 
analytical thin layer chromatography (TLC) with 0.25 mm E. Merck pre-coated 
silica gel plates (60F-254) using UV light (254 nm) as visualizing agent, and 
ceric ammonium molybdate, KMnO4 or ninhydrin as developing stains. Flash 
chromatography was performed on silica gel 60 (0.040 – 0.063 mm) purchased 
from SiliCycle or ACME Research Support. Preparative thin layer 
chromatography (prep. TLC) was performed on 1 mm thickness Merck pre-
coated silica gel plates (60F-254). 1H NMR and 13C NMR spectra were 
recorded on Bruker AMX500 (500 MHz) and Bruker ACF300 (300 MHz) 
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NMR spectrometer at ambient atmosphere. 2D NOESY was performed on 
Bruker AMX500 (500 MHz) NMR spectrometer. Deuterated solvent used was 
CDCl3. Chemical shifts were reported in parts per million (ppm), and the 
residual undeuterated solvent peak was used as an internal reference: proton (δ 
7.26), carbon (δ 77.0). 1H NMR coupling constants (J) were reported in Hertz 
(Hz), and multiplicities were represented as follows: s (singlet), d (doublet), t 
(triplet), q (quartet), m (multiplet), dd (doublet of doublet), ddd (doublet of 
doublet of doublet), dt (doublet of triplet), td (triplet of doublet), and br 
(broad).  
Low resolution mass spectra were obtained on a Finnigan/MAT LCQ 
spectrometer in ESI mode, and a Micromass VG7035 double focusing mass 
spectrometer in EI-mode. High resolution ESI mass spectra were obtained on a 
Shimadzu LCMS-IT-TOF spectrometer, and high resolution EI mass spectra 
were obtained on a Micromass VG7035 double focusing mass spectrometer. 
Mass samples were dissolved in CH3CN (HPLC Grade), unless otherwise 
stated. Optical rotations were recorded on a Jasco DIP-1000 polarimeter with a 
sodium lamp of wavelength 589 nm. Single crystal X-ray diffraction analysis 
was obtained on a Bruker-AXS Smart Apex CCD single-crystal diffractometer. 
Enantiomeric excess was determined by chiral-phase HPLC analysis on 






Experimental Procedures and Characterization Data: 
 
Part I. Preparation of Diazomethane: Diazald 2-18 (39.05 g, 96%) was 
prepared from TsCl (36 g, 0.189 mol) according to the procedure[68] in 
“Vogel’s Textbook of Practical Organic Chemistry”. This experiment was 
conducted with minimum exposure to light to prevent early decomposition of 
the light sensitive diazomethane. To a solution of KOH (6.4 g) in H2O (9.6 mL) 
was added 96% EtOH (32 mL) and placed in a two-necked 250-mL round 
bottom flask (rbf-1). To one end was fitted with a fractional column [20 cm x 
3-3.5 cm (ID)] joined to a double surface condenser which opened into one end 
of another two-necked 250-mL rbf-2, and its other end was connected to a 
second two-necked 100-mL rbf-3 by means of Teflon tubing and glass tube 
connectors. The other end of rbf-3 was then fitted with a calcium chloride 
guard tube. Both rbfs-2 and 3 contained KOH pellets, and were immersed in 
ice-salt mixtures maintained below -10 °C. It was arranged that the inlet tube 
(adapted from a glass dropper) leading from rbf-2 to rbf-3 dipped below the 
surface of a charge of 16 mL of Et2O (HPLC). A solution of Diazald 2-18 (27.5 
g) in Et2O (HPLC, 160 mL) was placed in a dropping funnel fitted to the other 
end of rbf-1, and the etheral solution was introduced into the stirring solution 
of ethanolic KOH over a period of 30 min. After 5 min of addition, rbf-1 was 
heated in a water bath at 60-65 °C, and the bright yellow etheral solution of 
diazomethane began to distil over into the receiving flask (rbf-2). The rate of 
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addition was then adjusted to be approximately equal to the rate of distillation. 
Upon the completion of addition, an additional 20 mL of Et2O (HPLC) was 
added gradually until the Et2O distilling over became colourless. The combined 
etheral solutions of diazomethane collected in rbfs-2 and 3 was temporarily 
stoppered and stored at -20 °C for no longer than 2 h before the next step.  
Part II. α-Diazoketone 2-7 formation: To a solution of levulinic acid 2-14 
(2 mL, 19.5 mmol) in anhydrous Et2O (100 mL) was added Et3N (2.8 mL, 20.1 
mmol) and ethyl chloroformate (1.9 mL, 20.0 mmol) at 0 °C. The resulting 
mixture was stirred for 30-35 min at the same temperature before the Et3N·HCl 
salt was filtered under partial vacuum and continuous N2 flow. The filtrate was 
cooled to 0 °C, and the etheral solution of diazomethane was directly added in 
one portion. The resulting mixture was stirred at 0 °C to room temperature over 
16 h before the excess diazomethane was carefully bubbled off under a stream 
of N2 for 15-20 min. The remaining solvent was carefully concentrated in 
vacuo on the rotary evaporator with the water bath temperature kept at 28 °C. 
Flash column chromatography of the crude product over silica gel (10% 
EtOAc/hexane → 45% EtOAc/hexane) afforded α-diazoketone 2-7 (2.19 g, 
80%) as a bright yellow oil.  
2-7: 1H NMR (300 MHz, CDCl3): δ 5.29 (brs, 1H), 2.79 (t, J = 6.3 Hz, 2H), 
2.59 (brs, 2H), 2.18 (s, 3H); 13C NMR (75 MHz, CDCl3): δ 207.0, 193.2, 54.6, 





















Oxabicyclo[3.2.1]octene cycloadduct 2-15: Benzene was distilled over 
Na/benzophenone, and stored over activated 4Å MS. To a solution of α-
diazoketone 2-7 (1.3 g, 9.28 mmol) in benzene (180 mL) was added methyl 
propiolate 2-8 (2.48 mL, 27.9 mmol). The solution was degassed by purging 
the solvent with a continuous stream of Ar for 45 min before Rh2(OAc)4 (41 
mg, 0.0928 mmol) was added at room temperature. Bubbles (of N2) were 
liberated within 1-2 min. The resulting mixture was stirred at room temperature 
for 1 h in which (1) the bubbling has ceased, and (2) the yellowish colour (from 
2-7) has disappeared. Benzene was removed in vacuo, and flash column 
chromatography of the crude product over silica gel (hexane → 4% 
EtOAc/hexane → 10% EtOAc/hexane) afforded the desired 1,3-dipolar 
cycloadduct 2-15 (1.19 g, 66%), and further elution (12% EtOAc/hexane) 
afforded the undesired regio-isomer 2-16 (0.298 g, 16%) as pale yellow oils.   
2-15 (major): 1H NMR (300 MHz, CDCl3): δ 7.02 (d, J = 2.3 Hz, 1H), 4.67 
(s, 1H), 3.81 (s, 3H), 2.70-2.59 (m, 1H), 2.54-2.44 (m, 1H), 2.21-2.15 (m, 2H), 
1.65 (s, 3H); 13C NMR (75 MHz, CDCl3): 201.3, 163.1, 141.6, 139.8, 85.7, 
51.9, 33.1, 32.8, 31.5, 22.8; ESI-MS: m/z calcd for C10H12O4Na+ [M + Na]+ 
219.1, found 219.3.  
2-16 (minor): 1H NMR (300 MHz, CDCl3): δ 7.04 (s, 1H), 4.81 (s, 1H), 
3.77 (s, 3H), 2.75-2.64 (m, 1H), 2.52-2.43 (m, 1H), 2.31-2.21 (m, 1H), 1.99-
1.91 (m, 1H), 1.53 (s, 3H); 13C NMR (75 MHz, CDCl3): δ 200.5, 162.2, 147.4, 
80 
 
136.4, 86.5, 85.8, 52.2, 32.3, 32.6, 23.2; ESI-MS: m/z calcd for C10H12O4Na+ 
[M + Na]+ 219.1, found 219.1. 
 
endo-Methyl ester 2-6: To a solution of α,β-unsaturated methyl ester 2-15 
(1.19 g, 6.07 mmol) in EtOAc (AR, 60 mL) was added 10% Pd-C (5 wt%, 59.5 
mg) at room temperature. The resulting mixture was stirred under a hydrogen 
atmosphere (balloon) for 12 h before it was filtered through a pad of Celite, 
eluted with EtOAc and concentrated in vacuo. Flash column chromatography 
of the crude product over silica gel (hexane → 10% EtOAc/hexane) afforded 
endo-methyl ester 2-6 (1.08 g, 90%) as a pale yellow oil.   
2-6 (Appendix 5, p368): 1H NMR (300 MHz, CDCl3): δ 4.28 (d, J = 8.4 Hz, 
1H), 3.77 (s, 3H), 3.04-2.98 (m, 1H), 2.73-2.55 (m, 1H), 2.53-2.38 (m, 2H), 
2.36-2.28 (m, 1H), 2.08-1.97 (m, 1H), 1.94-1.87 (m, 1H), 1.57 (s, 3H); 13C 
NMR (75 MHz, CDCl3): δ 206.2, 172.0, 82.0, 81.2, 52.11, 52.07, 33.6, 31.9, 












endo-Keto-acid 2-17: To a solution of methyl ester 2-6 (0.47 g, 2.37 mmol) 
in THF (9 mL) and H2O (3 mL) was added LiOH (0.17 g, 7.11 mmol) at 0 °C. 
The resulting mixture was stirred at 0 °C to room temperature over 2 h before it 
was diluted with water, and extracted with CH2Cl2 (2x). The aqueous layer was 
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acidified with 1M HCl, and extracted with EtOAc (3x). The combined EtOAc 
extracts were washed with water (1x), followed by brine, dried over Na2SO4, 
filtered, and concentrated in vacuo to afford the keto-acid 2-17 (0.336 g, 77%) 
as a pale yellow viscous oil. 2-17 was carried forward to the next step without 
further purification.     
2-17: 1H NMR (300 MHz, CDCl3): δ 8.64 (brs, 1H), 4.30 (d, J = 8.5 Hz, 
1H), 3.10-3.04 (m, 1H), 2.71-2.48 (m, 2H), 2.41-2.31 (m, 2H), 2.10-2.05 (m, 
2H), 1.60 (s, 3H); 13C NMR (75 MHz, CDCl3): δ 207.0, 177.0, 83.6, 82.4, 81.3, 
52.4, 33.4, 32.1, 31.7, 26.2, 26.0; ESI-MS: m/z calcd for C9H11O4- [M – H]- 
183.1, found 183.3. 
 
Diol 2-20: To a solution of keto-acid 2-17 (78.2 mg, 0.425 mmol) in THF (4 
mL) was added 1M BH3·THF in THF (1.2 mL) at 0 °C. The resulting mixture 
was stirred at 0 °C to room temperature over 16 h before the excess BH3·THF 
complex was carefully quenched with MeOH in a cold water bath. The mixture 
was concentrated in vacuo, followed by partitioned between 1M HCl and 
EtOAc. The organic layer was separated, and the aqueous layer was extracted 
with EtOAc (3x). The combined organic layers were washed with brine, dried 
over Na2SO4, filtered, and concentrated in vacuo. Flash column 
chromatography of the crude product over silica gel (50% EtOAc/hexane → 
EtOAc → 5% MeOH/EtOAc) afforded an inconsequential diastereomeric 
mixture of diol 2-20 (65.8 mg, 90%) as a colourless sticky oil. 
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2-20: 1H NMR (300 MHz, CDCl3): δ 4.18 (brs, 1H), 3.89-3.84 (m, 1H), 
3.79-3.74 (m, 1H), 3.70-3.65 (m, 2H), 2.16 (m, 2H), 1.88-1.84 (m, 1H), 1.68-
1.62 (m, 3H), 1.59-1.44 (m, 1H), 1.29 (s, 3H); 13C NMR (75 MHz, CDCl3): δ 
80.2, 67.7, 61.9, 49.9, 31.9, 28.5, 26.5, 25.8; ESI-MS: m/z calcd for 
C9H16O3Na+ [M + Na]+ 195.1, found 195.2. 
 
Keto-tosylate 2-21: To a solution of diol 2-20 (0.14 g, 0.813 mmol) in 
CH2Cl2 (8 mL) was added Et3N (0.67 mL, 4.81 mmol), DMAP (20 mg, 0.164 
mmol), and TsCl (0.324 g, 1.70 mmol) at 0 °C. The resulting mixture was 
stirred at room temperature for 20 h before it was diluted with water, and 
extracted with EtOAc (3x). The combined organic extracts were washed with 
saturated aq. NaHCO3 (1x) and water (1x), followed by brine, dried over 
Na2SO4, filtered, and concentrated in vacuo. Flash column chromatography of 
the crude product over silica gel (10% EtOAc/hexane → 45% EtOAc/hexane 
→ 70% EtOAc/hexane) afforded an inconsequential diastereomeric mixture of 
mono-tosylated diol (0.182 g, 69%) as a yellow oil.  
  To a solution of this mono-tosylated diol (0.182 g, 0.558 mmol) in CH2Cl2 
(6 mL) was added NaHCO3 (0.352 g, 4.19 mmol) and Dess-Martin (0.715 g, 
1.69 mmol) at room temperature. The resulting mixture was stirred at room 
temperature for 3 h before it was quenched with saturated aq. NaHCO3 and 
saturated aq. Na2S2O3 solutions (1:1), and stirred at room temperature to obtain 
a clear solution. The mixture was diluted with water, and extracted with EtOAc 
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(3x). The combined organic extracts were washed with brine, dried over 
Na2SO4, filtered, and concentrated in vacuo. Flash column chromatography of 
the crude product over silica gel (10% EtOAc/hexane → 28% EtOAc/hexane) 
afforded keto-tosylate 2-21 (0.176 g, 97%) as a pale yellow solid. 
2-21: mp 81.4-84.4 °C; 1H NMR (300 MHz, CDCl3): δ 7.78 (d, J = 8.4, 1H), 
7.36 (d, J = 8.1, 1H), 4.21-4.08 (m, 3H), 2.50-2.30 (m, 7H), 2.05-1.86 (m, 2H), 
1.49-1.43 (m, 1H), 1.39 (s, 3H); 13C NMR (75 MHz, CDCl3): δ 206.7, 145.3, 
132.4, 130.0, 127.8, 81.2, 80.5, 69.2, 45.7, 32.2, 31.9, 31.4, 26.2, 21.6; ESI-
MS: m/z calcd for C16H20O5SNa+ [M + Na]+ 347.1, found 347.1. 
 
Keto-phenyl sulfide 2-22: To a solution of keto-tosylate 2-21 (0.11 g, 
0.339 mmol) in anhydrous DMSO (4.5 mL) was added anhydrous K2CO3 
(0.116 g, 0.839 mmol) and PhSH (56 µL, 0.549 mmol) at room temperature. 
The resulting mixture was stirred at room temperature for 18 h before it was 
diluted with water, and extracted with Et2O (3x). The combined organic 
extracts were washed with water (1x), followed by brine, dried over Na2SO4, 
filtered, and concentrated in vacuo. Flash column chromatography of the crude 
product over silica gel (5% EtOAc/hexane → 12% EtOAc/hexane) afforded 
keto-phenyl sulfide 2-22 (62.3 mg, 70%) as a colourless oil. 
2-22: 1H NMR (300 MHz, CDCl3): δ 7.38-7.20 (m, 5H), 4.21 (d, J = 8.7 Hz, 
1H), 3.15-2.92 (m, 2H), 2.69-2.22 (m, 4H), 2.14-1.97 (m, 1H), 1.41 (s, 3H); 
13C NMR (75 MHz, CDCl3): δ 207.2, 135.4, 129.8, 129.1, 126.7, 81.7, 80.5, 
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46.3, 35.7, 35.6, 32.1, 31.6, 25.6; ESI-MS: m/z calcd for C15H18O2SNa+ [M + 
Na]+ 285.1, found 285.0. 
 
Keto-phenyl sulfide α-methylene 2-4: To a solution of keto-phenyl sulfide 
2-22 (78 mg, 0.297 mmol) in THF was added 1M LiHMDS in THF (0.8 mL) at 
-78 °C. The resulting mixture was stirred at the same temperature for 30 min 
before the addition of TESCl (0.16 mL, 0.953 mmol) at -78 °C, and stirred for 
a further 45 min before it was warmed to 0 °C for 5-10 min. The reaction was 
quenched with saturated aq. NaHCO3, diluted with water, and extracted with 
Et2O (3x). The combined organic extracts were washed with brine, dried over 
Na2SO4, filtered, and concentrated in vacuo. The crude silyl enol ether was 
azeotroped twice with (dry) THF, and placed under high vacuum pull for 1 h 
which was used in the next step without further purification.  
To this crude silyl enol ether in CH2Cl2 (2 mL) was added Eschenmoser’salt 
(0.172 g, 0.930 mmol) in a N2-filled Aldrich® AtmosBag glove bag at room 
temperature. The resulting mixture was stirred at room temperature for 14 h 
before it was quenched with 2M HCl to pH 1-2, and stirred for 30 min. The 
mixture was extracted with Et2O (3x) to remove any starting material 2-22 
and/or impurities. The aqueous layer was basified with 3M NaOH to pH 11-12, 
and stirred for 1 h at room temperature before it was extracted with CH2Cl2 
(3x). The combined CH2Cl2 extracts were washed with water (1x), followed by 
brine, dried over Na2SO4, filtered, and concentrated in vacuo. Flash column 
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chromatography of the crude product over silica gel (hexane → 10% 
EtOAc/hexane) afforded keto-phenyl sulfide α-methylene 2-4 (41.6 mg, 51% 
over two steps) as a colourless oil. 
2-4 (Appendix 5, p369): 1H NMR (300 MHz, CDCl3): δ 7.28-7.16 (m, 5H), 
6.14 (brs, 1H), 5.32 (brs, 1H), 4.36 (d, J = 8.0 Hz, 1H), 3.01-2.57 (m, 5H), 
2.28-2.17 (m, 1H), 1.56-1.49 (m, 1H), 1.41 (s, 3H); 13C NMR (75 MHz, 
CDCl3): δ 196.8, 138.4, 135.4, 129.6, 129.1, 126.6, 124.2, 82.7, 80.1, 45.9, 
39.0, 36.5, 35.9, 26.2; ESI-MS: m/z calcd for C16H18O2SNa+ [M + Na]+ 297.1, 
found 297.2. 
 
L-Valinol 2-42[76]: NaBH4 (2.37 g, 62.6 mmol) was suspended in THF (69 
mL), followed by the addition L-valine (3 g, 25.6 mmol) at room temperature. 
The resulting suspension was cooled to 0 °C before a solution of I2 (6.5 g, 25.6 
mmol) in THF (17 mL) was slowly added to the stirring suspension over a 15-
20 min period via an addition funnel. After addition of the I2 solution was 
completed and gas evolution has ceased, the resulting mixture was heated to 
reflux for 18 h, and then cooled to room temperature. MeOH was added 
cautiously until the mixture became clear, and the solution was stirred for 30 
min before it was concentrated in vacuo. The residue was dissolved in 20% aq. 
KOH solution (50 mL), and stirred for 4 h. The aqueous layer was extracted 
with CH2Cl2 (3x), and the combined organic extracts were washed with brine, 
dried over Na2SO4, filtered, and concentrated in vacuo. The crude product was 
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purified by distillation under reduced pressures in an oil bath heated at 120-125 
°C to afford L-valinol 2-42 (1.62 g, 61%) as a white solid (lit. 81 °C/8 mm).  
2-42: 1H NMR (300 MHz, CDCl3): δ 3.62 (dd, J = 3.8, 10.5 Hz, 1H), 3.28 
(dd, J = 8.7, 10.5 Hz, 1H), 2.58-2.51 (m, 1H), 2.10 (brs, 1H), 1.64-1.48 (m, 
1H), 0.91 (d, J = 3.8 Hz, 3H), 0.89 (d, J = 3.6 Hz, 3H); ESI-MS: m/z calcd for 
C5H13ONNa+ [M + Na]+ 126.1, found 126.2. 
 
Meyers’ bicyclic lactam 2-41[75b]: To a stirring mixture of levulinic acid 2-
14 (1.61 mL, 15.7 mmol) and L-valinol 2-42 (1.62 g, 15.7 mmol) in toluene 
(HPLC, 200 mL) was refluxed under Dean-Stark conditions for 40 h. The 
resulting solution was cooled to room temperature and concentrated in vacuo. 
Flash column chromatography of the crude product over silica gel (10% 
EtOAc/hexane → 35% EtOAc/hexane) afforded Meyers’ bicyclic lactam 2-41 
(2.73 g, 95%) as a colourless oil. 
2-41: 1H NMR (300 MHz, CDCl3): δ 4.14 (dd, J = 7.6, 8.7 Hz, 1H), 3.84 
(dd, J = 6.2, 8.7 Hz, 1H), 3.62-3.54 (m, 1H), 2.79-2.67 (m, 1H), 2.50-2.40 (m, 
1H), 2.17-2.12 (m, 2H), 1.72-1.59 (m, 1H), 1.46 (s, 3H), 1.02 (d, J = 6.7 Hz, 
3H), 0.88 (d, J = 6.6 Hz, 3H); 13C NMR (75 MHz, CDCl3): δ 178.9, 99.9, 70.9, 
61.6, 33.9, 33.4, 32.9, 24.9, 20.5, 19.0; ESI-MS: m/z calcd for C10H17O2NNa+ 






















    Allylated bicyclic lactams 2-49 and 2-50: LDA was prepared by the 
addition of 1.35M nBuLi in hexanes (2.5 mL, 3.37 mmol) to a solution of 
iPr2NH (0.51 mL, 3.63 mmol) in THF (9.2 mL) at 0 °C, and stirred for 35 min 
at the same temperature. To a solution of Meyers’ bicyclic lactam 2-41 (0.51 g, 
2.78 mmol) in THF (17 mL) was added a solution of LDA in THF (3.37 mmol) 
at -78 °C. The resulting mixture was stirred at -78 °C for 1.5 h before the 
addition of allyl bromide (0.33 mL, 3.76 mmol) at the same temperature. The 
mixture was stirred at -78 °C to -40 °C over 6 h before it was quenched with 
saturated aq. NH4Cl, and briefly stirred at room temperature. The mixture was 
diluted with water, and extracted with CH2Cl2 (3x). The combined organic 
extracts were washed with brine, dried over Na2SO4, filtered, and concentrated 
in vacuo. Flash column chromatography of the crude product over silica gel 
(5% EtOAc/hexane → 15% EtOAc/hexane → 27% EtOAc/hexane) afforded 
an inconsequential (separable) diastereomeric mixture of allylated bicyclic 
lactams 2-49 and 2-50 (3:1 dr at C8, 0.59 g, 95%) as a pale yellow oil. 
endo-2-49: 1H NMR (300 MHz, CDCl3): δ 5.85-5.68 (m, 1H), 5.10-5.01 (m, 
2H), 4.14 (dd, J = 7.2, 8.7 Hz, 1H), 3.85 (dd, J = 6.2, 8.7 Hz, 1H), 3.63-3.55 
(m, 1H), 2.96-2.85 (m, 1H), 2.64-2.56 (m, 1H), 2.39-2.29 (m, 1H), 2.17-2.07 
(m, 1H), 1.88-1.80 (m, 1H), 1.71-1.59 (m, 1H), 1.46 (s, 3H), 1.02 (d, J = 6.7 
Hz, 3H), 0.88 (d, J = 6.6 Hz, 3H); 13C NMR (75 MHz, CDCl3): δ 178.8, 135.4, 
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116.8, 97.5, 70.9, 61.2, 43.8, 41.4, 34.7, 33.4, 24.9, 20.5, 19.0; ESI-MS: m/z 
calcd for C13H21O2NNa+ [M + Na]+ 246.1, found 246.3. 
 
exo-Ethyl ester 2-51: LDA was prepared by the addition of 1.3M nBuLi in 
hexanes (4.0 mL, 5.20 mmol) to a solution of iPr2NH (0.8 mL, 5.69 mmol) in 
THF (14 mL) at 0 °C, and stirred for 35 min at the same temperature. To a 
solution of the inconsequential mixture of bicyclic lactams 2-49/50 (0.52 g, 
2.33 mmol) in THF (20 mL) was added a solution of LDA in THF (5.20 mmol) 
at -78 °C. The resulting mixture was stirred at -78 °C for 2 h before the 
addition of ethyl chloroformate (0.67 mL, 7.04 mmol) at the same temperature. 
The mixture was left to stir at -78 °C to room temperature over 12 h before it 
was quenched with saturated aq. NH4Cl. The mixture was diluted with water, 
and extracted with CH2Cl2 (3x). The combined organic extracts were washed 
with brine, dried over Na2SO4, filtered, and concentrated in vacuo. Flash 
column chromatography of the crude product over silica gel (hexane → 6% 
EtOAc/hexane → 12% EtOAc/hexane) afforded the only exo-selective 
diastereomer ethyl ester 2-51 (0.612 g, 89%) as a colourless viscous oil. 
2-51: 1H NMR (300 MHz, CDCl3): δ 5.71-5.58 (m, 1H), 5.14-5.08 (m, 2H), 
4.26-4.19 (m, 3H), 3.82 (dd, J = 6.9, 8.9 Hz, 1H), 3.64-3.56 (m, 1H), 2.79-2.68 
(m, 2H), 2.48 (dd, J = 6.9, 13.9 Hz, 1H), 2.17 (d, J = 13.6 Hz, 1H), 1.71-1.59 
(m, 1H), 1.51 (s, 3H), 1.27, (t, J = 7.1 Hz, 3H), 1.02 (d, J = 6.6 Hz, 3H), 0.87 
(d, J = 6.7 Hz, 3H); 13C NMR (75 MHz, CDCl3): δ 175.1, 171.0, 132.6, 119.3, 
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97.1, 71.1, 61.8, 61.5, 59.4, 42.7, 39.3, 34.0, 24.5, 20.5, 18.9; ESI-MS: m/z 
calcd for C16H25O4NNa+ [M + Na]+ 318.2, found 318.2. 
 
Hydroxy methyl bicyclic lactam 2-52: To a stirring solution of exo-ethyl 
ester 2-51 (0.225 g, 0.762 mmol) in absolute EtOH (6 mL) was added 2M 
CuSO4 aqueous solution (38.1 µL, 76.2 µmol) at room temperature. The 
resulting mixture was cooled to 0 °C before the addition of NaBH4 (0.144 g, 
3.81 mmol), and stirred at room temperature for 40 min. Black deposits were 
formed, and the reaction mixture was heated to reflux for a further 2 h. The 
reaction was cooled to room temperature before EtOH was removed on the 
rotary evaporator. The residue was partitioned between EtOAc and water, and 
the aqueous layer was then separated. The organic layer was washed with 
water (1x), followed by brine, dried over Na2SO4, filtered, and concentrated in 
vacuo. Flash column chromatography of the crude product over silica gel (5% 
EtOAc/hexane → 16% EtOAc/hexane → 35% EtOAc/hexane) afforded 
alcohol 2-52 (0.168 g, 87%) as a colourless sticky oil. 
2-52: 1H NMR (300 MHz, CDCl3): δ 5.73-5.59 (m, 1H), 5.13-5.08 (m, 2H), 
4.18 (m, 1H), 3.79-3.71 (m, 2H), 3.60-3.52 (m, 2H), 2.37-2.22 (m, 3H), 2.07 
(d, J = 13.9 Hz, 1H), 2.01 (brs, 1H), 1.71-1.59 (m, 1H), 1.49 (s, 3H), 1.05 (d, J 
= 6.6 Hz, 3H), 0.88 (d, J = 6.6 Hz, 3H); 13C NMR (75 MHz, CDCl3): δ 182.3, 
133.1, 119.0, 97.4, 70.4, 67.5, 62.6, 53.4, 40.2, 38.5, 34.1, 25.1, 20.9, 18.6; 




Benzyloxy methyl bicyclic lactam 2-40: To a solution of hydroxy methyl 
bicyclic lactam 2-52 (0.259 g, 1.02 mmol) in THF (5 mL) was added NaH 
(60% dispersion in mineral oil, 90 mg, 2.25 mmol) at 0 °C. The resulting 
mixture was stirred at the same temperature for 30 min before BnBr (0.17 mL, 
1.43 mmol) and TBAI (38 mg, 0.103 mmol) were added, and the final mixture 
was stirred at room temperature for 12 h. The reaction was quenched with 
saturated aq. NH4Cl, and diluted with water before it was extracted with Et2O 
(3x). The combined organic extracts were washed with water (1x), followed by 
brine, dried over Na2SO4, filtered, and concentrated in vacuo. Flash column 
chromatography of the crude product over silica gel (5% EtOAc/hexane → 
15% EtOAc/hexane) afforded benzyloxy methyl bicyclic lactam 2-40 (0.341 g, 
97%) as a pale yellow oil.    
2-40 (Appendix 5, p370): 1H NMR (300 MHz, CDCl3): δ 7.33-7.26 (m, 
5H), 5.70-5.56 (m, 1H), 5.09-5.04 (m, 2H), 4.58-4.47 (m, 2H), 4.19-4.13 (m, 
1H), 3.78-3.72 (m, 1H), 3.62-3.54 (m, 2H), 3.40 (d, J = 8.9 Hz, 1H), 2.35-2.15 
(m, 4H), 1.69-1.61 (m, 1H), 1.43 (s, 3H), 1.08 (d, J = 6.7 Hz, 3H), 0.88 (d, J = 
6.7 Hz, 3H); 13C NMR (75 MHz, CDCl3): δ 181.3, 138.2, 133.3, 128.3, 127.53, 
127.45, 118.8, 97.4, 74.9, 73.3, 70.4, 62.3, 52.9, 40.8, 39.1, 34.3, 24.8, 20.8, 




Butylated bicyclic lactam 2-54: Byproduct obtained 
when ethyl ester 2-51 was over-reduced with NaBH4-
CuSO4 system. Bn-protection of the hydroxyl group as 
a mixture with 2-52 was repeated, as described, followed by column 
chromatography (5% EtOAc/hexane → 12% EtOAc/hexane → 15% 
EtOAc/hexane) with slower elution provided 2-54 as a colourless sticky oil. 
2:54: 1H NMR (300 MHz, CDCl3): δ 7.28-7.22 (m, 5H), 4.56 (d, J = 12.0 Hz, 
1H), 4.47 (d, J = 12.0 Hz, 1H), 4.15-4.10 (m, 1H), 3.73-3.68 (m, 1H), 3.58-
3.49 (m, 2H), 3.33 (d, J = 8.7 Hz, 1H), 2.23-2.11 (m, 2H), 1.61-1.53 (m, 1H), 
1.42-1.18 (m, 7H), 1.04 (d, J = 6.7 Hz, 3H), 0.84-0.80 (m, 6H); 13C NMR (75 
MHz, CDCl3): δ 182.1, 138.2, 128.2, 127.44, 127.39, 97.4, 75.3, 73.2, 70.3, 
62.4, 53.1, 40.9, 36.7, 34.4, 24.7, 20.8, 18.9, 17.4, 14.4; ESI-MS: m/z calcd for 
C21H31O3NNa+ [M + Na]+ 368.2, found 368.1. 
 
 p-Bromo-benzoate ester 2-55: To a solution of hydroxy methyl bicyclic 
lactam 2-52 (37 mg, 0.146 mmol) in CH2Cl2 (7 mL) was added pyridine (19 
µL, 0.235 mmol), DMAP (20 mol%), and p-bromo-benzoyl chloride (39 mg, 
0.178 mmol) at room temperature. The resulting mixture was stirred at room 
temperature for 16 h before it was quenched with saturated aq. NH4Cl. The 
mixture was diluted with water, and extracted with CH2Cl2 (3x). The combined 
organic extracts were washed with brine, dried over Na2SO4, filtered, and 








silica gel (5% EtOAc/hexane → 18% EtOAc/hexane) afforded p-bromo-
benzoate ester 2-55 (38.9 mg, 61%) as a pale yellow viscous oil.    
2-55: 1H NMR (300 MHz, CDCl3): δ 7.88 (d, J = 8.7 Hz, 2H), 7.58 (d, J = 
8.7 Hz, 2H), 5.75-5.61 (m, 1H), 5.17-5.12 (m, 2H), 4.44 (d, J = 10.8 Hz, 1H), 
4.31 (d, J = 11.1 Hz, 1H), 4.22-4.16 (m, 1H), 3.80-3.75 (m, 1H), 3.67-3.58 (m, 
1H), 2.46-2.31 (m, 3H), 2.10 (d, J = 14.3 Hz, 1H), 1.74-1.60 (m, 1H), 1.44 (s, 
3H), 1.09 (d, J = 6.6 Hz, 3H), 0.90 (d, J = 6.6 Hz, 3H); 13C NMR (75 MHz, 
CDCl3): δ 180.7, 165.4, 132.4, 131.8, 131.1, 128.4, 119.6, 97.0, 70.3, 68.7, 
62.7, 51.4, 40.4, 39.2, 34.2, 25.2, 20.7, 18.9; EI-MS: m/z calcd for 
C21H26O4N79Br+ [M]+ 435.1, found 435.1, and m/z calcd for C21H26O4N81Br+ 
[M]+ 437.1, found 437.1 (intensity ratio ~1:1). 
Representative Procedure for the Preparation of Lactone Hemiacetals (2-
59/70/73) via Reductive-Hydrolytic Cleavage: 
 
 Part I. Keto-aldehyde 2-58: To a solution of benzyloxy methyl bicyclic 
lactam 2-40 (0.642 g, 1.87 mmol) in THF (24 mL) was added 2.7M Red-Al in 
toluene (2.1 mL, 5.67 mmol) at -78 °C. The resulting mixture was stirred at -78 
°C for 5-10 min before the temperature of the reaction was raised to -20 °C, 
and stirred at the same temperature for 48 h. Excess Red-Al was quenched with 
MeOH at -20 °C, and stirred at room temperature for 1 h. Solvent was removed 
on the rotary evaporator, and the residue was partitioned between water and 
Et2O. The organic layer was separated, and the aqueous layer was extracted 
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with Et2O (2x). The aqueous layer was then basified to pH 12-13 with 10% 
NaOH, and further extracted with Et2O (2x). The combined organic layers 
were washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo 
to afford carbinolamine 2-57 (0.664 g, quantitative conversion) as a colourless 
sticky oil. 
To a solution of this crude carbinolamine 2-57 (0.664 g) in EtOH (94 mL) 
was added 1M nBu4H2PO4 aqueous solution (94 mL) at room temperature. The 
resulting mixture was stirred at room temperature for 40 h before it was 
concentrated to half its volume in vacuo. The resulting solution was diluted 
with water, and extracted with Et2O (3x). The combined organic extracts were 
washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo. 
Flash column chromatography of the crude product over silica gel (10% 
EtOAc/hexane → 25% EtOAc/hexane) afforded keto-aldehyde 2-58 (0.396 g, 
81% over two steps) as a colourless oil.    
2-58: 1H NMR (300 MHz, CDCl3): δ 9.64 (s, 1H), 7.36-7.25 (m, 5H), 5.67-
5.56 (m, 1H), 5.10-5.03 (m, 2H), 4.50-4.44 (m, 2H), 3.67-3.55 (m, 2H), 2.88-
2.73 (m, 2H), 2.50 (dd, J = 7.6, 13.8 Hz, 1H), 2.40 (dd, J = 7.6, 13.8 Hz, 1H), 
2.11 (s, 3H); 13C NMR (75 MHz, CDCl3): δ 206.6, 204.0, 137.8, 132.2, 128.4, 
127.7, 127.6, 119.3, 73.5, 71.1, 51.8, 44.4, 35.2, 30.5; EI-MS: m/z calcd for 






Part II. Lactone hemiacetal 2-59: To a stirring solution of keto-aldehyde 
2-58 (0.231 g, 0.888 mmol) and 2-methyl-2-butene (1.2 mL) in THF (10 mL) 
and t-BuOH (10 mL) was slowly added an ice-cold aqueous solution of 
NaClO2 (0.281 g, 3.11 mmol) and NaH2PO4 (0.852 g, 7.10 mmol) in H2O (5 
mL) at room temperature. The resulting mixture was stirred at room 
temperature for 12 h before it was quenched with pH 2 KH2PO4-HCl buffer. 
The mixture was then extracted with EtOAc (4x), and the combined organic 
extracts were washed with brine, dried over Na2SO4, filtered, and concentrated 
in vacuo. Flash column chromatography of the crude product over silica gel 
(10% EtOAc/hexane → 40% EtOAc/hexane) afforded lactone hemiacetal 2-59 
(0.228 g, 93%) as a colourless oil.    
2-59 (Appendix 5, p371): 1H NMR (300 MHz, CDCl3): δ 7.40-7.28 (m, 
5H), 5.70-5.53 (m, 1H), 5.29-5.10 (m, 2H), 4.66-4.51 (m, 2H), 3.73 (d, J = 8.5 
Hz, 1H), 3.49 (d, J = 8.4 Hz, 1H), 2.43-2.11 (m, 4H), 1.60 (s, 3H); 13C NMR 
(75 MHz, CDCl3): δ 178.4, 135.7, 131.5, 128.8, 128.6, 128.1, 120.4, 104.4, 
74.9, 74.2, 49.9, 43.2, 38.3, 26.5; EI-MS: m/z calcd for C16H20O4+ [M]+ 276.1, 
found 276.1. 
Keto-acid 2-60: Desired keto-acid 2-60 was only 
observed in DMSO-d6. 2-60: 1H NMR (300 MHz, 
DMSO-d6): δ 12.29 (broad hump, 1H), 7.34-7.27 (m, 








2.76-2.72 (m, 1H), 2.36-2.33 (m, 2H), 2.03 (s, 3H); 13C NMR (75 MHz, 
DMSO-d6): δ 206.2, 175.0, 138.3, 133.6, 128.2, 127.43, 127.36, 118.2, 72.4, 
70.9, 47.4, 45.0, 37.8, 30.4.  
Lactone hemiacetal 2-70: (I) The reductive cleavage 
protocol was repeated for MOM-protected hydroxy 
methyl bicyclic lactam 2-68 (89 mg, 0.299 mmol), and 
flash column chromatography of the crude product over silica gel (hexane → 
12% EtOAc/hexane → 30% EtOAc/hexane) afforded keto-aldehyde 2-69 (32.7 
mg, 51% over two steps) as a pale yellow oil. (II) This keto-aldehyde 2-69 was 
subjected to the same Pinnick oxidation conditions as described, and flash 
column chromatography of the crude product over silica gel (10% 
EtOAc/hexane → 40% EtOAc/hexane) afforded lactone hemiacetal 2-70 (33.0 
mg, 94%) as a colourless oil. 2-70: 1H NMR (500 MHz, CDCl3): δ 5.67-5.59 
(m, 1H), 5.39 (brs, 1H), 5.19-5.13 (m, 2H), 4.66 (s, 2H), 3.79 (d, J = 9.4 Hz, 
1H), 3.51 (d, J = 9.4 Hz, 1H), 3.35 (s, 3H), 2.44-2.42 (m, 2H), 2.25-2.22 (m, 
2H), 1.61 (s, 3H); 13C NMR (125 MHz, CDCl3): δ 178.2, 131.4, 120.5, 104.3, 
96.4, 72.0, 56.0, 49.6, 43.2, 38.5, 26.5; EI-MS: m/z calcd for C11H18O5+ [M]+ 
230.1, found 230.1. 
Lactone hemiacetal 2-73: (I) The reductive cleavage 
protocol was repeated for Me-protected hydroxy methyl 
bicyclic lactam 2-71 (0.2 g, 0.748 mmol), and flash column 
chromatography of the crude product over silica gel (5% EtOAc/hexane → 
20% EtOAc/hexane) afforded keto-aldehyde 2-72 (0.124 g, 90% over two 













same Pinnick oxidation conditions as described, and flash column 
chromatography of the crude product over silica gel (10% EtOAc/hexane → 
35% EtOAc/hexane) afforded lactone hemiacetal 2-73 (0.127 g, 94%) as a 
colourless oil. 2-73: 1H NMR (300 MHz, CDCl3): δ 5.71-5.63 (m, 1H), 5.21-
5.12 (m, 2H), 3.62 (d, J = 8.5 Hz, 1H), 3.45-3.38 (m, 4H), 2.43-2.34 (m, 2H), 
2.24-2.15 (m, 2H), 1.61 (s, 3H); EI-MS: m/z calcd for C10H16O4+ [M]+ 200.1, 
found 200.2. 
Representative Procedure for the Preparation of α-Diazoketones 2-39/75: 
 
Benzyloxy α-diazoketone 2-39:  For smaller quantities of diazomethane, 
a simpler set-up for its preparation was adopted. To a solution of Diazald 2-18 
(2.5 g, 11.7 mmol) in Et2O (HPLC, 35 mL) was added a solution of KOH (0.65 
g) in 96% EtOH (12 mL) at 0 °C. The resulting mixture was stirred at 0 °C for 
5 min before the bright yellow etheral diazomethane solution was distilled 
from a water bath at 55-60 °C, and collected in the receiving flask immersed in 
an ice-salt bath maintained below -10 °C. The etheral solution was dried with 
KOH pellets, and kept at -20 °C no longer than 2 h before the next step.   
To a solution of lactone hemiacetal 2-59 (40 mg, 0.145 mmol) in THF (1.5 
mL) was added KOtBu (25.5 mg, 0.227 mmol) under an Ar atmosphere at -10 
°C in an ice-salt bath. The resulting mixture was stirred at the same 
temperature for 10-15 min, and the solution gradually became pale yellowish. 
To the mixture was then added ethyl chloroformate (15 µL, 0.156 mmol) at -10 
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°C and stirred for 15 min before the temperature was raised to 0 °C and stirred 
for a further 15 min. Water was added to quench the reaction, and the aqueous 
mixture was extracted with CH2Cl2 (3x). The combined organic extracts were 
washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo. The 
crude mixed anhydride was azeotroped twice with (dry) THF, and placed under 
high vacuum pull for 1 h which was directly used in the subsequent step. 
To a solution of this crude mixed anhydride in CH2Cl2 (1.5 mL) was added 
the etheral solution of diazomethane in one portion at 0 °C. The resulting 
mixture was stirred at 0 °C to room temperature over 20 h before the excess 
diazomethane was carefully bubbled off under a stream of N2 for 15-20 min. 
The remaining solvent was carefully concentrated in vacuo on the rotary 
evaporator with the water bath temperature kept at 28 °C. Flash column 
chromatography of the crude product over silica gel (6% EtOAc/hexane → 
20% EtOAc/hexane → 25% EtOAc/hexane) afforded benzyloxy α-diazoketone 
2-39 (7.8 mg, 18%) as a bright yellow oil.  
2-39 (Appendix 5, p372): 1H NMR (500 MHz, CDCl3): δ 7.37-7.28 (m, 
5H), 5.70-5.61 (m, 1H), 5.56 (s, 1H), 5.09-5.05 (m, 2H), 4.51 (d, J = 12.0 Hz, 
1H), 4.45 (d, J = 12.0 Hz, 1H), 3.73 (d, J = 8.8 Hz, 1H), 3.50 (d, J = 8.8 Hz, 
1H), 2.84 (d, J = 17.6 Hz, 1H), 2.68 (d, J = 17.6 Hz, 1H), 2.50 (dd, J = 6.9, 
13.2 Hz, 1H), 2.42 (d, J = 7.6, 13.2 Hz, 1H), 2.10 (s, 3H); 13C NMR (125 MHz, 
CDCl3): δ 206.6, 197.2, 137.9, 132.9, 128.4, 127.8, 127.6, 119.1, 73.4, 71.7, 
54.0, 52.2, 45.9, 37.8, 30.8; HRMS (IT-TOF): m/z calcd for C17H20O3N2Na+ 




Methyl keto-ester 2-67: Major byproduct obtained from 
diazo substitution of the mixed anhydride of keto-acid 2-
60. 2-67: 1H NMR (500 MHz, CDCl3): δ 7.33-7.28 (m, 
5H), 5.66-5.61 (m, 1H), 5.06-5.01 (m, 2H), 4.46 (s, 2H), 3.71-3.62 (m, 5H), 
2.92-2.77 (m, 2H), 2.47 (dd, J = 7.5, 13.8 Hz, 1H), 2.40 (d, J = 7.5, 13.8 Hz, 
1H), 2.08 (s, 3H); 13C NMR (125 MHz, CDCl3): δ 206.5, 174.6, 138.3, 133.0, 
128.3, 127.6, 127.5, 118.7, 73.2, 70.7, 51.8, 48.4, 45.5, 38.6, 30.5; ESI-MS: 
m/z calcd for C17H22O4Na+ [M + Na]+ 313.1, found 313.3. 
Methoxymethyl α-diazoketone 2-75: Procedure was 
repeated with lactone hemiacetal 2-70 (28 mg, 0.121 
mmol) and freshly distilled etheral diazomethane 
solution (prepared from 2.1 g Diazald 2-18). Flash column chromatography of 
the crude product over silica gel (10% EtOAc/hexane → 28% EtOAc/hexane) 
afforded methoxymethyl α-diazoketone 2-75 (3.7 mg, 12% + impurities) as a 
yellow oil. 2-75: 1H NMR (300 MHz, CDCl3): δ 5.77-5.63 (m, 1H), 5.54 (s, 
1H), 5.12-5.06 (m, 2H), 4.61-4.56 (m, 2H), 3.75-3.58 (m, 2H), 3.33 (s, 3H), 
2.85-2.70 (m, 2H), 2.47-2.45 (m, 2H), 2.12 (s, 3H); MS (IT-TOF): m/z calcd 
for C12H18O4N2Na+ [M + Na]+ 277.1, found 277.2. 
 
Part I. Preparation of MOM-Cl in-situ[85]: A stock solution (50 mg/mL) 
of anhydrous ZnBr2 (150 mg) in dimethoxymethane (3 mL) was prepared in a 













solution of ZnBr2 (6.5 mg, 28.9 µmol) in dimethoxymethane (0.13 mL, 1.47 
mmol) was added toluene (1.5 mL), followed by dropwise addition of acetyl 
chloride (0.12 mL, 1.69 mmol) at room temperature. The resulting mixture was 
gently warmed in a water bath at 40-45 °C for 10 min before it was stirred at 
room temperature for a further 4 h. This clear, colourless solution of MOM-Cl 
in toluene (and methyl acetate) was used in the next step without further 
purification.        
Part II. MOM-protected hydroxyl methyl bicyclic lactam 2-68: To this 
solution of MOM-Cl in toluene, immersed in a cold water bath, was added a 
solution of hydroxy methyl bicyclic lactam 2-52 (0.202 g, 0.797 mmol) in 
toluene (2 mL), followed by DIPEA (0.18 mL, 1.03 mmol) at 5 °C. The 
resulting mixture was stirred at 5 °C to room temperature over 14 h before the 
orange solution was diluted with EtOAc and saturated aq. NH4Cl. The mixture 
was vigorously stirred for 5-10 min to decompose any excess MOM-Cl before 
the organic layer was separated. The aqueous layer was extracted with EtOAc 
(2x), and the combined organic layers were washed with water (1x), followed 
by brine, dried over Na2SO4, filtered, and concentrated in vacuo. Flash column 
chromatography of the crude product over silica gel (5% EtOAc/hexane → 
18% EtOAc/hexane) afforded MOM-protected hydroxy methyl bicyclic lactam 
2-68 (71.1 mg, 30%) as a yellow oil. 
2-68: 1H NMR (500 MHz, CDCl3): δ 5.68-5.60 (m, 1H), 5.09-5.06 (m, 2H), 
4.61-4.60 (m, 2H), 4.18-4.15 (m, 1H), 3.78-3.74 (m, 1H), 3.66-3.55 (m, 2H), 
3.44-3.40 (m, 1H), 3.34 (s, 3H), 2.33-2.15 (m, 3H), 1.67-1.60 (m, 1H), 1.50 (s, 
3H), 1.04 (d, J = 6.3 Hz, 3H), 0.87 (d, J = 6.3 Hz, 3H); 13C NMR (125 MHz, 
CDCl3): δ 181.1, 133.1, 118.9, 97.3, 96.4, 92.1, 72.1, 70.5, 62.3, 55.3, 52.5, 
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40.8, 39.1, 34.3, 24.7, 20.7, 18.9; ESI-MS: m/z calcd for C16H27O4NNa+ [M + 














Me-protected hydroxyl methyl bicyclic lactam 2-71: To a solution of 
hydroxy methyl bicyclic lactam 2-52 (0.205 g, 0.809 mmol) in THF (4 mL) 
was added NaH (60% dispersion in mineral oil, 0.11 g, 2.75 mmol) at 0 °C. 
The resulting mixture was stirred at the same temperature for 30 min before 
MeI (0.31 mL, 4.98 mmol) was added, and the final mixture was stirred at 
room temperature for 12 h. The reaction was quenched with saturated aq. 
NH4Cl, and diluted with water before it was extracted with Et2O (3x). The 
combined organic extracts were washed with water (1x), followed by brine, 
dried over Na2SO4, filtered, and concentrated in vacuo. Flash column 
chromatography of the crude product over silica gel (5% EtOAc/hexane → 
12% EtOAc/hexane) afforded Me-protected hydroxy methyl bicyclic lactam 2-
71 (0.216 g, 100%) as a pale yellow oil.    
2-71: 1H NMR (300 MHz, CDCl3): δ 5.70-5.56 (m, 1H), 5.09-5.04 (m, 2H), 
4.18-4.13 (m, 2H), 3.78-3.73 (m, 1H), 3.60-3.43 (m, 2H), 3.34 (s, 3H), 3.30-
3.24 (m, 1H), 2.32-2.13 (m, 3H), 1.68-1.60 (m, 1H), 1.47 (s, 3H), 1.05 (d, J = 
6.6 Hz, 3H), 0.86 (d, J = 6.6 Hz, 3H); 13C NMR (75 MHz, CDCl3): δ 181.3, 
133.3, 118.7, 97.4, 70.4, 62.3, 59.2, 52.8, 40.8, 39.1, 34.3, 24.8, 20.8, 18.9; 




Lactone 2-90: To a solution of lactone hemiacetal 2-59 (0.56 g, 2.03 mmol) 
in THF (20 mL) and MeOH (10 mL) was added NaBH4 (0.811 g, 20.3 mmol) 
at 0 °C. The resulting mixture was stirred at 0 °C until the bubbling has ceased 
before it was brought to reflux for 6 h. The mixture was then concentrated in 
vacuo, and the residue was partitioned between 1M HCl to pH 1-2 and CH2Cl2. 
The resulting biphasic mixture was stirred vigorously for 30 min before the 
organic layer was separated. The aqueous layer was extracted with CH2Cl2 
(3x), and the combined organic layers were washed with brine, dried over 
Na2SO4, filtered, and concentrated in vacuo. Flash column chromatography of 
the crude product over silica gel (hexane → 12% EtOAc/hexane) afforded an 
inconsequential diastereomeric mixture of lactone 2-90 (0.402 g, 76%) as a 
colourless oil.    
2-90: 1H NMR (500 MHz, CDCl3): δ 7.37-7.27 (m, 5H), 5.75-5.65 (m, 1H), 
5.17-5.10 (m, 2H), 4.68-4.63 + 4.60-4.46 (m each, 3H), 3.64-3.60 (m, 1H), 
3.47-3.41 (m, 1H), 2.41-2.34 (m, 1H), 2.27-2.21 (m, 2H), 2.15-2.11 + 1.85-
1.81 (m each, 1H), 1.40-1.35 (m, 3H); 13C NMR (125 MHz, CDCl3): δ 179.2, 
137.9, 132.1, 128.4, 128.3, 127.6, 127.4, 119.6, 74.0, 73.4, 73.1, 50.0, 38.6, 





Chlorohydrin 2-91: To a solution of lactone 2-90 (100 mg, 0.384 mmol) 
and chloro-iodomethane (89 µL, 1.23 mmol) in THF (3 mL) was added 1.5M 
nBuLi in hexanes (0.77 mL, 1.15 mmol) dropwise at -78 °C. The resulting 
mixture was stirred at -78 °C for 3 h before it was quenched with excess 
saturated aq. NH4Cl and briefly stirred at room temperature. The mixture was 
diluted with water, and extracted with Et2O (3x). The combined organic 
extracts were washed with brine, dried over Na2SO4, filtered, and concentrated 
in vacuo. Flash column chromatography of the crude product over silica gel 
(5% EtOAc/hexane → 14% EtOAc/hexane) afforded an inconsequential 
diastereomeric mixture of chlorohydrin 2-91 (74 mg, 62%) as a pale yellow oil.    
2-91: 1H NMR (500 MHz, CDCl3): δ 7.32-7.29 (m, 5H), 5.79-5.67 (m, 1H), 
5.13-5.04 (m, 2H), 4.56-4.41 (m, 2H), 4.32-4.29 (m, 1H), 4.01-3.99 + 3.86-
3.70 + 3.48-3.43 + 3.22-3.20 (m each, 4H), 2.55-2.40 + 2.29-2.25 (m each, 
2H), 2.12-1.99 + 1.65-1.61 (m each, 2H), 1.33 + 1.22 (d each, J = 6.3 Hz, 3H); 
EI-MS: m/z calcd for C17H23O335Cl+ [M]+ 310.1, found 310.1, and m/z calcd for 
C17H23O337Cl+ [M]+ 312.1, found 312.1 (intensity ratio 3:1).  
      
α-Chloro-diketone 2-89: To a solution of chlorohydrin 2-91 (0.345 g, 1.11 
mmol) in CH2Cl2 (45 mL) was added NaOAc (1.37 g, 16.7 mmol) and PCC 
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(2.4 g, 11.1 mmol) at 0 °C. The resulting mixture was stirred at room 
temperature for 24 h before silica gel (10 g) was added and stirred for 5-10 
min. The paste was filtered through a pad of Celite, eluted with Et2O and 
EtOAc mixture (1:1). The clear, and colourless to pale yellow filtrate was then 
concentrated in vacuo. Flash column chromatography of the crude product over 
silica gel (hexane → 11% EtOAc/hexane → 15% EtOAc/hexane) afforded α-
chloro-diketone 2-89 (0.267 g, 78%) as a pale yellow oil.    
2-89: 1H NMR (300 MHz, CDCl3): δ 7.37-7.25 (m, 5H), 5.67-5.53 (m, 1H), 
5.11-5.02 (m, 2H), 4.57-4.40 (m, 4H), 3.60 (d, J = 8.9 Hz, 1H), 3.47 (d, J = 8.8 
Hz, 1H), 2.90 (d, J = 18.2 Hz, 1H), 2.78 (d, J = 18.2 Hz, 1H), 2.62 (dd, J = 7.0, 
13.5 Hz, 1H), 2.49 (dd, J = 8.1, 13.5 Hz, 1H), 2.07 (s, 3H); 13C NMR (75 MHz, 
CDCl3): δ 206.3, 204.1, 137.4, 132.2, 128.5, 127.9, 127.7, 119.7, 73.5, 71.8, 
52.9, 48.6, 47.1, 36.0, 30.0; EI-MS: m/z calcd for C17H21O335Cl+ [M]+ 308.1, 
found 308.1, and m/z calcd for C17H21O337Cl+ [M]+ 310.1, found 310.0 











An Oxirane Rearrangement Carbonyl 















3.1 Epoxy Ketone 3-7 as Carbonyl Ylide Precursor 
Epoxides are important and useful intermediates for the synthesis of 
complex organic structures due to their ease of preparation, and more 
importantly, their propensity for strain-induced ring-opening reactions. For 
example, Lewis acid-induced pinacol-type rearrangement of epoxides into 
carbonyl compounds through C-O bond cleavage has been widely studied, and 
applied in complex molecule syntheses.[92] A different type of organic 
transformation involving these 3-membered rings had already emerged from 
the 1970s, but saw few synthetic applications, where diaryl-substituted 
oxiranes have been demonstrated to undergo photo-induced isomerizations via 
carbonyl ylides from selective C-C bond scission under UV irradiations.[93]  
In 1980, Harold Hart and co-workers first reported an interesting photo-
rearrangement reaction with a [4-5-3] epoxy ketone 3-1 upon irradiation with a 
Hanovia mercury lamp at 315 nm.[94] The carbonyl ylide 3-2, thus generated, 
underwent an intramolecular [3+2] cycloaddition with its cyclobutene 
component to liberate a cage-like carbocycle 3-3 in 70% yield (Figure 3.1). 
This is the only report in the literature, to our knowledge, that described such a 
controlled photo-induced oxirane rearrangement and cycloaddition sequence 
within a strained aliphatic epoxide bearing a single electron-withdrawing group 
for activation. Photo-interconversion of epimers of pulegone epoxide has also 
been used to demonstrate the intermediacy of carbonyl ylide in similar 






Figure 3.1. Hart’s photo-induced carbonyl ylide cycloaddition protocol of epoxy 
ketone 3-1. 
 
We envisaged that the oxatricycle 2-38 could be accessed through Hart’s 
reported conditions based on a similar photo-rearrangement carbonyl ylide 
cycloaddition cascade of epoxy ketone 3-7. The preparation of 3-7 was 
achieved via two independent routes conducted in parallel (Scheme 3.1).  
Beginning from the Bn-protected bicyclic lactam 2-40, α,β-unsaturated 
cyclopentenone 3-6 was prepared according to an earlier reported Meyers’ 
procedure (Scheme 3.1A).[90] MeLi addition to 2-40, followed by hydrolysis 
with mildly acidic KH2PO4 in H2O/EtOH mixture uneventfully delivered dione 
3-5 in 83% yield over two steps. Subjecting 3-5 with a catalytic amount of 
ethanolic KOH at ambient temperatures afforded a steric-controlled 
regioselective intramolecular aldol condensation to furnish 3-6 in 90% yield. 
After several unsuccessful epoxidation attempts, an inseparable diastereomeric 
mixture of epoxy ketone 3-7 was eventually afforded in 58% yield via 
nucleophilic epoxidation of 3-6 with H2O2 in excess methanolic NaOH.[96]  
With the preparation of the α-chloro-diketone 2-89 achieved previously, we 
recognized that the latter was a ready precursor to 3-7 through a Darzens 






Scheme 3.1. A. Synthesis of the epoxy ketone 3-7 from the bicyclic lactam 2-40. B. 
Synthesis of 3-7 from the α-chloro-diketone 2-89. 
 
3.2 Photo-Induced Carbonyl Ylide Cycloaddition to the Compact Core   
With epoxy ketone 3-7 in hand, we investigated the anticipated photo-
induced carbonyl ylide formation and [3+2] cycloaddition cascade with 
different wavelength irradiations from various sources (Table 3.1, entries 1-5). 
Unfortunately, we could not get our hands on a high pressure mercury lamp of 
UV 315 nm to examine Hart’s irradiation protocol with 3-7. The application of 
other wavelengths such as 254 nm and 266 nm from a low power mercury 
lamp only recovered the starting material after 24 h of irradiation (entries 1-2); 
while a high power mercury lamp of 254 nm completely degraded 3-7 to a 
complex mixture after 12 h (entry 3).  
After 20 h of UV irradiation at 300 nm wavelength (entry 4), the conversion 
was incomplete. We isolated the two new spots observed on TLC, and 
unfortunately, neither corresponded to the desired oxatricycle 2-38. NMR 
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analyses suggested that the epoxide has rearranged (decomposed) but the allyl 
function remained unreacted. Focal excitation of a cyclohexane solution of 3-7 
with laser[98] at 325 nm was also unsuccessful and recovered the starting 
epoxide (entry 5). Bentabed’s procedure for thermal-induced carbonyl ylide 
formation of α,β-epoxy 1,1-bisnitriles under microwave conditions[99] was 
tested on 3-7. Ungratifyingly, microwave irradiations at 120 °C in 1,2-
dichloroethane (entry 6), and 150 °C in α,α,α-trifluorotoluene (entry 7) 
recovered 3-7 quantitatively.  
Table 3.1. Screening of conditions to promote the carbonyl ylide cycloaddition of the 
epoxy ketone 3-7. 
 
entry conditions remarks 
1 3 UV tubes (02 x 6W + 01 x 4W),             
λ 254 nm, benzene, 24 h  
Recovered 3-7. Unknown 
baseline material on TLC. 
2 2 UV tubes (low power), λ 266 nm, 
cyclohexane, 24 h 
Recovered 3-7. No reaction 
observed. 
3 7 UV tubes (25-30W each), λ 254 nm, 
benzene, 12 h 
Complex mixture. Traces of 3-7 
on TLC. Complex ESI-MS 
spectrum. 
4 6 UV tubes (25-30W each), λ 300 nm, 
benzene, 20 h 
Two new spots isolated but none 
corresponded to oxatricycle 2-38. 




5 laser at 325 nm, cyclohexane,                   
3-4 h each interval (x3) 
Recovered 3-7. Some unknown 
baseline material on TLC. 
6 1,2-dichloroethane, 120 °C (microwave), 
40 mins 
Recovered 3-7. No reaction 
observed. 
7 α,α,α-trifluorotoluene, 150 °C 
(microwave), 45 mins 
Recovered 3-7. No reaction 
observed. 
 
From these results, we proposed that the strained tricyclic [4-5-3] ring 
architecture in Hart’s epoxy ketone 3-1 was important for the ring expansion. 
Furthermore, the fused cyclobutene dipolarophile in 3-1 has proximal and 
orientational advantages for a facile cycloaddition to occur with the resulting 
carbonyl ylide. Comparatively, our substrate 3-7 lacks of this strain release as 
driving force to generate the carbonyl ylide. In addition, the internal double 
bond being positioned further away and possesses higher degrees of rotational 
freedom probably disfavored the desired cycloaddition. 
3.3 Eun Lee’s Formal Synthesis of (-)-Platensimycin via the Carbonyl 
Ylide Cycloaddition Strategy 
Whilst efforts to synthesize the oxatricycle 2-38 were still ongoing via our 
proposed carbonyl ylide cycloaddition strategy using (1) dirhodium(II)-
catalyzed decomposition of the α-diazoketone 2-39, and (2) photo-
rearrangement of the epoxy ketone 3-7, Eun Lee and co-workers have recently 
completed a formal synthesis of (-)-platensimycin using the same 1,3-dipolar 
approach (Figure 3.2, also Table 1.4 entry 17).[38d] Notably, they have also 
experienced similar struggles in the preparations of the α-quaternary 
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diazoketone unit when the other non-dipolarophile side arm was either vinyl, 
methoxymethyl, or (N-methoxy-N-methylaminocarbonyl)ethyl derivative. 
Installing a cyano-group at the C8 quaternary center circumvented the problem, 
and smoothly delivered the pivotal keto-acid 3-8. Diazo substitution of 3-8 
through mixed anhydride activation proceeded uneventfully to furnish the 
crucial α-diazoketone 1-117 which have eluded us hitherto. According to the 
authors, both cyano and iodoallyl functionalities were essential in ensuring a 
high yielding and highly regioselective carbonyl ylide cycloaddition sequence 
with 1-117 to produce the oxatricyclic ketone 1-118. Another few steps 
forward through keto-aldehyde 1-121 (similarly proposed), the group 
successfully completed the tetracyclic enone 1-23 of (-)-platensimcyin.  
 
Figure 3.2. Eun Lee’s formal synthesis of (-)-platensimycin (1-4) via a carbonyl ylide 
cycloaddition approach. 
 
3.4 Designing a Photo-Labile Precursor for the Synthesis of the Tetracyclic 
Enone 1-23  
Not dissuaded by the efforts of Eun Lee and co-workers, we decided to re-
design our epoxy ketone 3-7 making the functionality more electronically 
favorable for the critical oxirane photo-rearrangement sequence. Facile photo-
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isomerization of β-aryl-substituted-α,β-epoxy carbonyl and nitrile systems[100] 
have been previously described because of the antagonistic abilities of the 
substituents to stabilize the resulting carbonyl ylide intermediate from photo-
cleavage of the epoxide’s C-C bond (c.f. 3-12). This inspired us to propose the 
epoxide 3-12 as a precursor to the oxabicyclo[3.2.1]octane framework in 
benzotetrahydrofuran 3-11 via the anticipated photo-induced carbonyl ylide 
cycloaddition sequence (Scheme 3.2).  
 
 
Scheme 3.2. Retrosynthetic analysis of the tetracyclic enone 1-23 via a photo-induced 
carbonyl ylide cycloaddition sequence of the β-aryl-substituted-α,β-epoxy-1,1-diester 
3-12.  
 
Subsequent functional group manipulations of the 1,1-diester in 3-11, 
including a chemoselective oxidation of the methylene acetal, were conceived 
to provide the dibromo-benzotetrahydrofuran 3-10. Carbonate opening to drive 
a regioselective alkylative dearomatization process in 3-10 was envisioned to 
assemble the cage-like core of dienone 3-9. Enroute to the tetracyclic enone 1-
23 through a series of redox transformations would be pursued.  
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Recently, alkylative cyclodearomatization of silyl-protected phenyl ethers 1-
89 and 1-128 were respectively reported by the groups of Corey[37b] and 
Njardarson[38e] as part of their end-game strategy in the formal synthesis of 
platensimycin.[37b] Retrosynthetically, epoxide 3-12 could be obtained from a 
sequential Stille cross-coupling of the commercially available 6-bromo-
piperonal (3-13) with allyl tributylstannane; followed by a dirhodium(II)-
catalyzed epoxidation of the aryl aldehyde with dimethyl diazomalonate 3-16 
via diazo-decomposition.  
3.5 Efforts toward a Modified Second-Generation Synthesis of the 
Oxabicyclo[3.2.1] Carbon Skeleton 
Our synthesis efforts commenced with the acetal protection of 6-bromo-
piperonal (3-13) with ethylene glycol under Dean-Stark conditions to afford 
acetal 3-14 in 95% yield (Scheme 3.3). Stille coupling between the aryl 
bromide 3-14 and allyltributylstannane under microwave irradiation at 160 °C 
proceeded uneventfully, and subsequent acetal deprotection via acid-promoted 
trans-acetalization gave the 6-allylpiperonal 3-15 in 97% yield over two steps. 
We initially attempted to access 3-15 directly from a Stille coupling with 6-
bromopiperonal (3-13) but the reaction was low-yielding due to undesired 
allylation of the aldehyde as a major byproduct. Epoxide formation, followed 
by Stille coupling was also examined but the method was met with limited 
success due to significant decomposition of the epoxide under microwave 
conditions.  
Finally, epoxidation of aldehyde 3-15 using Doyle’s carbonyl ylide 
methodology[101] with 1 mol% Rh2(OAc)4 catalyzing carbenoid formation of 
dimethyl diazomalonate 3-16 through diazo-decomposition, and its addition 
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across the C=O bond of 3-15, provided the epoxide 3-12, albeit in 32% low 
yield. When 2 mol% Cu(acac)2 was used instead, 3-12 was furnished in 69% 
yield. Dimethyl diazomalonate 3-16 was prepared from dimethyl malonate 
using the Regitz-type diazo transfer method with p-ABSA and triethylamine.  
 
 
Scheme 3.3. Preparation of the β-aryl-substituted-α,β-epoxy-1,1-diester 3-12. 
 
Subjecting epoxide 3-12 under UV 254 nm irradiation with a high power 
mercury lamp for 11 h, indeed promoted the anticipated photo-induced oxirane 
rearrangement-[3+2] cycloaddition cascade (Scheme 3.4). Unfortunately, the 
cycloaddition process gave only the undesired [3+2]-regioisomer 3-17 in 54% 
yield. The formation of the desired [3+2]-regioisomer was not detected. The 
structure of 3-17 was elucidated based on 2D NMR analyses and DEPT 
studies. One noteworthy feature of this [3+2] cycloaddition was the excellent 





Scheme 3.4. Photo-induced carbonyl ylide cycloaddition of 3-12. 
 
Photochemical decomposition of the epoxide 3-12 via a possible 
electrocyclic ring opening eliminated dimethyl malonate and liberated the aryl 
aldehyde 3-15 as the minor byproduct (Figure 3.5A). In fact, minor quantities 
of this [3+2] cycloadduct 3-17 has also been observed during the Cu(acac)2-
catalyzed epoxide formation of 3-12. A competing carbonyl ylide-[3+2] 
cycloaddition sequence (pathway B) versus the intended cyclization process 
(pathway A) has probably occurred (Scheme 3.5).  
 
 
Scheme 3.5. Competing carbonyl ylide cycloaddition versus cyclization in the Cu(II)-
catalyzed epoxidation of 6-allyl piperonal 3-15.    
 
In order to investigate and possibly correct the regioselectivity of this 
oxirane rearrangement-[3+2] cycloaddition process, we attempted to install an 
electron-withdrawing group at the terminal olefin position to reverse the olefin 
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HOMO coefficient such that the desired regio-cycloaddition would be 
electronically favored. Beginning with dioxolane-protected allyl benzene 3-19 
(Scheme 3.6), olefin cross-metathesis with methyl acrylate using 4 mol% 
Grubbs II catalyst in refluxing dichloromethane afforded α,β-unsaturated ester 
3-20 in 93% yield and 22:1 E/Z ratio. Removal of the acetal group, followed by 
epoxidation with the Cu-carbenoid of 3-16, gave epoxide 3-21 in 67% yield 
over two steps. Similarly, formation of the tetrahydrofuran 3-22, with all-cis 
configuration, was also observed in 13% yield over 2 steps.    
 
Scheme 3.6. Preparation of the α,β-unsaturated Me ester derivative (3-21) of epoxide 
3-12.  
 
Treatment of a solution of 3-21 in benzene under the same UV conditions 
promoted the carbonyl ylide cycloaddition to again furnish the undesired 
regioselective cycloadduct 3-22 in 52% yield, and the latter was demonstrated 
to possess excellent syn-selectivity by 1D NOE studies (Scheme 3.7). Similar 
byproducts – the aryl aldehyde 3-23 and dimethyl malonate were also liberated 
from this photochemical system. From these results, we hypothesized that (1) 
the desired regioselective cycloaddition could be favored by having a more 
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substituted internal olefin with greater sterics at the terminal position, or (2) the 
reaction could be driven by a concerted mechanism rather than the anticipated 
stepwise fashion via the stabilized carbonyl ylide intermediate as described (3-
18, Scheme 3.5), thus efforts to explore other systems or methods of activation 
were explored.   
 
 
Scheme 3.7. Photo-induced carbonyl ylide cycloaddition of 3-21. 
 
3.6 Efforts to Study the Regioselectivity of the Photo-Induced Carbonyl 
Ylide Cycloaddition 
Following the findings from the photo-induced and Cu(II)-catalyzed 
intramolecular [3+2] cycloaddition reactions to 3-17 and 3-22, we were 
interested to test some intermolecular systems to study their reactivity and 
regioselectivity (Scheme 3.8). Piperonal (3-24) in toluene was refluxed with 
Cu(acac)2 and dimethyl diazomalonate 3-16 in the presence of (1) allyl 
bromide, and (2) propargyl bromide but only to produce the 1,1-diester epoxide 
3-25. No intermolecular cycloadducts (1) 3-27, and (2) 3-29 or their regio-
isomers were observed this time. Epoxide 3-25 was then subjected to the same 
photochemical irradiation conditions, in the presence of various dipolarophiles 
(1-4). Ungratifyingly, the anticipated oxirane rearrangement-[3+2] 
cycloaddition sequence (3-27-3-30) did not occur. Electrocyclic ring opening 





































































Scheme 3.8. Screening of dipolarophiles for intermolecular carbonyl ylide 
cycloaddition. 
 
Other substrate designs (Figure 3.3) we have proposed to replace the 
olefinic functionality for further regioselectivity studies include: (1) a halogen-
substituted olefin in 3-31 to reverse the olefin HOMO coefficient which was 
proved essential for the success of Eun Lee’s strategic efforts[38d]; (2) a methyl 
α-bromoacrylate moiety in 3-32 envisioned to increase steric interaction with 
the quaternary end of the epoxide; and (3) a 6-membered cyclic bis-sulfoxide 






Figure 3.3. Olefin derivatives for the regioselectivity studies of the intramolecular 
carbonyl ylide cycloaddition.  
       
The synthesis proceeded with one-pot oxidative cleavage of the allyl 
benzene 3-19 using catalytic amount of potassium osmate and NaIO4 in 
THF/H2O mixture (Scheme 3.9). While the aldehyde was formed from the 
double bond cleavage, the acetal group was also deprotected under this 
condition to give bis-aldehyde 3-34. When pH 7.0 phosphate buffer was used 
instead in a tBuOH/THF/H2O mixture, the oxidative cleavage of 3-19 provided 
the 2-piperonyl acetaldehyde 3-35 in 37% low yield. However, benzaldehye 3-
36 was also observed as a major side product from a double bond migration 
prior to oxidative cleavage.  
With acetaldehyde 3-35 in hand, we then attempted Wittig olefination with 
various Wittig reagents as described in Scheme 3.10. Wittig reaction with the 
Wittig salt [PPh3CH2I]+I- (prepared from PPh3 and CH2I2 in toluene refluxed) 
and nBuLi afforded the vinyl iodide 3-37, but it decomposed during flash 
column chromatography. Subjecting 3-35 to Takai conditions using CHI3 and 









































Method 2 (buf f ered conditions)
 
 
Scheme 3.9. Oxidative cleavage of the dioxolane-protected allyl benzene 3-19. 
 
We originally planned to access the E-vinyl bromide 3-40 via a proposed 
selective debromination of the 1,1-dibromoalkene 3-38 by halogen-metal 
exchange.[102] However, the initial step to generate 3-38 with PPh3 and CBr4 
conditions resulted in acetal cleavage of the aldehyde 3-35 instead, and the 
reaction was further complicated in situ. Alternatively, a Hunsdiecker reaction 
with the acid (3-39) of the α,β-unsaturated ester 3-20 using NBS and catalytic 
TBATFA[103] was conceived to access the E-selective vinyl bromide 3-40. 
However, several hydrolysis conditions with 3-20 such as LiOH in THF/H2O, 
Ba(OH)2·8H2O in MeOH, and TMSOK in THF all resulted in double bond 
migration to the undesired β,γ-unsaturated acid 3-41.  
When aldehyde 3-35 was reacted with Brückner’s HWE reagent 
(PhO)2P(O)CHBrCO2Me[104] under NaH conditions, methyl α-bromoacrylate 
3-43 was furnished in 77% yield with excellent stereoselectivity (E- or Z- 
designation was, however, not further confirmed). Subsequent dioxolane 
deprotection, followed by copper(II)-catalyzed epoxidation with 3-16 was, 
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however, unsuccessful and several unidentified byproducts were generated. 





















































3-41 E/Z = ~1:1
TBATFA, NBS,
DCE, rt














































Preparation of vinyl iodide
Preparation of vinyl bromide
Preparation of -bromo , -unsaturated ester
 
 
Scheme 3.10. Attempts to prepare the vinyl halide functionalities. 
 
Accompanying dioxolane deprotection and ensuing decomposition of the 
unmasked aldehyde was a major issue during preparation of the vinyl halide 
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derivatives with the aldehyde 3-35. Thus, reduction of the 6-allylpiperonal 3-15 
was pursued to provide the piperonyl alcohol 3-45 with NaBH4, followed by 
TBS-protection to afford the TBS-protected piperonyl alcohol 3-46 in 87% 
over two steps (Scheme 3.11).  
  
 
Scheme 3.11. Attempts to prepare the vinyl halide intermediates with protected 
derivatives of piperonyl alcohol 3-45. 
  
However, efforts to derivatize 3-46 further to its vinyl iodide 3-50 or 1,1-
dibromoalkene 3-52 via the aldehyde 3-48 were met with limited success. E-
vinyl iodide 3-50, from Takai olefination of 3-48, decomposed during flash 
column chromatography, while the TBS group did not survive PPh3/CBr4 
conditions too. Manipulation of protecting group to the pivaloyl ester 3-47 also 
failed to advance the synthesis under the same olefination conditions.   
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To build the ketene equivalent moiety (Scheme 3.12A), bis-sulfoxide HWE 
reagent 3-56 was first prepared from 1,3-dithiane (3-54). 1,3-dithiane was first 
treated with NCS, followed by an Arbuzov-type reaction with triethylphosphite 
to form diethyl phosphonate 3-55 in a modest 52% yield.[105] Oxidation of 3-55 
to its sulfoxide was non-trivial in our hands despite the latter step being a 
reported procedure. After considerable attempts, excess NaIO4 in a MeOH/H2O 
mixture finally afforded the racemic HWE reagent 3-56 in 42% yield after 4 
days.[106] An aqueous work-up of the reaction mixture with immediate flash 
column purification was necessitated to minimize product decomposition. 
 
 
Scheme 3.12. Preparation of the bis-sulfoxide HWE reagent 3-56 (A) in olefination 
reaction with aldehydes 3-35 (B) and 3-15 (C).    
 
With 3-56 in hand, we proceeded with the HWE olefination of the 
acetaldehyde 3-35 using Aggarwal’s reported conditions[106], but no reaction 
occurred (Scheme 3.12B). However, when the olefination was tested on 6-allyl 
piperonal 3-15 with 3-56, ketene dithioacetal 3-58 was obtained in a low yield 
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of 24% (Scheme 3.12C). The enolizable α-center of acetaldehyde 3-35 under 
basic conditions probably accounted for the observed difference in reactivity 
towards condensation with bis-sulfoxide 3-56. We then proposed with 
subjecting 3-58 to nucleophilic epoxidation with either sodium hydroperoxide 
which gave no reaction, or prolonged exposure to lithium tert-butyl peroxide 
led to decomposition only (Scheme 3.13).  
 
 
Scheme 3.13. Epoxidation of the ketene thioacetal 3-58. 
 
3.7 Exploration of a Lewis Acid-Promoted Carbonyl Ylide Cycloaddition 
with the α,β-Epoxy-1,1-Diester 3-12 
Lewis acid-promoted C-C bond cleavage of epoxides to afford carbonyl 
ylides is unprecedented, and the reaction is conceptually difficult as the C-O 
bonds in epoxides are more sensitive toward Lewis acid rearrangements.[92] 
Following Carrie’s initial report in 1978,[107] the Johnson group recent 
disclosure on Lewis acid-promoted C-C bond cleavage of aziridines to generate 
azomethine ylides (3-60, Figure 3.4) that participated in formal [4+2] and 
[3+2] cycloaddition reactions[108] is synthetically intriguing which attracted us 




Figure 3.4. Representative examples of Johnson’s formal [4+2] and [3+2] 
cycloaddition reactions of ZnCl2-promoted azomethine ylides from aziridines.  
 
Preliminary investigations into the carbonyl ylide cycloaddition of epoxide 
3-12 with various Lewis acids activation (Table 3.2), however, did not produce 
promising results or suggested any real evidence of possible carbonyl ylide 
intermediacy. Although some amounts of [3+2] cycloadduct 3-17 was possibly 
observed, based on TLC comparisons, after 24 h of stirring with 2 equivalents 
of ZnCl2 (entry 3), the desired product spot disappeared after 36 h and only 
starting material 3-12 and the aldehyde byproduct 3-15 were observed. The 
reaction was, however, not reproducible when we attempted to re-produce and 




Table 3.2. Lewis acid activation of epoxy-1,1-diester 3-12 towards a sequential 
carbonyl ylide formation and [3+2] cycloaddition. 
 
entry Lewis acid  equiv. conditions products (%) 
 3-12 3-15 3-61 
1 SnCl4 1 equiv. CH2Cl2, rt, 48 h Complex mixture 
2 LiClO4 1 equiv. CH3CN, rt, 24 h 72 trace - 
3 ZnCl2 fuseda 2 equiv. toluene, rt, 48 h 30 32 - 
4 Cu(OTf)2 0.5 equiv. toluene, rt, 12 h - 43 19 
5 Yb(OTf)3 25 mol% toluene, rt, 24 h - 12 54 
6 Sm(OTf)3 25 mol% toluene, rt, 12 h - 8 56 
7 Sc(OTf)3 0.5 equiv. toluene, rt, 24 h 13 32 18 
 
a
 Small amounts of the cycloadduct 3-17 might be observed at the 24th h (based on TLC), but 





          
Figure 3.5. A & B. Lewis acid (LA)-mediated rearrangements of the epoxide 3-12. 
 
   Electrocyclic ring opening of epoxide 3-12 to give aldehyde 3-15 and 
dimethyl malonate (Figure 3.5A) was one of the two major side reactions 
occurred under Lewis acid conditions (entries 2-7). Another highly polar 
compound (entries 4-7) was isolated as the major byproduct for Yb(OTf)3- 
(entry 5) and Sm(OTf)3- (entry 6) catalyzed reaction. The structure of dimer 3-
61 was elucidated by NMR and mass spectroscopy techniques, and eventually 
verified by single-crystal X-ray analysis (Figure 3.6). We rationalized that the 
large size and highly oxophilic lanthanide triflates coordinated to three oxygen 
centers which promoted an initial intramolecular epoxide opening (3-63). 
Subsequent attack by residual water (3-64) present in the reaction mixture or 
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flask liberated the resulting diol 3-65 which further reacted with another 
species of 3-64 to afford the dimer 3-61 (Figure 3.5B). 







Figure 3.6. X-ray crystallographic structure of dimer 3-61 (Colourless crystals of 3-61 
were recrystallized from CH2Cl2/MeOH). 
 
Recently, Wang and co-workers applied a Lewis acid-catalyzed 
intramolecular [3+2] cycloaddition of a cyclopropane 1,1-diester with a C=O 
bond to successfully complete a formal synthesis of (±)-platensimycin (Figure 
3.7A, also Table 1.4, entry 19).[38f] The ability of the carbonyl group in 
reversing regioselectivity for a type II intramolecular [3+2] cycloaddition 
process to occur, and gave rise to platensimycin’s common oxa-bridged 
bicyclic [3.2.1] skeleton brought success to their synthesis. On the contrary, 
olefin as dipolarophile with epoxide strongly favored the type I intramolecular 
reaction which generated the undesired fused bicyclic [7.3.0] skeleton observed 





Figure 3.7. A. Wang’s intramolecular [3+2] cycloaddition of cyclopropane 1,1-diester 
to (±)-platensimycin. B. Two types of intramolecular [3+2] cycloadditions.  
 
3.8 Summary 
In summary, efforts to assemble the cage-like framework of tetracyclic 
enone 1-23 via a photochemical approach towards the carbonyl ylide 
cycloaddition strategy were unsuccessful. Although a practical synthesis of the 
epoxy ketone 3-7 was achieved from the common bicyclic lactam intermediate 
2-40, considerable attempts to further convert 3-7 to the desired oxatricycle 2-
38 either photochemically or thermally have not been uneventful. Its 
unreactivity towards the desirable C-C rearrangement was probably attributed 
by the molecule’s poor intrinsic electronic properties.  
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Our revised second-generation synthesis re-designed the oxirane moiety to 
include stabilizing groups in a β-aryl-substituted-α,β-epoxy carbonyl system 
that proved to favor the anticipated photochemical oxirane rearrangement. 
Unfortunately, the ensuing intramolecular carbonyl ylide [3+2] cycloaddition 
preferred the undesired regioselectivity in exclusive fashion, regardless our 
efforts to reverse the olefin’s HOMO coefficient. Further regioselectivity 
studies to improve this cascade sequence have been hindered with the 
instability of aldehydes 3-35, 3-48 and its pivaloyl derivative (3-49) toward 
functional group manipulations. The highly regio- and syn-selective 
photochemical formation of the [3+2] cycloadducts 3-17 and 3-22 possessing a 
common oxa-[6-5-5] carbocyclic skeleton is currently being optimized and 


























Experimental Procedures and Characterization Data: 
 
1,4-Di-Ketone 3-5: To a solution of benzyloxymethyl bicyclic lactam 2-40 
(0.573 g, 1.67 mmol) in THF (12 mL) was added a solution of MeLi in 
diethoxymethane (1.8 mL, 5.40 mmol) at -78 °C. The resulting mixture was 
stirred at -78 °C for 10 min before raising the temperature of the reaction to -25 
°C, and stirred for a further 2.5 h. The reaction was quenched with saturated aq. 
NH4Cl at -25 °C and briefly stirred at room temperature before it was diluted 
with water, followed by extraction with CH2Cl2 (3x). The combined organic 
extracts were washed with brine, dried over Na2SO4, filtered, and concentrated 
in vacuo. To this crude methylated carbinolamine 3-4 (0.612 g) was dissolved 
in ethanol (54 mL), and added a solution of KH2PO4 (9.1 g, 66.9 mmol) in H2O 
(80 mL) at room temperature. The resulting suspension was vigorously stirred 
at room temperature for 40 h before the salt was filtered and washed with Et2O. 
The organic layer was separated, and the aqueous layer was extracted with 
Et2O (4x). The combined organic layers were washed with brine, dried over 
Na2SO4, filtered, and concentrated in vacuo. Flash column chromatography of 
the crude product over silica gel (5% EtOAc/hexane → 20% EtOAc/hexane) 
afforded 1,4-di-ketone 3-5 (0.381 g, 83% over two steps) as a pale yellow oil. 
3-5: 1H NMR (300 MHz, CDCl3): δ 7.34-7.28 (m, 5H), 5.67-5.53 (m, 1H), 
5.07-4.99 (m, 2H), 4.50-4.40 (m, 2H), 3.64-3.56 (m, 2H), 2.89 (d, J = 17.9 Hz, 
1H), 2.74 (d, J = 17.9 Hz, 1H), 2.51-2.46 (m, 2H), 2.18 (s, 3H), 2.08 (s, 3H); 
13C NMR (75 MHz, CDCl3): δ 211.0, 207.3, 138.1, 132.2, 128.3, 127.6, 119.7, 
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73.3, 71.5, 54.0, 45.9, 35.7, 30.7, 26.3; ESI-MS: m/z calcd for C17H22O3Na+ [M 
+ Na]+ 297.1, found 297.1. 
 
Cyclopentenone 3-6: To a solution of 1,4-di-ketone 3-5 (0.328 g, 1,2 
mmol) in THF (24 mL) was added 2M ethanolic KOH (60 µL, 0.12 mmol) at 
room temperature. The resulting mixture was stirred at room temperature for 
16 h before it was concentrated in vacuo, and the residue was re-dissolved in 
Et2O. The organic layer was washed with water (3x), followed by brine, dried 
over Na2SO4, filtered, and concentrated in vacuo. Flash column 
chromatography of the crude product over silica gel (5% EtOAc/hexane → 
18% EtOAc/hexane) afforded cyclopentenone 3-6 (0.276 g, 90%) as a 
colourless oil. 
3-6: 1H NMR (500 MHz, CDCl3): δ 7.34-7.24 (m, 5H), 5.91 (d, J = 1.2 Hz, 
1H), 5.62-5.54 (m, 1H), 5.06-4.99 (m, 2H), 4.50-4.41 (m, 2H), 3.53 (d, J = 8.8 
Hz, 1H), 3.38 (d, J = 8.8 Hz, 1H), 2.73 (d, J = 18.3 Hz, 1H), 2.42 (d, J = 18.3 
Hz, 1H), 2.27 (dd, J = 6.3, 13.2 Hz, 1H), 2.18 (dd, J = 8.1, 13.2 Hz, 1H), 2.11 
(d, J = 1.2 Hz, 3H); 13C NMR (75 MHz, CDCl3): δ 211.3, 177.9, 138.2, 132.8, 
129.8, 128.2, 127.44, 127.36, 118.3, 74.0, 73.3, 52.8, 41.6, 38.6, 19.5; ESI-MS: 





Preparation of Epoxy-Ketone 3-7 via Nucleophilic Epoxidation (Method 1) 
and Darzens Condensation (Method 2):  
 
Method 1: 35% aq. H2O2 solution (47 µL) was added to 0.4M methanolic 
NaOH (2.3 mL, 0.913 mmol) at 0 °C, and stirred for 5 min before a solution of 
cyclopentenone 3-6 (30 mg, 0.117 mmol) in THF (1 mL) was added dropwise 
at 0 °C. The resulting mixture was stirred at room temperature for 4.5 h before 
it was diluted with brine, and extracted with CH2Cl2 (4x). The combined 
organic extracts were back-washed with brine (1x), dried over Na2SO4, filtered, 
and concentrated in vacuo. Flash column chromatography of the crude product 
over silica gel (hexane → 12% EtOAc/hexane) afforded epoxy-ketone 3-7 













 Method 2: To a solution of α-chloro-ketone 2-89 (81 mg, 0.262 mmol) in 
CH2Cl2 (1.5 mL) and anhydrous DMF (1.5 mL) was added K2CO3 (82 mg, 
0.593 mmol) at room temperature. The resulting mixture was stirred at room 
temperature for 24 h before it was diluted with water, and extracted with Et2O 
(4x). The combined organic extracts were washed with water (1x), followed by 
brine, dried over Na2SO4, filtered, and concentrated in vacuo. Flash column 
chromatography of the crude product over silica gel (hexane → 10% 
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EtOAc/hexane) afforded an inseparable diastereomeric mixture of epoxy-
ketone 3-7 (62.9 mg, 88%) as a colourless oil. 
3-7 (Appendix 5, p373): 1H NMR (300 MHz, CDCl3): δ 7.38-7.23 (m, 5H), 
5.63-5.57 (m, 1H), 5.10-4.98 (m, 2H), 4.50-4.39 (m, 2H), 3.57-3.54 + 3.41 + 
3.30-3.23 (m1 + s2 + m3, 3H), 2.41-2.15 + 1.93 (m1 + d2, J = 14.8 Hz, 4H), 1.57 
+ 1.55 (s each, 3H); 13C NMR (125 MHz, CDCl3): δ 211.4, 210.9, 138.1, 
138.0, 133.3, 133.1, 128.3, 127.61, 127.57, 127.55, 127.51, 127.47, 127.37, 
119.18, 118.16, 74.37, 73.37, 73.27, 64.94, 62.78, 62.60, 52.41, 51.88, 40.07, 
38.99, 36.16, 35.55, 17.99, 17.96; EI-MS: m/z calcd for C17H20O3+ [M]+ 272.1, 
found 272.1. 
 
Dioxolane-protected 6-bromo piperonal 3-14: To a stirring solution of 6-
bromo piperonal 3-13 (1.1 g, 4.80 mmol) in toluene (30 mL) was added 
ethylene glycol (0.54 mL, 9.68 mmol) and PTSA (27 mg, 0.142 mmol) at room 
temperature. The resulting mixture was refluxed under Dean-Stark conditions 
for 30 h before it was stirred at room temperature with K2CO3 (110 mg) for 1 
h. The suspension was filtered through a pad of Celite, eluted with CH2Cl2 and 
concentrated in vacuo. Flash column chromatography of the crude product over 
silica gel (hexane → 12% EtOAc/hexane) afforded 1,3-dioxolane 3-14 (1.241 
g, 95%) as a white solid.   
3-14: mp 70.0-72.3 °C; 1H NMR (500 MHz, CDCl3): δ 7.07 (s, 1H), 6.99 (s, 
1H), 6.00 (s, 1H), 5.97 (s, 2H), 4.15-4.10 (m, 2H), 4.07-4.02 (m, 2H); 13C 
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NMR (125 MHz, CDCl3): δ 149.0, 147.4, 130.0, 113.9, 112.8, 107.7, 102.5, 
101.9, 65.4; EI-MS: m/z calcd for C10H9O479Br+ [M]+ 272.0, found 271.9, and 
m/z calcd for C10H9O481Br+ [M]+ 274.0, found 273.9 (intensity ratio ~1:1). 
 
6-Allyl piperonal 3-15: Anhydrous DMF was degassed under a constant 
stream of Ar for 20-25 min. Pd(PPh3)4 (0.151 g, 0.131 mmol) was added to 
dioxolane-protected 6-bromo piperonal 3-14 (0.357 g, 1.31 mmol) in a N2-
filled Aldrich® AtmosBag glove bag at room temperature. To this mixture in a 
microwave vial was added degassed DMF (4.4 mL) and allyl tributylstannane 
(0.65 mL, 2.10 mmol) at room temperature under Ar atmosphere. The resulting 
mixture was heated at 160 °C, with stirring, under microwave (Biotage) 
conditions for 30 min before it was cooled to room temperature, and filtered 
through a pad of Celite, eluted with EtOAc. To the mixture was added 
saturated aq. KF solution (40 mL) and vigorously stirred for 1 h. The organic 
layer was separated, and the aqueous layer was extracted with CH2Cl2 (3x). 
The combined organic layers were washed with brine, dried over Na2SO4, 
filtered, and concentrated in vacuo. Flash column chromatography of the crude 
product over silica gel (hexane → 10% EtOAc/hexane) afforded dioxolane-
protected 6-allyl piperonal 3-19 with organotin-impurities, and was carried 
forward to the next step without further purification.  
To a solution of this dioxolane-protected 6-allyl piperonal 3-19 (0.784 g) in 
acetone (HPLC, 18 mL) was added PTSA (0.125 g, 0.657 mmol) at room 
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temperature. The resulting mixture was stirred at room temperature for 4.5 h 
before K2CO3 (0.55 g) was added and stirred for a further 1 h. The suspension 
was filtered through a pad of Celite, eluted with EtOAc, and the filtrate was 
dried over Na2SO4, filtered and concentrated in vacuo. Flash column 
chromatography of the crude product over silica gel (hexane → 8.5% 
EtOAc/hexane) afforded 6-allyl piperonal 3-15 (0.241 g, 97% over two steps) 
as a colourless oil.  
3-15: 1H NMR (300 MHz, CDCl3): δ 10.12 (s, 1H), 7.33 (s, 1H), 6.72 (s, 
1H), 6.05-5.92 (m, 3H), 5.12-4.95 (m, 2H), 3.74-3.71 (m, 2H); 13C NMR (75 
MHz, CDCl3): δ 189.4, 152.5, 147.0, 139.7, 136.9, 128.4, 116.6, 110.6, 108.5, 
101.9, 36.0; MS (IT-TOF): m/z calcd for C11H10O3Na+ [M + Na]+ 213.1, found 
213.2. 
3-19: 1H NMR (300 MHz, CDCl3): δ 7.07 (s, 1H), 6.67 
(s, 1H), 6.03-5.88 (m, 3H), 5.08-4.98 (m, 2H), 4.15-3.98 
(m, 4H), 3.45-3.42 (m, 2H); 13C NMR (75 MHz, CDCl3): 
δ 148.1, 146.1, 137.2, 132.5, 128.7, 115.8, 109.9, 106.5, 101.1, 101.0, 65.2, 
36.2; MS (IT-TOF): m/z calcd for C13H15O4+ [M + H]+ 235.1, found 235.1. 
Representative Procedure for the Preparation of Dialkyl Diazomalonate 
esters: 
 
Dimethyl diazomalonate 3-16: To a solution of dimethyl malonate (1.3 
mL, 11.4 mmol) in CH3CN (32 mL) was added p-ABSA (2.73 g, 11.4 mmol) 








stirred at room temperature for 48 h before it was filtered through a pad of 
Celite, eluted with CH2Cl2. The filtrate was dried over Na2SO4, filtered and 
concentrated in vacuo. Flash column chromatography of the crude product over 
silica gel (10% EtOAc/hexane → 25% EtOAc/hexane) afforded dimethyl 
diazomalonate 3-16 (1.54 g, 86%) as a bright yellow oil.  
3-16: IR (thin film on NaCl cells) vmax = 2118 (C=N str.), 1711 (C=O str.); 
1H NMR (500 MHz, CDCl3): δ 3.84 (s, 6H); 13C NMR (125 MHz, CDCl3): 
δ 161.4, 52.5; ESI-MS: m/z calcd for C5H6O4N2Na+ [M + Na]+ 181.0, found 
180.9.  
Di-tert-butyl diazomalonate 5-69: Procedure was 
repeated with di-tert-butyl malonate (0.35 mL, 1.56 
mmol), p-ABSA (0.566 g, 2.36 mmol) and Et3N (0.37 
mL, 2.65 mmol) in CH3CN (10 mL) at room temperature for 72 h. Flash 
column chromatography of the crude product over silica gel (10% 
EtOAc/hexane) afforded di-tert-butyl diazomalonate 5-69 (0.302 g, 80%) as a 
pale yellow oil. 5-69: IR (thin film on NaCl cells) vmax = 2093 (C=N str.), 1688 
(C=O str.); 1H NMR (300 MHz, CDCl3): δ 1.50 (major) + 1.47 (minor) (s each, 
18H); 13C NMR (75 MHz, CDCl3): δ 160.3, 82.7, 28.3 (major) + 27.9 (minor); 
















β-Piperonyl-substituted α,β-epoxy-1,1-diester 3-12: To a stirring solution 






Cu(acac)2 (1 mol%) at room temperature. The resulting mixture was brought to 
a gentle reflux, followed by the dropwise addition of a solution of dimethyl 
diazomalonate 3-16 (0.102 g, 0.645 mmol) in toluene (2 mL) over 1 h via a 
syringe pump. The reaction was refluxed for a further 1 h upon the completion 
of addition before it was cooled to room temperature. The mixture was filtered 
through a pad of silica gel, eluted with CH2Cl2, and the filtrate was 
concentrated in vacuo. Flash column chromatography of the crude product over 
silica gel (hexane → 10% EtOAc/hexane → 15% EtOAc/hexane → 25% 
EtOAc/hexane) afforded epoxy-1,1-diester 3-12 (95.3 mg, 69%) as a pale 
yellow viscous oil.  
3-12 (Appendix 5, p374): 1H NMR (300 MHz, CDCl3): δ 6.77 (s, 1H), 6.65 
(s, 1H), 5.95-5.82 (m, 3H), 5.10-4.99 (m, 2H), 4.56 (s, 1H), 3.86 (s, 3H), 3.58 
(s, 3H), 3.37-3.35 (m, 2H); 13C NMR (75 MHz, CDCl3): δ 165.8, 163.9, 148.1, 
146.1, 135.8, 132.5, 123.4, 116.4, 109.8, 105.9, 101.2, 62.5, 60.9, 53.4, 52.6, 
36.8; HRMS (EI): m/z calcd for C16H16O7+ [M]+ 320.0896, found 320.0892. 
 
Oxa-[6-5-5] carbocycle 3-17: A solution of epoxy-1,1-diester 3-12 (30 mg, 
0.0937 mmol) in benzene (HPLC, 1.8 mL) was sealed in a quartz vessel under 
an Ar atmosphere. The solution was irradiated with a high power mercury lamp 
(7 UV tubes – 25-30W each) of 254 nm for 11 h at ambient temperatures. 
Solvent was then concentrated in vacuo, and flash column chromatography of 
the crude product over silica gel (5% EtOAc/hexane → 10% EtOAc/hexane → 
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22% EtOAc/hexane) afforded the [3+2] cycloadduct 3-17 (16.2 mg, 54%) as a 
colourless oil. The structure of 3-17 was elucidated based on 2D NMR 
analyses and DEPT studies.  
3-17 (Appendix 5, p375): 1H NMR (500 MHz, CDCl3): δ 6.90 (s, 1H), 6.60 
(s, 1H), 5.93-5.92 (m, 2H), 5.68 (d, J = 7.2 Hz, 1H), 3.80 (s, 3H), 3.60 (s, 3H), 
3.26-3.20 (m, 1H), 3.04 (dd, J = 8.2, 16.2 Hz, 1H), 2.78-2.69 (m, 2H), 2.34 
(dd, J = 7.2, 13.1, Hz, 1H); 13C NMR (125 MHz , CDCl3): δ 170.1, 169.2, 
148.9, 147.2, 135.1, 133.9, 105.7, 104.9, 101.2, 89.9, 87.5, 53.2, 52.9, 41.7, 
40.5, 36.6; HRMS (EI): m/z calcd for C16H16O7+ [M]+ 320.0896, found 
320.0892. 
 
(Ε)−α,β-Unsaturated methyl ester 3-20: To a stirring solution of 
dioxolane-protected 6-allyl piperonal 3-19 (0.2 g, 0.854 mmol) in CH2Cl2 (5 
mL) was added Grubbs II catalyst (30 mg, 0.0353 mmol) and methyl acrylate 
(154 µL, 1.71 mmol) at room temperature. The resulting mixture was refluxed 
for 13 h before it was concentrated in vacuo. Flash column chromatography of 
the crude product over silica gel (hexane → 12% EtOAc/hexane → 22% 
EtOAc/hexane → 24% EtOAc/hexane) afforded (E)-α,β-unsaturated ester 3-20 
(0.223 g, 89%) as a pale yellow oil.  
To a solution of α,β-unsaturated ester 3-20 (61.5 mg, 0.205 mmol) in 
acetone (HPLC, 3 mL) was added PTSA (20 mg, 0.105 mmol) at room 
temperature. The resulting mixture was stirred at room temperature for 6 h 
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before K2CO3 (80 mg) was added and stirred for a further 1 h. The suspension 
was filtered through a pad of Celite, eluted with EtOAc, and the filtrate was 
dried over Na2SO4, filtered and concentrated in vacuo. Flash column 
chromatography of the crude product over silica gel (5% EtOAc/hexane → 
25% EtOAc/hexane) afforded the dioxolane-deprotected aryl aldehyde 3-23 
(52.1 mg, 100%) as a white solid.   
3-23: 1H NMR (300 MHz, CDCl3): δ 10.0 (s, 1H), 7.30 (s, 1H), 7.10 (dt, J = 
6.4, 15.6 Hz, 1H), 6.69 (s, 1H), 6.05 (s, 2H), 5.74-5.68 (m, 1H), 3.89-3.87 (m, 
2H), 3.70 (s, 3H). 
 
β-Piperonyl-substituted α,β-epoxy-1,1-diester 3-21: To a stirring solution 
of aryl aldehyde 3-23 (52.1 mg, 0.210 mmol) in toluene (5 mL) was added 
Cu(acac)2 (1 mol%) at room temperature. The resulting mixture was brought to 
a gentle reflux, followed by the dropwise addition of a solution of dimethyl 
diazomalonate 3-16 (59.6 mg, 0.377 mmol) in toluene (2 mL) over 1 h via a 
syringe pump. The reaction was refluxed for a further 2 h upon the completion 
of addition before it was cooled to room temperature. The mixture was filtered 
through a pad of silica gel, eluted with CH2Cl2, and the filtrate was 
concentrated in vacuo. Flash column chromatography of the crude product over 
silica gel (5% EtOAc/hexane → 16% EtOAc/hexane → 25% EtOAc/hexane) 
afforded epoxy-1,1-diester 3-21 (52 mg, 67%) as a pale yellow viscous oil.  
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3-21 (Appendix 5, p376): 1H NMR (500 MHz, CDCl3): δ 6.99 (dt, J = 6.6, 
15.7 Hz, 1H), 6.78 (s, 1H), 6.61 (s, 1H), 5.93 (s, 2H), 5.75 (d, J = 15.7 Hz, 1H), 
4.47 (s, 1H), 3.85 (s, 3H), 3.70 (s, 3H), 3.57 (s, 3H), 3.49 (d, J = 6.3 Hz, 2H); 
13C NMR (125 MHz , CDCl3): δ 166.5, 165.6, 163.7, 148.3, 146.7, 145.8, 
130,1, 123.6, 122.4, 109.9, 106.2, 101.4, 62.5, 60.5, 53.5, 52.7, 51.5, 35.1; 
HRMS (EI): m/z calcd for C18H18O9+ [M]+ 378.0951, found 378.0947. 
 
Oxa-[6-5-5] carbocycle 3-22: A solution of epoxy-1,1-diester 3-21 (21 mg, 
0.0555 mmol) in benzene (HPLC, 1.8 mL) was sealed in a quartz vessel under 
an Ar atmosphere. The solution was irradiated with a high power mercury lamp 
(7 UV tubes – 25-30W each) of 254 nm for 10 h at ambient temperatures. 
Solvent was then concentrated in vacuo, and flash column chromatography of 
the crude product over silica gel (10% EtOAc/hexane → 22% EtOAc/hexane 
→ 32% EtOAc/hexane) afforded the [3+2] cycloadduct 3-22 (10.9 mg, 52%) 
as a colourless oil.  
3-22 (Appendix 5, p377): 1H NMR (500 MHz, CDCl3): δ 6.87 (s, 1H), 6.61 
(s, 1H), 5.94 (m, 2H), 5.83 (d, J = 7.6 Hz, 1H), 3.80 (s, 3H), 3.74 (s, 3H), 3.62-
3.61 (m, 4H), 3.57-3.52 (m, 1H), 3.10 (dd, J = 8.2, 16.4 Hz, 1H), 2.88 (d, J = 
16.4 Hz, 1H); 13C NMR (125 MHz , CDCl3): δ 171.0, 168.4, 168.1, 149.1, 
147.5, 134.6, 133.4, 105.5, 104.9, 101.3, 89.3, 88.9, 57.1, 53.2, 53.1, 52.5, 





α-Bromo α,β-unsaturated methyl ester 3-43: To a solution of dioxolane-
protected 6-allyl piperonal 3-19 (30 mg, 0.128 mmol) in t-BuOH (1.5 mL), 
0.1M Na phosphate buffer (pH 7.0, 1.5 mL), and THF (1 mL) was added 
NaIO4 (82.2 mg, 0.384 mmol) and potassium osmate (10 mg, 0.0271 mmol) at 
room temperature. The resulting mixture was stirred at room temperature for 5 
h, and diluted with water followed by extraction with EtOAc (3x). The 
combined organic extracts were washed with brine, dried over Na2SO4, 
filtered, and concentrated in vacuo. Flash column chromatography of the crude 
product over silica gel (fast elution: 20% EtOAc/hexane) afforded aldehyde 3-
35 (11.2 mg, 37%) as a pale yellow oil. 
To a solution of Brückner’s HWE reagent 3-42 (22 mg, 0.0571 mmol) in 
THF (1.5 mL) was added NaH (60% dispersion in mineral oil, 3 mg, 0.0750 
mmol) at 0 °C. The mixture was stirred at 0 °C for 30 min before a solution of 
aldehyde 3-35 (11.2 mg, 0.0474 mmol) in THF (1.5 mL) was added dropwise 
at the same temperature. The resulting mixture was stirred from 0 °C to room 
temperature over 1.5 h before it was quenched with water. The mixture was 
extracted with Et2O (3x), and the combined organic extracts were washed with 
brine, dried over Na2SO4, filtered, and concentrated in vacuo. Flash column 
chromatography of the crude product over silica gel (hexane → 12% 
EtOAc/hexane) afforded α-bromo α,β-unsaturated methyl ester 3-43 (13.5 mg, 
77%) as a yellow oil.  
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3-43: 1H NMR (500 MHz, CDCl3): δ 7.05 (s, 1H), 6.77 (t, J = 7.9 Hz, 1H), 
6.72 (s, 1H), 5.94 (s, 2H), 5.84 (s, 1H), 4.13-4.08 (m, 2H), 4.04-3.99 (m, 2H), 
3.89 (d, J = 7.5 Hz, 1H), 3.86 (s, 3H); EI-MS: m/z calcd for C15H15O679Br+ 
[M]+ 370.0, found 370.1, and m/z calcd for C15H15O681Br+ [M]+ 372.0, found 
372.3 (intensity ratio ~1:1). 
 
6-Allyl piperonyl alcohol 3-45: To a solution of 6-allyl piperonal 3-15 (0.2 
g, 1.05 mmol) in THF (7 mL) and MeOH (3.5 mL) was added NaBH4 (92.5 
mg, 2.31 mmol) at 0 °C. The resulting mixture was stirred from 0 °C to room 
temperature over 14 h before it was concentrated in vacuo, and the residue was 
carefully partitioned between 1M HCl and CH2Cl2. The organic layer was 
separated, and the aqueous layer was extracted with CH2Cl2 (2x). The 
combined organic layers were washed with brine, dried over Na2SO4, filtered, 
and concentrated in vacuo. Flash column chromatography of the crude product 
over silica gel (10% EtOAc/hexane → 30% EtOAc/hexane) afforded piperonyl 
alcohol 3-45 (0.188 g, 93%) as a creamy-white solid. 
3-45: mp 93.2-95.6 °C; 1H NMR (500 MHz, CDCl3): δ 6.88 (s, 1H), 6.69 (s, 
1H), 6.00-5.92 (m, 3H), 5.08-4.97 (m, 2H), 4.59 (s, 2H), 3.39-3.37 (m, 2H), 
1.60 (brs, 1H); 13C NMR (125 MHz, CDCl3): δ 147.2, 146.1, 137.6, 132.0, 
131.5, 115.8, 110.1, 109.0, 101.0, 63.0, 36.6; ESI-MS: m/z calcd for 




TBS-protected piperonyl acetaldehyde 3-48: To a solution of 6-allyl 
piperonyl alcohol 3-45 (0.112 g, 0.583 mmol) in anhydrous DMF (3 mL) was 
added TBSCl (0.123 g, 0.816 mmol) and imidazole (99.2 mg, 1.46 mmol) at 
room temperature. The resulting mixture was stirred at room temperature for 
12 h before it was diluted with water, and extracted with Et2O (4x). The 
combined organic extracts were washed with water (1x), followed by brine, 
dried over Na2SO4, filtered, and concentrated in vacuo. Flash column 
chromatography of the crude product over silica gel (hexane → 3% 
EtOAc/hexane) afforded TBS-protected piperonyl alcohol 3-46 (0.172 g, 96%) 
as a pale yellow oil. 
To a solution of this TBS-protected alcohol 3-46 (0.17 g, 0.554 mmol) in 
THF (15 mL) and H2O (5 mL) was added catalytic OsO4 (1 crystal) at room 
temperature. The resulting mixture was stirred at room temperature for 15 min 
before the addition of NaIO4 (0.361 g, 1.69 mmol) in one portion, and the 
suspension was vigorously stirred at room temperature for 4.5 h. The mixture 
was diluted with water, and extracted with EtOAc (3x). The combined organic 
layers were washed with H2O (1x), followed by brine, dried over Na2SO4, 
filtered, and concentrated in vacuo. Flash column chromatography of the crude 
product over silica gel (fast elution with 8% EtOAc/hexane) afforded TBS-
protected piperonyl acetaldehyde 3-48 (0.116 g, 68%) as a pale yellow oil. 
3-48: 1H NMR (500 MHz, CDCl3): δ 9.66 (t, J = 2.2 Hz, 1H), 6.90 (s, 1H), 
6.65 (s, 1H), 5.95 (s, 2H), 4.56 (s, 2H), 3.64 (d, J = 2.5 Hz, 2H), 0.91 (s, 9H), 
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0.08 (s, 6H); 13C NMR (125 MHz, CDCl3): δ 199.4, 147.1, 146.9, 133.7, 123.5, 
110.8, 108.9, 101.1, 63.4, 47.3, 25.9, 18.3, -5.3. 
 
Piperonyl pivaloate 3-47: To a solution of 6-allyl piperonyl alcohol 3-45 
(0.25 g, 1.30 mmol) in CH2Cl2 (5.4 mL) was added pyridine (0.17 mL, 2.08 
mmol) and pivaloyl chloride (0.2 mL, 1.62 mmol) at 0 °C. The resulting 
mixture was stirred at 0 °C to room temperature over 22 h before it was 
quenched with water, followed by extraction with CH2Cl2 (3x). The combined 
organic extracts were washed with saturated aq. NaHCO3 (1x) and water (1x), 
followed by brine, dried over Na2SO4, filtered, and concentrated in vacuo. 
Flash column chromatography of the crude product over silica gel (hexane → 
5% EtOAc/hexane) afforded piperonyl pivaloate 3-47 (0.314 g, 92%) as a pale 
yellow oil. 
3-47: 1H NMR (500 MHz, CDCl3): δ 6.84 (s, 1H), 6.69 (s, 1H), 5.95-5.87 
(m, 3H), 5.08-4.97 (m, 4H), 3.36-3.35 (m, 2H), 1.21 (s, 9H); 13C NMR (125 
MHz, CDCl3): δ 178.1, 148.2, 147.3, 128.8, 114.2, 112.9, 109.7, 101.9, 65.8, 






1,3-Dithiane-2-diethyl phosphonate 3-55[105]: To a solution of 1,3-dithiane 
3-54 (0.5 g, 4.16 mmol) in benzene (HPLC, 12.5 mL) was added NCS (0.555 
g, 4.16 mmol) at 0 °C. The resulting mixture was stirred at room temperature 
for 24 h before triethyl phosphite (0.86 mL, 5.02 mmol) was added, and heated 
at 60 °C for 5 h. The mixture was cooled to room temperature before it was 
filtered through a pad of Celite, eluted with CH2Cl2, and the filtrate was 
concentrated in vacuo. The residue was added with Et2O, and the white 
precipitate produced was filtered through a pad of Celite, eluted with Et2O. The 
filtrate was concentrated in vacuo, and flash column chromatography of the 
crude product over silica gel (5% EtOAc/hexane → 16% EtOAc/hexane → 
32% EtOAc/hexane) afforded 1,3-dithiane-2-diethyl phosphonate 3-55 (0.557 
g, 52%) as a pale yellow oil. 
3-55: 1H NMR (300 MHz, CDCl3): δ 4.30-4.20 (m, 4H), 3.60-3.45 (m, 3H), 
2.58-2.50 (m, 2H), 2.15-2.04 (m, 1H), 2.03-1.90 (m, 1H), 1.36 (t, J = 7.1 Hz, 
6H); ESI-MS: m/z calcd for C8H17O3PS2Na+ [M + Na]+ 279.0, found 279.7.      
 
1,3-Bis-sulfoxide-2-diethyl phosphonate 3-56[106]: To a solution of 1,3-
dithiane-2-diethyl phosphonate 3-55 (0.218 g, 0.852 mmol) in MeOH (3.6 mL) 
and H2O (1.2 mL) was added NaIO4 (0.729 g, 3.41 mmol) at room temperature. 
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The resulting mixture was sealed under an atmosphere of Ar, and stirred for 4 
days. The mixture was filtered through a filter paper under vacuum, eluted with 
MeOH. The filtrate was concentrated in vacuo, and the residue was partitioned 
between water and CHCl3. The organic layer was separated, and the aqueous 
layer was extracted with CHCl3 (5x). The combined organic extracts were 
washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo. 
Immediate flash column chromatography of the crude product over silica gel 
(CH2Cl2 → 10% EtOH/CH2Cl2) afforded bis-sulfoxide 3-56 (0.103 g, 42%) as 
a crystalline white solid. 
3-56: 1H NMR (500 MHz, CDCl3): δ 4.44 (d, J = 17.0 Hz, 1H), 4.32-4.23 
(m, 4H), 3.72 (m, 1H), 3.54-3.50 (m, 1H), 3.14-3.06 (m, 2H), 2.64-2.58 (m, 
2H), 1.38-1.33 (m, 6H); 13C NMR (125 MHz, CDCl3): δ 68.8 (d, 1JCP = 129.3 
Hz), 64.3 (d, 2JCP = 6.4 Hz), 63.7 (d, 2JCP = 7.3 Hz), 46.1, 45.6 (d, 3JCP = 4.5 
Hz), 16.23 (d, 3JCP = 3.6 Hz), 16.18 (d, 3JCP = 3.6 Hz), 14.0; 31P NMR (121 





















Ketene dithioacetal 3-58: To a solution of bis-sulfoxide 3-56 (32.6 mg, 
0.113 mmol) in THF (1.5 mL) was added LiOH (7.2 mg, 0.301 mmol) and a 
solution of 6-allyl piperonal 3-15 (39 mg, 0.205 mmol) in THF (2.5 mL) at 
room temperature. The resulting mixture was refluxed for 6 h before it was 
cooled to room temperature, and concentrated in vacuo. Water was added to 
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the residue, and extracted with CHCl3 (5x). The combined organic extracts 
were washed with brine, dried over Na2SO4, filtered, and concentrated in 
vacuo. Flash column chromatography of the crude product over silica gel 
(CH2Cl2 → 6% EtOH/CH2Cl2) afforded ketene dithioacetal 3-58 (8.7 mg, 24%) 
as a white solid. 
3-58: mp 79.5-83.8 °C; 1H NMR (300 MHz, CDCl3): δ 7.39 (s, 1H), 7.33 (s, 
1H), 6.72 (s, 1H), 6.03 + 6.02-5.96 (s1 + m2, 3H), 5.14-4.97 (m, 2H), 3.73-3.73 
(m, 2H), 3.69 (m, 1H), 3.26 (m, 1H), 3.16 (m, 1H), 2.74-2.92 (m, 2H), 2.38 (m, 
1H); EI-MS: m/z calcd for C15H16O4S2+ [M]+ 324.0, found 324.4.   
Dimer 3-61: A byproduct from the screening of Lewis 
acid-based activation of epoxy-1,1-diester 3-12 
towards intramolecular carbonyl ylide cycloaddition 
(Table 3.2). Representative procedure: To a solution 
of 3-12 (16 mg, 0.0500 mmol) in toluene (1.5 mL) was added Sm(OTf)3 (7.5 
mg, 0.0125 mmol) in a N2-filled Aldrich® AtmosBag glove bag at room 
temperature. The resulting mixture was stirred at room temperature for 12 h 
before it was filtered through a pad of silica gel, eluted with EtOAc. The 
filtrate was concentrated in vacuo, and flash column chromatography of the 
crude product over silica gel (10% EtOAc/hexane → 30% EtOAc/hexane → 
56% EtOAc/hexane) afforded dimer 3-61 (9.2 mg, 56%) as an off-white solid. 
Colourless single crystals of 3-61 for X-ray crystallographic analysis were 
recrystallized from CH2Cl2/MeOH. 3-61: mp 172.8-178.5 °C; 1H NMR (500 
MHz, CDCl3): δ 7.07 (s, 1H), 6.80* (s, 1H), 6.63 (s, 1H), 6.48* (s, 1H), 6.01 
(s, 1H), 6.00 (s, 1H), 5.91* (s, 2H), 5.82-5.61 (m, 1H + 1H*), 5.56* (s, 1H), 










(s, 3H), 3.94* (s, 3H), 3.63* (s, 3H), 3.57 (s, 3H), 3.18-3.06 (m, 2H), 3.04* 
(dd, J = 6.9, 16.4 Hz, 1H), 2.54* (dd, J = 7.5, 16.4 Hz, 1H); 13C NMR (125 
MHz, CDCl3): δ 169.8, 167.9*, 167.3, 148.2, 147.6*, 145.8, 145.4*, 136.8*, 
136.2, 134.2, 132.9*, 126.3*, 124.0, 117.1, 116.5*, 109.9*, 109.6, 108.3, 
107.8*, 101.1, 100.8*, 82.1, 82.0*, 75.9*, 72.5, 54.0, 53.1, 35.7*, 35.2; HRMS 
(IT-TOF): m/z calcd for C32H34O15Na+ [M + Na]+ 681.1795, found 681.1788.  
Note: (*) indicates other diastereomer. 
X-ray Crystal Data and Structure Refinement for Dimer 3-61: 
The crystal is triclinic, space group P-1. The asymmetric unit contains one 
molecule of C32H34O14 and one solvent molecule CH2Cl2 partially replaced by 
MeOH (27%). Final R values are R1= 0.0725 and wR2=0.1435 for 2-theta max 
of 55. 
Identification code  8675 
Empirical formula  C33 H36.50 Cl1.50 O15 
Formula weight  726.30 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 10.1474(9) Å, α = 93.366(2)° 
 b = 11.1294(10) Å, β = 92.373(2)° 
 c = 15.8066(14) Å, γ = 108.731(2)° 
Volume 1684.2(3) Å3 
Z 2 
Density (calculated) 1.432 mg/m3 




Crystal size 0.70 x 0.26 x 0.08 mm3 
Theta range for data collection 1.29 to 27.54° 
Index ranges                                              -13<=h<=13, -14<=k<=14,                     
                                                                  -20<=l<=20 
Reflections collected 21853 
Independent reflections 7756 [R(int) = 0.0480] 
Completeness to theta = 27.54° 99.7 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9821 and 0.8576 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 7756 / 2 / 468 
Goodness-of-fit on F2 1.039 
Final R indices [I>2sigma(I)] R1 = 0.0743, wR2 = 0.1801 
R indices (all data) R1 = 0.1029, wR2 = 0.1963 














Early Studies on a Friedel-Crafts 
Cyclization Strategy to Platensimycin 
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4.1 Third-Generation Retrosynthetic Analysis of (±)-Platensimycin via a 
Friedel-Crafts Cyclization Approach   
In our new retrosynthetic blueprint (Scheme 4.1), the third-generation 
approach towards the tetracyclic enone 1-23 continued to target the assembly 
of the oxabicyclo[3.2.1]octane framework present in the pivotal intermediate 
benzotetrahydrofuran 4-2.  
 
 
Scheme 4.1. Retrosynthetic analysis of the tetracyclic enone 1-23 via a Friedel-Crafts 
cyclization approach. 
 
A Friedel-Crafts cyclization strategy was conceived to deliver the C9-C10 
bond via Lewis acid-promoted Marson-type oxocarbenium chemistry[109-111] 
with the lactol 4-3. Recently, Jennings and coworker utilized this type of 
intramolecular Marson-type Friedel-Crafts arylation technique as key step in 
their total and formal syntheses of some β-C-glycoside natural products (Figure 
4.1), including (+)-Bruguierol C (4-4)[110], (±)-Brussonol (4-5) and (±)-




Figure 4.1. Jennings’ Marson-type Friedel-Crafts cyclization approach to the natural 
products (A) (+)-Bruguierol C (4-4), (B) (±)-Brussonol (4-5) and (±)-Abrotanone (4-
6). 
 
From the choice of starting material, an additional methoxy group was 
deliberately employed in our synthetic plan to further activate the aromatic ring 
towards Friedel-Crafts with para-selectivity (C9 versus C7) for the lactol 
moiety. In the forward sense via 4-2, an intramolecular alkylative 
dearomatization under Mitsunobu activation would be explored to complete the 
cage-like core of the tetracyclic dienone 4-1. Groups of Natsume[112] (Figure 
4.2A) and Boger[113] (Figure 4.2B) were the only few to have reported such 
intramolecular Mitsunobu Ar-3’ alkylation approach in their total syntheses of 




































































Fisure 4.2. Intramolecular Mitsunobu-promoted Ar-3’ alkylation approach to (A) 
Natsume’s duocarmycin SA (4-7), and (B) Boger’s duocarmycin A (4-8). 
 
The realization of a chemo- and diastereoselective conjugate reduction of 
the C4-C9 olefin in 4-1 was anticipated, with the C6-methoxy group believed 
to impart the needed electronic and steric control in securing the cis-C8/C9-
ring junction towards enone 1-23 (vide infra). Retrosynthetically, lactol 4-3 
was expected to arise from the reduction of its lactone obtained from the 
oxidative cyclization of acid 4-9 (Scheme 4.2). We proposed that 4-9 could be 























































Scheme 4.2. Retrosynthetic analysis of the Friedel-Crafts precursor 4-3 via (1) a 
conjugate reduction approach, or (2) an Ireland-Claisen approach.  
 
An asymmetric conjugate reduction[114] of 4-5 should define the required 
stereocenter at C12, followed by a Wittig olefination of the ketone to afford 4-
4. The C12 stereocenter would serve to control the formation of other chiral 
centers later in the synthesis. Finally, α,β-unsaturated ketone 4-5 could in turn 
be assembled by another olefination reaction between vanillin (4-6) and the 
HWE reagent 4-7. Alternatively, the origins of 4-4 were traced back to the allyl 
acetate 4-8 through a retro-Ireland-Claisen rearrangement reaction. However, 
the establishment of the stereocenter at C12 via this approach would be a 
challenge. 4-8 could be conveniently obtained through standard functional 
groups manipulation of the α,β-unsaturated ester 4-9 whose connection to 
eugenol (4-10) could be easily conceived. We initially adopted the first route 




4.2 Efforts to Prepare the Friedel-Crafts Precursor 4-3 via a Conjugate 
Reduction Approach   
The preparation of the HWE reagent 4-7 was achieved in a single step by 
NaH-mediated alkylation of diethyl (2-oxopropyl)phosphonate (4-11) with 
methyl bromoacetate (4-12) in quantitative yield (Scheme 4.3A). Vanillin (4-6) 
was protected under standard protocols either as the TBS-phenyl ether 4-13 or 




Scheme 4.3. A. Preparation of the HWE reagent 4-7. B. Protecting group 
manipulation of vanillin 4-6. 
 
Table 4.1 summarizes the various HWE conditions 4-13/14 and 4-7 were 
subjected to towards α,β-unsaturated ketone 4-15/16. Unfortunately, no desired 
reaction occurred regardless of the base we examined. TBS-group in 4-13 was 
labile under basic conditions and its deprotection was always observed (entries 
1-3). Under K2CO3/TBAHS condition[115], 4-7 was also hydrolyzed to its free 
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acid (entry 3). With 4-14, only starting materials (4-14 and 4-7) were observed 
from the various attempts (entries 4-6). 
Table 4.1. Screening of conditions for the HWE olefination of the protected vanillin 
4-13/14.  
 
entry Pg conditions remarks 
1 TBS 4-13 (1.2 equiv.), NaH (1.4 equiv.), 
THF, -5 °C to rt, 10 h 
4-15 not obtained. 4-7 
recovered. TBS-group (4-13) 
cleaved. 
2 TBS 4-13 (1.2 equiv.), LiHMDS (1.2 
equiv.), THF, -78 °C to -20 °C, 8 h 
4-15 not obtained. 4-7 and 4-
13 recovered. Some TBS-
group (4-13) cleavage 
observed. 
3 TBS 4-13 (1.5 equiv.), K2CO3 (17 equiv.), 
nBu4N(HSO4) (17 mol%), H2O, rt, 
12 h 
4-15 not obtained. Free acid of 
4-7, and TBS-group (4-13) 
cleavage afforded. 
4 Bn 4-14 (1.1 equiv.), NaH (1.3 equiv.), 
THF, -5 °C to rt, 12 h 
Traces of 4-16 observed. 
Mainly 4-7 and 4-14 
recovered. 
5 Bn 4-14 (0.7 equiv.), KHMDS (1 
equiv.), THF, -78 °C to -20 °C, 10 h 





6 Bn 4-14 (0.7 equiv.), LDA (1 equiv.), 
THF, -78 °C to rt, 12 h 
4-16 not obtained. 4-7 and 4-
14 recovered. 
 
Wakharkar et al. reported an interesting Stobbe condensation of several 
substituted arylaldehydes [including piperonal (4-17)] with ethyl levulinate 4-
18 to furnish a mixture of arylidene levulinic acids whose regioselectivity was 
found to be greatly dependent on the temperature of the reaction (Figure 
4.3).[116] Performing the condensation in the presence of ethanolic sodium 




Figure 4.3. Wakharkar’s synthesis of β,γ-acids (4-19) using Stobbe condensation 
conditions. 
 
At the beginning, we tested this Stobbe condensation procedure using 
commercially available piperonal (4-17) and methyl levulinate (4-21) in 
methanolic sodium hydroxide at -10 °C for an extended period of time to 
afford a mixture of piperonal and acids 4-22 and 4-23 (Scheme 4.4). The 
reported work-up procedure to remove levulinic acid from the reaction mixture 
did not work effectively in our hands, thus the mixture of acids was subjected 
to MeI and K2CO3 esterification conditions. The reaction was completed after 
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14 h, and the mixture of esters was separated to give the β,γ-unsaturated Me 
ester 4-24 (34%) and its regioisomer 4-25 (34%) in 1:1 selectivity. 
 
 
Scheme 4.4. Stobbe condensation between piperonal (4-17) and methyl levulinate (4-
21).   
 
We repeated the two-steps procedure with the Bn-protected vanillin 4-14 
(Scheme 4.5). To our dismay, much starting material 4-14 was recovered (65-
70%), and based on the TLC for the esterification step, the regioselectivity was 
in favor of undesired 4-29 over 4-28 with an approximate ratio of 2:1. We did 







Scheme 4.5. Stobbe condensation between Bn-protected vanillin (4-14) and methyl 
levulinate (4-21).   
 
4.3 Synthesis of the Friedel-Crafts Precursor 4-3 via a Claisen-type [3,3]-
Sigmatropic Rearrangement Approach   
The alternative approach to acid 4-4 was then pursued, beginning with the 
protection of commercially available eugenol (4-10) (Scheme 4.6). Eugenol 
was conveniently protected with TBSCl using imidazole in DMF to afford 
TBS-protected eugenol 4-30 in an excellent yield. One pot oxidative cleavage 
of the double bond in 4-30 was found to be low yielding, and did not give a 
clean reaction. A sequential procedure including an Upjohn dihydroxylation of 
the olefin, followed by periodate cleavage of the resulting diol to give aldehyde 
4-31 was adopted. The aldehyde 4-31, without further purification, was 
immediately subjected to a Wittig olefination reaction with methyl propionate 
ylide 4-32 (prepared by Roush’s reported procedure[117]) to afford the highly E-
selective α,β-unsaturated ester 4-33 in 96% yield over three steps. LAH 
reduction, followed by acylation converted 4-33 to the allyl acetate 4-35 





Scheme 4.6. Synthesis of the Ireland-Claisen precursor 4-35 from eugenol (4-10). 
 
Silyl ketene acetal of 4-35 was formed at -78 °C upon treatment with 
KHMDS and TBSOTf. The postulated [3,3]-sigmatropic Ireland-Claisen 
rearrangement leading to the homoallyl acid 4-36 was expected to take place at 
gently elevated temperatures. However, the conversion to 4-36 was 
surprisingly poor, even after raising the temperature of the reaction to room 
temperature and further refluxed in THF for 3 h. In an attempt to recover the 
acetate 4-35, the allyl alcohol 4-37 with TBS-deprotection was isolated instead 





Scheme 4.7. Ireland-Claisen rearrangement of the allyl acetate 4-35. 
 
When the allyl alcohol 4-34, from LAH reduction of 4-33, was refluxed in 
neat triethyl orthoacetate (4-38) and a catalytic amount of propionic acid, the 
latter gratifyingly underwent Johnson-Claisen rearrangement to furnish the 
homoallyl ethyl ester 4-39 in 88% yield (Scheme 4.8).[118] Oxidative 
cyclization in one pot proceeded uneventfully with 4-39 when exposed to 
Sharpless condition to afford a partially inseparable mixture of hydroxyl 
lactones 4-40 and 4-41 in 94% yield. Unfortunately, selectivity for the cis-
/trans-lactone was poor with dr 35:65 at best in favor of undesired trans-4-41 
over cis-4-40. This poor diastereoselectivity could be a result of competing 
substrate steric effect exerted by the existing stereocenter at C12, against 
reagent control from the dihydroquinine ligand in AD-mix-α. When 4-39 was 
subjected to the standard Upjohn dihydroxylation conditions, an approximately 






Scheme 4.8. Preparation of the hydroxyl lactones 4-40/41 via a Johnson-Claisen 
rearrangement and oxidative cyclization. 
 
When the partially inseparable mixture of hydroxyl lactones 4-40 and 4-41 
were exposed to TBSCl and imidazole in DMF, only 4-41 reacted to give the 
trans-TBS ether 4-42 exclusively in 72% yield (Scheme 4.9) while 4-40 was 
recovered with small amounts of unreacted 4-41. This difference in reactivity is 
steric-driven which allowed us to further separate the cis/trans-isomers 4-40 
and 4-41. The enriched mixture of cis-4-40 could then be protected under more 
powerful silylation conditions using TBSOTf and 2,6-lutidine to produce the 





Scheme 4.9. Preparation of an enriched mixture of cis-TBS protected hydroxyl lactone 
4-43. 
  
4-43 was then reduced with DIBAL-H at -78 °C to a diastereomeric mixture 
of lactol 4-44 in 70% yield (Scheme 4.10A). One pot reduction and PTSA-
mediated acetalization with trimethyl orthoacetate in MeOH was expected to 
convert trans-4-42 to the methyl acetal 4-45 (Scheme 4.10B). However, 
undesired bis-TBS-deprotection also occurred in the same pot to give 4-46 in 
81% yield; which we later realized that TBS ethers are generally labile even 
under mild acidic conditions in protic solvent such as PPTS/MeOH.[119] To 
examine protecting group effects with the Friedel-Crafts cyclization, methyl 
acetal 4-46 was re-protected as the bis-Bn ether trans-4-47 in a modest yield of 






Scheme 4.10. A-D. Preparation of various Friedel-Crafts cyclization precursors.  
 
One pot deprotection and re-protection conveniently converted cis-4-40 to 
the bis-Bn lactone cis-4-48 in 84% yield under NaH, BnBr conditions in the 
presence of “wet” DMF (Scheme 4.10C). Both bis-Bn lactol cis-4-49 and its 
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methyl acetal cis-4-50 were prepared from 4-48 via the same reduction and 
acetalization sequence[120] as potential precursors for the Friedel-Crafts 
cyclization.  
Iodolactone trans-4-51, an undesired diastereomer obtained from the 
iodolactonization of the Bn-phenyl ether derivative of ester 4-39 (vide infra), 
could be isomerized to the desirable cis-hydroxyl lactone 4-53 through a two-
step procedure (Scheme 4.10D). Lactone opening of trans-4-51 with ester 
exchange triggered epoxide formation to the epoxy ester 4-52. Subsequent 
ester hydrolysis under potassium silanoate conditions was found best at 
promoting the epoxide re-opening with a clean inversion of stereochemistry. 
The 5-membered lactone re-formation was favored to liberate the cis-hydroxyl 
lactone 4-53, which was then converted to the bis-Bn lactol cis-4-49 by a 
standard protection and reduction sequence.             
4.4 Friedel-Crafts Cyclization via Marson-type Oxocarbenium Chemistry   
The stage was set to explore the highly anticipated Friedel-Crafts cyclization 
with the free lactols cis-4-44/49, as well as the methyl acetal derivatives trans-
4-47 and cis-4-50 (Table 4.2). In the beginning of our study, BF3·Et2O was 
chosen to promote the intramolecular Friedel-Crafts arylation reaction, and we 
found that the Lewis acid has to be used in excess (entries 1-7) as lesser 
equivalents observed longer, yet incomplete conversion coupled with several 
unknown side reactions. Under Jennings’ reported condition in CH2Cl2 at -20 
°C[110-111], cis-TBS lactol 4-44 was unstable and a complex reaction mixture (a 
dark green solution) was resulted after just 15 min of exposure to BF3·Et2O 
(entry 1).  
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Similarly with the protocol of Nagumo and Kawahara[121], both TBS-groups 
of 4-44 were cleaved in CH3CN at 0 °C to give unidentified white solids that 
did not suggest any cyclization has taken place (entry 2). When freshly 
prepared 1M solution of BF3·Et2O in CH2Cl2 was added at lower temperatures 
of -78 °C, and carefully raising to -20 °C over 6 h, bis-Bn methyl acetal trans-
4-47 gratifyingly underwent the desired Friedel-Crafts cyclization across C9-
C10 to furnish trans-derived benzotetrahydrofuran 4-56 in almost quantitative 
yield (entry 3). When the same procedure was repeated with bis-Bn methyl 
acetal cis-4-50, cis-derived benzotetrahydrofuran 4-55 was also obtained, albeit 
in a lower yield of 60% (entry 4).  
Table 4.2. Screening of substrates for the BF3·Et2O-promoted intramolecular Friedel-
Crafts arylation reaction.    
 
entry scale (mg) R
1
, R2 conditions yield (%)a remarks 
1 8.3 TBS, H 
(4-44) 
BF3·Et2O (3 equiv.), 
CH2Cl2, -20 °C, 15 min 
- 4-44 decomposition. 
2 7.6 TBS, H 
(4-44) 
BF3·Et2O (3 equiv.), 
CH3CN, 0 °C, 20 min 
- 4-44 decomposition. 
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3 8.5 Bn, Me 
(4-47) 
1M BF3·Et2O in CH2Cl2 
(6 equiv.), CH2Cl2,           
-78 °C to -20 °C, 6 h 
99 trans-derived isomer 
4-56 obtained. 
4 11.4 Bn, Me 
(4-50) 
1M BF3·Et2O in CH2Cl2 
(6 equiv.), CH2Cl2,           
-78 °C to -20 °C, 6 h 
60 cis-derived isomer 4-
55 obtained. 
5 9.3 Bn, H 
(4-49) 
1M BF3·Et2O in CH2Cl2 
(6 equiv.), CH2Cl2,           
-78 °C to -40 °C, 4 h 
78 cis-derived isomer 4-
55 obtained. 
6 48 Bn, H 
(4-49) 
1M BF3·Et2O in CH2Cl2 
(6 equiv.), CH2Cl2,           
-78 °C to -40 °C, 3 h 
3 4-49 recovered 
(71%). 
7 40 Bn, H 
(4-49) 
1M BF3·Et2O in CH2Cl2 
(6 equiv.), CH2Cl2,           
-78 °C to -40 °C, 3.5 h 




 Isolated yield of cis-/trans-derived benzotetrahydrofurans accordingly. b Water has been used 
to quench the reactions in entries 1-6. 
 
Notably, this intramolecular arylation step proceeded with high stereo- and 
regioselectivity at C9/C10. The alternative C7/C10 regioisomer and C8/C10 
ipso-isomer were not detected. However, the reaction with cis-4-50 was not as 
clean compared with trans-4-47 and lactol cis-4-49 was identified as the major 
side product. Bis-Bn free lactol cis-4-49 was also found to be activated towards 
Friedel-Crafts cyclization to afford 4-55 in 78% yield (entry 5), thus suggesting 
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that protection as the methyl acetal derivative was unduly. However, at only an 
infinitesimal increased in scale of 4-49 (entry 6), the key step was not 
reproducible, and only a trace amount of the desired product 4-55 was 
observed with 71% recovery of the starting lactol 4-49.  
Puzzled, we repeated the cyclization with 4-49 under the same conditions (6 
equivalents of BF3·Et2O at -78 °C to -40 °C), but excess saturated aq. NaHCO3 
solution instead of water (entries 1-6) was used to quench the reaction. This 
change in procedure resulted in the benzotetrahydrofuran 4-55 isolated in 84% 
yield at best (entry 7). At this juncture, we understood that the method of 
quenching is crucial towards minimizing decomposition of the desired product 
4-55, especially from an (Lewis) acid-mediated retro-Friedel-Crafts arylation 
to regenerate the starting lactol 4-49 in the presence of water as nucleophile. 
4.5 Towards Tetracyclic Dienone 4-1 via Alkylative Cyclodearomatization 
under Mitsunobu Activation   
With the key intermediate 4-55 in hand, we were eager to examine the next 
anticipated intramolecular alkylative dearomatization event via Mitsunobu 
activation. However, an attempted bis-debenzylation of 4-55 resulted in a 
global hydrogenolysis which included a reductive opening of the 
tetrahydrofuran ring via reduction of the activated benzylic position at C10, 
and produced diol 4-58 quantitatively (Table 4.3, entry 1). We postulated that 
the opening of the five-membered ring would be thermodynamically favored 
through the release of steric strain; however, the C10 center would be most 
sterically encumbersome towards hydrogenation over Pd-C.  
Henceforth, during our optimization study, we observed that the phenolic 
Bn-group would be most readily cleaved followed by the hydroxyl Bn-group to 
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afford the desired alcohol 4-57. Continuous hydrogenation over catalytic Pd-C 
would then result in further hydrogenolysis at the C10 benzylic position giving 
4-58. Solvent effects were also found to contribute towards the rate of 
hydrogenolysis of the relatively robust hydroxyl Bn-group, and the best 
conversion was achieved with a 2:1 EtOAc/EtOH mixture (entry 5). Selective 
debenzylation and/or incomplete conversion were observed with other 
EtOAc/EtOH ratios even after long hours of reaction (entries 2-4). 
Table 4.3. Conditions for the bis-debenzylation of the benzotetrahydrofuran 4-55.  
 




1 3 1 10% Pd-C (100% w/w), 
H2 (1 atm), rt, 12 h 
- 4-58 was obtained 
quantitatively. 
2 0 1 10% Pd-C (25% w/w), 
H2 (1 atm), rt, 2 h 
- Only phenolic Bn 
cleaved.  
After 10 h, little 
conversion to 4-57. 
3 1 2.5 10% Pd-C (25% w/w), 
H2 (1 atm), rt, 17 h 
32 50% conversion to 
4-57 (TLC). 
4 1 1 10% Pd-C (20% w/w), 
H2 (1 atm), rt, 22 h 





5 2 1 10% Pd-C (20% w/w), 
H2 (1 atm), rt, 20 h 




 Isolated yield of alcohol 4-57. 
 
Alcohol 4-57 was then subjected to Mitsunobu condition[112-113] with 
Tsunoda’s reagent ADDP[122] and tributylphosphine in efforts to promote the 
alkylative cyclodearomatization (C8-C14) and assemble the cage-like structure 
in the tetracyclic dienone 4-1 (Scheme 4.11). When the reaction was performed 
in THF at room temperature, no reaction was observed. A higher boiling point 
solvent mixture of benzene/THF was changed, and the reaction was repeated 
from 50 °C to reflux over 12 h, but only to recover the starting alcohol 4-57 
again. The procedure was also repeated with Mitsunobu reagent DEAD and 
tributylphosphine, but to no success.  
 
 
Scheme 4.11. Alkylative dearomatization of alcohol 4-57 under Mitsunobu activation. 
 
We proposed that the phenolic proton in 4-57 might not be sufficiently 
acidic under these conditions due to the electron-rich aryl system; coupled with 
the inaccessibility of the hydroxyl group located at the more sterically 
encumbersome concave face (towards the diazo-phosphine complex) could 
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render the intended Mitsunobu reaction difficult. The smaller and more 
nucleophilic trimethylphosphine was considered as a substitute for 
tributylphosphine, together with Tsunoda’s reagent to re-examine the 
anticipated alkylative cyclization step[123]. Unfortunately, at that time, we could 
not procure trimethylphosphine in our lab to test our proposition.  
 
 
Scheme 4.12. Attempted iodination of 4-57 resulted in the ring expansion product 4-
60 (A) and its proposed mechanism of formation (B). 
 
We then decided to convert the hydroxyl group in the recovered starting 
alcohol 4-57 to a leaving group in realization of a Masamune-inspired 
version[124] of the intramolecular Ar-3’ alkylation strategy to assemble 4-1. 
When 4-57 was subjected to the iodination conditions with PPh3 and I2 at 
reflux (Scheme 4.12A), benzopyran 4-60 was surprisingly isolated instead of 
the desired iodo-benzotetrahydrofuran 4-59. Upon activation of the hydroxyl 
group by the iodo-phosphonium species (Scheme 4.12B), we rationalized that 
furan ring expansion in the intermediate 4-107 would occur faster than  
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intermolecular substitution with iodide via the oxonium species 4-108. The 
resulting tert-carbocation 4-109 was then probably quenched by residual water 
in the reaction mixture selectively from the less-hindered convex face to 
generate 4-60.  























Scheme 4.13. Synthesis of the Bn-protected homoallyl acid 4-62.  
 
Henceforth, these results necessitated a modification in the synthesis to 
install the iodo-functionality earlier in the sequence via an envisioned 
diastereoselective iodolactonization of acid 4-4 to furnish a cis-iodolactone 
derivative. Owing to its lability to cleave under basic conditions (vide supra), 
the TBS-protecting group in ester 4-39 was converted to its Bn-phenyl ether 
via standard TBAF deprotection followed by benzylation to afford ester 4-61 in 
89% yield over two steps (Scheme 4.13). Subsequent saponification of 4-61 
with aq. NaOH in ethanol gave homoallyl acid 4-62 in inconsistent yields 
between 48-97 %. 
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Table 4.4. Screening of conditions for the stereoselective iodolactonization of acid 4-
62. 
 





1 4-61: 15 CH2Cl2, 0 °C 58 Mainly trans-4-51, traces 
of cis-4-63. Some 
debenzylated (deBn) 4-63 
and 4-51 observed. 
2 13.4 CH3CN, 0 °C 84 1:1 
3 92 CH3CN, 0 °C 49 < 1:1. Significant deBn-   
4-63 and -4-51 observed. 
4 23 sat’d aq. NaHCO3 in 
CH3CN/H2O (1:1 v/v), rt 
90 3:2. No deBn observed. 
5 23 sat’d aq. NaHCO3 in 





 Isolated yield of iodolactones cis-4-63 and trans-4-51 (inseparable mixture). b Diastereomeric 





Optimization of diastereoselectivity with the iodolactonization of acid 4-62 
in preference for the desired cis-iodolactone 4-63 over trans-iodolactone 4-51 
has been nontrivial (Table 4.4). Conditions promoting thermodynamic and 
kinetic controls over the stereochemistry of the iodolactonization process[125] 
were investigated. Ester 4-61 was initially subjected to iodolactonization with 
I2 in CH2Cl2 at 0 °C to afford mainly the undesired trans-iodolactone 4-51 with 
only traces of cis-4-63, and their debenzylated byproducts in minor quantities 
(entry 1). An inseparable mixture of 1:1 dr cis-4-63/trans-4-51 in 84% yield 
was obtained through the thermodynamic iodolactonization of acid 4-62 in 
acetonitrile, and in the absence of base (entry 2).  
Cis- to trans-isomer equilibration via the protonated putative cyclic 
intermediate 4-64 was mechanistically rationalized to account for the formation 
of the more stable isomer trans-4-51.[126] We postulated that the double bond in 
4-62 would favor syn-orientation with the aromatic ring due to pi-pi interactions 
which provided the kinetic formation of the cis-iodolactone 4-63 via 
iodolactonization, followed by deprotonation of 4-64. Protonation of cis-4-63 
back to 4-64, and equilibration to the tert-carbocation intermediate 4-110 
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readily occurred in acidic conditions (entries 1-3). Positioning of the sterically-
large groups anti to each other, followed by re-cyclization into the cationic 
center, finally gave the trans-isomer 4-51 (thermodynamically-favored 
product) preferably.  
The final deprotonation step would generate “HI in-situ” which could cleave 
the benzyl phenyl ether as an undesirable side-reaction. Debenzylation was 
thus observed when the reaction was repeated under the same conditions (entry 
2) on a comparatively larger scale (entry 3). The addition of saturated aq. 
NaHCO3 prevented this undesired benzyl deprotection, and even gave an 
improved dr of 3:2 in CH3CN in favor of the desired cis-4-63 over trans-4-51 
in 90% yield (entry 4). The optimal solvent mixture for the kinetically-
controlled iodolactonization of 4-62 was later found to be THF/H2O (2:1 v/v) 
in the presence of NaHCO3 to furnish cis-4-63 and trans-4-51 in 2.5:1 dr and 
92% yield (entry 5). Diastereoselectivity in the iodolactonization reaction was 
also found to vary with protecting group manipulation.  
 
 
Scheme 4.14. Synthesis of an inseparable mixture of cis-/trans-iodolactols-derived 
iodo-benzotetrahydrofurans 4-67/68.  
 
DIBAL-H reduction of the inseparable mixture of cis-4-63 and trans-4-51 
gave lactols 4-65/66 in 89% yield in preparation for the anticipated Friedel-
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Crafts cyclization (Scheme 4.14). Exposing the mixture of 4-65/66 to BF3·Et2O 
conditions at -78 °C realized the desired regioselective intramolecular Friedel-
Crafts alkylation across C9-C10 to an inseparable mixture of 
benzotetrahydrofurans 4-67 (desired) and 4-68 (undesired). The reaction with 
the iodo-derivative was, however, not as clean as the previous benzyloxy-
derivative based on TLC monitoring.  
While we have earlier found that saturated aq. NaHCO3 quench was 
favorable for the conversion of the benzyloxy-derivative cis-4-49 to 4-55, the 
same procedure resulted in substantial decomposition of the reaction mixture to 
afford 4-67/68 in 45% yield, and several (unidentified) byproducts including 
the starting lactols 4-65/66. Attempted cannula transfer of the reaction mixture 
to a stirring ice-cold solution of saturated aq. NaHCO3, such that the quenching 
environment was always present in surplus, did not improve the reaction 
(48%). Changing the Lewis acid to either TMSOTf or AlCl3 to promote the 
Friedel-Crafts cyclization was unsuccessful. Having excess TMSOTf (10-20 
equivalents) only lead to 50% conversion of 4-65/66 after 5 h at -20 °C, while 
the presence of AlCl3 gave rise to a complex reaction mixture containing some 
amounts of starting lactols. Nevertheless, the synthesis was pushed forward to 
investigate the chemistry towards dienone 4-1. Although the 
benzotetrahydrofurans 4-67 (desired) and 4-68 (undesired) were still 
inseparable at this stage, the ensuing intramolecular alkylative dearomatization 






4.7 Deprotection Strategies for Iodo-Benzotetrahydrofurans 4-67/68  
Table 4.5. Debenzylation of the iodo-benzotetrahydrofurans 4-67/68.   
 
entry conditions remarks 
1 hydrogenolysis 
(entries 1-5) 
10% Pd-C cat., H2 balloon, 
EtOH, rt, 2 h 
Iodo-group cleaved (4-71) 
and poisoned Pd-catalyst.   
2 PdCl2(CH3CN)2 cat., H2 
balloon, EtOH/EtOAc (1:1), 
rt, 2 h 
Mainly 4-67/68 recovered 
and unidentified side-
products.   
3 20% Pd(OH)2-C cat., H2 
balloon, EtOAc, rt, 2 h 
Iodo-group cleaved (4-71) 
and poisoned Pd-catalyst.   
 
4 10% Pd-C cat.,                 
1,4-cyclohexadiene, EtOH, 
rt, 3 h 
Iodo-group cleaved (4-71) 
and poisoned Pd-catalyst.   
5 Pd(OAc)2 cat., Et3SiH, Et3N, 
CH2Cl2, rt, 12 h 
Iodo-group cleaved (4-71) 
and poisoned Pd-catalyst.   
6 oxidation DMDO in acetone, CH2Cl2, 
rt, 30 min 
Complex mixture.  
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7 reduction Na, sec-BuOH, 80 °C,        
6-12 h 
Complex mixture.  
8 Lewis & 
Brønsted acids 
(entries 8-10) 
BF3·Et2O, EtSH, anhyd. 
Na2SO4, 0 °C, 30 min 
C10 proton missing in crude 
1H NMR. Unidentified side-
product. 
9 SnCl4, CH2Cl2, 0 °C to rt,  
12 h 
No reaction. 4-67/68 was 
recovered.  
10 30% MeSO3H (v/v) in 





Cleavage of the benzyl protecting group in 4-67/68 to afford the phenols 4-
69/70 was then pursued, but with no success (Table 4.5). The iodo-
functionality proved to be highly sensitive towards hydrogenation over 
catalytic Pd-C and Pearlman’s catalyst (entries 1 and 3), while with catalytic 
PdCl2(CH3CN)2 no reaction occurred (entry 2). Mild transfer hydrogenation 
procedures employing 1,4-cyclohexadiene/Pd-C, and Et3SiH/Pd(OAc)2 were 
also attempted but failed (entries 4-5). In these experiments, the iodo-group 
was preferentially reduced and the iodine impurities in turn poisoned the 
hydrogenation catalyst, and stopped further hydrogenolysis. Thus, the starting 
material iodo-benzotetrahydrofurans 4-67/68 were mainly recovered along 
with minor amounts of iodo-reduced dimethyl benzotetrahydrofuran 4-71.  
179 
 
Other methods to oxidatively (entry 6) or reductively (entry 7) cleave the 
benzyl protecting group selectively turned out harsh, and complex reaction 
mixtures were generated. The same result was also observed under strongly 
protic acidic (MeSO3H) conditions (entry 10). Lewis acid-mediated benzyl 
deprotections were also disappointing (entries 8-9). These could largely be 
attributed by the presence of the more reactive benzylic position (C10) being 
highly sensitive towards redox and acidic conditions compared to the Bn-
phenyl ether. We anticipated that 4-67/68 would not easily succumb to other 
known debenzylation conditions, and further screening would be futile.    
In light of these results, we attempted to convert the iodo-functionality of 4-
67/68 to the trifluoroacetate leaving group, using the sodium and silver salts of 
trifluoroacetic acid in DMF. The trifluoroacetate group should be robust 
enough to withstand against catalytic hydrogenolysis, while capable of 
participating in the subsequent alkylative dearomatization step. Steric 
encumbersome from the concave face, however, impeded the desired 










Table 4.6. Debenzylation of the iodolactones cis-4-63 and trans-4-51. 
 
entry conditions yield (%)a remarks 
1 SnCl4, CH2Cl2, 0 °C to rt,     
4 h [127] 
11 Mainly 4-63/51 recovered. 
Unidentified side-products. 
2 BF3·Et2O, LiI, CH3CN, 0 °C, 
1 h 
- Iodo-group cleaved (4-74). Dark 
brown color of iodine observed. 
3 TMSCl, LiI, CH3CN, 50 °C, 
5 h 
- ~ 50% iodo-group cleaved (4-
74). Dark brown color of iodine 
observed. 40-45% 4-63/51 
recovered. 
4 HI (57% in H2O), THF, rt,  
12 h 
- Only 4-63/51 recovered.  
5 20% glacial AcOH (v/v) in 
CH2Cl2, rt, 12 h 
- Only 4-63/51 recovered. 
6 30% MeSO3H (v/v) in 
CHCl3, rt, 1 h 
31 54% 4-75/76 isolated. 
7 30% MeSO3H (v/v) in 
CHCl3, PhSMe (20 equiv.),  
0 °C, 15-20 min 
 
 
84 No 4-75/76 observed. 3-4% 
iodo-group cleaved (4-77).  
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8 10% MeSO3H (v/v) in 
CHCl3, PhSMe (20 equiv.),  
0 °C, 50 min 
96 No 4-75/76 or 4-77b observed.  
9 30% MeSO3H (v/v) in 
CHCl3,                              
1,3-dimethoxybenzene (20 
equiv.), 0 °C, 1 h 
36 Still traces of starting 4-63/51 
observed. 40% 4-75/76 isolated. 
No 4-77 observed.  
10 30% MeSO3H (v/v) in 
CHCl3, resorcinol (20 
equiv.), 0 °C, 30 min 
52 ~ 25% 4-75/76 isolated. No 4-77 
observed. 
11 30% MeSO3H (v/v) in 
CHCl3, Et3SiH (40 equiv.),   
0 °C, 45 min 




 Isolated yield of phenols cis-4-72 and trans-4-73 (inseparable mixture). b Iodo-group 
cleavage (4-77) may be observed in different reactions. 
 
 
Early stage debenzylation of the inseparable mixture of cis-/trans-
iodolactones 4-63/51 using various conditions, excluding hydrogenation 
procedures, were pursued (Table 4.6). SnCl4 was ineffective in promoting 
nucleophilic cleavage of the benzyl group through a proposed chelation 
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between the 1,2-dialkoxybenzene (entry 1).[127] Surprisingly, a facile cleavage 
of the iodo-group occurred when exposed to either Lewis acid combinations of 
BF3·Et2O (entry 2) or TMSCl (entry 3) with LiI in CH3CN. Dimethyl lactone 
4-74 was generated through a reductive de-iodination of 4-63/51. Brønsted 
acid-mediated benzyl deprotection was also unsuccessful – hydroiodic acid 
(entry 4) could not debenzylate the Bn-phenyl ether unlike the earlier reported 
“HI in-situ” under non-basic iodolactonization conditions (Table 4.4, entry 3); 
while in the presence of glacial acetic acid observed no reaction (entry 5).  
However, in the presence of 30% methanesulfonic acid (v/v in CHCl3), we 
were gratified to find that the desired deBn-iodolactones 4-72/73 were 
produced in 31% yield (entry 6). A major byproduct (54%) found in this 
reaction was an ortho-benzylated phenol 4-75/76 liberated from the Friedel-
Crafts alkylation of the resulting benzyl cation. Naturally, we proposed that a 
cationic scavenger would be required as co-reagent to suppress this undesired 
Friedel-Crafts alkylation.  
A few scavengers were thus screened (entries 7-11) and thioanisole was 
found to demonstrate superiority in driving the debenzylation reaction to 
completion within 15-20 mins (entry 7). The amount of methanesulfonic acid 
was subsequently reduced to 10% v/v in CHCl3 to similarly achieve an 
excellent conversion, albeit in slightly longer time of 50 min (entry 8). 
Thioanisole was also proved to be most successful in suppressing the unwanted 
Friedel-Crafts alkylation to give 4-75/76.  
However, unlike the other scavengers (1,3-dimethoxybenzene, resorcinol, 
and triethylsilane), thioanisole would inconsistently lead to iodo-group 
cleavage (between 3-12%) from phenols 4-72/73 to generate the dimethyl 
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lactone 4-77, especially in larger reaction scales. The cause for the iodo-group 
cleavage with thioanisole is still not understood. However, we found that the 
iodo-functionality was particularly sensitive to the purity of the reagent where 
in one attempt 60% iodo-cleavage was resulted when a lower grade thioanisole 
was used. Running a large scale debenzylation under these conditions also 
posed other difficulties, such as product purification since thioanisole 
(unpleasant odor) was always required in huge excess. 
 
Scheme 4.15. Protecting group manipulation to different Friedel-Crafts cyclization 
precursors.   
  
A mild deprotection strategy necessitated by the sensitive 
benzotetrahydrofuran intermediate, as previously described, would need to be 
taken into consideration when choosing protecting groups for the phenols 4-
72/73. Any oxidative or reductive procedures have been earlier proven 
incompatible beyond that stage. Henceforth, we decided to protect 4-72/73 as 
the corresponding aryl mesylates 4-78/79 and as its allyl phenyl ethers 4-82/83 
(Scheme 4.15). DIBAL-H reduction to afford the respective lactols was 




4.8 Synthesis of Tetracyclic Dienone 4-1 from Aryl Mesylate 4-80  
The aryl mesylate lactols 4-80/81 gratifyingly underwent the desired 
intramolecular Friedel-Crafts arylation when exposed to BF3·Et2O (Scheme 
4.16). However, in the presence of the aromatic deactivating mesylate, 4-80/81 
necessitated more equivalents of the Lewis acid reagent and longer reaction 
time to afford the iodo-benzotetrahydrofurans 4-86/87 in modest yields 
between 44-63%. Similar to previous experiments, the bigger the reaction scale 
(up to 190 mg of 4-80/81 was attempted), the lower the yield afforded. 
Significant byproducts were produced from this reaction but no starting lactols 
were observed (c.f. the lactols were re-generated as byproducts in previous 
Friedel-Crafts systems).  
 
 
Scheme 4.16. Synthesis of the iodo-phenols 4-88/89 via aryl mesylate protection. 
 
When the benzotetrahydrofurans 4-86/87 were exposed to 2 equivalents of 
freshly prepared LDA,[128] the conversion was low but the reaction was 
encouragingly clean. 6 equivalents of LDA were found to be necessary to 
cleanly deprotect the aryl mesylates selectively at 0 °C to furnish the iodo-
phenols 4-88/89 in 84% yield for the first time (Scheme 4.16). This sets the 
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stage for the highly anticipated Masamune-inspired intramolecular alkylative 
dearomatization to assemble the cage-like core in tetracyclic dienone 4-1.       
Table 4.7. Screening of conditions for the intramolecular alkylative dearomatization 
to tetracyclic dienone 4-1. 
 
entry conditions yield (%)a remarks 
1 From 4-86/87: 
i. LDA, THF, 0 °C, 30 min; 
ii. 0 °C to rt to reflux 
- 4-88/89 observed with unknown 
baseline material (TLC). 
2 From 4-86/87: 
i. LDA, THF, 0 °C, 30 min; 
ii. MeOH (5 equiv.), 0 °C to   
rt to reflux 
- 4-88/89 cleanly isolated in 84% 
yield. 
3 NaH, THF/DMF (1:1 v/v),     
0 °C to rt, 12 h 
- Only 4-88/89 recovered. 
4 NaOtBu, tBuOH, reflux, 5 h   - Complex mixture  
5 DBU (20 equiv.), CH3CN,    
rt, 20 hb 
trace Mainly 4-88/89 recovered. 
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6 DBU (15 equiv.), CH3CN,    
65 °C, 8 h 
86 4-89 recovered quantitatively. 
7 From 4-86/87: 
i. LDA, THF, 0 °C, 30 min; 
ii. DBU (15 equiv.), CH3CN,  
68 °C – 78 °C, 10 h 
85  
(2 steps) 
4-89 recovered quantitatively. 
No purification required after 
aryl mesylate deprotection. 
 
a
 Isolated yield of dienone 4-1 wrt 4-88. b Condition was successfully tested with the mixture 
of iodo-lactones 4-72/73 in a model reaction to give 1:1 4-90/91.  
 
 
Various conditions were experimented to promote alkylative 
cyclodearomatization of the cis-iodo-phenol 4-88 selectively (Table 4.7). 
Originally, we thought to perform the reaction in the same pot following 
mesylate deprotection of 4-86/87 by gradually raising the temperature from 0 
°C to reflux. The first attempt, without quenching excess LDA, probably led to 
some decomposition of the intermediates 4-88/89 (entry 1), while the second 
attempt with prior MeOH quenched afforded only 4-88/89 cleanly (entry 2).  
Subjecting 4-88/89 directly to other Winstein Ar-3’ spirocyclization 
conditions, including NaH in THF/DMF[129] and NaOtBu in tBuOH[124a] were 
also unsuccessful (entries 3-4). Boger’s protocol with DBU in CH3CN[113] was 
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eventually applied with success to afford the tetracyclic dienone 4-1 (entries 5-
6). In the presence of excess base and elevated temperatures at 65 °C, 4-88 was 
specifically spirocyclized to 4-1 in 86% yield, while the trans-iodo-phenol 4-
89 was recovered quantitatively. Finally, we optimized the condition to furnish 
4-1 through its mixture of aryl mesylates precursors 4-86/87, without stepwise 
purification, in 85% yield over two steps (entry 7). 
 
 
Scheme 4.17. Improved synthesis to the Ms-protected cis-/trans-iodolactones 4-78/79. 
   
In order to minimize protecting group manipulations, we next examined the 
influence of the aryl mesylate versus the benzyl phenyl ether towards cis-
/trans-selectivity in the iodolactonization process (Scheme 4.17). TBS-
protecting group in ester 4-39 was converted to the mesylate via standard 
TBAF-mediated desilylation, followed by treatment with MsCl and Et3N to 
furnish ester 4-92 in 92% yield over two steps. Hydrolysis of 4-92 by treatment 
with aq. LiOH in THF was more reproducible [cf. saponification of 4-61 to 4-
62 gave yields between 48-97% (Scheme 4.13)] giving acid 4-93 in 84% yield.  
However, to our disappointment, the same kinetic iodolactonization 
procedure with 4-93 in the presence of I2 in saturated aq. NaHCO3 and THF (or 
CHCl3) afforded only a 1:1 cis-/trans-isomer of iodolactones 4-78/79 in 89% 
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yield. Diastereoselectivity was marginally improved to 3:2 dr (4-78/79), albeit 
in only 43% yield when we applied Wirth’s iodolactonization methodology 
using in-situ generated ICl-amine complex at -78 °C.[130] In a trial experiment 
with the free phenol of acid 4-93, the same iodolactonization protocol using I2 
produced a complex mixture, and this justified the need for an appropriate 
protecting-group strategy. 
4.9 Optimization of Synthetic Sequence 
Benzyl protection (acid 4-62) proved to be most favorable for maximizing 
the yield and diastereoselectivity of the iodolactonization process. Henceforth, 
our next step was to shorten and optimize the current synthetic endeavor by 
avoiding unnecessary TBS-protection (Scheme 4.6), and to obtain greater 
quantities of the Bn-protected cis-iodolactone 4-63. The new synthesis 
commenced with the benzyl protection of eugenol (4-10) in excellent yield 
(Scheme 4.18).  
Cross-metathesis of Bn-protected eugenol 4-94 with methyl methacrylate 
(4-95) was attempted in the hope of accessing the α,β-unsaturated ester 4-96 in 
one step. However, in the presence of either Grubbs II[131] or Hoveyda-Grubbs 
II[132] catalyst, both catalytic conditions yielded complex reaction mixtures with 
highly viscous tar-like substances. While we tried to isolate the desired ester 4-
96 through column chromatography, it was found to be contaminated with the 
one methylene short ester 4-97 of similar Rf – resulted from a preceeding 





Scheme 4.18. Cross-metathesis to prepare the α,β-unsaturated Me ester 4-96. 
  
Thus, a similar sequence of events to elaborate the TBS-protected eugenol 
4-30 (Scheme 4.6) was repeated with 4-94 (Scheme 4.19). Oxidative cleavage 
of the olefin, followed by Wittig olefination afforded α,β-unsaturated ester 4-
96 in 93% yield over three steps. LAH reduction, followed by the ortho-ester 
(Johnson) Claisen rearrangement furnished the homoallyl ethyl ester 4-61 in 
good yield over two steps. However, the capricious yields obtained during the 
saponification of the ester 4-61 to its acid 4-62 (vide supra) resulted in 
substantial loss of materials during the scale-up, while iodolactonization with 





Scheme 4.19. Improved synthesis to the deBn-iodolactones 4-72/73 from the Bn-
protected eugenol 4-94.  
 
We circumvented the problem with an Eschenmoser-Claisen rearrangement 
of the allyl alcohol 4-99 with amide acetal 4-100 to afford the dimethyl amide 
4-101 quantitatively. This was followed by iodolactonization under biphasic 
conditions, without the need of NaHCO3, to provide the inseparable mixture of 
iodolactones cis-4-63 and trans-4-51 in 2:1 dr and 96% yield. Subsequent 
benzyl deprotection (4-72/73) with 10% MeSO3H and PhSMe provided the 
entry point for suitable protecting-group manipulation, allowing us to further 




4.10 SnCl4-Mediated Friedel-Crafts Cyclization of the Free Lactol of Aryl 
Allyl Ethers 4-84/85 
The lactols of allyl phenyl ether 4-84/85 were prepared from 4-72/73 in two 
steps (Scheme 4.15) and explored in our Friedel-Crafts optimization study 
(Table 4.8). They were similarly subjected to BF3·Et2O-mediated cyclization 
conditions to afford the iodo-benzotetrahydrofurans 4-102/103 in again modest 
yield (48%) after saturated aq. NaHCO3 quench (entry 1). However, 4-84/85 
were found to be more reactive than the mesylate derivatives (4-80/81), and 
they gave a cleaner reaction compared to their benzyl counterparts (4-65/66).  
A different Lewis acid reagent SnCl4[133] was experimented with 4-84/85, 
and Friedel-Crafts cyclization was completed within 50 min characterized by a 
bright yellow color change from a clear colorless reaction mixture. 4-102/103 
was obtained in an improved 74% yield (entry 2). The rate of reaction was also 
found to be increased significantly with higher equivalents of SnCl4 (entries 2-
4). However, when this condition was repeated with 250 mg of 4-84/85, the 
yield dropped drastically to 35% with the same saturated aq. NaHCO3 quench 
(entry 5). Approximately 40% of the starting lactols 4-84/85 were re-generated 
along with some unidentified byproducts. This disappointing result prompted 
us the need to scrutinize various aqueous and non-aqueous based methods to 






























entry scale (mg) F-C conditions quenching method yield (%)a 
1 30 BF3·Et2O (6 equiv.), 
CH2Cl2, -78 °C, 3.5 h 
Sat’d NaHCO3 to reaction 
mixture above -40 °C 
48 
2 30  SnCl4 (6 equiv.), 
CH2Cl2, -78 °C, 50 min 
Sat’d NaHCO3 to reaction 
mixture above -40 °C 
74 
3 60 SnCl4 (3.5 equiv.), 
CH2Cl2, -78 °C, 4 h 
Sat’d NaHCO3 to reaction 
mixture above -40 °C 
55 
4 30 SnCl4 (10 equiv.), 
CH2Cl2, -78 °C, 10 min 
Sat’d NaHCO3 to reaction 
mixture above -40 °C 
64 
5 250 SnCl4 (6 equiv.), 
CH2Cl2, -78 °C, 50 min 
Sat’d NaHCO3 to reaction 
mixture above -40 °C 
35 
6 30 SnCl4 (6 equiv.), 
CH2Cl2, -78 °C, 50 min 
Direct addition of silica at 




7 30 SnCl4 (6 equiv.), 
CH2Cl2, -78 °C, 50 min 
Addition of excess 





8 30 SnCl4 (6 equiv.), 
CH2Cl2, -78 °C, 50 min 
Reaction mixture to 0.1 M 
Na phosphate buffer (pH 




9 30 SnCl4 (6 equiv.), 
CH2Cl2, -78 °C, 50 min 
Reaction mixture to brine 
at 0 °Cd 
77 
10 30 SnCl4 (6 equiv.), 
CH2Cl2, -78 °C, 50 min 
Reaction mixture to sat’d 
aq. NH4Cl at 0 °Cd 
84 
11 200 SnCl4 (6 equiv.), 
CH2Cl2, -78 °C, 50 min 
 
Reaction mixture to sat’d 
aq. NH4Cl at 0 °Cd,e 
77 
12 280 SnCl4 (6 equiv.), 
CH2Cl2, -78 °C, 50 min 
Reaction mixture to sat’d 
aq. NH4Cl at 0 °Cd,e 
54 
13 480f SnCl4 (6 equiv.), 
CH2Cl2, -78 °C, 50 min 
Reaction mixture to sat’d 




 Isolated yield of benzotetrahydrofurans 4-102 and 4-103 (inseparable mixture).                        
b
 Decomposition in the flash column. c Mainly 4-84 and 4-85 were re-generated upon work-up. 
d
 Vigorous stirring at 0 °C to uniformly mixed the SnCl4 was essential for reproducible results.  
e
 At least 400 mL of sat’d NH4Cl was required to quench every 200 mg scale of 4-84/85 (based 
on 6 equiv. of SnCl4). f Divided into 3 batches of 96 mg, 156 mg, and 228 mg. 
 
Non-aqueous based techniques such as directly adding silica gel to the 
reaction mixture and loading onto a flash column was undesirable (entry 6). A 
complex streak of byproducts were collected from the column, including iodine 
was observed during the initial elution. Using Et2NH to mop up SnCl4 before 
subjecting the mixture to aqueous work-up gave mainly re-generated lactols 4-
84/85, and trace amounts of desired 4-102/103 only (entry 7).  
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Aqueous based protocols including the rapid pouring of the reaction mixture 
(at -78 °C) into an ice-cold stirring solution of 0.1 M sodium phosphate buffer 
(entry 8), brine (entry 9) and saturated aq. NH4Cl (entry 10) was initially 
practiced and promising results were afforded. An optimized yield of 84% at 
30 mg scale (4-84/85) was obtained with SnCl4 quenched in saturated aq. 
NH4Cl. For scales up to 200 mg (entry 11), satisfying and reproducible yields 
between 72-77% were furnished.  
However, one practical drawback with this method was the large volume of 
saturated aq. NH4Cl (400 mL/200 mg) required to quench the excess SnCl4 
with vigorous stirring at 0 °C. This procedure became rather impractical with 
reactions going above 200 mg scale and accompanied by a significant drop in 
yield (entry 12). Consequentially, the Friedel-Crafts cyclization of 4-84/85 has 
to be best performed in batches for a larger scale such as in entry 13, with an 
overall good yield of 70-72% obtained. 
4.11 Completion of the Tetracyclic Dienone (±)-4-1 
Initial attempt towards the deallylation of benzotetrahydrofurans 4-102/103 
under palladium-catalyzed reductive cleavage[134] afforded iodo-phenols 4-
88/89 in 70% yield. A minor byproduct (4-104) resulting from a further iodo-
group cleavage with Pd(PPh3)4 and NaBH4 transfer hydrogenation-type system 
was also isolated. A mild and high-yielding aryl allyl ether cleavage was then 
achieved by exposing 4-102/103 to the conditions [Pd(PPh3)4, K2CO3, MeOH] 
developed by Thayumanavan and co-workers[135] to smoothly provide 4-88/89 
in 96% yield. Employing the same intramolecular alkylative dearomatization 
conditions to 4-88/89 reliably furnished the dienone 4-1, and the undesired 4-





Scheme 4.20. Synthesis towards the tetracyclic enone 1-23 through dienone 4-1 from 
iodo-benzotetrahydrofuran 4-102.   
  
After the racemic synthesis of (±)-4-1 was completed, Corey’s[37b] and 
Mulzer’s[37c,38c] reported sequential of events – (1) treatment of their C6-
demethoxy analog of 4-1 to a stereoselective double olefinic reduction, 
followed by (2) a regioselective oxidation to provide the C6/C7 α,β-
unsaturation in enone 1-23 was conceived. Interestingly, our results revealed 
that the C6 α-OMe group actually exert a strong influence over the reduction 
process of 4-1. Catalytic hydrogenation of 4-1 over Pd-C in ethanolic 
KOH/EtOAc mixture furnished a 1:3 dr in favour of undesired C8/C9-trans 
decalin 4-106 over desired C8/C9-cis decalin 4-105. This selectivity turns out 
poorer than Mulzer’s original report of 1:2 dr (C8/C9-cis/trans decalin) with 
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their C6-demethoxy analog of 4-1. In addition, Mulzer’s investigation on using 
Crabtree’s Ir-catalyst under 1 atmosphere of H2 afforded a 1.3:1 dr C8/C9-
cis/trans decalin mixture at best from their C6-demethoxy intermediate. No 
reaction was, however, observed with 4-1 in our hands under the same 
conditions.  
High diastereoselectivity across the C8/C9 ring junction has been reported 
to be achievable via high pressure hydrogenation conditions that required 
specialized apparatus and reagents. These include Corey’s 600-psi 
Rh(I)/DIOP-catalyzed hydrogenation[37b] and, recently, Mulzer and Pfaltz 
optimized their Ir(I)/N,P-ligand-catalyzed hydrogenation procedure at 50 bar of 
pressure.[37c] Neither possessing the specialized apparatus nor reagents, we 
pursued alternative methods to realize a stereocontrolled reduction process. We 
proposed that the additional α–OMe group would be an important chemo- and 
stereocontrol for the conjugate reduction of the more electron-deficient C4-C9 
olefin of 4-1 to the C6-methoxy enone of 1-23 (versus its C9-epimer). The 
development of an asymmetric route to 4-1 was pursued and the details are 
described in the following chapter which include the investigative study on the 
stereoselective conjugate reduction of the dienone towards the assembly of 
enone (-)-1-23. 
4.12 Summary                                            
A new Friedel-Crafts cyclization strategy was devised to assemble the 
tetrahydrofuran moiety in our third-generation approach to the tetracyclic 
enone (±)-1-23 of platensimycin (1-4). The pivotal C9-C10 bond was formed 
through a direct para-arylation of a Marson-type oxocarbenium species 
generated from the free iodolactols 4-84/85 promoted by SnCl4 at best.  
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Beginning from eugenol, the inseparable mixture of cis-4-84 and trans-4-85 
in 2:1 dr across C12/C15 was accessed through a longest linear sequence of 
nine steps in 62% overall yield. Protecting group strategy has been essential in 
realizing our synthetic efforts. Diastereoselectivity in the iodolactonization step 
was found to be best achieved with the benzyl protection of the phenol unit. 
After considerable investigation, the benzyl group in iodolactones 4-63/51 was 
selectively cleaved under MeSO3H-catalyzed condition in the presence of 
PhSMe as the cation scavenger. The free phenol was re-protected as the aryl 
allyl ether to activate the Friedel-Crafts cyclization, while having the advantage 
over its Bn-phenyl ether counterpart for its mild deprotection by treating the 
redox-sensitive benzotetrahydrofurans 4-102/103 to Pd(0)-catalyst and K2CO3.  
The desired intramolecular alkylative dearomatization that ensued with 
iodo-phenols 4-88/89 was screened against different bases, and DBU in 
CH3CN was found optimal in driving the cyclodearomatization of cis-4-88 
specifically to dienone 4-1. Investigations would be carried out to determine 
the conditions required to install the desired cis-C8/C9 relative stereochemistry 
in enone 1-23 under reagent control. Atmospheric hydrogenation of 4-1 over 
catalytic Pd-C hinted that the substrate’s inherent steric favors the undesired 
C8/C9-trans decalin 4-106 formation over C8/C9-cis decalin 4-105 in the 
























Experimental Procedures and Characterization Data: 
 
Methyl 3-(diethoxyphosphoryl)-4-oxopentanoate 4-7: To a solution of 
diethyl-(2-oxopropyl)-phosphonate 4-11 (150 mg, 0.773 mmol) in THF (3.5 
mL) was added NaH (60% dispersion in mineral oil, 48 mg, 1.2 mmol) at 0 °C. 
The resulting mixture was stirred at 0 °C for 10 min, followed by 2 h at room 
temperature before it was cooled to 5 °C. To the mixture was added methyl 
bromoacetate 4-12 (0.11 mL, 1.16 mmol), and stirred at room temperature for 
12 h before it was quenched with water. The organic layer was separated, and 
the aqueous layer was extracted with EtOAc (5x). The combined organic layers 
were washed with brine, dried over Na2SO4, filtered, and concentrated in 
vacuo. Flash column chromatography of the crude product over silica gel (50% 
EtOAc/hexane → 65% EtOAc/hexane) afforded phosphonate 4-7 (206 mg, 
100%) as a yellow oil. 
4-7: 1H NMR (500 MHz, CDCl3): δ 4.15-4.08 (m, 4H), 3.75-3.65 + 3.66 (m1 
+ s2, 4H), 3.17-3.09 (m, 1H), 2.69 (ddd, J = 3.1, 9.4, 17.6 Hz, 1H), 2.41 (s, 
3H), 1.34-1.30 (m, 6H); 13C NMR (125 MHz, CDCl3): δ 202.2 (d, 2JCP = 4.5 
Hz), 171.9 (d, 3JCP = 19.1 Hz), 63.0 (d, 2JCP = 6.4 Hz), 62.7 (d, 2JCP = 6.4 Hz), 
50.4 (d, 1JCP = 126.3 Hz), 31.2 (d, 2JCP = 2.7 Hz), 16.3 (d, 3JCP = 6.4 Hz); ESI-




Vanillin TBS ether 4-13: To a solution of vanillin 4-6 (1.0 g, 6.57 mmol) 
in anhydrous DMF (13 mL) was added imidazole (1.07 g, 15.7 mmol) and 
TBSCl (1.29 g, 8.56 mmol) at room temperature. The resulting mixture was 
stirred at room temperature for 14 h before it was diluted with Et2O, and 
poured into water. The organic layer was separated, and the aqueous layer was 
extracted with Et2O (3x). The combined organic layers were washed with water 
(1x), followed by brine, dried over Na2SO4, filtered, and concentrated in vacuo. 
Flash column chromatography of the crude product over silica gel (hexane → 
7.5% EtOAc/hexane) afforded TBS ether 4-13 (1.61 g, 92%) as a orangish-
yellow oil.  
4-13: 1H NMR (500 MHz, CDCl3): δ 9.85 (s, 1H), 7.40-7.36 (m, 2H), 6.96 
(d, J = 8.2 Hz, 1H), 3.87 (s, 3H), 1.00 (s, 9H), 0.20 (s, 6H).    
 
Vanillin Bn ether 4-14: To a solution of vanillin 4-6 (0.5 g, 3.29 mmol) in 
anhydrous DMF (11 mL) was added anhydrous K2CO3 (1.36 g, 9.84 mmol), 
TBAI (158 mg, 0.428 mmol) and BnBr (0.59 mL, 4.96 mmol) at room 
temperature. The resulting mixture was warmed to 52 °C and stirred for 12 h 
before it was cooled to room temperature, and quenched with cold water. 
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Vigorous stirring was maintained for 5-10 min until a homogenous layer was 
obtained, and extracted with Et2O (3x). The combined organic extracts were 
washed with water (1x), followed by brine, dried over Na2SO4, filtered, and 
concentrated in vacuo. Flash column chromatography of the crude product over 
silica gel (hexane → 10% EtOAc/hexane → 20% EtOAc/hexane) afforded 
benzyl ether 4-14 (0.796 g, 100%) as a pale yellow solid.  
4-14: mp 55.0-58.9 °C; 1H NMR (500 MHz, CDCl3): δ 9.84 (s, 1H), 7.45-






































Piperonal-derived α,β-unsaturated methyl ketone 4-24: To a solution of 
piperonal 4-17 (100 mg, 0.67 mmol) and methyl levulinate 4-21 (0.21 mL, 1.7 
mmol) in MeOH (2 mL) was added 2M aq. NaOH solution (0.85 mL, 1.7 
mmol) dropwise at -10 °C. The resulting mixture was stirred at the same 
temperature for 11 h before it was concentrated in vacuo, and diluted with 
water. The aqueous layer was extracted with CH2Cl2 (2x) before it was 
acidified with a few drops of conc. HCl to pH 1 with stirring. The resulting 
aqueous layer was extracted with EtOAc (3x), and the combined EtOAc 
extracts were washed with water (1x), followed by brine, dried over Na2SO4, 
filtered, and concentrated in vacuo.  
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To this crude mixture of acids in anhydrous DMF (9 mL) was added 
anhydrous K2CO3 (0.793 g, 5.74 mmol) and MeI (0.71 mL, 11.4 mmol) at 
room temperature. The resulting mixture was stirred at room temperature for 
14 h before it was diluted with water, and extracted with Et2O (3x). The 
combined organic extracts were washed with water (1x), followed by brine, 
dried over Na2SO4, filtered, and concentrated in vacuo. Flash column 
chromatography of the crude product over silica gel (hexane → 20% 
EtOAc/hexane) afforded α,β-unsaturated methyl ketone 4-24 (59.4 mg, 34%) 
and α,β-unsaturated methyl ester 4-25 (59.4 mg, 34%) as pale yellow oils.  
4-24: 1H NMR (500 MHz, CDCl3): δ 6.82 (s, 1H), 6.78 (d, J = 7.5 Hz, 1H), 
6.70-6.68 (m, 2H), 5.99 (s, 2H), 3.69 (s, 3H), 3.45 (s, 2H), 2.09 (s, 3H); 13C 
NMR (125 MHz, CDCl3): δ 199.5, 170.4, 148.2, 147.8, 136.5, 135.1, 129.4, 
123.1, 108.6, 108.3, 101.3, 53.4, 37.6, 29.7.    
4-25: 1H NMR (500 MHz, CDCl3): δ 7.61 (s, 1H), 6.90-6.84 (m, 3H), 6.01 
(s, 2H), 3.71 (s, 3H), 3.52 (s, 2H), 2.46 (s, 3H); 13C NMR (125 MHz, CDCl3): 
δ 205.8, 167.8, 148.6, 148.0, 143.1, 133.3, 128.4, 124.2, 109.0, 108.6, 101.5, 
54.9, 40.7, 30.2.     
 
Eugenol TBS ether 4-30: To a solution of eugenol 4-10 (1.0 g, 6.09 mmol) 
in anhydrous DMF (12 mL) was added imidazole (0.995 g, 14.6 mmol) and 
TBSCl (1.19 g, 7.89 mmol) at room temperature. The resulting mixture was 
stirred at room temperature for 20 h before it was diluted with Et2O, and 
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poured into water. The organic layer was separated, and the aqueous layer was 
extracted with Et2O (3x). The combined organic layers were washed with water 
(1x), followed by brine, dried over Na2SO4, filtered, and concentrated in vacuo. 
Flash column chromatography of the crude product over silica gel (hexane → 
5% EtOAc/hexane) afforded TBS ether 4-30 (1.69 g, 99%) as a yellow oil.  
4-30: 1H NMR (300 MHz, CDCl3): δ 6.71 (d, J = 7.9 Hz, 1H), 6.61-6.56 (m, 
2H), 5.97-5.83 (m, 1H), 5.03-4.97 (m, 2H), 3.72 (s, 3H), 3.26 (d, J = 6.7 Hz, 
1H), 0.93 (s, 9H), 0.08 (s, 6H); 13C NMR (75 MHz, CDCl3): δ 150.7, 143.2, 
137.8, 133.4, 120.7, 120.6, 115.4, 112.6, 55.4, 39.9, 25.7, 18.4, -4.7; ESI-MS: 














H2O, 70 °C rt
 
Methyl propionate ylide 4-32[117]: A mixture of triphenylphosphine (14.8 
g, 56.4 mmol) and methyl-2-bromopropionate (7.00 mL, 62.7 mmol) in H2O 
was stirred at 70 °C for 24 h. The yellow mixture was cooled to room 
temperature and a solution of NaOH (5.02 g, 125.5 mmol) in H2O (147 mL) 
was added. The resulting mixture was swirled for 5 min at room temperature 
and CH2Cl2 was added to dissolve the yellow sticky solid that formed. The 
organic layer was separated and the aqueous layer was extracted with CH2Cl2 
(2x). The combined organic layers were washed with brine, dried over Na2SO4, 
filtered, and concentrated in vacuo. The solid residue was triturated with 
hexane and filtered. The resulting solid was dried in vacuo to give the ylide 4-
32 (18.3 g, 93%) as a yellow solid.  
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4-32: 1H NMR (500 MHz, CDCl3): δ 7.86-7.43 (m, 15 H), 3.59 (42 %) + 
3.13 (58 %) (brs, 3H), 1.61 (d, J = 13.8 Hz, 3H). [Lit.: 1H NMR (200 MHz, 
CDCl3): δ 7.9-7.4 (m, 15 H), 3.61 (40%) + 3.13 (60%) (3H), 1.61 (d, J = 13.7 
Hz, 3H).] 
 
α,β-Unsaturated methyl ester 4-33: To a solution of TBS ether 4-30 (0.5 
g, 1.80 mmol) in t-BuOH (30 mL) and THF (12 mL) was added a solution of 
NMO (50% w/w in H2O, 0.505 g, 2.16 mmol) in H2O (6 mL) and OsO4 (2 
mol%) at room temperature. The resulting mixture was stirred at room 
temperature for 14 h before it was cooled to 0 °C, and quenched with NaHSO3 
(20 g, 3 M in H2O). The mixture was warmed to room temperature and stirred 
for 45 min. The organic layer was separated and concentrated in vacuo, and 
EtOAc was added to re-dissolve the residue that formed. The aqueous layer 
was extracted with EtOAc (3x), and the combined organic layers were washed 
with H2O (1x), followed by brine, dried over Na2SO4, filtered, and 
concentrated in vacuo.  
To this crude diol in THF (18 mL) and H2O (9 mL) was added NaIO4 (0.621 
g, 2.90 mmol) at room temperature, and stirred for 3 h. The resulting mixture 
was carefully concentrated to less than half its volume by removing THF under 
vacuo at 30 °C. The mixture was diluted with water/brine (1:1) and extracted 
with Et2O (3x). The combined organic extracts were washed with brine, dried 
over Na2SO4, filtered, and concentrated in vacuo.  
205 
 
To this crude aldehyde 4-31 in CH2Cl2 (30 mL) was added ylide 4-32 (0.76 
g, 2.18 mmol) at 0 °C. The resulting mixture was stirred from 0 °C to room 
temperature over 12 h before it was concentrated in vacuo. Flash column 
chromatography of the crude product over silica gel (hexane → 6% 
EtOAc/hexane) afforded (E)-α,β-unsaturated methyl ester 4-33 (0.541 g, 86% 
over three steps) as a colourless oil.  
4-33: 1H NMR (300 MHz, CDCl3): δ 6.91 (t, J = 6.9 Hz, 1H), 6.77 (d, J = 
8.2 Hz, 1H), 6.64-6.60 (m, 2H), 3.79 (s, 3H), 3.74 (s, 3H), 3.45 (d, J = 7.6 Hz, 
2H), 1.95 (s, 3H), 0.99 (s, 9H), 0.14 (s, 6H); ESI-MS: m/z calcd for 
C19H31O4Si+ [M + H]+ 351.2, found 352.2. 
 
Methallyl alcohol 4-34: To a solution of (E)-α,β-unsaturated methyl ester 
4-33 (0.54 g, 1.54 mmol) in THF (30 mL) was carefully added LiAlH4 (0.15 g, 
3.95 mmol) at -10 °C. The resulting mixture was stirred at -10 °C for 20 min 
before it was stirred at room temperature for 1.5 h. The mixture was cooled to 
0 °C and quenched with EtOAc. At the same temperature, Na2SO4 (5 mL, sat. 
aq.) was added and warmed to room temperature. The resulting white 
suspension was stirred at room temperature for a further 20 min before Celite 
(3 g) was added and stirred for another 30 min. The mixture was filtered 
through glass frit, eluted with EtOAc and concentrated in vacuo. Flash column 
chromatography of the crude product over silica gel (10% EtOAc/hexane → 
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21% EtOAc/hexane) afforded allyl alcohol 4-34 (0.402 g, 81%) as a colourless 
oil.  
4-34: 1H NMR (500 MHz, CDCl3): δ 6.75 (d, J = 7.6 Hz, 1H), 6.66-6.61 (m, 
2H), 5.62-5.59 (m, 1H), 4.06 (brs, 2H), 3.78 (s, 3H), 3.33 (d, J = 7.5 Hz, 2H), 
1.78 (s, 3H), 0.99 (s, 9H), 0.14 (s, 6H); ESI-MS: m/z calcd for C18H31O3Si+ [M 












Methallyl acetate 4-35: To a solution of methallyl alcohol 4-34 (42.8 mg, 
0.133 mmol) in CH2Cl2 was added DMAP (3.2 mg, 26.2 µmol) and Et3N (74 
µL, 0.531 mmol) at room temperature. The resulting mixture was cooled to 0 
°C before Ac2O (38 µL, 0.402 mmol) was added, and stirred at the same 
temperature for 5 min. The mixture was stirred at room temperature for the 
next 7 h before it was diluted with Et2O, and poured into water. The organic 
layer was separated, and the aqueous layer was extracted with Et2O (3x). The 
combined organic layers were washed with 3% NaOH, followed by 1M HCl, 
brine, dried over Na2SO4, filtered, and concentrated in vacuo. Flash column 
chromatography of the crude product over silica gel (hexane → 10% 
EtOAc/hexane) afforded allyl acetate 4-35 (45.5 mg, 98%) as a yellow oil.  
4-94: 1H NMR (500 MHz, CDCl3): δ 6.76 (d, J = 7.5 Hz, 1H), 6.65-6.60 (m, 
2H), 5.67-5.64 (m, 1H), 4.51 (s, 2H), 3.78 (s, 3H), 3.34 (d, J = 7.5 Hz, 2H), 
2.08 (s, 3H), 1.76 (s, 3H), 0.99 (s, 9H), 0.14 (s, 6H); ESI-MS: m/z calcd for 




Homoallyl ethyl ester 4-39: To a stirring methallyl alcohol 4-34 (0.342 g, 
1.06 mmol) was added triethyl orthoacetate 4-38 (4 mL, 21.8 mmol), followed 
by catalytic amount of propionic acid (8 µL, 0.1 mmol) at room temperature. 
The resulting mixture was heated at 125 °C for 3.5 h before it was cooled to 
room temperature, and diluted with Et2O. The organic layer was washed with 
5% HCl (1x), saturated aq. NaHCO3 (1x), and water (1x), followed by brine, 
dried over Na2SO4, filtered, and concentrated in vacuo. Flash column 
chromatography of the crude product over silica gel (hexane → 5% 
EtOAc/hexane → 20% EtOAc/hexane) afforded homoallyl ethyl ester 4-39 
(0.366 g, 88%) as a pale yellow oil, and recovered 4-34 (22.6 mg). 
4-34: 1H NMR (500 MHz, CDCl3): δ 6.74 (d, J = 8.2 Hz, 1H), 6.65-6.58 (m, 
2H), 4.74 (brs, 1H), 4.67 (brs, 1H), 4.07 (q, J = 7.1 Hz, 2H), 3.78 (s, 3H), 2.85-
2.79 (m, 1H), 2.68 (dd, J = 7.5, 13.8 Hz, 1H), 2.56 (dd, J = 7.5, 13.8 Hz, 1H), 
2.38-2.36 (m, 2H), 1.70 (s, 3H), 1.22 (t, J = 7.2 Hz, 3H), 0.99 (s, 9H), 0.14 (s, 
6H); 13C NMR (125 MHz, CDCl3): δ 172.6, 150.6, 146.4, 143.3, 133.3, 121.3, 
120.5, 113.1, 111.7, 60.2, 55.5, 45.2, 39.8, 38.2, 25.7, 20.0, 18.4, 14.2, -4.7; 




cis- and trans-Hydroxyl lactones 4-40/41: To a solution of homoallyl ethyl 
ester 4-39 (64 mg, 0.163 mmol) in 50% v/v aq. t-BuOH (1 mL) was added a 
solution of AD-mix-α (0.229 g, 1.4 g/mmol) and CH3SO2NH2 (16.3 mg, 0.1 
g/mmol) in 50% v/v aq. t-BuOH at 0 °C. The resulting mixture was stirred at 0 
°C for 3 days before Na2SO3 (0.47 g) was added at the same temperature, and 
stirring was continued at room temperature for 1 h. The mixture was diluted 
with water, and extracted with EtOAc (4x). The combined organic extracts 
were washed with 5% NaOH (x1) and water (1x), followed by brine, dried over 
Na2SO4, filtered, and concentrated in vacuo. Flash column chromatography of 
the crude product over silica gel (20% EtOAc/hexane → 40% EtOAc/hexane) 
afforded only a partially separable mixture of cis-hydroxyl lactone 4-40 and 
trans-hydroxyl lactone 4-41 [54.7 mg combined, 88%, 35:65 dr (4-40/41)] as 
colourless viscous oil. 
cis-4-40: 1H NMR (500 MHz, CDCl3): δ 6.77 (d, J = 8.2 Hz, 1H), 6.66-6.62 
(m, 2H), 3.84-3.71 + 3.79 (m1 + s2, 5H), 2.87-2.77 (m, 2H), 2.73-2.67 (m, 2H), 
2.62-2.55 (m, 1H), 2.43-2.38 (m, 1H), 1.28 (s, 3H), 0.98 (s, 9H), 0.14 (s, 6H); 
13C NMR (125 MHz, CDCl3): δ 176.8, 151.0, 143.7, 132.7, 121.0, 120.6, 
112.5, 88.1, 66.4, 55.5, 47.1, 36.3, 34.8, 25.7, 22.6, 18.4, -4.7; ESI-MS: m/z 
calcd for C20H32O5SiNa+ [M + Na]+ 403.2, found 403.0.       
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trans-4-41: 1H NMR (500 MHz, CDCl3): δ 6.76 (d, J = 8.2 Hz, 1H), 6.65-
6.59 (m, 2H), 3.79 (s, 3H), 3.64 (dd, J = 5.0, 11.9 Hz, 1H), 3.39 (dd, J = 8.2, 
12,6 Hz, 1H), 3.01-2.94 (m, 1H), 2.72 (dd, J = 5.6, 13.8 Hz, 1H), 2.58-2.51 (m, 
2H), 2.39 (dd, J = 10.7, 17.6 Hz, 1H), 2.29 (hump, 1H), 1.30 (s, 3H), 0.98 (s, 
9H), 0.13 (s, 6H); 13C NMR (125 MHz, CDCl3): δ 175.5, 151.0, 143.7, 132.0, 
121.0, 120.7, 112.3, 88.6, 66.7, 55.5, 39.9, 35.4, 34.8, 25.7, 18.4, 17.5, -4.7; 
ESI-MS: m/z calcd for C20H32O5SiNa+ [M + Na]+ 403.2, found 403.0.       
 
cis- and trans-(TBS-protected)-hydroxyl lactones 4-43/42: To a solution 
of inseparable mixture of cis- and trans-hydroxyl lactones 4-40/41 (55 mg, 
0.145 mmol) in anhydrous DMF (2 mL) was added imidazole (48.2 mg, 0.708 
mmol), DMAP (1 small crystal, 0.1 equiv.), and TBSCl (32.7 mg, 0.217 mmol) 
at room temperature. The resulting mixture was stirred at room temperature for 
16 h before it was diluted with water, and extracted with Et2O (3x). The 
combined organic extracts were washed with saturated aq. NH4Cl (1x) and 
water (1x), followed by brine, dried over Na2SO4, filtered, and concentrated in 
vacuo. Flash column chromatography of the crude product over silica gel (12% 
EtOAc/hexane → 40% EtOAc/hexane) afforded trans-TBS-protected-hydroxyl 
lactone 4-42 (33.5 mg, 72% based on 4-41) as a colourless oil, and recovered 
starting material cis-hydroxyl lactone 4-40 containing a small amount of trans-
hydroxyl lactone 4-41.  
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To a solution of these hydroxyl lactones 4-40/41 (35.3 mg, 0.0928 mmol) in 
CH2Cl2 (1 mL) was added 2,6-lutidine (65 µL, 0.558 mmol) and TBSOTf (50 
µL, 0.232 mmol) at -10 °C. The resulting mixture was stirred at the same 
temperature for 45 min before it was stirred at 0 °C for the next 12 h. The 
reaction was quenched with saturated aq. NaHCO3, diluted with water, and 
extracted with Et2O (3x). The combined organic extracts were washed with 
water (1x), followed by brine, dried over Na2SO4, filtered, and concentrated in 
vacuo. Flash column chromatography of the crude product over silica gel (12% 
EtOAc/hexane) afforded an enriched mixture of cis-TBS-protected-hydroxyl 
lactone 4-43 (31.2 mg of 41.5 mg final mixture with 4-42, ~68% based on 4-
40) as a colourless oil.  
trans-4-42: 1H NMR (500 MHz, CDCl3): δ 6.78 (d, J 
= 3.1 Hz, 1H), 6.77-6.58 (m, 2H), 3.78 (s, 3H), 3.65 
(d, J = 10.7 Hz, 1H), 3.51 (d, J = 10.7 Hz, 1H), 2.90-
2.80 (m, 2H), 2.53 (dd, J = 8.2, 17.0 Hz, 1H), 2.45 (dd, J = 10.7, 13.2 Hz, 1H), 
2.34-2.29 (m, 1H), 1.30 (s, 3H), 0.99 (s, 9H), 0.90 (s, 9H), 0.14 (s, 6H), 0.08 (s, 
6H); 13C NMR (125 MHz, CDCl3): δ 175.6, 151.0, 143.7, 132.5, 121.0, 120.7, 
112.5, 87.8, 68.4, 55.5, 40.9, 36.1, 34.9, 25.8, 25.7, 18.4, 18.2, 17.9, -4.7, -5.5; 
ESI-MS: m/z calcd for C26H47O5Si2+ [M + H]+ 495.3, found 495.1.            
cis-4-43 (enriched): 1H NMR (500 MHz, CDCl3): δ 
6.76 (d, J = 3.7 Hz, 1H), 6.63-6.58 (m, 2H), 3.80 + 
3.78 (d1 + s2, 4H), 3.66 (d, J = 11.4 Hz, 1H), 2.88-
2.79 (m, 1H), 2.64 (dd, J = 12.0, 16.5 Hz, 1H), 2.58-2.50 (m, 1H), 2.48-2.43 















6H), 0.08 (s, 6H); ESI-MS: m/z calcd for C26H47O5Si2+ [M + H]+ 495.3, found 
495.2.                   
Representative Procedure for the Preparation of Bis-Benzyl-Protected 
Hydroxyl Lactone:  
 
cis-(Bis-Bn-protected)-hydroxyl lactone 4-48: To a solution of cis-
hydroxyl lactone 4-40 (75 mg, 0.197 mmol) in “wet” DMF (old bottle of 
anhydrous DMF, 2.6 mL) was added NaH (60% dispersion in mineral oil, 55.2 
mg, 1.38 mmol) at 0 °C. The resulting mixture was stirred at the same 
temperature for 20 min before BnBr (0.24 mL, 2.02 mmol) and TBAI (36.4 
mg, 98.5 µmol) were added, and the final mixture was stirred at room 
temperature for 12 h. The reaction was quenched with saturated aq. NH4Cl, and 
diluted with water before it was extracted with Et2O (3x). The combined 
organic extracts were washed with water (1x), followed by brine, dried over 
Na2SO4, filtered, and concentrated in vacuo. Flash column chromatography of 
the crude product over silica gel (hexane → 12% EtOAc/hexane → 30% 
EtOAc/hexane) afforded bis-Bn ether cis-4-48 (74 mg, 84%) as a pale yellow 
oil.     
cis-4-48: 1H NMR (300 MHz, CDCl3): δ 7.42-7.29 (m, 10H), 6.78 (d, J = 
8.0 Hz, 1H), 6.61-6.54 (m, 2H), 5.12 (s, 2H), 4.64 (d, J = 11.8 Hz, 1H), 4.48 (d, 
J = 12.0 Hz, 1H), 3.84 (s, 3H), 3.67 (d, J = 10.7 Hz, 1H), 3.51 (d, J = 10.7 Hz, 
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1H), 2.82-2.68 (m, 3H), 2.65-2.50 (m, 1H), 2.41-2.33 (m, 1H), 1.27 (s, 3H); 
ESI-MS: m/z calcd for C28H31O5+ [M + H]+ 447.2, found 447.5.        
trans-(Bis-Bn-protected)-hydroxyl lactone 4-107:  
Procedure was repeated with trans-hydroxyl lactone 
4-41 (0.128 g, 0.336 mmol) to afford bis-Bn ether 
trans-4-107 (0.134 g, 89%) as a pale yellow oil. trans-4-107: 1H NMR (500 
MHz, CDCl3): δ 7.46-7.29 (m, 10H), 6.80 (d, J = 7.5 Hz, 1H), 6.67-6.60 (m, 
2H), 5.13 (s, 2H), 4.58-4.51 (m, 2H), 3.85 (s, 3H), 3.52 (d, J = 10.7 Hz, 1H), 
3.38 (d, J = 10.7 Hz, 1H), 2.90-2.85 (m, 1H), 2.80 (dd, J = 5.0, 13.8 Hz, 1H), 
2.60-2.55 (m, 1H), 2.49 (dd, J = 10.7, 13.8 Hz, 1H), 2.36-2.30 (m, 1H), 1.35 (s, 
















Methyl epoxy-ester 4-52: To a stirring solution of trans-iodo lactone 4-51 
(95 mg, 0.204 mmol) in MeOH (10 mL) was added anhydrous K2CO3 (42.2 
mg, 0.305 mmol) at room temperature. The resulting mixture was refluxed for 
1 h 15 min before it was cooled to room temperature, and saturated aq. NH4Cl 
was added to adjust the pH to pH 4-5. The mixture was concentrated in vacuo, 
removing as much MeOH as possible, followed by dilution with water, and the 
aqueous layer was extracted with EtOAc (3x). The combined organic extracts 
were washed with water (1x), followed by brine, dried over Na2SO4, filtered, 









over silica gel (10% EtOAc/hexane → 28% EtOAc/hexane) afforded epoxy 
ester 4-52 (67.2 mg, 89%) as a colourless oil.   
4-52: 1H NMR (500 MHz, CDCl3): δ 7.42-7.29 (m, 5H), 6.79 (d, J = 8.2 Hz, 
1H), 6.71 (s, 1H), 6.64-6.62 (m, 1H), 5.12 (s, 2H), 3.87 (s, 3H), 3.63 (s, 3H), 
2.67-2.58 (m, 2H), 2.53 (dd, J = 5.7, 15.1 Hz, 1H), 2.40 (d, J = 4.4 Hz, 1H), 
2.37-2.32 (m, 1H), 2.29 (d, J = 4.4 Hz, 1H), 2.05-1.99 (m, 1H), 1.30 (s, 3H); 
13C NMR (125 MHz, CDCl3): δ 172.9, 149.6, 146.7, 137.2, 132.5, 128.4, 
127.7, 127.3, 121.0, 114.3, 112.7, 71.2, 57.8, 56.0, 55.0, 51.6, 44.7, 37.4, 35.7, 
17.1; ESI-MS: m/z calcd for C22H26O5Na+ [M + Na]+ 393.2, found 393.2.            
 
cis-Hydroxyl lactone 4-53: To a solution epoxy ester 4-52 (59.4 mg, 0.16 
mmol) in THF (3.6 mL) was added TMSOK (0.104 g, 0.804 mmol) in a N2-
filled Aldrich® AtmosBag glove bag at room temperature. The resulting 
mixture was stirred at room temperature under an atmosphere of Ar for 3 h 
before it was quenched with water. The mixture was extracted with Et2O (3x), 
and the combined organic extracts were washed with brine, dried over Na2SO4, 
filtered, and concentrated in vacuo. Flash column chromatography of the crude 
product over silica gel (20% EtOAc/hexane → 50% EtOAc/hexane) afforded 
cis-hydroxyl lactone 4-53 (47.4 mg, 83%) as a white solid. 
cis-4-53: mp 68.4-70.3 °C; 1H NMR (500 MHz, CDCl3): δ 7.42-7.28 (m, 
5H), 6.82 (d, J = 8.1 Hz, 1H), 6.71 (d, J = 1.9 Hz, 1H ), 6.67-6.65 (m, 2H), 
5.12 (s, 2H), 3.88 (s, 3H), 3.83 (d, J = 12.6 Hz, 1H), 3.74 (d, J = 12.6 Hz, 1H), 
2.86 (dd, J = 5.7, 13.9 Hz, 1H), 2.81-2.76 (m, 1H), 2.68 (dd, J = 11.9, 17.0 Hz, 
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1H), 2.62-2.55 (m, 1H), 2.44-2.39 (m, 1H), 1.31 (s, 3H); 13C NMR (125 MHz, 
CDCl3): δ 176.1, 149.6, 146.4, 137.3, 132.7, 128.4, 127.7, 127.3, 121.1, 114.3, 
113.1, 88.6, 71.2, 66.8, 56.0, 41.2, 36.0, 34.8, 25.5; ESI-MS: m/z calcd for 
C21H24O5Na+ [M + Na]+ 379.2, found 379.2.     
Representative Procedure for the DIBAL-H Reduction of Protected-
















cis-(TBS-protected)-hydroxyl lactol 4-44: To a solution of cis-(TBS-
protected)-hydroxyl lactone 4-43 (36.1 mg, 0.073 mmol) in Et2O (1 mL) was 
added DIBAL-H in cyclohexane (0.15 mL, 0.112 mmol) at -78 °C. The 
resulting mixture was stirred at -78 °C for 3 h before it was quenched with 
MeOH (0.5 mL) at the same temperature, followed by addition of saturated aq. 
Rochelle salt solution (1.5 mL) and stirred at room temperature for 3 h. The 
mixture was then partitioned between EtOAc and water, and the organic layer 
was separated. The aqueous layer was extracted with EtOAc (3x), and the 
combined organic layers were washed with brine, dried over Na2SO4, filtered, 
and concentrated in vacuo. Flash column chromatography of the crude product 
over silica gel (5% EtOAc/hexane → 18% EtOAc/hexane) afforded TBS-
protected hydroxyl lactol cis-4-44 (25.4 mg, 70%) as a colourless sticky oil. 
cis-4-44: 1H NMR (500 MHz, CDCl3): δ 6.77 (m, 1H), 6.68-6.60 (m, 2H), 
5.58-5.49 + 5.35-5.26 (m each, 1H), 3.78-3.73 (m, 3H), 3.71-3.33 (m, 2H), 
2.81-2.65 (m, 2H), 2.50-2.45 (m, 1H), 2.34-2.05 + 1.93-1.89 (m each, 2H), 
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1.80-1.69 (m, 1H), 1.21 + 1.12 (s each, 3H), 0.99 + 0.94 (s each, 18H), 0.21-
0.07 (m, 12H); 13C NMR (125 MHz, CDCl3): δ 150.8, 150.7, 150.6, 143.1, 
134.8, 125.5, 120.82, 120.76, 120.73, 120.64, 120.6, 112.8, 112.7, 96.6, 85.6, 
85.2, 72.1, 71.6, 68.6, 55.5, 55.4, 41.3, 39.6, 37.1, 36.0, 34.2, 31.9, 30.3, 29.7, 
25.7, 19.5, 18.4, -4.6, 5.4.  
cis-(Bn-protected)-hydroxyl lactol 4-49: 
Procedure was repeated with cis-(bis-Bn-
protected)-hydroxyl lactone 4-48 (82 mg, 0.184 
mmol), and flash column chromatography of the crude product over silica gel 
(20% EtOAc/hexane → 38% EtOAc/hexane) afforded Bn-protected hydroxyl 
lactol cis-4-49 (70 mg, 85%) as a colourless sticky oil. cis-4-49: 1H NMR (300 
MHz, CDCl3): δ 7.44-7.28 (m, 10H), 6.83-6.78 (m, 1H), 6.66-6.54 (m, 2H), 
5.53-5.50 + 5.38-5.30 (m1 + m2, 1H), 5.12 (s, 3H), 4.69-4.50 (m, 2H), 3.85 (s, 
3H), 3.53 + 3.46-3.34 (q1 + m2, J1 = 9.9 Hz, 2H), 2.78-2.54 (m, 3H), 4.12 + 
2.39-2.05 (d1 + m2, J1 = 11.7 Hz, 2H), 1.87-1.69 (m, 1H), 1.28 + 1.13 (s each, 
3H).        
cis-(Bn-protected)-hydroxyl lactol methyl 
acetal 4-50: Procedure was repeated with cis-(bis-
Bn-protected)-hydroxyl lactone 4-48 (26 mg, 
0.0582 mmol). To a solution of this crude lactol 4-49 (23.7 mg) in MeOH (2.3 
mL) was added trimethyl orthoacetate (60.5 µL, 0.475 mmol) and PTSA (5 mg, 
0.0263 mmol) at room temperature. The resulting mixture was stirred at room 
temperature for 12 h before it was concentrated in vacuo, and the residue was 
partitioned between Et2O and saturated aq. NaHCO3. The organic layer was 















organic layers were washed with water (1x), followed by brine, dried over 
Na2SO4, filtered, and concentrated in vacuo. Flash column chromatography of 
the crude product over silica gel (5% EtOAc/hexane → 16% EtOAc/hexane) 
afforded methyl acetal cis-4-50 (21.3 mg, 79% over two steps) as a single 
diastereomer in the form of a colourless oil. cis-4-50: 1H NMR (500 MHz, 
CDCl3): δ 7.45-7.29 (m, 10H), 6.76 (d, J = 8.2 Hz, 1H), 6.67 (d, J = 1.9 Hz, 
1H), 6.59-6.57 (m, 2H), 5.11 (s, 2H), 4.99 (d, J = 5.0 Hz, 1H), 4.61 (d, J = 12.6 
Hz, 1H), 4.53 (d, J = 11.9 Hz, 1H), 3.85 (s, 3H), 3.46 (d, J = 10.7 Hz, 1H), 3.38 
(d, J = 10.0 Hz, 1H), 3.33 (s, 3H), 2.76 (dd, J = 5.7, 13.9 Hz, 1H), 2.59-2.54 
(m, 1H), 2.50-2.43 (m, 1H), 2.02 (td, J = 5.0, 12.0 Hz, 1H), 1.82 (dd, J = 6.9, 
12.6 Hz, 1H), 1.25 (s, 3H); ESI-MS: m/z calcd for C29H35O5Na+ [M + H]+ 
463.2, found 463.1.                         
trans-(Bn-protected)-hydroxyl lactol methyl 
acetal 4-47: The sequence of events was repeated 
with trans-(bis-Bn-protected)-hydroxyl lactone 4-
107 (24.6 mg, 0.0551 mmol), and flash column chromatography of the final 
crude product over silica gel (5% EtOAc/hexane → 16% EtOAc/hexane) 
afforded methyl acetal trans-4-47 (20.3 mg, 80% over two steps) as a 
colourless oil. trans-4-47: 1H NMR (500 MHz, CDCl3): δ 7.44-7.29 (m, 10H), 
6.77-6.75 (m, 1H), 6.68 (m, 1H), 6.62 (m, 1H), 5.12-5.11 (brs, 2H), 4.97-4.95 
+ 4.90 (m1 + d2, J2 = 4.4 Hz, 1H), 4.62-4.54 (m, 2H), 3.84-3.83 (m, 3H), 3.41-
3.37 + 3.28 (m1 + s2, 5H), 2.77 + 2.68 (dd1 + d2, J1 = 5.0, 13.8 Hz, J2 = 8.1 Hz, 
1H), 2.56-2.49 + 2.41-2.36 (m each, 2H), 2.26-2.21 + 1.91 + 1.78-1.72 (m1 + 









Representative Procedure for the BF3·Et2O-Promoted Friedel-Crafts 
Cyclization of Benzyloxy Free-Lactol and its Methyl Acetal: 
 
Benzyloxy benzotetrahydrofuran 4-55: To a solution of benzyloxyl free-
lactol cis-4-49 (40 mg, 0.0892 mmol) in CH2Cl2 (4.5 mL) was added 1M 
BF3·Et2O in CH2Cl2 (0.54 mL) at -78 °C. The resulting mixture was stirred at -
78 °C for 2 h before it was warmed up to -40 °C over 30 min, and stirred at -40 
°C for the next 1 h. Saturated aq. NaHCO3 (8 mL) was quickly syringed to 
quench the reaction at -40 °C, followed by immediate raising to room 
temperature with swirling or stirring before it was extracted with CH2Cl2 (3x). 
The combined organic extracts were washed with water (1x), followed by 
brine, dried over Na2SO4, filtered, and concentrated in vacuo. Flash column 
chromatography of the crude product over silica gel (hexane → 14% 
EtOAc/hexane) afforded (cis-lactol-derived) benzyloxy benzotetrahydrofuran 
4-55 (32.3 mg, 84%) as a colourless oil. 
4-55: 1H NMR (300 MHz, CDCl3): δ 7.45-7.27 (m, 10H), 6.61 (s, 1H), 6.48 
(s, 1H), 5.30-5.03 (m, 2H), 4.66 (d, J = 4.9 Hz, 1H), 4.54 (d, J = 12.3 Hz, 1H), 
4.40 (d, J = 12.0 Hz, 1H), 3.82 (s, 3H), 3.25 (s, 2H), 2.90 (brs, 2H), 2.44-2.37 
(m, 2H), 1.90 (d, J = 10.2 Hz, 1H), 1.32 (s, 3H); 13C NMR (125 MHz, CDCl3): 
δ 149.4, 146.1, 138.5, 137.4, 133.3, 128.5, 128.3, 127.8, 127.6, 127.51, 127.49, 
127.3, 113.2, 112.3, 83.6, 73.5, 71.2, 56.1, 38.8, 35.0, 32.7, 29.7, 21.5; ESI-
MS: m/z calcd for C28H30O4Na+ [M + Na]+ 453.2, found 453.2.     
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Benzyloxy benzotetrahydrofuran 4-56: Procedure 
was repeated with trans-(Bn-protected)-hydroxyl 
lactol methyl acetal 4-47 (8.5 mg, 0.0184 mmol) and 
1M BF3·Et2O in CH2Cl2 (6 equiv.). The temperature of the reaction was raised 
from -78 °C to -20 °C across 6 h. Water (3-4 mL) was syringed to quench the 
reaction at -20 °C, followed by immediate raising to room temperature with 
swirling or stirring before it was extracted with CH2Cl2 (3x). The combined 
organic extracts were washed with water (1x), followed by brine, dried over 
Na2SO4, filtered, and concentrated in vacuo. Flash column chromatography of 
the crude product over silica gel (hexane → 12% EtOAc/hexane) afforded 
(trans-lactol-derived) benzyloxy benzotetrahydrofuran 4-56 (7.8 mg, 99%) as a 
colourless oil. 4-56: 1H NMR (500 MHz, CDCl3): δ 7.42-7.28 (m, 10H), 6.66 
(s, 1H), 6.65 (s, 1H), 5.13-5.05 (m, 2H), 4.61 (d, J = 5.0 Hz, 1H), 4.59-4.52 (m, 
2H), 3.85 (s, 3H), 3.37 (d, J = 9.4 Hz, 1H), 3.21 (d, J = 9.4 Hz, 1H), 2.99 (dd, J 
= 4.4, 17.6 Hz, 1H), 2.92-2.89 (m, 1H), 2.62 (brs, 1H), 2.40-2.36 (m, 1H), 1.91 
(d, J = 11.3 Hz, 1H), 1.21 (s, 3H); 13C NMR (125 MHz, CDCl3): δ 149.3, 
146.1, 138.5, 137.4, 132.3, 128.5, 127.8, 127.6, 127.5, 127.4, 113.1, 112.4, 
84.5, 72.5, 71.3, 56.0, 38.9, 35.0, 32.6, 28.6, 21.4; ESI-MS: m/z calcd for 


















Hydroxyl-phenol 4-57: To a solution of benzyloxy benzotetrahydrofuran 4-
55 (27.5 mg, 0.0639 mmol) in 2:1 v/v EtOAc (4 mL) and EtOH (2 mL) was 









was stirred under a hydrogen atmosphere (balloon – changed once to maintain 
strong positive outlet pressure) for 20 h before it was filtered through a pad of 
Celite, eluted with EtOAc and concentrated in vacuo. Flash column 
chromatography of the crude product over silica gel (12% EtOAc/hexane → 
25% EtOAc/hexane → 65% EtOAc/hexane) afforded hydroxyl-phenol 4-57 
(11 mg, 69%) as a colourless sticky oil.   
4-57: 1H NMR (500 MHz, CDCl3): δ 6.62 (s, 1H), 6.58 (s, 1H), 5.55 (s, 1H), 
4.71 (d, J = 5.0 Hz, 1H), 3.83 (s, 3H), 3.55-3.46 (m, 2H), 3.00-2.92 (m, 2H), 
2.49-2.44 (m, 2H), 1.93 (d, J = 10.7 Hz, 1H), 1.72 (brs, 1H), 1.28 (s, 3H); ESI-
MS: m/z calcd for C14H19O4+ [M + H]+ 251.1, found 251.0.   
Phenoxy-diol 4-58: To a solution of 4-55 (13.8 mg, 
0.0321 mmol) in 3:1 v/v EtOAc (1.8 mL) and EtOH 
(0.6 mL) was added 10% Pd on carbon (14 mg) at 
room temperature. The resulting mixture was stirred under a hydrogen 
atmosphere (balloon) for 12 h before it was filtered through a pad of Celite, 
eluted with EtOAc and concentrated in vacuo to afford the crude diol 4-58 (8.2 
mg) as a colourless sticky oil. Crude 4-58: 1H NMR (500 MHz, CDCl3): δ 6.64 
(s, 1H), 6.54 (s, 1H), 3.83 (s, 3H), 3.66 (d, J = 10.7 Hz, 1H), 3.51 (d, J = 10.7 
Hz, 1H), 2.79-2.67 (m, 3H), 2.50 (t, J = 13.9 Hz, 1H), 2.37 (brs, 1H), 2.11-2.08 
(m, 1H), 1.92-1.88 (m, 1H), 1.47-1.39 (m, 1H), 1.17 (s, 3H); ESI-MS: m/z 
calcd for C14H20O4+ [M]+ 252.1, found 252.0.       
Pyran 4-60: To a solution of hydroxyl-phenol 4-57 
(11 mg, 0.0439 mmol) in THF (2 mL) was added 
PPh3 (15.5 mg, 0.0593 mmol), I2 (13.9 mg, 0.0549 
















resulting mixture was heated to reflux for 2 h before it was cooled to room 
temperature, and diluted with EtOAc. The organic layer was washed with 1M 
HCl (1x), saturated aq. Na2SO3 (1x), and water (1x), followed by brine, dried 
over Na2SO4, filtered, and concentrated in vacuo. Flash column 
chromatography of the crude product over silica gel (10% EtOAc/hexane → 
40% EtOAc/hexane → 65% EtOAc/hexane) afforded pyran 4-60 (7.9 mg, 
72%) as a pale yellow oil. 4-60: 1H NMR (500 MHz, CDCl3): δ 6.79 (s, 1H), 
6.57 (s, 1H), 5.49 (s, 1H), 4.67 (brs, 1H), 3.89 (s, 3H), 3.23 (d, J = 12.6 Hz, 
1H), 3.15 (d, J = 12.6 Hz, 1H), 3.00 (dd, J = 6.3, 17.6 Hz, 1H), 2.76 (d, J = 
17.6 Hz, 1H), 2.67 (s, 1H), 2.59-2.54 (m, 1H), 2.09 (brs, 1H), 1.64 (d, J = 13.2 
Hz, 1H), 1.14 (s, 3H); 13C NMR (125 MHz, CDCl3): δ 146.9, 144.1, 128.8, 
126.1, 115.5, 109.5, 70.5, 69.5, 67.9, 55.9, 37.1, 31.3, 27.7, 23.2; ESI-MS: m/z 













(Benzyloxy)-homoallyl ethyl ester 4-61: To a solution of homoallyl ethyl 
ester 4-39 (0.633 g, 1.61 mmol) in THF (23 mL) was added 1M TBAF in THF 
(4.2 mL) at 5 °C. The resulting mixture was then stirred at room temperature 
for 1 h before it was quenched with saturated aq. NH4Cl. The mixture was 
diluted with water, and extracted with CH2Cl2 (3x). The combined organic 
extracts were washed with brine, dried over Na2SO4, filtered, and concentrated 
in vacuo. Flash column chromatography of the crude product over silica gel 
(7% EtOAc/hexane → 18% EtOAc/hexane) afforded the free phenol (0.428 g, 
96%) as a colourless oil. 
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To a stirring solution of this free phenol (0.428 g, 1.54 mmol) in anhydrous 
DMF (7.7 mL) was added anhydrous K2CO3 (0.64 g, 4.63 mmol), TBAI (74 
mg, 0.20 mmol), and BnBr (0.274 mL, 2.30 mmol) at room temperature. The 
resulting mixture was heated at 52 °C for 12 h before it was cooled to room 
temperature, and cold water was added. The mixture was extracted with Et2O 
(3x), and the combined organic extracts were washed with water (1x), followed 
by brine, dried over Na2SO4, filtered, and concentrated in vacuo. Flash column 
chromatography of the crude product over silica gel (hexane → 10% 
EtOAc/hexane) afforded (benzyloxy)-homoallyl ethyl ester 4-61 (0.525 g, 
93%) as a pale yellow oil. 
4-61: 1H NMR (500 MHz, CDCl3): δ 7.44-7.28 (m, 5H), 6.79 (d, J = 8.1 Hz, 
1H), 6.71 (s, 1H), 6.64-6.62 (m, 1H), 5.12 (s, 2H), 4.76 (s, 1H), 4.70 (s, 1H), 
4.07 (q, J = 7.1 Hz, 2H), 3.88 (s, 3H), 2.85-2.81 (m, 1H), 2.69 (dd, J = 6.9, 
13.9 Hz, 1H), 2.57 (dd, J = 7.6, 13.9 Hz, 1H), 2.37 (d, J = 7.5 Hz, 1H), 1.72 (s, 
3H), 1.21 (t, J = 7.2 Hz, 1H); 13C NMR (125 MHz, CDCl3): δ 172.6, 149.4, 
146.6, 146.3, 137.4, 133.1, 128.5, 127.7, 127.3, 121.1, 114.0, 112.9, 111.8, 
71.1, 60.2, 56.0, 45.1, 39.6, 38.2, 19.9, 14.2; ESI-MS: m/z calcd for 
C23H28O4Na+ [M + Na]+ 391.2, found 391.1.         
 
(Benzyloxy)-homoallyl acid 4-62: To a solution of homoallyl ethyl ester 4-
61 (100 mg, 0.271 mmol) in EtOH (6 mL) and H2O (2 mL) was added 1M aq. 
NaOH (1.36 mL) at 0 °C. The resulting mixture was stirred at 0 °C for 10 min 
before it was raised to room temperature and stirred for the next 12 h. The 
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mixture was diluted with water and extracted with CH2Cl2 (2x) before the 
aqueous layer was acidified with 2M HCl to pH 1-2. The aqueous layer was 
then extracted with EtOAc (3x), and the combined EtOAc extracts were 
washed with water (1x), followed by brine, dried over Na2SO4, filtered, and 
concentrated in vacuo to afford homoallyl acid 4-62 (89.6 mg, 97%) as a 
colourless viscous oil. 4-62 was carried forward to the next step without further 
purification. 
4-62: 1H NMR (500 MHz, CDCl3): δ 7.44-7.28 (m, 5H), 6.79 (d, J = 8.2 Hz, 
1H), 6.71 (s, 1H), 6.64-6.62 (m, 1H), 5.12 (s, 2H), 4.79 (s, 1H), 4.73 (s, 1H), 
3.87 (s, 3H), 2.84-2.81 (m, 1H), 2.74-2.70 (m, 1H), 2.58 (dd, J = 7.6, 13.9 Hz, 
1H), 2.43-2.41 (m, 2H), 1.73 (s, 3H); ESI-MS: m/z calcd for C21H23O4- [M – 
H]- 339.2, found 339.4.         
Representative Procedure for the Iodolactonization of Homoallyl Acids 
under Biphasic Conditions: 
 
cis- and trans-(Benzyloxy)-iodolactones 4-63/51: To a solution of 
homoallyl acid 4-62 (23 mg, 0.0676 mmol) in THF (0.5 mL) was added 
saturated aq. NaHCO3 solution (1.25 mL) at room temperature. The mixture 
was cooled to 0 °C before the addition of a solution of I2 (52 mg, 0.205 mmol) 
in THF (2 mL) at the same temperature. The resulting mixture was allowed to 
stir at 0 °C to room temperature over 12 h before the excess I2 was quenched 
with saturated aq. Na2S2O3 at room temperature to obtain a clear solution. The 
resulting solution was diluted with water, and extracted with CH2Cl2 (3x). The 
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combined organic extracts were washed with brine, dried over Na2SO4, 
filtered, and concentrated in vacuo. Flash column chromatography of the crude 
product over silica gel (5% EtOAc/hexane → 25% EtOAc/hexane) afforded a 
largely inseparable mixture of cis- and trans-iodolactones 4-63/51 (2.5:1 dr, 29 
mg, 92%) as a colourless oil. 
cis-4-63: 1H NMR (300 MHz, CDCl3): δ 7.42-7.29 (m, 5H), 6.82 (d, J = 8.2 
Hz, 1H), 6.68-6.62 (m, 2H), 5.13 (s, 2H), 3.89 (s, 3H), 3.44 (d, J = 11.1 Hz, 
1H), 3.37 (d, J = 10.8 Hz, 1H), 2.98 (dd, J = 4.4, 12.9 Hz, 1H), 2.75-2.67 (m, 
1H), 2.66-2.53 (m, 3H), 1.58 (s, 3H); 13C NMR (75 MHz, CDCl3): δ 174.5, 
149.9, 147.2, 137.0, 131.2, 128.5, 127.9, 127.3, 120.6, 114.4, 112.2, 84.7, 71.1, 
56.1, 46.0, 34.9, 34.6, 27.1, 9.0; EI-MS: m/z calcd for C21H23O4I+ [M]+ 466.1, 
found 466.3.    
trans-4-51: 1H NMR (300 MHz, CDCl3): δ 7.42-7.29 (m, 5H), 6.82 (d, J = 
8.2 Hz, 1H), 6.73 (s, 1H), 6.67-6.62 (m, 2H), 5.13 (s, 2H), 3.90 (s, 3H), 3.39 (d, 
J = 11.1 Hz, 1H), 3.13 (d, J = 11.1 Hz, 1H), 2.99-2.87 (m, 1H), 2.77 (dd, J = 
6.4, 13.7 Hz, 1H), 2.66-2.55 (m, 2H), 2.41 (dd, J = 10.8, 17.5 Hz, 1H), 1.53 (s, 
3H); 13C NMR (75 MHz, CDCl3): δ 173.8, 149.9, 147.1, 137.0, 131.3, 128.5, 
127.9, 127.3, 120.5, 114.4, 112.0, 84.7, 71.1, 56.1, 44.4, 35.9, 35.0, 20.4, 14.6; 
EI-MS: m/z calcd for C21H23O4I+ [M]+ 466.1, found 466.3.    
Aryl mesylate cis- and trans-iodolactones 4-
78/79: Procedure was repeated with homoallyl acid 
4-93 (61.4 mg, 0.187 mmol), and flash column 
chromatography of the crude product over silica gel (10% EtOAc/hexane → 
45% EtOAc/hexane) afforded an inseparable mixture of cis- and trans-










4-78/79: 1H NMR (300 MHz, CDCl3): δ 7.23 (m, 1H), 6.83-6.77 (m, 2H), 3.92 
+ 3.90 (s each, 3H), 3.47-3.35 + 3.22 (m each, 2H), 3.19 (s, 3H), 3.08 + 2.92-
2.83 + 2.75-2.54 + 2.41 (dd1 + m2 + m3 + dd4, J1 = 6.0, 12.7 Hz, J4 = 10.5, 17.8 
Hz, 5H), 1.63 + 1.56 (s each, 3H); EI-MS: m/z calcd for C15H19O6SI+ [M]+ 
454.0, found 454.2.        
Representative Procedure for the DIBAL-H Reduction of Iodo-Lactones to 
Iodo-Lactols: 
 
cis- and trans-(Benzyloxy)-iodolactols 4-65/66: To a solution of the 
inseparable mixture of cis- and trans-iodolactones 4-63/51 (61.5 mg, 0.132 
mmol) in CH2Cl2 (2.5 mL) was added DIBAL-H in cyclohexane (0.28 mL, 
0.266 mmol) at -78 °C. The resulting mixture was stirred at -78 °C for 3 h 
before it was quenched with MeOH (0.5 mL) at the same temperature, 
followed by addition of saturated aq. Rochelle salt solution (3 mL) and stirred 
at room temperature for 3 h. The mixture was then partitioned between CH2Cl2 
and water, and the organic layer was separated. The aqueous layer was 
extracted with CH2Cl2 (3x), and the combined organic layers were washed with 
brine, dried over Na2SO4, filtered, and concentrated in vacuo. Flash column 
chromatography of the crude product over silica gel (5% EtOAc/hexane → 
28% EtOAc/hexane) afforded an inseparable mixture of cis- and trans-
iodolactols 4-65/66 (55.1 mg, 89%) as a colourless sticky oil. 
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cis- and trans-4-65/66: 1H NMR (500 MHz, CDCl3): δ 7.44-7.29 (m, 5H), 
6.81-6.64 (m, 3H), 5.53-5.50 + 5.49-5.42 (m each, 1H), 5.13 (s, 2H), 3.90 + 
3.88 (s each, 3H), 3.37-3.28 (m, 1H), 3.21 + 3.05 (dd1 + d2, J1 = 2.5, 10.0 Hz, 
J2 = 10.1 Hz, 1H), 2.79-2.71 + 2.66-2.62 + 2.59-2.50 (m each, 3H), 2.38-2.27 + 
2.04 + 1.95-1.94 + 1.88-1.79 (m1 + dd2 + m3 + m4, J2 = 5.6, 12.6 Hz, 2H), 1.45 
+ 1.28 (s each, 3H); 13C NMR (75 MHz, CDCl3): δ 149.7, 137.2, 133.0, 128.5, 
127.8, 127.3, 120.6, 114.4, 112.4, 97.6, 96.8, 96.4, 83.5, 82.9, 71.2, 56.0, 50.0, 
47.6, 45.1, 40.5, 40.0, 36.4, 36.1, 35.8, 35.1, 29.0, 22.1, 21.8, 20.0, 18.6.          
Aryl mesylate cis- and trans-iodolactols 4-80/81: 
Procedure was repeated with the inseparable 
mixture of cis- and trans-iodolactones 4-78/79 
(0.191 g, 0.421 mmol), and flash column chromatography of the final crude 
product over silica gel (10% EtOAc/hexane → 50% EtOAc/hexane) afforded 
an inseparable mixture of cis- and trans-iodolactols 4-80/81 (0.186 g, 97%) as 
a colourless sticky oil. cis- and trans-4-80/81: 1H NMR (500 MHz, CDCl3): δ 
7.21-7.18 (m, 1H), 6.86-6.77 (m, 2H), 5.55-5.44 (m, 1H), 3.90 + 3.89 (s each, 
3H), 3.71 + 3.44 + 3.35-3.26 + 3.21-3.12 (d1 + d2 + m3 + m4, J1 = 10.1 Hz, J2 = 
10.0 Hz, 2H), 3.17 (s, 3H), 2.89-2.73 + 2.64-2.51 (m each, 3H), 2.44-2.42 + 
2.34-2.27 + 2.02-2.00 (m each, 1H), 1.94 + 1.87-1.75 + 1.67-1.60 (d1 + m2 + 
m3, J1 = 8.8 Hz, 2H), 1.51 + 1.38 + 1.31 (s each, 3H); 13C NMR (125 MHz, 
CDCl3): δ 151.3, 140.5, 140.4, 136.9, 124.5, 124.4, 121.1, 121.0, 113.23, 
113.16, 113.1, 97.7, 96.8, 96.5, 83.4, 82.8, 82.6, 56.1, 56.0, 49.5, 46.8, 40.3, 










cis- and trans-(Allyloxy)-iodolactols 4-84/85: 
Procedure was repeated with the inseparable 
mixture of cis- and trans-iodolactones 4-82/83 
(0.119 g, 0.285 mmol), and flash column chromatography of the final crude 
product over silica gel (5% EtOAc/hexane → 38% EtOAc/hexane) afforded an 
inseparable mixture of cis- and trans-iodolactols 4-84/85 (0.117 g, 98%) as a 
colourless sticky oil. cis- and trans-4-84/85: 1H NMR (500 MHz, CDCl3): δ 
6.81-6.72 (m, 1H), 6.70-6.66 (m, 2H), 6.12-6.05 (m, 1H), 5.54-5.49 + 5.44-
5.38 (m each, 2H), 5.29-5.27 (m, 1H), 4.59 (d, J = 4.9 Hz, 2H), 3.89 + 3.87 (s 
each, 3H), 3.73 + 3.37-3.28 + 3.22 (d1 + m2 + d3, J1 = 9.4 Hz, J3 = 10.1 Hz, 
2H), 2.80-2.73 + 2.65-2.52 (m each, 3H), 2.48-2.41 + 2.34-2.28 + 2.06-2.02 (m 
each, 1H), 1.96-1.92 + 1.90-1.78 (m1 + m2, 2H), 1.46 + 1.34 + 1.29 (s each, 
3H).       
 
(Benzyloxy)-iodo-benzotetrahydrofurans 4-67 and 4-68: To a solution of 
the inseparable mixture of cis- and trans-iodolactols 4-65/66 (51.4 mg, 0.11 
mmol) in CH2Cl2 (5.5 mL) was added 1M BF3·Et2O in CH2Cl2 (0.66 mL) at -
78 °C. The resulting mixture was stirred at -78 °C for 2 h before the reaction 
was quenched via cannula transferred into a stirring solution of saturated aq. 
NaHCO3 cooled to 0 °C. The organic layer was separated, and the aqueous 
layer was extracted with CH2Cl2 (3x). The combined organic layers were 
washed with water (1x), followed by brine, dried over Na2SO4, filtered, and 









silica gel (hexane → 10% EtOAc/hexane) afforded an inseparable mixture of 
(cis-lactol-derived)-iodo-benzotetrahydrofuran 4-67 and (trans-lactol-derived)-
iodo-benzotetrahydrofuran 4-68 (23.6 mg, 48%) as a colourless oil. 
4-67/68: 1H NMR (500 MHz, CDCl3): δ 7.44-7.28 (m, 5H), 6.66-6.63 (m, 
2H), 5.13-5.05 (m, 2H), 4.75 + 4.72 (d1 + d2, J1 = 5.0 Hz, J2 = 5.7 Hz, 1H), 
3.86 + 3.85 (s each, 3H), 3.30 + 3.25-3.19 (d1 + m2, J1 = 10.1 Hz, 2H), 3.07-
2.92 (m, 2H), 2.83 + 2.58 (brs each, 1H), 2.57-2.50 + 2.04-1.97 (m each, 1H), 
1.50 + 1.38 (s each, 3H); 13C NMR (125 MHz, CDCl3): δ 149.6, 146.3, 137.3, 
137.2, 132.9, 132.3, 128.5, 127.8, 127.32, 127.30, 126.8, 126.6, 113.2, 113.1, 
112.3, 112.2, 83.5, 82.9, 78.2, 78.1, 71.28, 71.25, 56.1, 41.6, 40.2, 35.6, 35.0, 
32.8, 31.9, 27.8, 23.6, 17.6, 13.9; EI-MS: m/z calcd for C21H23O3I+ [M]+ 450.1, 
found 450.3.          
 
cis- and trans-(Phenoxy)-iodolactones 4-72/73: To a stirring solution of 
the inseparable mixture of cis- and trans-iodolactones 4-63/51 (0.276 g, 0.592 
mmol) and PhSMe (1.4 mL, 11.9 mmol) in CHCl3 (HPLC grade, 30 mL) was 
slowly added MeSO3H (10% v/v with CHCl3, 3 mL) at 0 °C. The resulting 
mixture was stirred at 0 °C for 50 min before it was quickly poured into a 
stirring mixture of brine, water, and CH2Cl2 (1:1:1 v/v) cooled to 0 °C. The 
resulting mixture was stirred at 0 – 5 °C for 15 min before the organic layer 
was separated, and the aqueous layer was extracted with CH2Cl2 (3x). The 
combined organic layers were washed with brine, dried over Na2SO4, filtered, 
and concentrated in vacuo. Flash column chromatography of the crude product 
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over silica gel (8% EtOAc/hexane → 35% EtOAc/hexane) afforded an 
inseparable mixture of free phenols cis-4-72 and trans-4-73 (0.214 g, 96%) as a 
pale yellow oil. 
cis- and trans-4-72/73: 1H NMR (300 MHz, CDCl3): δ 6.87-6.84 (m, 1H), 
6.69-6.63 (m, 2H), 5.56 (brs, 1H), 3.91 + 3.89 (s each, 3H), 3.46-3.35 + 3.13 
(m1 + d2, J2 = 11.0 Hz, 2H), 3.01-2.87 (m, 1H), 2.81-2.36 (m, 4H), 1.59 + 1.53 
(s each, 3H); 13C NMR (125 MHz, CDCl3): δ 174.5, 173.9, 146.7, 144.5, 
129.99, 129.95, 121.1, 114.63, 114.56, 110.93, 110.87, 110.8, 110.7, 84.7, 
77.3, 76.8, 55.9, 46.1, 44.4, 34.8, 34.6, 27.0, 20.3; ESI-MS: m/z calcd for 
C14H16O4I- [M – H]- 375.0, found 375.2.           
 
Aryl mesylate cis- and trans-iodolactones 4-78/79: To a solution of cis- 
and trans-(phenoxy)-iodolactones 4-72/73 (92.6 mg, 0.246 mmol) in CH2Cl2 (5 
mL) was added Et3N (206 µL, 1.48 mmol) and MsCl (114 µL, 1.47 mmol) at 0 
°C. The resulting mixture was then stirred at room temperature for 4 h before it 
was diluted with water. The mixture was extracted with CH2Cl2 (3x), and the 
combined organic extracts were washed with saturated aq. NaHCO3, followed 
by brine, dried over Na2SO4, filtered, and concentrated in vacuo. Flash column 
chromatography of the crude product over silica gel (10% EtOAc/hexane → 
45% EtOAc/hexane) afforded an inseparable mixture of aryl mesylates cis-4-




cis- and trans-(Allyloxy)-iodolactones 4-82/83: To a stirring solution of 
cis- and trans-(phenoxy)-iodolactones 4-72/73 (0.116 g, 0.308 mmol) in 
acetone (HPLC grade, 6 mL) was added anhydrous K2CO3 (85.2 mg, 0.616 
mmol) and allyl bromide (80 µL, 0.924 mmol) at room temperature. The 
resulting mixture was refluxed for 7 h before it was cooled to room 
temperature, and diluted with H2O and brine (1:1). The mixture was extracted 
with CH2Cl2 (3x), and the combined organic extracts were washed with brine, 
dried over Na2SO4, filtered, and concentrated in vacuo. Flash column 
chromatography of the crude product over silica gel (5% EtOAc/hexane → 
28% EtOAc/hexane) afforded an inseparable mixture of allyl phenyl ethers cis-
4-82 and trans-4-83 (0.118 g, 92%) as a pale yellow oil. 
cis- and trans-4-82/83: 1H NMR (300 MHz, CDCl3): δ 6.83-6.80 (m, 1H), 
6.71-6.66 (m, 2H), 6.12-6.01 (m, 1H), 5.42-5.26 (m, 2H), 4.60 + 4.58 (s each, 2 
H), 3.89 + 3.87 (s each, 3H), 3.46-3.36 + 3.14 (m1 + d2, J2 = 11.0 Hz, 2H), 
3.01-2.87 (m, 1H), 2.77-2.37 (m, 4H), 1.59 + 1.53 (s each, 3H); EI-MS: m/z 






(Mesylate)-iodo-benzotetrahydrofurans 4-86 and 4-87: To a solution of 
the inseparable mixture of cis- and trans-iodolactols 4-80/81 (42.9 mg, 0.094 
mmol) in CH2Cl2 (4.7 mL) was added 1M BF3·Et2O in CH2Cl2 (0.85 mL) at -
78 °C. The resulting mixture was stirred at -78 °C for 3 h before the 
temperature of the reaction was raised to -20 °C over the next 3-4 h. The 
reaction was quenched by pouring the mixture quickly into a stirring solution 
of saturated aq. NaHCO3 and water (1:1) cooled to 0 °C. The organic layer 
was separated, and the aqueous layer was extracted with CH2Cl2 (3x). The 
combined organic layers were washed with brine, dried over Na2SO4, filtered, 
and concentrated in vacuo. Flash column chromatography of the crude product 
over silica gel (5% EtOAc/hexane → 30% EtOAc/hexane) afforded an 
inseparable mixture of (cis-lactol-derived)-iodo-benzotetrahydrofuran 4-86 and 
(trans-lactol-derived)-iodo-benzotetrahydrofuran 4-87 (25.9 mg, 63%) as a 
colourless oil. 
4-86/87: 1H NMR (500 MHz, CDCl3): δ 7.01 (s, 1H), 6.76 + 6.73 (s each, 
1H), 4.84 + 4.79 (d1 + d2, J1 = J2 = 5.0 Hz, 1H), 3.87 + 3.86 (s each, 3H), 3.33-
3.17 (m, 2H), 3.16 (s, 3H), 3.12-2.99 (m, 1H), 2.96 + 2.86 (d1 + brs2, J1 = 10.1 
Hz, 1H), 2.60-2.56 + 2.47-2.42 (m each, 2H), 2.04-1.98 (m, 1H), 1.51 + 1.38 (s 
each, 3H); ESI-MS: m/z calcd for C15H19O5SINa+ [M + Na]+ 461.0, found 




























6-Methoxydienone 4-1: To a solution of the inseparable mixture of iodo-
benzotetrahydrofurans 4-86/87 (79.4 mg, 0.181 mmol) in THF (9 mL) was 
added ~2M LDA in THF (0.57 mL, 1.14 mmol) dropwise at -78 °C. The 
resulting mixture was stirred at -78 °C for 5 min before allowing it to stir at 0 
°C for the next 30 min. The reaction was quenched with 10% citric acid to pH 
2-3 before the mixture was extracted with CH2Cl2 (3x). The combined organic 
extracts were washed with brine, dried over Na2SO4, filtered, and concentrated 
in vacuo.  
To a stirring solution of this inseparable mixture of free phenols 4-88/89 (66 
mg) in CH3CN (12 mL) was added DBU (0.41 mL, 2.74 mmol) at room 
temperature. The resulting mixture was heated between 68 – 78 °C for 10 h 
before it was cooled to room temperature, and quenched with 10% citric acid to 
pH 2-3. The mixture was diluted with EtOAc and water, and the organic layer 
was separated. The aqueous layer was extracted with EtOAc (3x), and the 
combined organic layers were washed with water (1x), followed by brine, dried 
over Na2SO4, filtered, and concentrated in vacuo. Flash column 
chromatography of the crude product over silica gel (5% EtOAc/hexane → 
24% EtOAc/hexane → 70% EtOAc/hexane) afforded 6-methoxydienone (±)-4-
1 [25.2 mg, 85% over two steps (based on cis-isomer)] as a pale yellowish-
white solid, and unreacted (trans-lactol-derived)-iodo-phenol 4-89 (18.6 mg) as 
a colourless sticky oil.  
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4-1: mp 76.1-78.4 °C; 1H NMR (500 MHz, CDCl3): δ 6.16 (s, 1H), 5.56 (s, 
1H), 4.73 (d, J = 4.4 Hz, 1H), 3.68 (s, 3H), 2.56 (t, J = 6.0 Hz, 1H), 2.26-2.16 
(m, 2H), 1.99 (d, J = 10.7 Hz, 1H), 1.93 (dd, J = 3.1, 10.7 Hz, 1H), 1.76 (d, J = 
11.3 Hz, 1H), 1.52 (d, J = 3.1 Hz, 1H), 1.51 (s, 3H); 13C NMR (125 MHz, 
CDCl3): δ 182.0, 160.6, 152.2, 121.4, 117.9, 86.7, 79.6, 55.8, 54.9, 49.7, 44.1, 
42.4, 22.2; ESI-MS: m/z calcd for C14H16O3Na+ [M + Na]+ 255.1, found 255.1. 
 
Aryl mesylate homoallyl ethyl ester 4-92: Procedure for TBS-deprotection 
of homoallyl ethyl ester 4-39 using 1M TBAF in THF was repeated as 
previously described. To a solution of this free phenol (0.104 g, 0.374 mmol) 
in CH2Cl2 (7 mL) was added Et3N (312 µL, 2.24 mmol) and MsCl (174 µL, 
2.25 mmol) at 0 °C. The resulting mixture was then stirred at room temperature 
for 5 h before it was diluted with water. The mixture was extracted with 
CH2Cl2 (3x), and the combined organic extracts were washed with saturated 
aq. NaHCO3, followed by brine, dried over Na2SO4, filtered, and concentrated 
in vacuo. Flash column chromatography of the crude product over silica gel 
(5% EtOAc/hexane → 28% EtOAc/hexane) afforded aryl mesylate 4-92 (0.128 
g, 96%) as a pale yellow oil. 
4-92: 1H NMR (300 MHz, CDCl3): δ 7.19 (d, J = 8.0 Hz, 1H), 6.80-6.74 (m, 
2H), 4.78 (s, 1H), 4.70 (s, 1H), 4.08 (q, J = 7.1 Hz, 2H), 3.87 (s, 3H), 3.16 (s, 
3H), 2.91-2.82 (m, 1H), 2.77-2.62 (m, 2H), 2.39 (d, J = 6.4 Hz, 2H), 1.72 (s, 
3H), 1.22 (t, J = 7.1 Hz, 3H); ESI-MS: m/z calcd for C17H24O6SNa+ [M + Na]+ 




Aryl mesylate homoallyl acid 4-93: To a solution of homoallyl ethyl ester 
4-92 (0.108 g, 0.303 mmol) in THF (4.8 mL) and H2O (1.6 mL) was added 
LiOH (14.5 mg, 0.605 mmol) at 0 °C. The resulting mixture was stirred at 0 °C 
to room temperature over 20 h before it was concentrated in vacuo. The residue 
was diluted with water and extracted with CH2Cl2 (2x) before the aqueous 
layer was acidified with 2M HCl to pH 1-2. The aqueous layer was then 
extracted with EtOAc (3x), and the combined EtOAc extracts were washed 
with water (1x), followed by brine, dried over Na2SO4, filtered, and 
concentrated in vacuo to afford homoallyl acid 4-93 (83.1 mg, 84%) as a 
colourless viscous oil. 4-93 was carried forward to the next step without further 
purification. 
4-93: 1H NMR (500 MHz, CDCl3): δ 7.18 (d, J = 8.2 Hz, 1H), 6.79-6.74 (m, 
2H), 4.80 (s, 1H), 4.72 (s, 1H), 3.88 (s, 3H), 3.15 (s, 3H), 2.88-2.82 (m, 1H), 
2.76 (dd, J = 7.6, 13.9 Hz, 1H), 2.68-2.64 (m, 1H), 2.47-2.40 (m, 2H), 1.72 (s, 
3H); 13C NMR (125 MHz, CDCl3): δ 182.0, 160.6, 152.2, 121.4, 117.9, 86.8, 
79.7, 55.9, 54.9, 49.8, 49.7, 44.1, 42.5, 22.2; ESI-MS: m/z calcd for C15H19O6S- 






Aryl mesylate cis- and trans-iodolactones 4-78/79: To a solution of 
BnNH2 (30 µL, 0.275 mmol) in CH2Cl2 (1 mL) was added ICl (7 µL, 0.140 
mmol) at 0 °C, and stirred for 30 min before cooling the resulting reddish-
orange mixture to -78 °C. To this mixture was added a solution of homoallyl 
acid 4-93 (22.1 mg, 0.0673 mmol) in CH2Cl2 (1 mL) at -78 °C. The reaction 
was stirred at the same temperature before it was quenched with saturated aq. 
Na2S2O3 at -78 °C and warmed to room temperature. The mixture was diluted 
with water, and extracted with CH2Cl2 (3x). The combined organic extracts 
were washed with brine, dried over Na2SO4, filtered, and concentrated in 
vacuo. Flash column chromatography of the crude product over silica gel (10% 
EtOAc/hexane → 45% EtOAc/hexane) afforded an inseparable mixture of cis- 
and trans-iodolactones 4-78/79 (3:2 dr, 13.2 mg, 43%) as a pale yellow oil. 
               
Eugenol Bn ether 4-94: To a solution of eugenol 4-10 (10 g, 60.9 mmol) in 
anhydrous DMF (100 mL) was added anhydrous K2CO3 (25.3 g, 182.7 mmol), 
TBAI (0.1 equiv.) and BnBr (10.9 mL, 91.4 mmol) at room temperature. The 
resulting mixture was warmed to 55 °C and stirred for 16 h before it was 
cooled to room temperature, and quenched with cold water. Vigorous stirring 
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was maintained for 5-10 min until a homogenous layer was obtained, and 
extracted with Et2O (4x). The combined organic extracts were washed with 
water (1x), followed by brine, dried over Na2SO4, filtered, and concentrated in 
vacuo. Flash column chromatography of the crude product over silica gel 
(3.5% EtOAc/hexane) afforded benzyl ether 4-94 (15.4 g, 99%) as a pale 
yellow oil.  
4-94: 1H NMR (500 MHz, CDCl3): δ 7.46 (d, J = 7.6 Hz, 2H), 7.37 (t, J = 
7.6 Hz, 2H), 7.31 (t, J = 7.3 Hz, 1H), 6.83 (d, J = 8.2 Hz, 1H), 6.75 (s, 1H), 
6.68 (d, J = 8.2 Hz, 1H), 6.01-5.93 (m, 1H), 5.14 (s, 2H), 5.11-5.06 (m, 2H), 
3.89 (s, 3H), 3.35 (d, J = 7.0 Hz, 2H); 13C NMR (125 MHz, CDCl3): δ 149.7, 
146.5, 137.6, 137.4, 133.3, 128.4, 127.7, 127.2, 120.4, 115.6, 114.4, 112.5, 
71.2, 55.9, 39.8; HRMS (EI): m/z calcd for C17H18O2+ [M]+ 254.1307, found 
254.1303. 
 
α,β-Unsaturated methyl ester 4-96: To a solution of benzyl ether 4-94 (10 
g, 39.3 mmol) in t-BuOH (200 mL) and THF (80 mL) was added a solution of 
NMO (50% w/w in H2O, 11.1 g, 47.2 mmol) in H2O (40 mL) and OsO4 (2 
mol%) at room temperature. The resulting mixture was stirred at room 
temperature for 16 h before it was cooled to 0 °C, and quenched with NaHSO3 
(20 g, 3 M in H2O). The mixture was warmed to room temperature and stirred 
for 45 min. The organic layer was separated and concentrated in vacuo, and 
EtOAc was added to re-dissolve the residue that formed. The aqueous layer 
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was extracted with EtOAc (3x), and the combined organic layers were washed 
with H2O (1x), followed by brine, dried over Na2SO4, filtered, and 
concentrated in vacuo.  
To this crude diol in THF (200 mL) and H2O (100 mL) were added NaIO4 
(17.0 g, 79.5 mmol) at room temperature, and stirred for 4 h. The resulting 
mixture was carefully concentrated to less than half its volume by removing 
THF under vacuo at 30 °C. The mixture was diluted with water/brine (1:1) and 
extracted with Et2O (3x). The combined organic extracts were washed with 
brine, dried over Na2SO4, filtered, and concentrated in vacuo.  
To this crude aldehyde 4-98 in CH2Cl2 (150 mL) was added ylide 4-32 (17.8 
g, 51.1 mmol) at 0 °C. The resulting mixture was stirred from 0 °C to room 
temperature over 12 h before it was concentrated in vacuo. Flash column 
chromatography of the crude product over silica gel (10% EtOAc/hexane → 
15% EtOAc/hexane → 20% EtOAc/hexane) afforded (E)-α,β-unsaturated 
methyl ester 4-96 (11.9 g, 93% over three steps) as a white solid.  
4-96: mp 46.6-47.8 °C; 1H NMR (500 MHz, CDCl3): δ 7.45 (d, J = 8.2 Hz, 
2H), 7.36 (t, J = 7.6 Hz, 2H), 7.30 (t, J = 6.9 Hz, 1H), 6.91 (t, J = 7.3 Hz, 1H), 
6.82 (d, J = 8.2 Hz, 1H), 6.72 (s, 1H), 6.65 (d, J = 8.2 Hz, 1H), 5.13 (s, 2H), 
3.88 (s, 3H), 3.74 (s, 3H), 3.46 (d, J = 7.6 Hz, 2H), 1.96 (s, 3H); 13C NMR (125 
MHz, CDCl3): δ 168.5, 149.8, 146.8, 140.5, 137.2, 132.1, 128.4, 127.9, 127.7, 
127.2, 120.3, 114.5, 112.4, 71.2, 56.0, 51.7, 34.4, 12.5; HRMS (EI): m/z calcd 




Methallyl alcohol 4-99: To a solution of (E)-α,β-unsaturated methyl ester 
4-96 (11.8 g, 36.2 mmol) in THF (200 mL) was carefully added LiAlH4 (3.3 g, 
87.0 mmol) in portion-wise (4x) at -10 °C. The resulting mixture was stirred at 
-10 °C for 20 min before it was stirred at room temperature for 1.5 h. The 
mixture was cooled to 0 °C and quenched with EtOAc. At the same 
temperature, Na2SO4 (50 mL, sat. aq.) was added and warmed to room 
temperature. The resulting white suspension was stirred at room temperature 
for a further 20 min before Celite (45 g) was added and stirred for another 30 
min. The mixture was filtered through glass frit, eluted with EtOAc (1 L) and 
concentrated in vacuo. Flash column chromatography of the crude product over 
silica gel (10% EtOAc/hexane → 35% EtOAc/hexane) afforded allyl alcohol 4-
99 (9.49 g, 88%) as a white solid.  
4-99: mp 41.2-42.1 °C; 1H NMR (500 MHz, CDCl3): δ 7.44 (d, J = 8.2 Hz, 
2H), 7.36 (t, J = 7.6 Hz, 2H), 7.29 (t, J = 7.3 Hz, 1H), 6.81 (d, J = 8.2 Hz, 1H), 
6.73 (d, J = 1.9 Hz, 1H), 6.65 (dd, J = 8.2 Hz, 1.9 Hz, 1H), 5.62-5.58 (m, 1H), 
5.13 (s, 2H), 4.05 (s, 2H), 3.88 (s, 3H), 3.34 (d, J = 7.6 Hz, 2H), 1.78 (s, 3H); 
13C NMR (125 MHz, CDCl3): δ 149.6, 146.4, 137.4, 135.5, 134.2, 128.4, 
127.7, 127.2, 124.78, 120.1, 114.3, 112.3, 71.2, 68.7, 56.0, 33.4, 13.7; HRMS 




(Benzyloxy)-homoallyl dimethyl amide 4-101: To a stirring solution of 
methallyl alcohol 4-99 (2.345 g, 7.86 mmol) in xylene (87 mL) was added 
N,N’-dimethyl acetamide dimethyl acetal 4-100 (10.4 mL, 63.1 mmol) at room 
temperature. The resulting mixture was refluxed at 152-154 °C for 6.5 h before 
it was concentrated in vacuo at 55 °C. Flash column chromatography of the 
crude product over silica gel (10% EtOAc/hexane → 30% EtOAc/hexane → 
68% EtOAc/hexane) afforded homoallyl dimethyl amide 4-101 (2.86 g, 99%) 
as pale yellow oil. 
4-101: 1H NMR (500 MHz, CDCl3): δ 7.41-7.28 (m, 5H), 6.78-6.75 (m, 
2H), 6.64-6.62 (m, 1H), 5.11 (s, 3H), 4.75 (s, 1H), 4.67 (s, 1H), 3.86 (s, 3H), 
2.92 (s, 3H), 2.90 (s, 3H), 2.66 (d, J = 7.5 Hz, 2H), 2.44-2.32 (m, 2H), 1.73 (s, 
3H); 13C NMR (125 MHz, CDCl3): δ 171.8, 149.4, 147.3, 146.4, 137.4, 133.6, 
128.4, 127.7, 127.3, 121.1, 114.0, 112.9, 111.1, 71.2, 56.0, 44.5, 39.7, 37.3, 
36.8, 35.4, 20.7; ESI-MS: m/z calcd for C23H29O3NNa+ [M + Na]+ 390.2, found 







  cis- and trans-(Benzyloxy)-iodolactones 4-63/51: To a solution of 
homoallyl dimethyl amide 4-101 (98.1 mg, 0.267 mmol) in THF (1.5 mL) and 
H2O (1.5 mL) was added I2 (0.21 g, 0.827 mmol) in one portion at 0 °C. The 
resulting mixture was stirred at 0 °C for 12 h before the excess I2 was quenched 
with saturated aq. Na2S2O3, and stirred to room temperature to obtain a clear 
solution. The resulting solution was diluted with water, and extracted with 
CH2Cl2 (3x). The combined organic extracts were washed with brine, dried 
over Na2SO4, filtered, and concentrated in vacuo. Flash column 
chromatography of the crude product over silica gel (5% EtOAc/hexane → 
30% EtOAc/hexane) afforded an inseparable mixture of cis- and trans-
iodolactones 4-63/51 (2:1 dr, 0.119 g, 96%) as a colourless oil. 
 
(Allyloxy)-iodo-benzotetrahydrofurans 4-102 and 4-103: To a solution of 
the inseparable mixture of cis- and trans-iodolactols 4-84/85 (30 mg, 0.0717 
mmol) in CH2Cl2 (3.6 mL) was quickly added SnCl4 (50.4 µL, 0.431 mmol) at 
-78 °C. The solution gave a bright yellow colour after 10-15 min of stirring at -
78 °C. The solution was stirred at -78 °C for 50 min before it was swiftly 
poured into an ice-cooled saturated aq. NH4Cl solution (60-70 mL) with 
vigorous stirring. The organic layer was separated, and the aqueous layer was 
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extracted with CH2Cl2 (3x). The combined organic layers were washed with 
brine, dried over Na2SO4, filtered, and concentrated in vacuo. Flash column 
chromatography of the crude product over silica gel (hexane → 12% 
EtOAc/hexane) afforded an inseparable mixture of (cis-lactol-derived)-iodo-
benzotetrahydrofuran 4-102 and (trans-lactol-derived)-iodo-
benzotetrahydrofuran 4-103 (24.2 mg, 84%) as a colourless oil. 
4-102/103: 1H NMR (500 MHz, CDCl3): δ 6.64-6.61 (m, 2H), 6.11-6.03 (m, 
1H), 5.40-5.37 (m, 1H), 5.27-5.25 (m, 1H), 4.79 + 4.75 (d1 + d2, J1 = J2 = 5.0 
Hz, 1H), 4.56-4.55 (m, 2H), 3.85 + 3.83 (s each, 3H), 3.30-3.20 + 3.07-2.92 
+2.83 (m1 + m2 + brs3, 5H), 2.59-2.52 + 2.43-2.41 (m each, 2H), 2.02 (dd, J = 
11.3, 17.0 Hz, 1H), 1.51 + 1.37 (s each, 3H); 13C NMR (125 MHz, CDCl3): δ 
149.4, 149.3, 145.9, 133.5, 133.4, 132.8, 132.2, 117.9, 117.8, 112.6, 112.5, 
112.0, 111.98, 83.5, 82.9, 78.2, 78.1, 70.0, 56.0, 41.6, 40.2, 35.6, 35.0, 32.7, 
31.9, 27.8, 23.6, 17.6, 13.8; EI-MS: m/z calcd for C17H21O3I+ [M]+ 400.1, 
found 400.3. 



























Method 1: To a solution of iodo-benzotetrahydrofurans 4-102/103 (12 mg, 
0.03 mmol) in THF (1.5 mL) was added Pd(PPh3)4 (5 mol%) in a N2-filled 
Aldrich® AtmosBag glove bag at room temperature. The resulting mixture was 
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stirred at room temperature for 5 min before NaBH4 (2 mg, 0.05 mmol) was 
added in one portion, and the solution turned brownish-black. The reaction was 
stirred at room temperature for a further 1 h before it was quenched with 10% 
citric acid to pH 2-3. The mixture was diluted with water and extracted with 
CH2Cl2 (3x). The combined organic extracts were washed with brine, dried 
over Na2SO4, filtered, and concentrated in vacuo. Flash column 
chromatography of the crude product over silica gel (5% EtOAc/hexane → 
18% EtOAc/hexane → 30% EtOAc/hexane → 60% EtOAc/hexane) afforded 
an inseparable mixture of iodo-phenols 4-88 and 4-89 (7.6 mg, 70%) as a white 
solid. 
Method 2: To a solution of iodo-benzotetrahydrofurans 4-102/103 (38.8 
mg, 0.0969 mmol) in MeOH (1.8 mL) was added Pd(PPh3)4 (1 mol%) in a N2-
filled Aldrich® AtmosBag glove bag at room temperature. The resulting 
mixture was stirred at room temperature for 5 min before anhydrous K2CO3 (42 
mg, 0.304 mmol) was added in one portion. The reaction was stirred at room 
temperature for a further 12 h before it was diluted with EtOAc and partially 
concentrated in vacuo. This sequence of dilution and concentration was 
repeated thrice to exchange the MeOH solvent with EtOAc. The mixture was 
then added with 10% citric acid to pH 2-3 before it was extracted with CH2Cl2 
(3x). The combined organic extracts were washed with brine, dried over 
Na2SO4, filtered, and concentrated in vacuo. Flash column chromatography of 
the crude product over silica gel (5% EtOAc/hexane → 18% EtOAc/hexane) 
afforded an inseparable mixture of iodo-phenols 4-88 and 4-89 (33.4 mg, 96%) 




4-88/89: mp 72.3-76.5 °C; 1H NMR (500 MHz, CDCl3): δ 6.66-6.59 (m, 
2H), 5.45 + 5.43 (brs each, 1H), 4.79 + 4.75 (d1 + d2, J1 = J2 = 5.0 Hz, 1H), 
3.87 + 3.86 (s each, 3H), 3.30 + 3.24-3.19 + 3.06-2.91 +2.84 (d1+m2 + m3 + 
brs4, J1 = 10.1 Hz, 5H), 2.57-2.51 + 2.43-2.39 (m each, 2H), 2.01 (dd, J = 10.7, 
17.0 Hz, 1H), 1.51 + 1.38 (s each, 3H); ESI-MS: m/z calcd for C14H18O3I+ [M 
+ H]+ 361.0, found 362.1.  
 
6-Methoxyketones 4-105/106: To a solution of 6-methoxydienone 4-1 (3.4 
mg, 0.0146 mmol) in 2:1 v/v EtOAc (1.2 mL) and ethanolic KOH (0.3M, 0.6 
mL) was added 10% Pd on carbon (2 mg) at room temperature. The resulting 
mixture was stirred under a hydrogen atmosphere (balloon) for 2 h 15 min 
before it was filtered through a micro-filter with EtOAc wash to remove the 
Pd-C, followed by the addition of 10% citric acid to the filtrate. The mixture 
was diluted with water, and extracted with EtOAc (3x). The combined organic 
extracts were washed with brine, dried over Na2SO4, filtered, and concentrated 
in vacuo. Flash column chromatography of the crude product over silica gel 
(5% EtOAc/hexane → 20% EtOAc/hexane → 40% EtOAc/hexane) afforded 
an inseparable mixture of 6-methoxyketones 4-105 (desired) and 4-106 (1:3 dr 
at C9, 2 mg, 70%) as a white solid. 
4-105(α)/106(β): mp 49.7-53.4 °C; 1H NMR (300 MHz, CDCl3): δ 4.12(α) 
+ 4.00(β) {brsα + dβ, Jβ = 4.3 Hz, 1H [integration ratio = 1:3 (α/β)]}, 3.83-3.75 
(mα + β, 1H), 3.45 (sα + β, 3H), 2.79 + 2.33-2.26 (tβ + mα+β, Jβ = 14.0 Hz, 4H), 
2.04-1.86 (mα + β, 3H), 1.79-1.70 (mα + β, 4H), 1.43 (sα + β, 3H); 13C NMR (125 
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MHz, CDCl3): δ 209.1, 207.9, 207.8, 87.4, 85.5, 85.3, 83.6, 82.1, 79.3, 78.9, 
77.3, 58.1, 57.3, 53.4, 52.6, 47.5, 46.5, 45.9, 45.2, 44.9, 43.3, 42.5, 42.1, 41.4, 
40.8, 38.1, 37.4, 29.7, 23.2; EI-MS: m/z calcd for C14H20O3+ [M]+ 236.1, found 
236.1.      
















5.1 Retrosynthetic Analysis of (-)-Platensimycin 
An asymmetric version of the dienone 4-1 was contemplated to study the 
key stereoselective conjugate reduction of the C4-C9 olefin with 
chemoselectivity controlled by the C6-methoxy group. A modification of our 
retrosynthesis as shown in Scheme 5.1 includes, in a forward sense, 
dialkylation of the C6/C7-α,β-unsaturated α-methoxy enone, derived from 4-1, 
to the 6-methoxyplatensinoate ester 5-1 (R = alkyl group) before cleavage of 
the C6-methoxy group ensues. Finally, ester hydrolysis to the platensic acid 1-
14, and amide coupling with the aromatic unit would afford (-)-platensimycin. 
The key strategic steps toward 4-1 anticipate a similar sequential order of 
transformations, but beginning from tosyl lactol 5-3, via a stereoselective 
Friedel-Crafts cyclization and intramolecular alkylative dearomatization as 
earlier described in Chapter 4. The desired stereochemistry at C10 in the 
benzotetrahydrofuran 5-2 would be defined by the stereocenter at C12. The 
requisite C12/C15-cis configuration in the lactol 5-3, which a 2.5:1 dr at best 
(cis/trans) could only be obtained from the previously optimized 
iodolactonization process, was anticipated to arise from a regioselective 
Grignard opening of a chiral epoxide derived from Sharpless epoxidation of the 
allyl alcohol 4-99.  
Mono-tosylation of the resulting diol would afford the alcohol 5-4, and the 
tosyl group was chosen for its stability towards reductive debenzylation, as 
well as its propensity as a suitable leaving group during the late-satge 
cyclodearomatization process. Although we were successful with aryl ring 
closure of the iodo-derived free lactol cis-4-65 (Scheme 4.14), the Lewis 
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basicity of the sulfonate group in 5-3 was forethought to pose a reactivity 
concern for the Lewis acid-mediated Friedel-Crafts cyclization. Alcohol 4-99 
has been conveniently prepared by a high-yielding four-step sequence from the 


































































Scheme 5.1. Retrosynthetic analysis of the tetracyclic dienone 4-1 of (-)-platensimycin 
via a stereoselective Friedel-Crafts cyclization approach. 
 
5.2 Synthesis of the Tetracyclic Dienone (-)-4-1 via SnCl4-Mediated 
Stereoselective Friedel-Crafts Cyclization 
Beginning with allyl alcohol 4-99 (Scheme 5.2), a catalytic Sharpless 
asymmetric epoxidation with L-(+)-DIPT afforded the epoxy alcohol 5-5 in 
98% yield and 91% ee.[136] The racemic version of 5-5 has been conveniently 
prepared by mCPBA oxidation (88%) for chiral HPLC analyses. By exploiting 
a 5-membered chelated transition (5-6) between Mg2+ and the unprotected 
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epoxy alcohol, a highly regioselective epoxide opening with allyl magnesium 
chloride afforded the diol 5-7 in 92% yield, and established the desired 
stereochemistry at C12.[137] It is noteworthy that allylmagnesium chloride was 
used in place of allyl magnesium bromide because of the latter’s propensity to 
predominantly result in competitive opening of the epoxide by the bromide 
anion.[138] We have also found that the addition of the Grignard reagent was 
best performed gradually with the temperature well-maintained below -20 °C 



























































































Scheme 5.2. Synthesis of (-)-dienone 4-1 via the tosyl lactol 5-3. 
 
Stoichiometric-controlled mono-tosylation of the 1,2-diol 5-7 under TsCl 
and Et3N conditions was sluggish, and significant amount of the geminal-
disubstituted epoxide 5-9 was observed. Martinelli’s regioselective catalytic 
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mono-tosylation protocol with 2 mol% nBu2SnO gratifyingly circumvented the 
problem to provide the alcohol 5-4 exclusively in excellent yield.[139] The 
sulfonylation occurred within 2-3 h, and formation of 5-9 was observed if the 
reaction was allowed to run for longer times. Oxidative double-bond cleavage 
with concomitant cyclization furnished the cis-tosyl lactol 5-3 in 85% yield.  
The anticipated SnCl4-mediated Marson-type Friedel-Crafts cyclization, 
based on previously established procedure, was performed with tosyl lactol cis-
5-3 (Scheme 5.2). However, formation of the tosyl-benzotetrahydrofuran 5-2 
was disappointingly capricious, as yields could range from below 50 to 74% at 
best when 8-10 equivalents of SnCl4 were employed. The cyclization was 
found comparatively sluggish and failed to go to completion even after 4 h of 
treatment with 6 equivalents of SnCl4 – the required stoichoimetric amount 
optimal for the ring closure of the cis-iodo lactol 4-84 within 50 min. These 
findings subtly suggested a possible retardation of Lewis acid reactivity by the 
sulfonyloxyl group as conjectured.  
Ungratifyingly, we were again encumbered by the decomposition of the 
desired Friedel-Crafts product 5-2 upon quenching with saturated aq. NH4Cl, 
and significant reversion back to the starting lactol 5-3 was observed. Deriving 
from a similar idea with quenching Ti(OiPr)4 in Sharpless epoxidation, 
quenching the remaining SnCl4 by pouring into half-saturated Rochelle salt 
solution effectively suppressed these side-reactions much to our delight.[140] 
With this newly improved quenching method, we were able to comfortably run 
practical scales of the Friedel-Crafts arylation and reliably provided 5-2 in 
good yields. 800 mg of 5-3 has been successfully attempted in a single run with 
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86% yield achieved, as compared to the earlier 200 mg (4-84/85) limitation per 
batch with saturated aq. NH4Cl quench.  
With 5-2 in hand, debenzylation proceeded uneventfully with catalytic 
hydrogenolysis over Pd-C at ambient pressures. Tosyl-phenol 5-8 was 
recrystallized from CH2Cl2/EtOAc as white crystals suitable for X-ray 
crystallographic analysis (Figure 5.1). The X-ray data verified the absolute 
stereochemistry assigned to each stereogenic centre, as deduced from the 
Sharpless asymmetric epoxidation mnemonic.  
 
 
Figure 5.1. Determination of the absolute configuration of tosyl-phenol 5-8 by X-ray 
crystallographic analysis. 
 
However, the ensuing alkylative cyclodearomatization with 5-8 was not as 
uneventful as proposed in the presence of excess DBU in CH3CN. The same 
procedure (15 equivalents of DBU at 70 °C for 10 h) mainly recovered the 
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starting tosyl-phenol 5-8 with only 14% conversion to the tetracyclic dienone 
4-1. Refluxing the CH3CN mixture at 80-85 °C for longer hours only improved 
the yield marginally to 21%, but also generated unknown byproducts in the 
process. We rationalized that the poor reactivity demonstrated by 5-8 towards 
ring closure could be because: (1) the tosylate was a poorer leaving group than 
the iodide under these strongly-basic conditions; and (2) the aprotic, polar 
solvated environment might have subtly promoted non-dipole – non-dipole 
type pi-stacking interactions between the aryl groups.     
5.3 Synthesis of the Tetracyclic Dienone (-)-4-1 via Bromohydrin 5-10 
Epoxide 5-9 could be recycled into our synthetic plan through a LiBr-
promoted regioselective ring opening to furnish bromohydrin 5-10 (Scheme 
5.3).[141] Functional group manipulation to the bromide, instead of the iodide, 
should better tolerate subsequent benzyl deprotection in the bromo-
benzotetrahydrofuran 5-12 using ammonium formate transfer hydrogenolysis 
reported by Njardarson and co-workers.[38e] It is noteworthy that the conversion 
to 5-10 from 5-9 was temperature-dependent and strong reflux at 90 °C was 
essential for the high yield obtained. Furthermore, the amount of AcOH used 
was experimentally found to influence the regioselectivity of the epoxide-ring 
opening, and two equivalents of the acid were proven optimal in our hands.  
Oxidative double-bond cleavage with concomitant cyclization then 
furnished the cis-bromo lactol 5-11 in 91% yield over two steps. Friedel-Crafts 
cyclization of 5-11 with only 5 equivalents of SnCl4 and a half-saturated 




transfer hydrogenolysis of the Bn-phenyl ether in 5-12 with ammonium 
formate in refluxing acetone was[38e] met with limited success. The reaction 
yielded a 1:1 mixture of the bromo-phenol 5-13 along with its debromo-
derivative, and some starting material 5-12 was also recovered. 
An alternative procedure using 1,4-cyclohexadiene as the “H-source” at 
ambient temperatures and pressures was attempted which gave a clean and 
quantitative conversion to phenol 5-13 gratifyingly. Without further 
purification, 5-13 was subjected to excess DBU in refluxing CH3CN and this 
time (versus tosyl-phenol 5-8) alkylative cyclodearomatization occurred 
effectively to furnish dienone 4-1 in 84% yield over two steps. This part of the 
synthesis could be scale-up through alcohol 5-4 via an efficient epoxide 
closure under K2CO3/MeOH condition.   
 
Scheme 5.3. Synthesis of (-)-dienone 4-1 via the bromo lactol 5-11. 
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5.4 Development of a New Catalytic Friedel-Crafts Cyclization with 
Bromo-Lactol 5-11 
Although the issue of undesired SnCl4-mediated benzotetrahydrofuran 
decomposition has been resolved through the discovery of a half-saturated aq. 
Rochelle salt work-up procedure, the large excess of the Lewis acid reagent (5-
10 equivalents) required to promote the Friedel-Crafts cyclization poses a real 
practical limitation and disadvantage in reagent economy. The highly toxic, 
highly moisture-sensitive and ecologically harmful SnCl4 as such is probably 
not among the most preferred Lewis acids of choice in contemporary organic 
synthesis and for the scale-up syntheses. To the best of our knowledge, reports 
on Friedel-Crafts arylation with an unactivated free lactol are few, and those 
reactions have been largely promoted by stoichoimetric reagents, including the 
most commonly used BF3·Et2O and SnCl4.  
To further improve these practical issues, we next decided to develop a 
direct catalytic Friedel-Crafts method to bromo-benzotetrahydrofuran 5-12 by 
screening bromo-lactol 5-11 against various oxophilic Lewis acids at 25-
100 mol% loadings (Table 5.1, entries 1-12). The conversion of the free lactol 
(5-11) to its oxocarbenium species through Lewis acids activation was 
surprisingly facile. However, one-pot cyclization into the aromatic ring varied, 
and competitive formation of the O-dimer 5-14 was observed predominantly 
with Lewis acids having little or no desired catalytic activity, including 
Al(OTf)3, Sc(OTf)3, Au(I)/Ag(I) and ZnCl2 (entries 1-2, 9-10). Triflimide, a 
strong Brønsted acid, was also examined and unlike earlier acids tested (PTSA, 
HCl and MeSO3H), 5-12 was interestingly furnished in a modest 59% yield 
(entry 11).  
252 
 
Considerable experimentations revealed that Bi(OTf)3, FeCl3, InCl3 and 
AuCl3 were all more effective than SnCl4 at promoting the cyclization in sub-
stoichoimetric amounts (entries 4-7). Bi(OTf)3 was our Lewis acid of interest, 
as the latter was superior in reactivity and afforded 5-12 with the highest yield 
of 94%. These findings were in further virtues of the reagent’s low cost, 
air/moisture tolerability and eco-benign property.[142] The poor results obtained 
with 1 equivalent or less HOTf (entry 12) supported our anticipation that the 
latter was not exactly the reagent responsible for catalyzing the Friedel-Crafts 
process with Bi(OTf)3. Furthermore, in the absence of 4Å molecular sieves 
(MS), the cyclization with Bi(OTf)3 would generate unidentified byproducts, 
which suggested the necessity to minimize water (either residual moisture or 
H2O produced from the reaction) in the flask, and possibly to indirectly reduce 
unnecessary HOTf formation.  
We next attempted to decrease the amount of Bi(OTf)3 employed in the 
Friedel-Crafts arylation step (entries 13-15). Catalyst loadings were eventually 
reduced to 5 mol% of Bi(OTf)3 with no adversity on the reactivity, and has 
successfully applied to 540 mg scale of 5-11 (entry 15). Lower catalyst 
loadings (e.g. 2 mol%, entry 14) were not optimal and led to sluggish 
formation of 5-12 and 5-14. By adding more Bi(OTf)3, dimer 5-14 was 
conveniently transformed to 5-12 in the same pot (note b). A secondary 
limitation with Bi(OTf)3 as the Friedel-Crafts catalyst was the undesired 
formation of bromohydrin 5-15 upon quenching with saturated aq. NH4Cl 
(quenching with Rochelle salt solutions led to more 5-15 generation). 
However, this unwanted etheral cleavage process was minimized with reduced 
catalyst loading of Bi(OTf)3.  
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In the absence of the C6-methoxy group, it has been experimentally 
demonstrated in our group that the Bi(OTf)3-catalyzed Friedel-Crafts 
cyclization of the C6-demethoxy analog of bromo-lactol 5-11 does not 
proceed. No conditions (BF3·Et2O, SnCl4, TfOH, InCl3 and etc.) have been 
found, thus far, to promote direct intramolecular arylation of the free lactol. 
Pre-activation of the free lactol, such as formation of the glycosyl acetate, 
glycosyl trichloroacetimidate, and glycosyl halides did not succumb under 
Lewis acid conditions toward Friedel-Crafts ring closure in the mono-activated 
aryl system. In light of these results, we realized that the tactic of pre-
employing a methoxy group to impart needed electronic and steric control 
(vide infra) has greatly helped us to quickly advance this key intramolecular 
Friedel-Crafts para-arylation transformation.  
Table 5.1. Lewis acid-promoted intramolecular Friedel-Crafts arylation of the bromo-
lactol 5-11.  
 
entrya Lewis acid equiv. t (h)  isolated yield (%) 
    5-12 5-14b 5-15 5-11 
1 Al(OTf)3 50 mol% 12 - 67 - - 
2 Sc(OTf)3 25 mol% 12 30 59 - - 
3 La(OTf)3 25 mol% 12 54 33 - - 
4 Bi(OTf)3 25 mol% 1.25 94 - 4 - 
5 FeCl3 50 mol% 1.5 78 - trace - 
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6 InCl3 25 mol% 3 85 - - - 
7 AuCl3 50 mol% 2 82 - - - 






12 - 62 - 22 
10 ZnCl2 1 equiv. 12 - 72 - 10 
11d,e HNTf2 40 mol% 2 59 - - - 
12d,e HOTf 25 mol%f 2 22 34 - - 
13 Bi(OTf)3 10 mol% 1.5 88 - trace - 
14 Bi(OTf)3 2 mol% 4 62 31 - - 
15g Bi(OTf)3 5 mol% 2 92 - 2 - 
 
a
 Reaction conditions: 5-11 (20-30 mg), Lewis acid, 4Å MS, CH2Cl2, rt. b 5-14 could be 
converted to 5-12 with 10 mol% Bi(OTf)3 in 80% yield. c A complex mixture was obtained.    
d
 Reaction was carried out at 0 °C. e Streaking of TLC was observed including the spotting of 
unknown baseline material. f 1 equivalent of HOTf provided a complex mixture. g 5-11 at 540 





5.5 Discovery of a New Bi(OTf)3-LiClO4 Combination for Catalytic 
Friedel-Crafts Cyclization of Tosyl-Lactol 5-3 
We were also interested to examine the new catalytic procedure with the 
cis-tosyl lactol 5-3 to expand the substrate scope of this Bi(OTf)3-catalyzed 
Friedel-Crafts cyclization (Table 5.2, entry 1). Disappointingly, the 
transformation was very slow and largely incomplete with 5-2 furnished in 
only 16% yield. Starting lactol 5-3 was mainly recovered and no O-dimer was 
actually observed in which these could suggest that the initial Bi(OTf)3-
catalyzed formation of the oxocarbenium species was impeded. Increasing the 
catalyst loading to 1 equivalent met with limited success and provided 5-2 in 
52% yield after 12 h (entry 2). In our earlier studies of this Friedel-Crafts 
process with 5-3, as much as 8-10 equivalents of SnCl4 were required to afford 
an effective and high-yielding transformation.  
Coupled with this information, we rationalized that there was a possible 
retardation of Lewis acid reactivity by the sulfonate group and the exploitation 
of Lewis acid promoters was proposed to circumvent the poor catalytic 
activity. Inspired by the report of Bartoli and Sambri on metal perchlorates as 
Lewis acids and/or promoters in catalyzing various organic 
transformations,[143] a new catalyst combination of 5 mol % Bi(OTf)3 with 3 
equivalents of LiClO4 as a co-catalyst[144] was eventually discovered to drive 
the Friedel-Crafts cyclization to furnish 5-2 in 94% yield within 3.5 h (entries 
3-4). Interestingly, LiClO4 alone was incapable of effecting the cyclization, but 
the addition of a catalytic amount of Bi(OTf)3 after 5 h in the same pot 
provided 5-2 in 74% yield (entry 5).  
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In Mukaiyama’s SbCl5-LiClO4 catalyzed Friedel-Crafts acylation,[144a] the 
formation of a highly active oxocarbenium perchlorate species is suggested 
between SbCl5 and LiClO4 with the acid anhydrides which promoted the 
reaction. Likewise, the combination of Bi(OTf)3 and LiClO4 could generate a 
more reactive cationic species “Bi(OTf)2(ClO4)” which would interact with the 
lactol 5-3 to accelerate the desired nucleophilic ring closure. By comparing 
with the Friedel-Crafts results for the bromo-equivalent of 5-3 (5-11), we also 
reason that Li+ can compete and coordinatively saturates the Lewis basic 
sulfonate group which release any trapped Bi(III), thereby allowing a catalytic 
cycle to persist.  
An attempt to decrease the catalyst loading to 2.5 mol% Bi(OTf)3 and 3 
equivalents LiClO4 resulted in a drop in yield, although the reaction was 
completed uneventfully within 6 h and no O-dimer formation was observed 
(entry 6). Another difference in reactivity between 5-3 and 5-11 was the 
absence of undesirable ethereal cleavage upon quenching the reaction, even at 
760 mg scale (entry 4).   
Table 5.2. Bi(OTf)3-promoted intramolecular Friedel-Crafts arylation of the tosyl-
lactol 5-3. 
 
entrya Lewis acid equiv. t (h) isolated yield (%) 
    5-2 5-3 
1 Bi(OTf)3 5 mol% 12 16 67 
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2 Bi(OTf)3 1 equiv. 12 52 38 
3 Bi(OTf)3/LiClO4 25 mol%/3 equiv. 3 96 - 
4b Bi(OTf)3/LiClO4 5 mol%/3 equiv. 3.5 94 - 
5 LiClO4 3 equiv. 5 No reactionc 
6 Bi(OTf)3/LiClO4 2.5 mol%/3 equiv. 6 82 trace 
 
a
 Reaction conditions: 5-3 (30-50 mg), Lewis acid, 4Å MS, CH2Cl2, rt. b Reaction was 
performed at 50 mg and 760 mg scales and reported comparable yields. c Without isolating 5-3, 
10 mol% Bi(OTf)3 was added into the same pot and 5-2 was afforded in 74% yield after 3 h. 
 
5.6 TBAF-Promoted Intramolecular Alkylative Dearomatization to the 
Tetracyclic Dienone 4-1 
Having secured a new and reliable catalytic Friedel-Crafts cyclization 
conditions with 5-3, we were determined to improve the subsequent 
intramolecular alkylative dearomatization of the benzyl deprotected tosyl-
phenol 5-8 [only 21% yield of dienone 4-1 has been attained with DBU in 
refluxing CH3CN (Table 5.3, entry 1)] and shorten the synthesis. Some of the 
earlier unsuccessful methods with the cyclodearomatization of iodo-phenol 4-
88 were repeated with 5-8, including NaH in DMF/THF mixture and NaOtBu 
in refluxing tBuOH remained futile.  
Higher boiling solvents were sought after as alternatives to DBU/CH3CN 
conditions as attempts to drive the cyclization at even elevated temperatures 
(Table 5.3). In nitroethane at 120 °C, a complex mixture due to active solvent 
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participation was resulted (entry 2). Switching to butyronitrile and increased 
the reflux temperature gradually above 130 °C, an improvement in yield (47%) 
was noted; however, significant byproducts were also observed (entry 3).  








 base solvent T (°C) t (h)  
1 30 DBU      
(15 eq.) 
CH3CN 85 20 21 20 mg 5-8 
recovered. 
2 19 DBU      
(15 eq.) 
C2H5NO2 120 12 - Complex TLC. 
3 28 DBU      
(15 eq.) 




4 23 TBAFb   
(20 eq.) 
C3H7CN 128 12 74 No 5-8 observed. 
Cleaner reaction. 
5 14 TBAF    
(20 eq.) 
xylenec 130 12 80 Only product spot 
(TLC). 
6 54 TBAF      
(5 eq.) 




7 790d TBAF      
(5 eq.) 




 Isolated yield of 4-1. b 1.0 M of TBAF in THF. c Mixture of isomers. d Crude 5-8 from 
quantitative debenzylation of 5-2. 
 
Although we were unclear of the unusual difference in reactivity between 
tosyl-phenol 5-8 and its bromo-equivalent 5-13 toward DBU-mediated 
cyclodearomatization, we reasoned that DBU may be too strongly basic and 
caused other side-reactions to compete in preference. In addition, we were 
wary about possible strong interactions forming between the tosyl-phenolic 
anion and the conjugated acid of DBU, which stabilized the intermediate and 
disfavored 4-1 formation, particularly in polar aprotic solvents.  
The application of ionic fluorides as basic reagents for various organic 
transformations is dated “old school” chemistry,[145] and that has interested us 
to examine TBAF’s properties as (1) a mild base, (2) a chemoselective reagent, 
and (3) exploit the peculiar fluoride-protic H-bonding interactions in our free 
phenol system. When 5-8 was treated with TBAF (1 M in THF) and heated at 
128 °C in butyronitrile, 4-1 was gratifyingly furnished in 74% yield (entry 4). 
Compared with the same conditions using DBU, the conversion was complete 
and a cleaner reaction was observed.  
Xylene was chosen as a cheaper solvent substitute for butyronitrile, and we 
anticipated that its non-polarity would help to reduce TBAF’s basicity, thereby 
allowing greater selectivity in the reaction (entry 5). Eventually, we found that 
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decreasing the amounts of TBAF from 20 equivalents to only 5 equivalents 
were suffice for the cyclization, and the reaction was actually completed within 
4 h (entry 6). A yield of 86% was afforded when the TBAF-mediated 
alkylative cyclodearomatization was performed with 5-8 on a larger scale 
(entry 7, 790 mg).  
Corey has recently reported a TBAF-mediated desilylation-promoted 
alkylative cyclization in their formal synthesis of (-)-platensimycin 1-4.[37b] 
Herein, this final ring closure of free phenol 5-8 could be facilitated by TBAF 
in xylene (at ambient pressures) or THF (in a sealed tube which we later 
investigated) at 130 °C, without the need to resort to better leaving groups or 
literature-reported phenyl silyl ether activation methods.[37b,38e,124b-c] The two 
characteristic features of fluorides as behaving both nucleophilic and basic are 
exemplified in this common alkylative cyclization step reported by Corey and 
our group.            
5.7 Conjugate Reduction of the Tetracyclic Dienone 4-1 
Amid the large number of enantioselective and racemic routes surfacing 
from the literature, installation of the required C8/C9 relative stereochemistry 
has been nontrivial under substrate and reagent controls.[36a,36c,36e,37a,38a-d,38h] 
Nevertheless, high diastereoselectivity has been achieved under high pressures 
and with optimized chiral reagents[37b-c], as mentioned earlier. In our pursuit for 
the cis-C8/C9 ring junction, a chemo- and stereocontrolled conjugate reduction 
at the electron-deficient C4-C9 olefin of 4-1 to the enone 5-16 (versus its C9-
epimer 5-17) was anticipated to be achievable by virtue of the C6-methoxy 
group (Table 5.4).  
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As our results found, substrate-controlled atmospheric hydrogenation of 
both olefins in 4-1 over catalytic Pd-C afforded a 1:3 dr in favor of undesired 
C8/C9-trans-decalin 5-19 over desired C8/C9-cis-decalin 5-18 (entry 1). The 
newly-formed stereocenter at C6 was inconsequential, thus the dr (C6) was not 
determine at that time. The unprecedented α-methoxy dienone system (4-1), 
however, proved to be unreactive towards various 1,4-reduction conditions 
(non-chiral methods, entries 3-7) such as Gregory Fu’s organo-tin hydride 
chemistry[147] and Ashfield’s low-valent titanium-catalyzed conjugate 
reduction[149], as efforts to furnish 5-16 selectively were met with limited 
success. Wilkinson’s Rh(I)-catalyzed chemoselective 1,4-hydrosilylation only 
afforded an inseparable 1:1 diastereomeric mixture of 5-16 and 5-17, albeit in 
9% yield (entry 3). The same conditions, however, gave Eun Lee modest 
selectivity and good yield for their α,β-unsaturated alicyclic carbonyl precursor 
of (-)-platensimycin (1-4) core structure.[38d]  
Asymmetric methods exploring chiral reagents to control the stereochemical 
outcome of the 1,4-reduction process were also difficult to achieve, as a result 
of poor substrate reactivity and intrinsic difficulty (entries 9-13). Buchwald’s 
in-situ prepared (R)-p-tol-BINAP-stabilized Cu-H complex, using 
Cu(I)/NaOtBu[150], gave a 1:4 dr in favor of undesired 5-17 over desired 5-16 
(entry 9). This observation was in contradictory with Buchwald’s original 
report whose inference strongly suggests that the desired α-facial 
stereochemical reduction of β-substituted enones should be achievable via the 
(R)-enantiomer of the bis-phosphine ligand.  
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Alternative Cu-H conditions using the air- and moisture-stable Cu(II) salts 
as precatalyst[151], however, were less powerful for the 1,4-reduction of 4-1. 
Conjugate reduction with either (R)-BINAP (entry 10) or (R)-p-tol-BINAP 
(entry 12) mainly recovered 4-1 with insignificant amounts of 1,4-reduction 
products and a 2:3 dr in favor of 5-17 over 5-16.  Interestingly, this set of 
Buchwald’s conditions with (S)-BINAP favored the undesired 5-17 exclusively 
(entry 11). Lastly, the attempted conjugate reduction of 4-1 with Sodeoka’s Pd-
H chemistry[152] using freshly prepared (R)-BINAP-binuclear Pd µ-hydroxo 
complex 5-20[153] in ethanol gave no reaction (entry 13).  
Table 5.4. Screening of conditions for a regio-, chemo- and stereoselective conjugate 
reduction of the tetracyclic dienone (-)-4-1.  
 
entrya conditions [a] or [b] product (dr)b yield (%)c 
1 [b] 10 % Pd-C cat., H2 (balloon), EtOAc,   
ethanolic KOH (0.3 M), rt, 2 h 
5-18/5-19 (1:3) 70  
2 [b] [Ir(cod)Py(PCy3)]PF6 cat., H2 
(balloon),CH2Cl2 (degassed), 12 h [38c] 
No reactiond - 
3 [a] RhCl(PPh3)3 cat., Me2PhSiH (4 eq.), 
toluene, 60 °C, 24 h [38d] 
 
5-16/5-17 (1:1) 9  
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4 [a] Na2S2O4 (6-8 eq.), NaHCO3,  
dioxane/H2O, 50 °C, 6 h [146]  
Complex mixture - 
5 [a] Me2PhSiH (5 equiv.), tBuOOtBu (5 M 
in decanes),  nBu3SnH, toluene, 120 °C,   
24 h [147] 




6 [a] Hantzsch ethyl ester 5-24, silica gel, 
benzene, reflux, 24 h (dark) [148]   
No reactiond - 
7 [a] Cp2TiCl2 cat., Zn dust, collidine·HCl, 
THF, rt, 10 h [149] 
No reactiond - 
8 [a] i. CuCl/NaOtBu/rac-BINAP (20 
mol%), PMHS (4 equiv.), toluene, rt,       
48 h [150]; then 
      ii. DMP, NaHCO3, CH2Cl2, rt, 7 h 
5-16/5-17 (1:7.6) 59           
(2 steps) 
9 [a] i. CuCl/NaOtBu/(R)-tol-BINAP (20 
mol%), PMHS (4 equiv.), toluene, rt,      
5.5 days [150]; then 
     ii. DMP, NaHCO3, CH2Cl2, rt, 7 h 
5-16/5-17 (1:4) 56           
(2 steps) 
10 [a] (R)-BINAP/Cu(OAc)2·H2O (0.5 
equiv.), PMHS, tBuOH/THF, rt, 36 h [151] 








11 [a] (S)-BINAP/Cu(OAc)2·H2O (0.5 
equiv.), PMHS, tBuOH/THF, rt, 36 h [151] 




12 [a] (R)-tol-BINAP/Cu(OAc)2·H2O (0.5 
equiv.), PMHS, tBuOH/THF, rt, 36 h [151] 
5-16/5-17 (2:3) 8 
13 
EtOH, rt, 48 h [152] 
No reactiond - 
14 
 
(i) THF, 0 °C, 24 h                                      
(ii) 1,4-dioxane, 70-85 °C, 48 h [154] 
No reaction for   
(i) and (ii) d 
- 
15 
     
0.02 M 1,4-dioxane, 60 °C, 48 h [155] 













                                                                  
(i) 1,4-dioxane, 75-85 °C, 4 days                          
(ii) nBu2O, 80-85 °C, 5 days [155] 
 (i) 5-16 and 5-17 
(dr not determined 
in dioxane) 
(ii) 5-16/5-17 
(1.2:1) in nBu2O 
 






 Reactions were performed on 10-20 mg scales. b dr at C9; ratios were based on isolated 
yields or by 1H NMR comparison. c Isolated yields of 5-16/17 (inseparable mixture) or 5-18/19 
(separable mixture). d No desired reaction based on TLC analyses; 4-1 was mainly recovered.   
e
 Based on recovered starting material (4-1). 
 
Collectively, these empirical results suggest an over-riding substrate-
controlled steric effect enforcing β-facial attack which has led to higher ratios 
of 5-17 and/or 5-19 formation. They are consistent with our initial investigation 
of Buchwald’s Cu-H conditions using rac-BINAP, which furnished a 1:7.6 dr 
in favor of undesired 5-17 over 5-16 (entry 8). To improve the 
diastereoselectivity, one can perceive with blocking the sterically favorable β-
face and simultaneously “expose” the encumbersome α-face to nucleophilic 
1,4-addition.  
Inspired by amine-based organocatalytic mechanistic rationales, we 
explored the possibility of reversing the facial preference of 4-1 towards 
hydride delivery by relaying steric information via C6-methoxy group-directed 
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a putative trans-iminium species 5-26 (Figure 5.2). Although MacMillan’s 
furyl imidazolidinone catalyst 5-21 in the presence of Hantzsch hydride donors 
like 5-22[154] were found unreactive (entry 14), List’s D-valine TFA salt 5-23 
with 5-24[155,156] gave a promising 3.5:1 dr in favor of desired 5-16 over 5-17, 
albeit in low yield (entry 15). This is the first time the intrinsic difficulty of 4-1 
was overcome after considerable experimentations, and a favorable 
diastereoselectivity was produced according to our general hypothesis. 
However, List’s optimal antipodal catalyst combination, the (S)-TRIP salt of D-
valine tert-butyl ester 5-25, gave poor conversions and a disappointing 1.2:1 dr 
(5-16/5-17), suggesting competing steric effects came into operation (entry 16).  
 
 
Figure 5.2. A putative trans-iminium species of the dienone 4-1 with amine-based 
organocatalyst. 
 
5.8 Stereocontrolled Organocatalytic Conjugate Reduction of the 
Tetracyclic Dienone 4-1 
We continue to explore the TFA salt of amino acid tert-butyl esters as 
catalysts for the chemo- and stereo-selective conjugate reduction of 4-1 with 5-
24 as hydride source (Table 5.5). The preparation of the D-amino acid catalysts 
followed a four-step procedure (Scheme 5.4): (1) Cbz-protection of the amino 
group; (2) tert-butyl esterification of the carboxylic acid; (3) hydrogenolysis of 
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the carbamate group over catalytic Pd-C; and (4) stoichiometric-controlled 
formation of the TFA salt (-)-5-23 or (-)-5-27.  
tert-Butyl ester formation with the Cbz-protected amino acid was nontrivial, 
as several conditions such as (i) Boc2O, DMAP in tBuOH, and (ii) DCC, 
DMAP in tBuOH were unsuccessful. Wright’s one-pot procedure[157] using 
sulfuric acid adsorbed onto anhydrous MgSO4, and in the presence of tBuOH, 
reliably provided the tert-butyl esters (-)-5-28 and (-)-5-29 between 60-65% 
yields. It is important to note that the tert-butyl ester of D-valine is volatile, 
thus THF solvent was selected for the Cbz-group hydrogenolysis to minimize 
their loss during concentration of solvent. We observed undesired side-
reactions when the THF used was not freshly distilled over Na/benzophenone, 









R = iPr, D-valine
R = Bn, D-phenylalanine
i. CbzCl, Na2CO3,
H2O/dioxane, rt
ii. H2SO4, MgSO4 anhyd.,
tBuOH, CH2Cl2, rt
R = iPr, (-)-5-28
R = Bn, (-)-5-29
i. H2, Pd-C,
THF, rt
ii. TFA (1 equiv.),
hexane, 0 °C to rt
R = iPr, (-)-5-23
R = Bn, (-)-5-27
55-60% 75-80%
 
Scheme 5.4. Synthesis of the TFA salts of amino acid tert-butyl esters.   
 
It was found that increasing the equivalents of Hantzsch ester 5-24 and 
extending the reaction time (up to 130 h) improved the yields of the 1,4-
reduction with TFA salt of D-valinate tert-butyl ester (-)-5-23 (Table 5.5, 
entries 1-3). Although raising temperatures helped to accelerate the reduction, 
the major drawback was the accompanying drop in dr (entry 3). Operating at 
80 °C for 130 h resulted in over-reduction of the C6-C7 olefin in the enones 5-
16/17 to afford minor amounts of the ketones 5-18/19, which could also be 
268 
 
directly obtained through atmospheric hydrogenation of 5-16/17 over catalytic 
Pd-C (entry 3). It is otherwise noteworthy that this organocatalytic 1,4-
reduction displayed high chemoselectivity for the C4-C9 olefin in 4-1 
controlled by the C6-methoxy group.   
Eventually, higher catalytic activity and selectivity were achieved with the 
unreported TFA salt of tert-butyl ester of D-phenylalanine (-)-5-27 in 1,4-
dioxane, although further reduction of 5-16/17 to 5-18/19 could not be avoided 
(entries 4-6). Reduced equivalent of the hydride donor 5-24 was possible with 
no adversity on the reactivity, and aided with the purification instead. Different 
etheral solvents were attempted but they did not prove beneficial to the 
organocatalytic reduction of 4-1. While 4-1 and 5-24 have reduced solubility in 
nBu2O, THF was a good solvent but dried up too easily under these conditions, 
and all in all, the resulting heterogeneous mixture was found unfavorable for 
the reduction process.  
The best selectivity, thus far, was achieved when dienone 4-1 in 1,4-dioxane 
(0.12 M) was uniformly heated at 60-65 °C for 130 h in the presence of 20 
mol% (-)-5-27, 3.2 equivalents of 5-24 (with 98-99% purity), and sealed under 
Ar at ambient pressures (entry 6) to afford the inseparable mixture of C9-
epimeric enones 5-16/17 in 61% yield (89% brsm) and 8:1 dr. The marginally 
separable mixture of C9-epimeric ketones 5-18/19 (4:1 dr at C9) could also be 
isolated in 73% yield over two steps by subjecting 4-1 to the newly-developed 
stereoselective organocatalytic conjugate reduction conditions, followed by 




Table 5.5. Optimization study for the conjugate reduction of 4-1 with TFA salts of 
amino acid tert-butyl esters.  
 







(M) T (°C) t (h)   
1 (-)-5-23 
(100) 








5 0.05 80 130 62           
(2 steps) 








5 0.08 60 130 70           
(2 steps) 




3.2 0.12 60 130 61 8:1g     
(5-16/17) 
      
73           
(2 steps) 






3.2 nBu2O  
(0.05 M) 










3.2 0.12 60 130 64           
(2 steps) 




3.2 0.12 60 130 69           
(2 steps) 




 Reactions were performed on 30-40 mg scales and sealed under Ar. b Isolated yields of an 
inseparable mixture of 5-16/17 or a separable mixture of 5-18/19 after hydrogenation over cat. 
Pd-C (2-steps yield). c Ratios of 5-16/17 based on 1H NMR dr at C9, and ratios of 5-18/19 
based on isolation. d 5-24 having ≥ 98% purity gave better yields. e 90% (entry 1), 91% (entry 
2) and 88% (entry 3) yields based on recovered starting material. f 5-18/19 also isolated in < 
5% yield (~2:1). g 5-18/19 also isolated in 17% yield (~1:1). 
   
 
The desirable pi-facial selectivity observed in the Hantzsch ester (5-24) 
hydride delivery to the 6-methoxydienone 4-1 could be rationalized to occur 
via a D-phenylalanine-derived trans-iminium intermediate (5-30), probably 
aided by an additional trifluoroacetate counter-anion hydrogen bonding 
network (Figure 5.3).[155] Conceivably, the sterically more congested α-face of 
4-1 would preferentially relay the benzyl and tert-butyl ester groups to the 
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opposite (β-) face illustrated in structure 5-30, thereby making the bottom (α-) 
face relatively more sterically accessible to incoming Hantzsch esters 5-24.  
This steric reversal reasoning could account for the low reactivity and 
diastereoselectivity observed with List’s TRIP catalyst (Table 5.4, entry 16), as 
the large TRIP counter-anion probably engendered severe steric clashes with 
both faces of 5-30 via the hydrogen bonding network. Using this proposed 
mechanistic rationale further developed our hypothesis that a C6-methoxy 
group-directed trans-iminium intermediate (5-31) with (+)-5-27 should ideally 
provide a similar stereocontrol (Figure 5.3). Conceivably, the 1,4-reduction of 
4-1 gave similar yields and selectivities irrespective of using (-)-, (+)- or even 
(±)-forms of phenylalanine 5-27 (entries 6, 9-10).  
To further improve the pi-facial selectivity of this step, non-chiral (5-32) or 
(±)-forms of primary amines-derived iminium species are being explored as a 
continual interest in our modified List-inspired organocatalytic 1,4-reduction of 
a 6-methoxydienone system (vide infra). The inseparable mixture of 6-
methoxyenones 5-16/17 (8:1) were brought forward in our total synthesis 
efforts to (-)-1-4. Hitherto, the separation of the C9-epimers was held in 






Figure 5.3. Phenylalanine-derived trans-iminium intermediate with 4-1 further 
stabilized by a counter-anion hydrogen bonding network.  
 
5.9 Synthesis of the 6-Methoxyplatensinoate Esters 
According to our retrosynthetic blueprint, substrate-controlled dialkylation 
of the inseparable mixture of C6-methoxy enones 5-16 and 5-17 would ensue 
based on Corey and Yeung’s Michael addition strategy[54] to directly install the 
propionate side chain in 5-1 (Scheme 5.5). Initial methylation of 5-16/17 using 
Nicolaou’s reported conditions[34] afforded an inseparable C9-epimeric mixture 
of the methylated caged intermediates 5-33 and 5-34 and their respective 
inconsequential C4-methyl epimers in 62% yield. Unlike Nicolaou’s report of 
an almost complete stereoselective methylation for the C6-demethoxy analog 
(1-23),[34,36g] the first alkylation in the presence of the C6-α-methoxy group 
was only fairly selective.  





Scheme 5.5. Synthesis of the alkyl 6-methoxyplatensinoates 5-35 and 5-37.  
  
The second alkylation via 1,4-addition to methyl acrylate (5-39) furnished 
the methyl 6-methoxyplatensinoates 5-35 and 5-36 in a disappointingly low 
yield. This C9-epimeric mixture remained inseparable which made the 
determination of dr at C4 difficult, although the desired stereoisomer 5-35 was 
the major product produced. Attempted 1,4-addition to tert-butyl acrylate (5-
40) instead, provided a separable C9-epimeric mixture of tert-butyl 6-
methoxyplatensinoates 5-37 and 5-38 along with several unknown byproducts. 
tert-Butyl 6-methoxyplatensinoate 5-37 and its C4-epimer (inseparable) were 
isolated in only 23% yield and 4:1 dr. The additional C6-α-methoxy group 
appeared to have repeatedly exerted an adverse influence on the substrate’s 
reactivity and intrinsic stereoselectivity in the Michael addition. While 
optimization studies to deliver 5-35 or 5-37 are required, the selective C6-
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methoxy group deprotection was anticipated to liberate their respective enol 
forms toward platensic acid 1-14 synthesis (Figure 5.4). 
 
 
Figure 5.4. Towards platensic acid 1-14 via the enol forms of alkyl 6-
methoxyplatensinoate esters.  
  
5.10 Efforts to Deprotect the C6-Methyl Enol Ether 
Various methods to deprotect the C6-methoxy group selectively were 
examined and summarized in Table 5.6. Conjugated to the (electron-
withdrawing) carbonyl group, the methyl enol ethers of the methyl 6-
methoxyplatensinoates 5-35/36 were proved to be withstanding toward metal-
catalyzed[158] (entries 1-2), CAN[159] (entry 3) and Brønsted acid-mediated 
(entries 4-5) hydrolyses to their enol forms. The pair of α-substituents on the 
vinyl group exerted electronic effects antagonistic to each other which have 
probably resulted in the alkenyl ether functionality to behave more like an 
electronically neutral (tri-substituted) double bond. Surprisingly, the 
supposedly hydrolytic labile methyl esters of 5-35 and 5-36 have also survived 




Table 5.6. Screening of conditions to cleave the C6-methoxy group of alkyl 6-
methoxyplatensinoates 5-35–5-37.   
entry scale (mg) R conditions remarks 
1 6.8 Me 5 mol% PdCl2(CH3CN)2, H2O 
(5 eq.), CH3CN, 40 °C [158] 
No reaction. Recovered 
5-35/36. 
2 5.6 Me 5 mol% CuCl2, H2O (5 eq.), 
CH3CN, 40 °C [158] 
No reaction. Recovered 
5-35/36. 
3 5.0 Me 10 mol% to > 1 eq. CAN, 
H2O/CH3CN (1:1), reflux [159] 
No reaction. Recovered 
5-35/36. 
4 5.0 Me 3N HCl, THF, rt No reaction. Recovered 
5-35/36. 
5 5.0 Me 6N HCl, MeOH, rt No reaction. Recovered 
5-35/36. 
6 5.9 tBu i. TMSCN (6 eq.), TMSOTf 
(4 eq.), CH2Cl2, 0 °C to rt; 
then                                       
ii. 1N HCl, THF, rt 
No hydrolysis of 
alkenyl ether. tBu ester 
hydrolyzed 
quantitatively to 5-43. 
7 5.2 5-43: 
H 








8 3.6 tBu SmI2 (xs), tBuOH, THF, 0 °C 
to rt 





Investigations toward understanding the alkenyl ether’s reactivity to aid the 
C6-α-methoxy deprotection necessitated a model study with the 6-
methoxyenone 5-16 for this nontrivial step (Table 5.7). The study revealed that 
oxidative methods with 5-16 did not work well, as the alkenyl ether was 
unreactive towards oxymercuration[160] (5-45, entry 1) and nucleophilic 
epoxidation (5-16, entry 2). The latter was also stable under mCPBA 
conditions, and 5-16 underwent Baeyer-Villiger oxidation instead (5-47, entry 
3). Direct methyl ether oxidation of 5-18 with Inoue’s conditions[161-162] (5-18, 
entry 4) was unsuccessful, probably due to its α-carbonyl position which 
disfavored the suggested radical mechanistic pathway.[161a]  
Protection of the ketone, followed by selective removal of the enol ether 
was then proposed. Surprisingly, 1,3-dioxolane formation with Noyori’s 
conditions[163] gave a bis-cyclic acetal 5-49 exclusively through a sequential 
protection, deprotection and acetalization series in one-pot (entry 5). Protection 
of 5-16 via cyanohydrin formation, followed by acid hydrolysis with 1N HCl 
afforded some promising transformations (5-44), although deprotection of the 
277 
 
cyanohydrin was observed along with incomplete enol ether hydrolysis (5-51, 
entry 6). When the tert-butyl 6-methoxyplatensinoate 5-37 was treated with 
TMSCN and TMSOTf, the methyl enol ether, however, survived and cleavage 
of the tert-butyl ester was observed instead (Table 5.6, entry 6). Further 
treatment with 1N HCl completed the ester hydrolysis to furnish the 6-
methoxyplatensic acid 5-43 quantitatively. 
Table 5.7. Screening of conditions to cleave the C6-methoxy group of 6-
methoxyenone 5-16 as model study. 
 
entry conditions expected product observed  
1 i. Hg(OAc)2 (2 eq.), THF/H2O, 
rt; then                                    
ii. NaBH4, 0 °C to rt [160] 
 
 
2 (a)  tBuOOH (3 eq.) , DBU (3 
eq.), CH2Cl2, 40 °C; or  
(b) H2O2 (5 eq.), NaOH (5 







Starting material 5-16 
3 mCPBA (1.6 eq.), 0.1 M 
phosphate buffer pH 7.5, 





4 i. H2, 10% Pd-C, 
EtOAc/ethanolic KOH (2:1), 
rt; then                                    
ii. (a) MnCl2·4H2O/tBu-terpy 
(5-53, 0.1 mol%), mCPBA (4 
eq.), H2O, CH3CN,                  
0 °C to rt [161]; or  
ii. (b) mCPBA (2 eq.), 
CCl3CN/CH3CN (1:1), rt [162] 
 
 
5 (TMSOCH2)2 (1.5 eq.),         
10 mol% TMSOTf, CH2Cl2,         
-15 °C [163] 
 
 
6 i. TMSCN (3 eq.), TMSOTf 
(1.5 eq.), CH2Cl2, 0 °C to rt; 
then                                        
ii. TBAF (3 eq.), THF, rt; then 














7 3N HCl, THF, reflux, 7 h 
 
8 BBr3 (3-4 eq.), CH2Cl2, -78 °C   
 




9 AlCl3 (20 eq.), TBAI (20 eq.), 
CH3CN/CH2Cl2, 0 °C 
 
Complex mixture 
10 SmI2 (xs), HMPA, tBuOH, 
THF, 0 °C to rt 
 
 
11 i. SmI2 (xs), tBuOH, THF,      
0 °C to rt; then                       
ii. Dess-Martin (2.5 eq.), 










Strong acidic conditions in the presence of Brønsted (5-44, entry 7) and 
Lewis acids (complex mixtures, entries 8-9) gave variable results, and the α-
keto methyl enol ether was gratifyingly hydrolyzed with 3N HCl under reflux 
in THF. The 6-methoxyenone acid 5-43, however, was recovered almost 
quantitatively when subjected to the same acid hydrolytic conditions (Table 6, 
entry 7) which we reason the cause as a possible steric limitation.  
280 
 
Kagan-Molander’s reagent SmI2 was exploited to perform a sequential 1,4-
reduction and α-deoxygenation of 5-16 to the saturated ketone 5-52 (entries 
10-11) which is an important late-stage tetrahydro-intermediate of Corey’s[37b] 
and Mulzer’s[38c]. In the absence of HMPA, the reduction went to completion 
along with non-selective 1,2-reduction which conceivably required 
optimization of the tBuOH stoichiometry and temperature-control.[164] Re-
oxidation of the resultant tetrahydro-alcohol with Dess-Martin periodinane 
afforded 5-52 in 52% yield over two steps (entry 11). Unfortunately, this 
newly-developed SmI2-mediated reductive-dealkoxylation method failed to 
reduce 5-37 (Table 6, entry 8).  
Due to unexpected difficulty in procurement of the reagent and its precursor 
(Sm powder), we could not optimize this step further. At this juncture, the 
consideration of several factors, including: (1) the poor selectivity and 
reactivity of the dialkylation steps with 5-16 in the presence of the C6-methoxy 
group; (2) working through the remaining synthesis with inseparable mixtures 
of the 6-methoxyenones 5-16/17 and their derivatives; and (3) the unsuccessful 
attempts to deprotect the unexpectedly robust α-keto methyl enol ether in 5-35 
and 5-37 necessitated a change of sequence to secure formation of the 
tetracyclic enone 1-23 from 5-16 (Scheme 5.6) before dialkylation towards 
completion of the natural product.   
5.11 Formal Synthesis of (-)-Platensimycin 
First demethylation to install the C6/C7-α,β-unsaturation from 5-18 prior 
treatment to the dialkylation sequence to afford the alkyl C6-
demethoxyplatensinoate was anticipated (Scheme 5.6). To optimize the 
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isolated yield of desired 5-18, the sequential Hantzsch-based and Pd/C-
mediated reduction of 4-1 (via 516/17) to a separable mixture of C9-epimeric 
6-methoxyketones 5-18/19 was found favorable. This gave a 73% yield over 
two steps and an overall 4:1 dr at C9.  
The methoxyketones, however, proved unstable on silica and 5-18 was best 
separated from 5-19 with 90-95% purity under N2 through Et3N-deactivated 
silica. Original dr ratios at C6 could not be determined on crude mixtures of 5-
18/19. Although minor amounts of 5-18-(6S) could be isolated, the newly-
formed C6 chiral center of 5-18 readily epimerized to the major diastereomer 
5-18-(6R) during silica gel chromatography. The C6 epimer of 5-19-(6R) was 
never detected.  
 
 




Nontrivial Lewis acid-promoted demethylation of 5-18 (Scheme 5.6, insert 
Table) was eventually achieved with a large excess of AlCl3 and TBAI[166] to 
afford acyloin 5-54 (an inseparable mixture of C6-epimers) in 83% yield. The 
in-situ “AlI3”-mediated chemoselective demethylation of the C6-methoxy 
group over the tetrahydrofuran ring was best performed at -1 to 0 °C, as lower 
temperatures deactivated the demethylation reaction, while complex mixtures 
were observed at ambient conditions. Finally, mesylation of 5-54 and heating 
with LiBr/Li2CO3 in DMSO,[167] furnished the targeted tetracyclic enone (-)-1-
23 in 72% yield over two steps via an α-dehydrohalogenation process. The 1H 
and 13C NMR spectra of (-)-1-23 were found identical to those reported by 
Nicolaou[36g] and others.         
5.12 A Michael Addition Strategy to (-)-Platensic Acid 1-14 
With (-)-1-23 in hand, the anticipated dialkylation sequence was pursued 
according to Nicolaou’s reported conditions.[36g] Methylation of 1-23 with 
KHMDS in THF/HMPA afforded the methylated caged intermediate 2-1 in 
80% yield and in almost complete stereoselectivity comparable with the 
literature. 1,4-Addition was, however, low-yielding with tert-butyl acrylate (5-
40), although a good substrate-controlled dr of 10:1 at C4 was afforded to 
furnish the tert-butyl platensinoate 5-56 (c.f. 4:1 dr at C4 was obtained for the 
C6-methoxy analog 5-37).  
Michael addition with methyl acrylate (5-39) under Corey and Yeung’s 
conditions[54] was, again, unsuccessful and the methyl ester derivative of 5-56 
was produced only in trace amounts. This second alkylation step via Michael 
addition approach with the methyl and/or tert-butyl acrylates has also been 
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reported with variable and limited success in the literature[168]. It is interesting 
to find, though, that a small structural change could result in a significant 
improvement in stereoselectivity of the dialkylation sequence, in the absence of 
the C6-methoxy group (5-16, Scheme 5.5), which reflects the subtle effects 
governing such processes. Subsequent TFA-mediated tert-butyl ester cleavage 
in CH2Cl2 transformed 5-56 to the platensic acid 1-14 quantitatively which 
marked the completion of the ketolide fragment in platensimycin (-)-1-4.                  
 
 
Scheme 5.7. Synthesis of the (-)-platensic acid 1-14.  
 
5.13 A Concise and High-Yielding Route to the Aromatic Fragment of (-)-
Platensimycin 
The synthesis of the aromatic fragment (1-151) of (-)-1-14 proceeded 
smoothly in four steps with an overall 57% yield from 2-nitroresorcinol (1-27) 
as outlined in Scheme 5.8. Friedel-Crafts acylation of 2-nitroresorcinol with 
AcOH in neat PPA[169] afforded the acetophenone 5-57 in 69% yield. 
Protection of 5-57 as the bis-Bn ether 5-58 proceeded uneventfully under 
K2CO3 and catalytic TBAI conditions. A classical two-step procedure was 
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initially adopted to transform 5-58 to the methyl benzoate 5-59 via a Lieben-
haloform reaction with sodium hypochlorite and sodium hydroxide,[170] 
followed by esterification of the resulting benzoic acid under SOCl2 and 
MeOH conditions in 70% yield over two steps.  
 
 
Scheme 5.8. A high-yielding synthesis of the aromatic unit (1-151) of platensimycin. 
   
To improve and shorten the synthesis, we proposed the development of a 
convenient method to access the ester 5-59 from the ketone 5-58 directly 
through modified Lieben-haloform conditions. There is no literature 
precedence of such transformation with the methyl ketones to the best of our 
knowledge, although direct methanolysis of the trihalomethyl ketones has been 
exploited.[171] Attempts to prepare the trichloromethyl aryl derivatives via 
Friedel-Crafts acylation with trichloroacetyl chloride [from Cl3CCO2H, 
(COCl)2, and catalytic DMF] were, however, unsuccessful with the bis-Me 
ether of 2-nitroresorcinol (1-27).  
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We then explored the possibility of using an electrophilic organohalide 
source to substitute NaOCl, together with NaOMe in MeOH (for the formation 
of methyl esters) to facilitate the proposed direct conversion to 5-59. Methyl 
ketone 5-58 was first treated with King-inspired modified Lieben-haloform 
conditions[172] using I2 and NaOMe in MeOH. Gratifyingly, 5-59 was obtained 
in 64% yield in a single step. tert-Butyl hypochlorite is a known versatile and 
inexpensive oxidizing agent, and we anticipated its utility as a more powerful 
electrophilic halide source than NaOCl. Freshly prepared from 14% NaOCl 
and tBuOH with AcOH,[173] tBuOCl combined with alkaline MeOH efficiently 
transformed 5-58 to the desired methyl ester 5-59 in 20 min with excellent 
yields.  
Here, we report a new modified Lieben-haloform condition using tBuOCl to 
convert aryl methyl ketones to their methyl esters in a direct practical fashion. 
This newly-developed condition may potentially represent an alternative 
protocol for the preparation of other esters and/or amides directly from ketones, 
in which the exploration of this new activation method will be our future 
subject of interest. Finally, atmospheric hydrogenation of 5-59 over catalytic 
Pd-C furnished the desired aniline unit 1-151 quantitatively. 1-151 was then 
carried forward to the coupling step without further purification.                           
5.14 Completion of the Total Synthesis of (-)-Platensimycin 
HATU-coupling[34] of aniline 1-151 with the 6-methoxyplatensic acid 5-43 
(Scheme 5.9) was first attempted to test the conditions and possibly prepare the 
6-methoxy analog of platensimycin (-)-1-4. Reaction was run in DMF at 
ambient temperatures and the major spot isolated by PrepTLC afforded amide 
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5-60 as the single desired diastereomer. The C4-epimer of 5-60 was not 
isolated. Residual 1-151 and the urea byproduct from HATU coupling were, 
however, inseparable from 5-60 and we proposed to functionalize the phenolic 
groups to facilitate purification. Unfortunately, treatment of the inseparable 
mixture-containing 5-60 with Ac2O in pyridine as solvent failed to produce any 
desired acylation product 5-61, but a complex mixture was obtained instead.     
 
Scheme 5.9. Preparation of the C6-methoxy analog (5-60) of (-)-platensimycin.  
 
The coupling of platensic acid 1-14 with aniline 1-151 was carried out by 
treatment with the same HATU/Et3N conditions, providing amide 5-62 cleanly 
as the single desired diastereomer in 71% yield. The C4-epimer of 5-62 was 
not detected during PrepTLC of the crude mixtuire. Final deprotection of the 
methyl ester was unexpectedly nontrivial with either LiOH in THF/H2O or 
KOH in MeOH. This decrease in reactivity was conceivably due to the free 
ortho- and para-phenolic hydroxyl groups deactivating the methyl ester. 
Eventually, amide 5-62 was subjected to hydrolysis with 2M aq. KOH in 1,4-
dioxane/MeOH mixture with gentle heating at 35 °C to furnish (-)-
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platensimycin (1-4) in 60% yield. The 1H and 13C NMR spectra of (-)-1-4 were 
found identical to those reported by Nicolaou.[36g]          
 
 
Scheme 5.10. Completion of the total synthesis of (-)-platensimycin.  
 
5.15 Future Work – Explorations into C2-Symmetry-Based 
Organocatalytic 1,4-Reduction of the Tetracyclic Dienone 4-1  
We have postulated and shown that the stereochemical 1,4-reduction of 4-1 
was achievable by a steric reversal mechanism, and not influenced by the 
chirality borne on the amine-based catalysts. Although we failed to grow any 
viable crystals with the iminium species (5-30) of 4-1, we attempted to explore 
this pi-facial selectivity further with various non-chiral amines and DL-amino 
acids-derived catalysts to (1) verify our hypothesis, and (2) improve the 
chemo- and diastereoselectivity of the 1,4-reduction (Table 5.8). The initial 




1,3-Diphenylacetone-derived C2-symmetrical catalyst 5-63 (via reductive 
amination) and its structural isomer (±)-5-64 (entries 1-2) showed that the tert-
butoxycarbonyl group is important for activity and selectivity in 5-27 (entries 
1-2). TFA salt of tert-butyl glycinate 5-65 demonstrated poor reactivity and 
almost no selectivity (entry 5) which suggested the essentiality of sec-alkyl 
amines for stereocontrol.  
Di-tert-butyl malonate-derived amino catalyst 5-66 (entry 6, note f) was 
synthesized via dirhodium(II)-catalyzed N-H insertion of the Bn carbamate 5-
71 with the di-tert-butyl diazomalonate 5-69[174] (Scheme 5.11). 5-69 has been 
prepared by the same procedure as the dimethyl diazomalonate 3-16 described 
previously in Scheme 3.3. 5-66, compared to phenylalanine 5-27, demonstrated 
comparable reactivity and exhibited greater chemoselectivity for the C4-C9 
olefin, as further reduction to the 6-methoxyketones 5-18/19 was subdued. 
Although treatment with catalyst 5-66 furnished a lower dr of 5:1 (C9) in favor 
of desired 5-16 over 5-17 compared to 8:1 dr (5-16/17) achieved with the 
catalyst 5-27, the sequential Hantzsch-based and Pd/C-mediated reduction of 4-
1 (via 5-16/17) to a separable mixture of the C9-epimeric ketones 5-18/19 was 
found favorable with 5:1 dr at C9 and 68% yield over two steps.  
Subsequent attempts to homologate 5-66 to (±)-5-67, derived from DL-
aspartic acid (entry 7), and (±)-5-68, derived from DL-glutamic acid (entry 8), 
catalyzed the conjugate reduction with decreased stereoselectivities and 
reduced conversions. Further screening of other amine-based reagents, such as 
the other alkyl esters of 5-66 and DL-serine or threonine-derived catalysts to 
relay the intrinsic sterics of 4-1 and catalyzed the desired facial 1,4-reduction 
with better selectivity was anticipated.  
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Table 5.8. Screening of other amine-based catalysts for the conjugate reduction of the 
tetracyclic dienone (-)-4-1.  
 
entrya amino catalyst yield (%)b 5-16/17c Remarks 
1d 
 
61 8:1 Sequential H2/Pd-C gave 
5-18/19 in 73% yield (2 
steps), 4:1 dr at C9. 
2d 
 
- - Sequential H2/Pd-C gave 
5-18/19 in 69% yield (2 
steps), 3.9:1 dr at C9. 
3e 
 







5 2.2:1 5-18/19 not observed. 
5 
 
18 1.4:1 5-18/19 isolated in 8% 




69 5:1 (i) 5-18/19 isolated in 6% 
yield, 5:1 dr at C9.        
(ii) Sequential H2/Pd-C 
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gave 5-18/19 in 68% yield 
(2 steps), 5:1 dr at C9. 
7 
 
37 3.2:1 5-18/19 isolated in 10% 








 Reactions were performed on 25-30 mg scales. b Isolated yields of an inseparable mixture of 
5-16/17. c Ratios based on 1H NMR dr at C9. d Results were taken from Table 5.5, entries 6 and 
10, accordingly. e 5-63 was prepared from reductive amination of 1,3-diphenylacetone. f 5-64 
was prepared from reductive amination of 1,1-diphenylacetone. g 5-66 was prepared from N-H 
insertion of di-tert-butyl diazomalonate 5-69 (Scheme 5.11). 
 
Scheme 5.11. Preparation of the TFA salt of amino di-tert-butyl malonate 5-66. 
 
5.16 Future Work – Acyl-Transfer Method in a More Convergent Total 
Synthesis Approach to (-)-Platensimycin   
Future optimizations of the Michael addition-inspired second alkylation step 
towards (-)-1-4 include exploring catalytic basic conditions, and/or using 
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acrylonitrile as the alternative Michael acceptor.[60,61] A more convergent 
strategy using late-stage acyl transfer techniques was also conceived towards 
the union of both fragments to complete 1-4 (Scheme 5.12A).  
In the forward sense, the proposed α,β-unsaturated aryl ester 5-73 was 
rationalized based on a Michael addition approach with 2-1 to afford aryl ester 
5-72. 5-73 contains a masked functionality (e.g. -NO2, -N3 and etc.) precursor 
to the aniline unit which we anticipate a tandem intramolecular acyl transfer 
process to occur upon reduction of the latter group. Basic hydrolysis of the 
dioxanone group will then furnish platensimycin 1-4.  
The retrosynthetic plan for both nitro- and azido groups of 5-73 is outlined 
in Scheme 5.12B. Disconnection of the acrylate ester and replaced with a 
suitable protecting group, such as the Bn ether is conceived to afford the Bn 
phenyl ether 5-74 which could be selectively cleaved in the later stages under 
transfer hydrogenation conditions. To prepare our aryl azide version of 5-73, 
the aryl iodide 5-75 was proposed as the entry point to its azido derivative via 
Ma’s CuI/L-proline-catalyzed coupling conditions with sodium azide.[175]  
Benzodioxanone protection in 5-74/75 is then expected to arise from acid-
promoted cyclization between the benzoic acid and the ortho-MOP phenyl 
ether in 5-76/77. The origins of 5-76/77 are in turn traced back to the 
acetophenones 5-78/79 whereby protection of the free phenol as the acyclic 
acetal is imperative to withstand Lieben-haloform transformation of the methyl 
ketone. Finally, a regioselective mono-protection of the bis-phenol-4-
acetophenone 5-57 is envisaged to provide 5-78. Acetophenone 5-79 will be 
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obtained through mono-protection of the 2-iodobenzene-1,3-diol (5-80), 
followed by a regioselective Friedel-Crafts acylation.  
Efforts to prepare the nitro-derivative of 5-73 via 5-57 are currently 
ongoing. Interestingly, during the pursuit, we found that neither 5-57 nor 2-
nitroresorcinol (1-27) could undergo selective mono-silylation. Bis-silylation 
of the two phenolic positions in one-pot would occur regardless of the 
conditions applied. Ultimately, a more convergent total synthesis of (-)-1-4 and 
its analogs development are anticipated through this new coupling approach.              
 
Scheme 5.12. A. An acyl-transfer strategy towards a more convergent coupling of 
both fragments of platensimycin (1-4). B. Retrosynthetic analysis of the acyl-transfer 
aromatic coupling partner 5-73. 





In summary, we have achieved a unique and enantioselective route to the 
core ketolide structure (-)-1-23 of (-)-platensimycin (1-4) from commercially 
available eugenol (4-10) in 16 steps, 18% overall yield which is competitive 
with the diverse synthetic approaches continually appearing in the literature.[34-
39]
 This work has been published as a communication to Organic Letters in 
2010.[176] The tactic of employing a methoxy group in our synthetic approach 
to impart needed electronic and steric control helped advance three key 
transformations to 1-23: (1) a direct para-arylation of an oxocarbenium species 
in a novel Bi(OTf)3/LiClO4-catalyzed Marson-type Friedel-Crafts cyclization 
of the free lactol 5-3; (2) a superior and direct TBAF-mediated intramolecular 
alkylative dearomatization of the free phenol 5-8, without unduly silyl pre-
activation; and (3) a new regio-, chemo-, and diastereoselective conjugate 
reduction of the 6-methoxydienone 4-1 mediated by TFA salts of tert-butyl 
(+)-, (-)-, or (±)-forms of phenylalaninate (5-27) to reverse the intrinsic 
stereoselectivity using readily available laboratory resources and techniques.  
Efforts are ongoing to further improve the pi-facial selectivity of this 
Hantzsch ester-mediated 1,4-reduction step through exploring C2-symmetrical 
and/or various (±)-forms of primary amines-based modified List-inspired 
organocatalysis. We have, thus far, empirically found better selectivity in the 
two-step sequence to 6-methoxyketones 5-18/19 (5:1 dr at C9) in 68% yield by 
treating 4-1 with the TFA salt of tert-butyl aminomalonate 5-66. Further 
examination of other homologous aminomalonates as catalysts for the 
conjugate reduction is anticipated.  
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Total synthesis of (-)-1-4 was eventually accomplished through a common 
substrate-controlled double alkylation sequence from the tetracyclic enone (-)-
1-23. This includes a nontrivial Michael addition approach to directly construct 
the desired propionic acid side-arm; however, the unimpressive yields 
necessitated further optimization of the latter step. An acyl-transfer process 
upon completion of the second alkylation will be explored in our future pursuit 
for a more convergent approach to assemble (-)-1-4 and its analogs.  
The desired aromatic domain was synthesized from 2-nitroresorcinol (1-27) 
by a four-step sequence (57%), uniquely efficient and high-yielding, compared 
to the approaches described by Nicolaou[34,49] and Giannis[50]. A noteworthy 
contribution from our synthetic efforts was the development of a new Lieben-
haloform condition to directly convert an aryl methyl ketone (5-58) to its 
methyl ester derivative (5-59) using tBuOCl and NaOMe in methanol. The 
amide coupling of both fragments by treatment with HATU, and a final 
hydrolysis step furnished platensimycin (-)-1-4 in 5 steps and 12% overall 






















Experimental Procedures and Characterization Data: 
    
Epoxy alcohol 5-5: To furnace-dried 4Å molecular sieves (2.01 g in 
powder) in a round-bottom flask was added CH2Cl2 (30 mL), followed by L-(-
)-DIPT (stored over 4Å molecular sieves, 0.8 mL, 3.80 mmol). After the 
mixture was cooled to -30 °C, Ti(OiPr)4 (1.1 mL, 3.72 mmol) was added, and 
the reaction was stirred at -30 °C for 30 min. After the addition of tBuOOH (5 
M in decanes, 4.4 mL, 22.1 mmol) at -25 °C, the solution stirred for a further 1 
h at -30 °C before being treated with a solution of allyl alcohol 4-99 (3.0 g, 
10.1 mmol) in CH2Cl2 (5 mL). The reaction was stirred for 3 h at -30 °C and 
then allowed to warm to room temperature over the next 3 h. The reaction was 
quenched by addition of half saturated Rochelle salt (32 mL) and stirred at 
room temperature for 12 h before addition of an aq sodium hydroxide solution 
(30%) saturated with NaCl (8 mL) and stirred for another 3 h. The resultant 
milky mixture was filtrated through sand under vacuo and then washed with 
CH2Cl2. The organic layer was separated, and the aqueous layer was extracted 
with CH2Cl2 (3x). The combined organic layers were washed with brine, dried 
over Na2SO4, filtered, and concentrated in vacuo. Flash column 
chromatography of the crude product over silica gel (10% EtOAc/hexane → 
50% EtOAc/hexane) afforded epoxy alcohol 5-5 (3.09 g, 98%) as a colourless 
viscous oil. The enantiomeric excess was determined through HPLC analysis 
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with Chiralpak-IC column (0.46 cm i.d. x 25 cm) using hexanes/2-propanol 
(85:15) at a flow rate of 1.0 mL/min; detection UV 254 nm; retention time 55.3 
min (major) and 35.5 min (minor); 91% ee.  
5-5: [α]D24 = -22.7 (c = 0.62, CHCl3); 1H NMR (500 MHz, CDCl3): δ 7.44 
(d, J = 7.6 Hz, 2H), 7.36 (t, J = 7.6 Hz, 2H), 7.30 (t, J = 7.3 Hz, 1H), 6.83 (d, J 
= 8.2 Hz, 1H), 6.80 (d, J = 1.9 Hz, 1H), 6.71 (dd, J = 1.3, 7.6 Hz, 1H), 5.13 (s, 
2H), 3.89 (s, 3H), 3.69-3.65 (m, 1H), 3.60-3.56 (m, 1H), 3.25 (t, J = 6.3 Hz, 
1H), 2.86 (dd, J = 6.3, 15.2 Hz, 1H), 2.81 (dd, J = 6.3, 15.2 Hz, 1H), 1.99 (brs, 
1H), 1.40 (s, 3H); 13C NMR (125 MHz, CDCl3): δ 149.7, 146.9, 137.2, 130.8, 
128.4, 127.7, 127.2, 120.6, 114.4, 112.5, 71.1, 65.3, 61.2, 60.4, 55.9, 34.2, 
14.4; HRMS (IT-TOF): m/z calcd for C19H22O4Na+ [M + Na]+ 337.1416, found 


















Diol 5-7: To a solution of epoxy alcohol 5-5 (3.09 g, 9.83 mmol) in THF 
(49 mL) was added allyl magnesium chloride (2.0 M in THF, 24.6 mL, 49.2 
mmol) at -40 °C. When the addition was completed, the resulting mixture was 
stirred at -40 °C for 5 min before the cooling bath was removed, and the 
reaction was warmed to room temperature with stirring for a further 1 h 45 
min. The solution was re-cooled to 0 °C and quenched by addition of a 1:1 
mixture of brine and 1 N NaHSO4 (6 mL). The solution was acidified to pH 2 
with 1 N NaHSO4 to dissolve the Mg residue. The organic layer was separated, 
and the aqueous layer was extracted with EtOAc (3x). The combined organic 
layers were washed with brine, dried over Na2SO4, filtered, and concentrated in 
vacuo. Flash column chromatography of the crude product over silica gel (12 
% EtOAc/hexane → 58 % EtOAc/hexane) afforded diol 5-7 (3.25 g, 93%) as a 
white solid.  
5-7: mp 74.6-76.3 °C; [α]D24 = +29.7 (c = 0.37, CHCl3); 1H NMR (500 
MHz, CDCl3): δ 7.43 (d, J = 7.0 Hz, 2H), 7.36 (t, J = 7.0 Hz, 2H), 7.34-7.28 
(m, 1H), 6.80 (d, J = 8.2 Hz, 1H), 6.76 (d, J = 1.9 Hz, 1H), 6.69 (dd, J = 1.9, 
8.2 Hz, 1H), 5.77-5.69 (m, 1H), 5.11 (s, 2H), 5.00-4.94 (m, 2H), 3.87 (s, 3H), 
3.61 (d, J = 11.3 Hz, 1H), 3.44 (d, J = 10.7 Hz, 1H), 2.96 (dd, J = 4.4, 13.8 Hz, 
1H), 2.42 (dd, J = 8.8, 13.8 Hz, 1H), 2.25 (brs, 2H), 2.15-1.99 (m, 3H), 1.16 (s, 
3H); 13C NMR (125 MHz, CDCl3): δ 149.6, 146.4, 138.1, 137.3, 134.9, 128.4, 
127.7, 127.3, 121.1, 115.9, 114.3, 113.1, 75.7, 71.2, 68.6, 56.0, 46.6, 34.8, 
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34.3, 20.3; HRMS (IT-TOF): m/z calcd for C22H28O4Na+ [M + Na]+ 379.1885, 
found 379.1878. 
 
Mono-tosylated diol 5-4: To a solution of diol 5-7 (3.25 g, 9.12 mmol) in 
CH2Cl2 (46 mL) was added nBu2SnO (0.113 g, 0.45 mmol), Et3N (2.8 mL, 20.1 
mmol), and p-TsCl (2.96 g, 15.5 mmol) in the following sequence at room 
temperature. The resulting mixture was stirred at room temperature for 3 h, 
before it was filtered over Celite and washed with CH2Cl2. The filtrate was 
concentrated in vacuo and flash column chromatography of the crude product 
over silica gel (10% EtOAc/hexane → 30% EtOAc/hexane) afforded mono-
tosylated diol 5-4 (4.62 g, 99%) as a off-white solid.  
5-4: mp 57.6-59.2 °C; [α]D24 = +20.4 (c = 1.97, CHCl3); 1H NMR (500 
MHz, CDCl3): δ 7.78 (d, J = 8.9 Hz, 2H), 7.44 (d, J = 7.6 Hz, 2H), 7.38-7.33 
(m, 4H), 7.30 (t, J = 7.3 Hz, 1H), 6.78 (d, J = 8.2 Hz, 1H), 6.71 (d, J = 1.9 Hz, 
1H), 6.62 (dd, J = 1.9, 8.2 Hz, 1H), 5.70-5.61 (m, 1H), 5.12 (s, 2H), 4.93-4.88 
(m, 2H), 3.97 (d, J = 9.5 Hz, 1H), 3.93 (d, J = 10.1 Hz, 1H), 3.87 (s, 3H), 2.91 
(dd, J = 4.4, 13.9 Hz, 1H), 2.44 (s, 3H), 2.38 (dd, J = 8.8, 13.8 Hz, 1H), 2.11-
1.96 (m, 3H), 1.91 (brs, 1H), 1.17 (s, 3H); 13C NMR (125 MHz, CDCl3): δ 
149.6, 146.5, 145.0, 137.33, 137.29, 134.3, 132.6, 129.9, 128.5, 128.0, 127.7, 
127.3, 121.1, 116.3, 114.2, 113.0, 75.4, 74.2, 71.2, 56.0, 46.4, 34.3, 33.9, 21.6, 
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Bromohydrin 5-10: To a solution of mono-tosylated diol 5-4 (0.766 g, 1.50 
mmol) in MeOH (AR grade, 20 mL) was added K2CO3 (0.415 g, 3.00 mmol) at 
room temperature. The resulting mixture was stirred at room temperature for 1 
h before it was concentrated in vacuo. The resulting white precipitate was re-
dissolved in saturated aq. NH4Cl, and extracted with Et2O (3x). The combined 
organic extracts were washed with brine, dried over Na2SO4, filtered, and 
concentrated in vacuo.  
To the crude epoxide 5-9 in THF (23 mL) were added dried LiBr·H2O (0.95 
g, 9.06 mmol) and glacial AcOH (0.17 mL, 3.00 mmol) at room temperature. 
LiBr·H2O was pre-dried under vacuo for 3 h at 125 °C. The resulting mixture 
was heated to reflux at 90 °C for 5 h before it was cooled to room temperature, 
and added brine. The organic layer was separated, and the aqueous layer was 
extracted with EtOAc (3x). The combined organic layers were dried over 
Na2SO4, filtered, and concentrated in vacuo. Flash column chromatography of 
the crude product over silica gel (5% EtOAc/hexane → 20% EtOAc/hexane) 
afforded bromohydrin 5-10 (0.573 g, 91% over two steps) as a colourless oil. 
 5-9: [α]D25 = +17.6 (c = 0.97, CHCl3); 1H NMR (500 MHz, CDCl3): δ 7.44 
(d, J = 7.6 Hz, 2H), 7.36 (t, J = 7.6 Hz, 2H), 7.29 (t, J = 7.3 Hz, 1H), 6.80 (d, J 
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= 8.2 Hz, 1H), 6.72 (d, J = 1.9 Hz, 1H), 6.65 (dd, J = 1.9, 8.2 Hz, 1H), 5.71-
5.66 (m, 1H), 5.12 (s, 2H), 5.01-4.94 (m, 2H), 3.87 (s, 3H), 2.95 (dd, J = 4.5, 
13.9 Hz, 1H), 2.61 (s, 2H), 2.44 (dd, J = 10.1, 13.9 Hz, 1H), 2.18-2.13 (m, 1H), 
2.05-1.96 (m, 1H), 1.49-1.44 (m, 1H), 1.29 (s, 3H); 13C NMR (125 MHz, 
CDCl3): δ 149.6, 146.6, 137.4, 136.7, 133.5, 128.5, 127.7, 127.3, 121.2, 116.1, 
114.1, 113.0, 71.2, 58.7, 56.0, 55.6, 47.9, 37.3, 35.6, 16.8; HRMS (IT-TOF): 
m/z calcd for C22H26O3Na+ [M + Na]+ 361.1780, found 361.1783.  
5-10: [α]D25 = +25.2 (c = 0.57, CHCl3); 1H NMR (500 MHz, CDCl3): δ 7.44 
(d, J = 7.6 Hz, 2H), 7.36 (t, J = 7.6 Hz, 2H), 7.30 (t, J = 7.3 Hz, 1H), 6.81 (d, J 
= 7.6 Hz, 1H), 6.77 (d, J = 1.3 Hz, 1H), 6.69 (dd, J = 1.9, 8.2 Hz, 1H), 5.79-
5.70 (m, 1H), 5.12 (s, 2H), 5.01-4.96 (m, 2H), 3.88 (s, 3H), 3.62 (d, J = 10.7 
Hz, 1H), 3.56 (d, J = 10.1 Hz, 1H), 3.02 (dd, J = 3.8, 14.5 Hz, 1H), 2.44-2.39 
(m, 1H), 2.17-2.05 (m, 3H), 1.32 (s, 3H); 13C NMR (125 MHz, CDCl3): δ 
149.7, 146.6, 137.44, 137.39, 134.6, 128.4, 127.7, 127.3, 121.2, 116.1, 114.5, 
113.2, 73.9, 71.3, 56.1, 47.6, 45.6, 34.9, 34.4, 22.4; HRMS (EI): m/z calcd for 
C22H27O379Br+ [M]+ 418.1144, found 418.1139, and m/z calcd for 
C22H27O381Br+ [M]+ 420.1123, found 420.1119 (intensity ratio 1:1). 
 
cis-Bromo lactol 5-11: To a solution of bromohydrin 5-10 (0.782 g, 1.87 
mmol) in t-BuOH (30 mL) and THF (12 mL) was added a solution of NMO 
(50% w/w in H2O, 0.524 g, 2.24 mmol) in H2O (6 mL) and OsO4 (2 mol%) at 
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room temperature. The resulting mixture was stirred at room temperature for 
12 h before it was cooled to 0 °C, and quenched with NaHSO3 (1.4 g, 3 M in 
H2O). The mixture was warmed to room temperature and stirred for 45 min. 
The organic layer was separated and concentrated in vacuo, and EtOAc was 
added to re-dissolve the residue that formed. The aqueous layer was extracted 
with EtOAc (3x), and the combined organic layers were washed with H2O (1x), 
followed by brine, dried over Na2SO4, filtered, and concentrated in vacuo.  
To this crude diol in THF (30 mL) and H2O (15 mL) were added NaIO4 (1.0 
g, 4.68 mmol) at room temperature, and stirred for 2 h. The resulting mixture 
was carefully concentrated to less than half its volume by removing THF under 
vacuo. The mixture was diluted with water and extracted with EtOAc (3x). The 
combined organic extracts were washed with brine, dried over Na2SO4, 
filtered, and concentrated in vacuo. Flash column chromatography of the crude 
product over silica gel (10% EtOAc/hexane → 45% EtOAc/hexane) afforded 
cis-bromo lactol 5-11 (0.713 g, 91% over two steps) as a white solid.  
5-11: mp 52.8-56.1 °C; [α]D25 = +15.7 (c = 0.71, CHCl3); 1H NMR (500 
MHz, CDCl3): δ 7.43 (d, J = 7.6 Hz, 2H), 7.36 (t, J = 7.6 Hz, 2H), 7.30 (t, J = 
7.3 Hz, 1H), 6.81 + 6.80 (d each, J = 8.2 Hz, 1H), 6.71 + 6.69 (d each, J = 1.9 
Hz, 1H), 6.66-6.63 (m, 1H), 5.52-5.50 (m, 1H), 5.13 (s, 2H), 3.89 + 3.88 (s 
each, 3H), 3.81 + 3.44 (d1, J1 = 10.1 Hz + d2, J2 = 10.7 Hz, 1H), 3.49 + 3.37 
(d1, J1 = 10.1 Hz + d2, J2 = 10.7 Hz, 1H), 3.09 + 2.81-2.71 (m each, 2H), 2.56 
(dd, J = 10.8, 13.3 Hz, 1H), 2.41-2.27 (m, 1H), 2.00-1.92 + 1.81-1.76 (m each, 
1H), 1.46 + 1.36 (s each, 3H); 13C NMR (125 MHz, CDCl3): δ 149.8, 149.7, 
146.79, 146.77, 137.2, 133.1, 133.0, 128.5, 127.8, 127.26, 127.25, 120.6, 
120.5, 114.4, 112.4, 97.8, 97.2, 83.6, 83.1, 71.2, 56.1, 56.0, 50.8, 47.9, 39.8, 
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39.5, 39.4, 39.3, 35.4, 34.8, 27.4, 25.0; HRMS (EI): m/z calcd for 
C21H25O479Br+ [M]+ 420.0936, found 420.0929, and m/z calcd for 


















Bromo benzotetrahydrofuran 5-12: To a solution of cis-bromo lactol 5-11 
(0.685 g, 1.63 mmol) in CH2Cl2 (20 mL) was quickly added SnCl4 (0.96 mL, 
8.20 mmol) at -78 °C. The solution gave a strong orange colour after 10-15 
min of stirring at -78 °C. The solution was stirred at -78 °C for 1 h 15 min 
before it was quenched with half-saturated Rochelle salt aq. solution. Half-
saturated Rochelle salt (90 g in 200 mL H2O) was cooled to 0 °C with vigorous 
stirring. The reaction mixture was lifted above the -78 °C dry ice/acetone bath, 
and its contents were immediately poured into the half-saturated Rochelle salt 
upon removing the rubber septum. After the transfer was completed and the 
resulting organic layer became colourless in less than 1 min, the mixture was 
diluted with some H2O, and the organic layer was separated. The aqueous layer 
was extracted with CH2Cl2 (2x). The combined organic layers were washed 
with brine, dried over Na2SO4, filtered, and concentrated in vacuo. Flash 
column chromatography of the crude product over silica gel (5% 
EtOAc/hexane → 18 % EtOAc/hexane) afforded bromo benzotetrahydrofuran 
5-12 (0.578 g, 88%) as a colourless oil.  
5-12: [α]D25 = +106.7 (c = 0.67, CHCl3); 1H NMR (500 MHz, CDCl3): δ 
7.43 (d, J = 7.0 Hz, 2H), 7.36 (t, J = 7.6 Hz, 2H), 7.30 (t, J = 7.3 Hz, 1H), 6.67 
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(s, 1H), 6.64 (s, 1H), 5.12 (d, J = 12.0 Hz, 1H), 5.07 (d, J = 12.0 Hz, 1H), 4.72 
(d, J = 5.1 Hz, 1H), 3.86 (s, 3H), 3.30 (d, J = 10.1 Hz, 1H), 3.21 (d, J = 10.1 
Hz, 1H), 3.19 (d, J = 5.0 Hz, 1H), 3.01 (dd, J = 4.4, 17.7 Hz, 1H), 2.56 (brs, 
1H), 2.52-2.48 (5, J = 5.4 Hz, 1H), 2.00 (d, J = 11.4 Hz, 1H), 1.45 (s, 3H); 13C 
NMR (125 MHz, CDCl3): δ 149.7, 146.2, 137.2, 132.8, 128.5, 127.8, 127.3, 
126.8, 113.1, 112.2, 84.1, 78.1, 71.3, 56.1, 41.4, 38.5, 35.3, 31.8, 26.2; HRMS 
(EI): m/z calcd for C21H23O379Br+ [M]+ 402.0831, found 402.0827, and m/z 
calcd for C21H23O381Br+ [M]+ 404.0810, found 404.0813 (intensity ratio 1:1). 
General Procedure for the Lewis Acid (LA) Catalyzed Marson-type 
Friedel-Crafts Cyclization with cis-Bromo Lactol 5-11:  
 
Activated 4Å MS powder (1.0 g/mmol) was added to 5-11 under an 
atmosphere of Ar, followed by CH2Cl2 (0.01 M – 0.02 M). Lewis acid (LA) 
was weighed either in the open or in a N2-filled Aldrich® AtmosBag glove 
bag, and transferred to the solution of 5-11 at room temperature under Ar. The 
resulting mixture was stirred at room temperature until TLC has indicated 
complete consumption of 5-11. At higher catalyst loadings of Bi(OTf)3, the 
colourless solution would turn to a persistent pink indicating the completion of 
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reaction. The reaction mixture was poured into an ice-cooled sat. aq. NH4Cl 
with vigorous stirring before the organic layer was separated. The aqueous 
layer was extracted with CH2Cl2 (2x). The combined organic layers were 
washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo. 
Flash column chromatography of the crude product over silica gel (5% 
EtOAc/hexane → 18% EtOAc/hexane) afforded bromo benzotetrahydrofuran 
5-12 as a colourless oil. Further elution at 22% EtOAc/hexane gave dimer 5-14 
as a colourless viscous oil, while alcohol 5-15 was obtained with 30% 
EtOAc/hexane as a yellow oil. 
Bromo lactol dimer 5-14: [α]D26 = -61.4 (c = 0.48, CHCl3); 1H NMR (500 
MHz, CDCl3): δ 7.44 (d, J = 7.6 Hz, 2H), 7.36 (t, J = 7.6 Hz, 2H), 7.30 (t, J = 
8.2 Hz, 1H), 6.82-6.80 (m, 1H), 6.69 (d, J = 1.9 Hz, 1H), 6.67-6.63 (m, 1H), 
5.56-5.54 + 5.45-5.44 (m each, 1H), 5.13 + 5.12 (s each, 2H), 3.89 + 3.88 (s 
each, 3H), 3.73 + 3.41-3.35 (d1, J1 = 10.1 Hz + m2, 2H), 2.81-2.73 (m, 1H), 
2.58-2.32 + 2.02-1.96 (m each, 3H), 1.86-1.82 + 1.77-1.72 (m each, 1H), 1.33 
(s, 3H); 13C NMR (125 MHz, CDCl3): δ 149.8, 149.7, 146.82, 146.78, 137.3, 
133.4, 133.1, 128.5, 127.8, 127.3, 120.7, 120.5, 114.4, 114.3, 112.7, 112.4, 
99.8, 98.7, 83.3, 82.9, 71.2, 56.13, 56.11, 50.4, 48.2, 39.7, 39.0, 38.8, 35.6, 
34.9, 29.7, 27.4, 24.5; HRMS (EI): m/z calcd for C42H48O779Br2+ [M]+ 
822.1767, found 822.1796, m/z calcd for C21H25O479Br81Br+ [M]+ 824.1746, 
found 824.1783, and m/z calcd for C21H25O481Br81Br+ [M]+ 826.1726, found 
826.1788 (intensity ratio 1:2:1).  
Tertiary alcohol 5-15: [α]D26 = -157.3 (c = 0.15, CHCl3); 1H NMR (500 
MHz, CDCl3): δ 7.43 (d, J = 6.9 Hz, 2H), 7.36 (t, J = 7.6 Hz, 2H), 7.30 (t, J = 
7.6 Hz, 1H), 6.70 (s, 1H), 6.62 (s, 1H), 6.42 (dd, J = 1.9, 10.1 Hz, 1H), 5.74 
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(dd, J = 4.4, 10.1 Hz, 1H), 5.11 (s, 2H), 3.88 (s, 3H), 3.61 (d, J = 10.7 Hz, 1H), 
3.47 (d, J = 10.1 Hz, 1H), 2.94 (d, J = 2.5 Hz, 2H), 2.78-2.77 (m, 1H), 2.02 (s, 
1H), 1.20 (s, 3H); 13C NMR (125 MHz, CDCl3): δ 149.2, 146.6, 137.3, 129.3, 
128.5, 128.0, 127.8, 127.3, 125.9, 124.7, 113.1, 112.0, 73.7, 71.5, 56.1, 44.6, 
41.6, 28.0, 22.3; HRMS (EI): m/z calcd for C21H23O379Br+ [M]+ 402.0831, 
found 402.0815, and m/z calcd for C21H23O381Br+ [M]+ 404.0810, found 
404.0816 (intensity ratio 1:1). 
 
Bromo-phenol 5-13: To a solution of bromo benzotetrahydrofuran 5-12 
(0.276 g, 0.684 mmol) in absolute EtOH (6 mL) was added 10% Pd on carbon 
(20% wt/wt, 55.2 mg), followed by 1,4-cyclohexadiene (1.6 mL, 17.1 mmol) at 
room temperature under an atmosphere of N2. The resulting mixture was stirred 
at room temperature for 3 h before it was filtered through a pad of Celite, 
eluted with EtOAc and concentrated in vacuo. Flash column chromatography 
of the crude product over silica gel (10% EtOAc/hexane → 40% 
EtOAc/hexane) afforded bromo-phenol 5-13 (0.213 g, 99%) as a colourless 
viscous oil.  
5-13: [α]D26 = +26.2 (c = 0.49, CHCl3); 1H NMR (500 MHz, CDCl3): δ 6.65 
(s, 1H), 6.62 (s, 1H), 5.45 (s, 1H), 4.76 (d, J = 5.5 Hz, 1H), 3.87 (s, 3H), 3.30 
(d, J = 10.0 Hz, 1H), 3.22-3.18 (m, 2H), 3.00 (dd, J = 4.4, 17.6 Hz, 1H), 2.56-
2.49 (m, 2H), 2.00 (d, J = 10.7 Hz, 1H), 1.45 (s, 3H); 13C NMR (125 MHz, 
CDCl3): δ 146.6, 143.4, 133.4, 125.4, 113.3, 111.0, 84.1, 78.0, 56.0, 41.4, 38.5, 
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35.3, 31.8, 26.2; ESI-MS: m/z calcd for C14H1679BrO3- [M – H]- 311.0, found 
311.3. 
 
6-Methoxydienone 4-1: To a stirred solution of bromo-phenol 5-13 (0.213 
g, 0.68 mmol) in CH3CN (35 mL) was added DBU (1.5 mL, 10.2 mmol) at 
room temperature, and heated at 70-75 °C for 10 h. The resulting mixture was 
concentrated in vacuo to half its volume, and added 10% aq. citric acid to 
adjust the pH of the solution to approximately pH 3. The organic layer was 
separated, and the aqueous layer was extracted with EtOAc (3x). The 
combined organic layers were washed with water (2x), followed by brine, dried 
over Na2SO4, filtered, and concentrated in vacuo. Flash column 
chromatography of the crude product over silica gel (20% EtOAc/hexane → 
65% EtOAc/hexane) afforded 6-methoxydienone 4-1 (0.134 g, 85%) as a pale 
yellowish-white solid.  
4-1 (Appendix 5, p379): mp 76.1-78.4 °C; [α]D26 = +44.7 (c = 0.68, CHCl3); 
1H NMR (500 MHz, CDCl3): δ 6.16 (s, 1H), 5.55 (s, 1H), 4.72 (d, J = 4.5 Hz, 
1H), 3.67 (s, 3H), 2.56 (t, J = 6.3 Hz, 1H), 2.24-2.16 (m, 2H), 1.99 (d, J = 11.4 
Hz, 1H), 1.93 (dd, J = 3.2, 11.3 Hz, 1H), 1.75 (d, J = 11.4 Hz, 1H), 1.52 (d, J = 
3.2 Hz, 1H), 1.50 (s, 3H); 13C NMR (125 MHz, CDCl3): δ 182.0, 160.6, 152.2, 
121.4, 117.9, 86.7, 79.6, 55.9, 54.9, 49.7, 44.1, 42.5, 22.2; HRMS (IT-TOF): 




cis-Tosyl lactol 5-3: To a solution of mono-tosylated diol 5-4 (3.80 g, 7.44 
mmol) in t-BuOH (50 mL) and THF (20 mL) was added a solution of NMO 
(50% w/w in H2O, 2.10 g, 8.96 mmol) in H2O (10 mL) and OsO4 (2 mol%) at 
room temperature. The resulting mixture was stirred at room temperature for 
12 h before it was cooled to 0 °C, and quenched with NaHSO3 (5.6 g, 3 M in 
H2O). The mixture was warmed to room temperature and stirred for 45 min. 
The organic layer was separated and concentrated in vacuo, and EtOAc was 
added to re-dissolve the residue that formed. The aqueous layer was extracted 
with EtOAc (3x), and the combined organic layers were washed with H2O (1x), 
followed by brine, dried over Na2SO4, filtered, and concentrated in vacuo.  
To this crude diol in THF (100 mL) and H2O (50 mL) were added NaIO4 
(4.10 g, 19.2 mmol) at room temperature, and stirred for 2 h. The resulting 
mixture was carefully concentrated to less than half its volume by removing 
THF under vacuo. The mixture was diluted with water and extracted with 
EtOAc (3x). The combined organic extracts were washed with brine, dried 
over Na2SO4, filtered, and concentrated in vacuo. Flash column 
chromatography of the crude product over silica gel (10% EtOAc/hexane → 
60% EtOAc/hexane) afforded cis-tosyl lactol 5-3 (3.24 g, 85% over two steps) 
as a white solid foam.  
5-3: mp 64.4-65.9 °C; [α]D25 = +21.1 (c = 0.51, CHCl3); 1H NMR (500 
MHz, CDCl3): δ 7.83 + 7.80 (d each, J = 8.2 Hz, 2H), 7.43 (d, J = 7.0 Hz, 2H), 
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7.36 (t, J = 6.9 Hz, 4H), 7.29 (t, J = 7.3 Hz, 1H), 6.80-6.77 (m, 1H), 6.70 + 
6.66 (d each, J = 1.9 Hz, 1H), 6.60-6.57 (m, 1H), 5.39 + 5.34 (m each, 1H), 
5.11 (s, 2H), 4.13-4.10 + 3.94 (m1 + d2, J2 = 10.1 Hz, 1H), 4.05 + 3.86-3.85 (d1, 
J1 = 10.1 Hz + m2, 1H), 3.87 (s, 3H), 2.73-2.70 + 2.62-2.48 (m each, 3H), 2.45 
(s, 3H), 2.26-2.24 + 1.93-1.84 (m each, 2H), 1.70-1.67 (m, 1H), 1.20 + 1.17 (s 
each, 3H); 13C NMR (125 MHz, CDCl3): δ 149.7, 146.7, 144.9, 137.3, 137.2, 
133.10, 133.07, 132.8, 132.7, 129.93, 129.86, 128.5, 128.0, 127.9, 127.78, 
127.76, 127.3, 120.53, 120.47, 114.4, 112.52, 112.48, 98.1, 97.4, 83.5, 82.4, 
72.8, 72.5, 71.2, 60.4, 56.1, 50.1, 47.2, 40.4, 40.2, 34.8, 34.4, 25.2, 23.5, 21.6; 
HRMS (IT-TOF): m/z calcd for C28H32O7SNa+ [M + Na]+ 535.1766, found 
535.1772. 
Friedel-Crafts Cyclization of 5-3 to Tosyl Benzotetrahydrofuran 5-2: 
 
Method 1: To a solution of cis-tosyl lactol 5-3 (0.392 g, 0.765 mmol) in 
CH2Cl2 (38 mL) was quickly added SnCl4 (0.68 mL, 5.81 mmol) at -78 °C. The 
solution gave a bright yellow colour after 65 min of stirring at -78 °C. The 
solution was stirred at -78 °C for 1 h 15 min before it was quenched with half-
saturated Rochelle salt aq. solution. Half-saturated Rochelle salt (80 g in 150 
mL H2O) was cooled to 0 °C with vigorous stirring. The reaction mixture was 
lifted above the -78 °C dry ice/acetone bath, and its contents were immediately 
poured into the half-saturated Rochelle salt solution (200-220 mL) upon 
removing the rubber septum. After the transfer was completed and the resulting 
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organic layer became colourless in less than 1 min, the mixture was diluted 
with some H2O, and the organic layer was separated. The aqueous layer was 
extracted with CH2Cl2 (2x). The combined organic layers were washed with 
brine, dried over Na2SO4, filtered, and concentrated in vacuo. Flash column 
chromatography of the crude product over silica gel (5% EtOAc/hexane → 22 
% EtOAc/hexane) afforded tosyl benzotetrahydrofuran 5-2 (0.325 g, 86%) as a 
colourless oil. 
Method 2: Activated 4Å MS powder (1.0 g/mmol) was added to cis-tosyl 
lactol 5-3 (0.518 g, 1.01 mmol) under an atmosphere of Ar, followed by 
CH2Cl2 (50 mL). LiClO4 (0.326 g, 3.06 mmol) was added to 5-3 at room 
temperature under Ar, and stirred for 45 min before Bi(OTf)3 (5 mol%, 35 mg) 
was added to the reaction at the same temperature under Ar. The resulting 
mixture was stirred at room temperature for 3.5 h before it was poured into an 
ice-cooled saturated aq. NH4Cl solution (150 mL) with vigorous stirring. The 
organic layer was separated, and the aqueous layer was extracted with CH2Cl2 
(3x). The combined organic layers were washed with brine, dried over Na2SO4, 
filtered, and concentrated in vacuo. Flash column chromatography of the crude 
product over silica gel (5% EtOAc/hexane → 22% EtOAc/hexane) afforded 
tosyl benzotetrahydrofuran 5-2 (0.469 g, 94%) as a colourless oil. 
5-2: [α]D25 = +45.5 (c = 0.47, CHCl3); 1H NMR (500 MHz, CDCl3): δ 7.72 
(d, J = 8.2 Hz, 2H), 7.42 (d, J = 7.6 Hz, 2H), 7.36 (t, J = 7.3 Hz, 2H), 7.31-7.28 
(m, 3H), 6.56 (s, 1H), 6.46 (s, 1H), 5.09 (d, J = 12.0 Hz, 1H), 5.04 (d, J = 12.6 
Hz, 1H), 4.63 (d, J = 5.1 Hz, 1H), 3.83 (s, 3H), 3.77 (d, J = 8.9 Hz, 1H), 3.70 
(d, J = 8.9 Hz, 1H), 2.93 (dd, J = 4.4, 17.7 Hz, 1H), 2.83 (d, J = 17.7 Hz, 1H), 
2.47 (brs, 1H), 2.45 (s, 3H), 2.40-2.36 (m, 1H), 1.92 (d, J = 11.4 Hz, 1H), 1.21 
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(s, 3H); 13C NMR (125 MHz, CDCl3): δ 149.7, 146.3, 144.8, 137.2, 132.5, 
132.4, 129.8, 128.5, 128.1, 127.8, 127.3, 126.3, 113.0, 112.3, 81.9, 77.9, 73.3, 
71.2, 56.1, 41.2, 34.8, 31.6, 25.4, 21.6; HRMS (IT-TOF): m/z calcd for 
C28H30O6SNa+ [M + Na]+ 517.1661, found 517.1661. 
 
6-Methoxydienone 4-1: To a solution of tosyl benzotetrahydrofuran 5-2 
(1.06 g, 2.14 mmol) in THF (45 mL) was added 10% Pd on carbon (10% 
wt/wt, 0.11 g) at room temperature. The resulting mixture was stirred under a 
hydrogen atmosphere (balloon) for 2.5 h before it was filtered through a pad of 
Celite, eluted with EtOAc and concentrated in vacuo. To obtain pure crystals 
for X-ray crystallographic analysis, flash column chromatography of the crude 
product over silica gel (10% EtOAc/hexane → 50% EtOAc/hexane) afforded 
tosyl-phenol 5-8 which was recrystallized from CH2Cl2/EtOAc as white 
crystals.  
Otherwise, to the crude tosyl-phenol 5-8 in xylene (98 mL) was added 1M 
TBAF in THF (10.8 mL) at room temperature, and refluxed at 130 °C for 4 h. 
The resulting mixture was concentrated in vacuo to half its volume, and added 
10% aq. citric acid to adjust the pH of the solution to approximately pH 3. The 
organic layer was separated, and the aqueous layer was extracted with EtOAc 
(3x). The combined organic layers were washed with water (1x), followed by 
brine, dried over Na2SO4, filtered, and concentrated in vacuo. Flash column 
chromatography of the crude product over silica gel (20% EtOAc/hexane → 
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65% EtOAc/hexane) afforded 6-methoxydienone 4-1 (0.428 g, 86% over two 
steps) as a pale yellowish-white solid.  
5-8 (Appendix 5, p378): mp 81.5-83.3 °C; [α]D25 = +20.3 (c = 0.27, CHCl3); 
1H NMR (500 MHz, CDCl3): δ 7.71 (d, J = 8.2 Hz, 2H), 7.29 (d, J = 8.2 Hz, 
2H), 6.55 (s, 1H), 6.46 (s, 1H), 5.46 (s, 1H), 4.65 (d, J = 5.1 Hz, 1H), 3.84 (s, 
3H), 3.83 (d, J = 8.9 Hz, 1H), 3.68 (d, J = 9.5 Hz, 1H), 2.93 (dd, J = 3.8, 17.7 
Hz, 1H), 2.85 (d, J = 17.7 Hz, 1H), 2.47 (brs, 1H), 2.43 (s, 3H), 2.41-2.37 (m, 
1H), 1.93 (d, J = 11.4 Hz, 1H), 1.20 (s, 3H); 13C NMR (125 MHz, CDCl3): δ 
146.5, 144.7, 143.4, 133.2, 132.4, 129.7, 128.1, 124.9, 113.1, 110.9, 81.8, 77.7, 
73.4, 56.0, 41.3, 34.8, 31.6, 25.3, 21.6; HRMS (IT-TOF): m/z calcd for 
C21H24O6SNa+ [M + Na]+ 427.1191, found 427.1196. 
X-ray Crystal Data and Structure Refinement for Tosyl-Phenol 5-8: 
The crystal is monoclinic, space group P2(1).The asymmetric unit contains one 
molecule of the compound C21H24O6S. The space group is chiral and the 
absolute structure parameter is 0.05 with a esd 0.07 which imply that the 
reported structure is the correct hand. Final R values are R1= 0.0458 and wR2= 
0.1029 for 2-theta max of 55º. 
Identification code  a053 
Empirical formula  C21 H24 O6 S 
Formula weight  404.46 
Temperature  223(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1) 
Unit cell dimensions a = 9.5667(7) Å, α = 90° 
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 b = 9.8577(7) Å, β = 111.336(10)° 
 c = 11.1610(8) Å, γ = 90° 
Volume 980.41(12) Å3 
Z 2 
Density (calculated) 1.370 mg/m3 
Absorption coefficient 0.201 mm-1 
F(000) 428 
Crystal size 0.30 x 0.20 x 0.10 mm3 
Theta range for data collection 1.96 to 27.49° 
Index ranges -12<=h<=12, -12<=k<=12,  
                                                                       -8<=l<=14 
Reflections collected 6863 
Independent reflections 4332 [R(int) = 0.0240] 
Completeness to theta = 27.49° 100.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9802 and 0.9423 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4332 / 1 / 257 
Goodness-of-fit on F2 1.083 
Final R indices [I>2sigma(I)] R1 = 0.0458, wR2 = 0.1029 
R indices (all data) R1 = 0.0485, wR2 = 0.1044 
Absolute structure parameter 0.05(7) 






Representative Procedure for the Preparation of TFA Salt of Amino Acid 
tert-Butyl Esters: 
 
Cbz-protected D-phenylalanine tert-Butyl ester (-)-5-29: To a mixture of 
D-phenylalanine (600 mg, 3.63 mmol) and Na2CO3 (0.962 g, 9.08 mmol) were 
added 1,4-dioxane (12 mL) and H2O (12 mL) at room temperature. The 
resulting mixture was cooled to 0 ºC before it was added CbzCl (1.2 mL, 7.84 
mmol), and the reaction was stirred at room temperature for 16 h. Water was 
added and the aqueous mixture was extracted with Et2O (2x). The aqueous 
layer was acidified with 1 N HCl to pH 1-2 before it was extracted with EtOAc 
(3x). The combined EtOAc extracts were washed with water (1x), followed by 
brine, dried over Na2SO4, filtered, and concentrated in vacuo to give crude 
Cbz-protected D-phenylalanine (1.024 g, 3.42 mmol) as a colourless oil.  
To a suspension of anhydrous MgSO4 (2.10 g, 17.4 mmol) in CH2Cl2 (5 
mL) was added conc. H2SO4 (0.42 mL, 7.56 mmol) at room temperature, and 
stirred under Ar for 15 min. To this mixture was added a solution of crude Cbz-
protected D-phenylalanine in CH2Cl2 before anhydrous t-BuOH (2.0 mL, 20.9 
mmol) was added at the same temperature. The resulting mixture was tightly 
stoppered, and stirred at room temperature for 25 h before it was carefully 
quenched with sat. aq. NaHCO3 to dissolve the MgSO4, and basified the 
solution. Diluted with water, the organic layer was separated, and the aqueous 
layer was extracted with Et2O (3x). The combined organic layers were washed 
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with brine, dried over Na2SO4, filtered, and concentrated in vacuo.  Flash 
column chromatography of the crude product over silica gel (7.5% 
EtOAc/hexane) afforded t-butyl ester (-)-5-29 (0.841 g, 65% over two steps) as 
a colourless oil. 
(-)-5-29: [α]D24 = -42.9 (c = 0.65, CHCl3); 1H NMR (500 MHz, CDCl3): δ 
7.37-7.21 (m, 8H), 7.15 (d, J = 7.0 Hz, 2H), 5.23 (d, J = 8.2 Hz, 1H), 5.13-5.07 
(m, 2H), 4.56-4.51 (m, 1H), 3.08 (d, J = 6.3 Hz, 2H), 1.40 (s, 9H); 13C NMR 
(125 MHz, CDCl3): δ 170.5, 155.6, 136.1, 129.5, 128.5, 128.4, 128.11, 128.06, 
126.9, 82.3, 66.8, 55.2, 38.4, 27.9; HRMS (IT-TOF): m/z calcd for 
C21H25O4NNa+ [M + Na]+ 378.1681, found 378.1687. 
Cbz-protected D-valine tert-butyl ester (-)-5-28: 
Procedure was repeated with D-valine (600 mg, 5.12 
mmol) to afford the t-butyl ester (-)-5-28 (0.976 g, 
62% over two steps) as a colourless oil. (-)-5-28: [α]D24 = -28.6 (c = 0.56, 
CHCl3); 1H NMR (500 MHz, CDCl3): δ 7.34-7.31 (m, 5H), 5.29-5.28 (m, 1H), 
5.14-5.08 (m, 2H), 4.20-4.18 (m, 1H), 2.17-2.13 (m, 1H), 1.47 (s, 9H), 0.96 (d, 
J = 6.9 Hz, 3H), 0.89 (d, J = 6.9 Hz, 3H); 13C NMR (125 MHz, CDCl3): δ 
171.1, 156.2, 136.4, 128.5, 128.07, 128.05, 81.9, 66.9, 59.3, 31.4, 28.0, 18.9, 


















TFA salt of D-phenylalanine tert-butyl ester (-)-5-27: To a solution of t-










Na/benzophenone, 10 mL) was added 10% Pd on carbon (10% wt/wt, 56 mg) 
at room temperature. The resulting mixture was stirred under a hydrogen 
atmosphere (balloon) for 3 h before it was filtered through a pad of Celite, 
eluted with CH2Cl2 and concentrated in vacuo at 28 °C.  
To this crude amine in hexane (AR, 10 mL) was added TFA (117 µL, 1.57 
mmol) at 0 °C. White precipitate was immediately observed upon addition of 
TFA. The resulting mixture was stirred at room temperature for 3 h before it 
was filtered, repeated washed with hexane, and dried in vacuo to obtain 
catalyst (-)-5-27 (0.438 g, 83% over two steps) as a white fluffy solid. 
(-)-5-27: mp 153.6-155.2 °C; [α]D23 = -18.0 (c = 0.52, CHCl3); 1H NMR 
(500 MHz, CDCl3): δ 7.31-7.22 (m, 5H), 4.11 (dd, J = 6.3, 7.6 Hz, 1H), 3.28 
(dd, J = 6.4, 13.9 Hz, 1H), 3.16 (dd, J = 7.6, 14.5 Hz, 1H), 1.32 (s, 9H); 13C 
NMR (125 MHz, CDCl3): δ 167.9, 162.3, 162.1, 134.0, 129.5, 128.8, 127.6, 
84.3, 54.3, 36.6, 27.6; HRMS (IT-TOF): m/z calcd for C13H20O2N+ [M]+ 
222.1489, found 222.1493, and m/z calcd for C2F3O2- [M]- 112.9856, found 
112.9852. 
TFA salt of D-valine tert-butyl ester (-)-5-23: 
Procedure was repeated with Cbz-protected D-valine 
t-butyl ester (-)-5-28 (0.124 g, 0.403 mmol) to afford 
catalyst (-)-5-23 (92.7 mg, 80% over two steps) as a white fluffy solid. (-)-5-
23: mp 128.3-130.1; [α]D24 = -7.1 (c = 0.69, CHCl3); 1H NMR (500 MHz, 
CDCl3): δ 3.77 (d, J = 3.8 Hz, 1H), 2.34-2.31 (m, 1H), 1.49 (s, 9H), 1.08 (d, J 
= 1.9 Hz, 3H), 1.07 (d, J = 1.9 Hz, 3H); ESI-MS: m/z calcd for C9H20O2N+ 






TFA salt of glycine tert-butyl ester 5-65: Procedure 
was repeated with available Cbz-protected glycine t-
butyl ester (87.2 mg, 0.329 mmol) to afford catalyst 5-65 (62.9 mg, 78% over 
two steps) as a white solid. 5-65: mp 120.8-122.6 °C; 1H NMR (300 MHz, 
CDCl3): δ 3.79 (s, 2H), 1.38 (s, 9H); ESI-MS: m/z calcd for C6H14O2N+ [M]+ 
132.1, found 132.3, and m/z calcd for C2F3O2- [M]- 113.0, found 113.0. 
 
Hantzsch ethyl ester 5-24[156]: A mixture of paraformaldehyde (300 mg, 
9.99 mmol), ethyl acetoacetate (5.05 mL, 39.9 mmol), and NH4OAc (1.54 g, 
20.0 mmol) in degassed H2O (20 mL) was refluxed with vigorous stirring for 2 
h. The resulting mixture was cooled to room temperature before it was quickly 
filtered, washed with water (3x), and dried in vacuo to give Hantzsch ethyl 
ester 5-24 (2.27 g, 90%, and 98-99% purity) as a yellow fluffy solid.   
5-24: mp 185.7-188.8 °C; 1H NMR (300 MHz, CDCl3): δ 5.16 (brs, 1H), 
4.16 (q, J = 11.8 Hz, 4H), 3.26 (s, 2H), 2.19 (s, 6H), 1.28 (t, J = 12.0 Hz, 6H); 
13C NMR (125 MHz, CDCl3): δ 168.1, 144.8, 99.5, 59.6, 24.8, 19.1, 14.4; ESI-









General procedure for the preparation of 6-methoxyenones 5-16/17 via 
Buchwald’s copper-catalyzed conjugate reduction: 
 
For these small scale reactions, a stock solution of bis-phosphine-stabilized 
Cu-H complex in toluene was prepared. The bis-phosphine [rac-BINAP or (R)-
tol-BINAP] (0.05 mmol) was placed in a flame-dried Schlenk tube and 
dissolved in toluene (2 mL) before it was moved into a N2-filled glovebox. In 
the glovebox, NaOtBu (5 mg, 0.05 mmol) and CuCl (5 mg, 0.05 mmol) were 
weighed into a flask, followed by addition of the toluene solution of bis-
phosphine via pipet to dissolve the solids. The resulting mixture was stirred at 
room temperature for 15-20 min before PMHS (63 µL, 1.05 mmol) was added, 
and the solution turned reddish-orange within a few seconds. To a solution of 
6-methoxydienone 4-1 (5.6 mg, 0.024 mmol) in toluene (0.5 mL) was added an 
aliquot (0.2 mL) from the stock solution of bis-phosphine-stabilized Cu-H 
complex in toluene via pipet at room temperature. The reaction mixture was 
tightly sealed before it was moved out from the glovebox and stirred at room 
temperature under an Ar atmosphere for the indicated period of time. The 
resulting mixture was partitioned between water and EtOAc, followed by 
separation of the aqueous layer. The organic layer was extracted with brine, 
and concentrated in vacuo. To this residue was dissolved in THF (1 mL), 
followed by the addition of 1M TBAF in THF (1 mL) and stirred at room 
319 
 
temperature for 3 h. Saturated aq. NH4Cl and water were added to the resulting 
solution before it was extracted with EtOAc (3x). The combined organic 
extracts were washed with brine, dried over Na2SO4, filtered, and concentrated 
in vacuo. Flash column chromatography of the crude product over silica gel 
(hexane → 14% EtOAc/hexane → 50% EtOAc/hexane) afforded an 
inseparable diastereomeric mixture of 6-methoxy cyclohex-6-en-5-ol.   
 To a solution of this 6-methoxy cyclohex-6-en-5-ol in CH2Cl2 (2 mL) was 
added NaHCO3 (9 equiv.) and Dess-Martin (4 equiv.) at room temperature. The 
resulting mixture was stirred at room temperature for 6 h before it was 
quenched with saturated aq. Na2S2O3 and saturated aq. NaHCO3 (1:1), and 
stirred for 30 min to obtain a clear solution. The solution was diluted with 
water, and extracted with EtOAc (3x). The combined organic extracts were 
washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo. 
Flash column chromatography of the crude product over silica gel (10% 
EtOAc/hexane → 52% EtOAc/hexane) afforded an inseparable mixture of 6-
methoxyenones 5-16/17 as a white solid. 
 
6-Methoxyketone 5-18: To a solution of 6-methoxydienone 4-1 (30 mg, 
0.129 mmol) in 1,4-dioxane (1.2 mL) was added catalyst (-)-5-27 (9 mg, 
0.0268 mmol, 20 mol%) and Hantzsch ethyl ester 5-24 (110 mg, 0.434 mmol) 
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at room temperature. The resulting mixture was tightly sealed under argon 
atmosphere, and stirred at 60 °C for 130 h before it was diluted with EtOAc, 
and treated with 2N NaOH aq. solution. The organic layer was separated, and 
the aqueous layer was extracted with EtOAc (1x). The combined organic layers 
were washed with water (1x), followed by brine, dried over Na2SO4, filtered, 
and concentrated in vacuo. Flash column chromatography of the crude product 
over Et3N-deactivated silica gel (0.05% Et3N v/v 30% EtOAc/hexane → 45% 
EtOAc/hexane) under N2 afforded an inseparable mixture of 6-methoxyenones 
5-16/17 (18.6 mg, 61%, 8:1 dr at C9) and 6-methoxyketones 5-18/19 
separated (5.2 mg, 17%, 1.1:1 dr at C9) as yellow-white solids. Further elution 
at 70% EtOAc/hexane (without Et3N) recovered 6-methoxydienone 4-1 (5.4 
mg) as a yellow-white solid.  
To the mixture of 6-methoxyenones 5-16/17 and 6-methoxyketones 5-18/19 
in EtOAc (6 mL) and 0.3 N KOH in EtOH (3 mL) was added 10% Pd on 
carbon (20% wt/wt, 5 mg) at room temperature. The resulting mixture was 
stirred under a hydrogen atmosphere (balloon) for 1.5 h before it was quickly 
filtered through a pad of Celite, eluted with EtOAc and concentrated in vacuo. 
Flash column chromatography of the crude product over Et3N-deactivated 
silica gel [0.05% Et3N v/v (10% EtOAc/hexane → 32% EtOAc/hexane)] under 
N2 afforded 6-methoxyketones 5-18 (17.8 mg combined) and 5-19 (4.5 mg 
combined) in a 4:1 C9 epimeric mixture (73% over 2 steps) as white solids. 
5-16 (major) + 5-17* (minor): mp 76.1-78.4 °C; [α]D25 = -68.1 (c = 0.16, 
CHCl3); 1H NMR (500 MHz, CDCl3): δ 5.46* (s), 5.45 (s, 1H), 4.12 (brs, 1H), 
4.06* (d, J = 4.4 Hz), 3.56 (s, 3H), 2.81* (dd, J = 15.2, 17.7 Hz), 2.44-2.37 (m, 
3H), 2.36-2.34* (m), 2.26 (t, J = 6.3 Hz, 1H), 2.03-1.95* (m), 1.92-1.89 (m, 
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2H), 1.82 (d, J = 11.4 Hz, 1H), 1.76-1.70 (m, 2H), 1.61 (d, J = 11.4 Hz, 1H), 
1.53-1.47* (m), 1.40 (s, 3H), 1.38* (s); 13C NMR (125 MHz, CDCl3): δ 193.3, 
150.9, 121.4, 120.7*, 86.5, 86.0*, 78.9*, 78.6, 54.8, 52.4, 48.2*, 47.6*, 45.4, 
45.2*, 44.6*, 44.1, 43.0, 42.6, 41.9*, 41.6*, 39.4*, 38.0, 37.2, 37.1*, 27.8*, 
23.1, 22.8*; HRMS (EI): m/z calcd for C14H18O3+ [M]+ 234.1256, found 
234.1254.    
5-18-(6R): mp 50.2-51.8 °C; [α]D25 = -35.1 (c = 0.31, 
CHCl3); 1H NMR (500 MHz, CDCl3): δ 4.11 (t, J = 3.5 
Hz, 1H), 3.82 (dd, J = 6.3, 12.6 Hz, 1H), 3.44 (s, 3H), 
2.32-2.30 (m, 3H), 2.07 (t, J = 9.5 Hz, 1H), 2.02 (dd, J = 3.5, 12.0 Hz, 1H), 
1.93 (dd, J = 6.3, 12.6 Hz, 1H), 1.86 (m, 2H), 1.78-1.71 (m, 2H), 1.55 (d, J = 
11.4 Hz, 2H), 1.41 (s, 3H); 13C NMR (125 MHz, CDCl3): δ 207.9, 85.6, 82.0, 
78.9, 58.1, 52.7, 45.9, 45.3, 44.9, 42.5, 41.1, 40.9, 37.2, 23.0; HRMS (EI): m/z 
calcd for C14H20O3+ [M]+ 236.1412, found 236.1409. 
5-18-(6S): mp 49.8-51.6 °C; [α]D25 = +42.6 (c = 0.23, 
CHCl3); 1H NMR (500 MHz, CDCl3): δ 4.09 (brs, 1H), 
3.48 (brs, 1H), 3.27 (s, 3H), 2.75 (dd, J = 12.6, 13.9 Hz, 
1H), 2.30 (dd, J = 3.8, 12.6 Hz, 1H), 2.25 (t, J = 6.3 Hz, 1H), 2.10-2.03 (m, 
2H), 1.88-1.83 (m, 4H), 1.63 (dd, J = 3.2, 11.4 Hz, 1H), 1.52 (d, J = 11.4 Hz, 
2H), 1.39 (s, 3H); 13C NMR (125 MHz, CDCl3): δ 210.7, 85.3, 83.6, 79.4, 57.3, 
53.4, 46.3, 45.6, 43.3, 42.9, 40.9, 38.1, 37.4, 23.0.  
5-19-(6R): [α]D25 = +38.7 (c = 0.32, CHCl3); 1H NMR 





















(dd, J = 6.3, 12.6 Hz, 1H), 3.45 (s, 3H), 2.79 (t, J = 13.9 Hz, 1H), 2.31-2.27 (m, 
3H), 2.01-1.99 (m, 1H), 1.93 (dd, J = 6.3, 12.6 Hz, 1H), 1.77-1.70 (m, 4H), 
1.48-1.43 (m, 1H), 1.42 (s, 3H), 1.34 (d, J = 11.4 Hz, 1H); 13C NMR (125 
MHz, CDCl3): δ 207.8, 85.5, 82.0, 78.9, 58.1, 52.6, 45.8, 44.8, 42.5, 41.1, 40.8, 
37.2, 23.0.   
 
Methylated 6-methoxyenones 5-33/34: To a solution of the inseparable 
mixture of 6-methoxyenones 5-16/17 (31 mg, 0.132 mmol) in THF (2 mL) was 
added 0.5M KHMDS in toluene (0.4 mL, 0.200 mmol) at -78 °C. The (bright) 
yellow solution was stirred at the same temperature for 30 min before the 
addition of HMPA (0.4 mL) and MeI (70 µL, 1.12 mmol). The resulting 
mixture was stirred at -78 °C and gradually warmed to -10 °C over 4 h before it 
was quenched with saturated aq. NaHCO3 and briefly stirred at room 
temperature. The mixture was diluted with water, and extracted with EtOAc 
(3x). The combined organic extracts were washed with water (1x), followed by 
brine, dried over Na2SO4, filtered, and concentrated in vacuo. Flash column 
chromatography of the crude product over silica gel (5% EtOAc/hexane → 
20% EtOAc/hexane → 40% EtOAc/hexane) afforded an inseparable C4-
diastereomeric mixture of methylated 6-methoxyenones 5-33/34 (20.3 mg, 
62%) as a white solid.  
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5-33/34: mp 76.2-80.4 °C; 1H NMR (500 MHz, CDCl3): δ 5.38 + 5.41 (s 
each, 1H), 4.33 + 4.41 (brs each, 1H), 3.58 + 3.56 (s each, 3H), 2.45-2.41 (m, 
1H), 2.34-2.28 (m, 1H), 2.06-2.04 (m, 1H), 1.96-1.67 (m, 4H), 1.63-1.58 (m, 
1H), 1.42-1.40 (m, 3H), 1.22-1.21 + 1.15-1.13 (m each, 3H); 13C NMR (125 
MHz, CDCl3): δ 195.8, 150.4, 120.5, 86.6, 77.6, 54.9, 52.7, 48.4, 45.1, 44.3, 













































Methyl 6-methoxyplatensinoates 5-35/36: The inseparable mixture of 
methylated 6-methoxyenones 5-33/34 (13.4 mg, 0.0540 mmol) was dissolved 
in THF (1.2 mL) and t-BuOH (0.8 mL) at room temperature. KOtBu (48.4 mg, 
0.431 mmol) was weighed in a separate vial in a N2-filled Aldrich® AtmosBag 
glove bag. The stirring solution was cooled to 0 °C before KOtBu was added in 
one portion under an Ar atmosphere. The resulting (bright) yellow solution was 
stirred at 0 °C for 30 min, followed by the addition of methyl acrylate 5-39 
(0.15 mL, 1.66 mmol), and the reaction was stirred at 0 °C for a further 1 h. 
The reaction was quenched with saturated aq. NH4Cl, and briefly stirred at 
room temperature. The mixture was diluted with water, and extracted with 
EtOAc (3x). The combined organic extracts were washed with brine, dried 
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over Na2SO4, filtered, and concentrated in vacuo. Flash column 
chromatography of the crude product over silica gel (5% EtOAc/hexane → 
12% EtOAc/hexane → 45% EtOAc/hexane) afforded an inseparable C4-
diastereomeric mixture of methyl 6-methoxyplatensinoates 5-35/36 (5.8 mg, 
32%) as a white oily paste (highly complex NMR spectra).  












































tert-Butyl 6-methoxyplatensinoates 5-37: To a solution of the inseparable 
mixture of methylated 6-methoxyenones 5-33/34 (21 mg, 0.0846 mmol) in 
THF (1.2 mL) was added 1M KOtBu in t-BuOH (0.17 mL) at 0 °C. The 
resulting (bright) yellow solution was stirred at 0 °C for 20 min, followed by 
the addition of t-butyl acrylate 5-40 (50 µL, 0.341 mmol). The resulting 
mixture was stirred at 0 °C for a further 3 h before it was quenched with 
saturated aq. NH4Cl, and briefly stirred at room temperature. The mixture was 
diluted with water, and extracted with EtOAc (3x). The combined organic 
extracts were washed with brine, dried over Na2SO4, filtered, and concentrated 
in vacuo. Flash column chromatography of the crude product over silica gel 
(10% EtOAc/hexane → 36% EtOAc/hexane) afforded an inseparable C4-
diastereomeric mixture of tert-butyl 6-methoxyplatensinoate 5-37 [7.4 mg, 
325 
 
23% based on (5-33 + 5-34)] with 4:1 dr at C4, and as a pale yellow oil. tert-
Butyl 6-methoxyplatensinoate 5-38 was observed in trace amount 
contaminated with unknown byproducts.   
5-37: 1H NMR (500 MHz, CDCl3): δ 5.34 (s, 1H), 4.37 (brs, 1H), 3.58 (s, 
3H), 2.39-2.36 (m, 1H), 2.33 (s, 1H), 2.26-2.22 (m, 2H), 2.17-2.10 (m, 1H), 
2.05-1.97 (m, 3H), 1.84 (dd, J = 3.8, 10.7 Hz, 1H), 1.75-1.67 (m, 2H), 1.58 (d, 
J = 11.3 Hz, 1H), 1.43 (s, 3H), 1.41 (s, 9H), 1.25 (s, 3H); 13C NMR (125 MHz, 
CDCl3): δ 197.9, 172.5, 149.1, 120.2, 86.8, 80.2, 76.5, 56.1, 55.0, 46.9, 45.7, 
44.6, 44.4, 44.2, 40.4, 31.1, 30.3, 28.1, 24.9, 23.1; EI-MS: m/z calcd for 
C22H32O5+ [M]+ 376.2, found 376.5. 
 
Tetracyclic 1,2-diketone 5-44: To a stirring solution of 6-methoxyenone 5-
16 (5.8 mg, 0.0248 mmol) in THF (1 mL) was added 3N HCl (1 mL) at room 
temperature. The resulting mixture was tightly sealed under an Ar purge, and 
brought to reflux for 7 h. The solution was poured into saturated aq. NaHCO3, 
and diluted with water before it was extracted with CH2Cl2 (3x). The combined 
organic extracts were washed with brine, dried over Na2SO4, filtered, and 
concentrated in vacuo. Flash column chromatography of the crude product over 
silica gel (10% EtOAc/hexane → 32% EtOAc/hexane) afforded a mixture of 
1,2-diketone 5-44 and its tautomers (2.6 mg, 49%) as a white oily paste.   
5-44: 1H NMR (500 MHz, CDCl3): δ 6.03 + 5.99 (s each, 1H), 5.85 + 5.78 
(s each, 1H), 4.39 + 4.18 (s each, 1H), 2.53-2.26 (m, 3H), 1.97-1.87 (m, 3H), 
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1.81-1.70 (m, 2H), 1.46-1.44 (m, 3H); EI-MS: m/z calcd for C13H16O3+ [M]+ 
220.1, found 222.1. 
 
Part I. Preparation of 0.1 M solution of SmI2 in THF: Sm powder (~40 
mesh, 50 mg, 0.33 mmol) was added to a flame-dried round bottom flask (rbf), 
followed by the addition of diiodoethane (85 mg, 0.3 mmol). The rbf was 
placed on the vacuum line to evacuate air and refilled it with Ar. This 
procedure was repeated twice before the rbf was immediately sealed and 
replaced with an Ar balloon. THF (3 mL) was added to the stirring mixture at 
room temperature, and the Ar balloon was removed and the reaction flask was 
tightly sealed. The resulting mixture was partially submerged to its solvent 
level in the sonicator, and sonicated for 5 min to trigger the reaction.[177] The 
resulting deep blue solution of SmI2 was stirred at room temperature for 12 h 
before it was directly used in the subsequent step.   
Part II. Tetracyclic tetrahydro-ketone 5-52: To a solution of 6-
methoxyenone 5-16 (major isomer) (3.6 mg, 0.0154 mmol) in THF (1 mL) was 
added anhydrous t-BuOH (15 µL, 0.157 mmol) at room temperature. The 
solution was cooled to 0 °C before 0.1M SmI2 in THF (2 mL) was added via a 
gas-tight syringe. The resulting mixture was stirred at 0 °C to room 
temperature over 5 h before the reaction was quenched with water. The mixture 
was extracted with EtOAc (3x), and the combined organic extracts were 
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washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo. The 
crude product was briefly purified through flash column chromatography over 
silica gel, eluted with EtOAc, before it was used in the subsequent step. 
  To a solution of this tetrahydro-alcohol (2.8 mg) in CH2Cl2 (1 mL) was 
added NaHCO3 (10.4 mg, 0.124 mmol) and Dess-Martin (21.5 mg, 0.0507 
mmol) at room temperature. The resulting mixture was stirred at room 
temperature for 7 h before it was quenched with saturated aq. NaHCO3 and 
saturated aq. Na2S2O3 solutions (1:1), and stirred at room temperature to obtain 
a clear solution. The mixture was diluted with water, and extracted with EtOAc 
(3x). The combined organic extracts were washed with brine, dried over 
Na2SO4, filtered, and concentrated in vacuo. Prep. TLC of the crude product 
(35% EtOAc/hexane x 03 elution) spread over 16 cm x 10 cm glass plate 
afforded tetrahydro-ketone 5-52 (1.7 mg, 52% over two steps) as a white solid. 
5-52: 1H NMR (500 MHz, CDCl3): δ 4.08 (s, 1H), 2.39-2.21 (m, 5H), 2.09-
2.02 (m, 2H), 1.91-1.77 (m, 3H), 1.70 (dd, J = 3.1, 11.3 Hz, 1H), 1.65-1.60 (m, 
1H), 1.52 (overlapped by impurity, 1H), 1.42-1.39 (m, 4H); 13C NMR (125 
MHz, CDCl3): δ 210.6, 86.1, 79.3, 52.8, 45.2, 45.0, 44.4, 41.6, 40.0, 39.2, 37.1, 
35.1, 23.1; HRMS (EI): m/z calcd for C13H18O2+ [M]+ 206.1307, found 
206.1302. 
 
Acyloin 5-54: To anhydrous AlCl3 (360 mg, 2.70 mmol) was added a 
solution of methoxy ketone 5-18 (25 mg, 0.106 mmol) in CH3CN (8 mL) and 
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CH2Cl2 (4 mL) at 0 °C. TBAI (980 mg, 2.65 mmol) was added in one portion 
at the same temperature under Ar. The resulting mixture was stirred at -1 °C 
for 20 h before it was quenched with water and diluted with CH2Cl2. The 
organic layer was separated, and the aqueous layer was extracted with CH2Cl2 
(2x). The combined organic layers were washed with 10% aq. Na2S2O3 (1x), 
followed by brine, dried over Na2SO4, filtered, and concentrated in vacuo. 
Flash column chromatography of the crude product over silica gel (10% 
EtOAc/hexane → 40% EtOAc/hexane) afforded acyloin 5-54 (19.5 mg, 83%) 
as a white crystalline solid. 
5-54: mp 53.6-56.2 °C; [α]D26 = -54.1 (c = 0.36, CHCl3); 1H NMR (500 
MHz, CDCl3): δ 4.23 (t, J = 3.5 Hz, 1H), 4.20-4.16 (m, 1H), 3.60 (d, J = 2.6 
Hz, 1H), 2.60 (d, J = 13.2 Hz, 1H), 2.29-2.22 (m, 3H), 2.16 (d, J = 13.2 Hz, 
1H), 1.86 (dd, J = 3.8, 11.4 Hz, 1H), 1.82 (t, J = 5.1 Hz, 1H), 1.78 (d, J = 11.4 
Hz, 1H), 1.61-1.59 (m, 2H), 1.53 (t, J = 13.6 Hz, 1H), 1.41 (s, 3H), 1.39-1.33 
(m, 1H); 13C NMR (125 MHz, CDCl3): δ 209.6, 85.3, 79.0, 74.4, 53.0, 48.7, 
47.7, 45.6, 42.2, 41.3, 37.6, 35.7, 22.9; HRMS (EI): m/z calcd for C13H18O3+ 
[M]+ 222.1256, found 222.1256. 
 
Tetracyclic enone (-)-1-23: To a solution of acyloin 5-54 (18 mg, 0.0810 
mmol) in CH2Cl2 (6 mL) was added MsCl (45 µL, 0.581 mmol) and Et3N (85 
µL, 0.610 mmol) at 0 °C. The resulting mixture was stirred at room 
temperature for 6 h before it was quenched with water and diluted with 
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CH2Cl2. The organic layer was separated, and the aqueous layer was extracted 
with CH2Cl2 (2x). The combined organic layers were washed with brine, dried 
over Na2SO4, filtered, and concentrated in vacuo at temperatures not exceeding 
30 °C.  
To this crude mesylate 5-55 in DMSO (1 mL) was added LiBr·H2O (175 
mg, 1.67 mmol) and Li2CO3 (155 mg, 2.10 mmol) at room temperature. The 
resulting mixture was vigorously stirred at 150 °C for 4 h before it was cooled 
to room temperature, and added 1:1 H2O/brine. The aqueous layer was 
extracted with Et2O (3x), and the combined organic extracts were back-
extracted with water (1x). The organic layer was washed with brine, dried over 
Na2SO4, filtered, and concentrated in vacuo. Flash column chromatography of 
the crude product over silica gel (10% EtOAc/hexane → 30% EtOAc/hexane) 
afforded tetracyclic enone (-)-1-23 (12 mg, 72% over two steps, single 
diastereomer with HPLC analysis) as a white solid. 
(-)-1-23 (Appendix 5, p380): mp 77.8-80.3 °C; [α]D26 = -26.2 (c = 0.07, 
CHCl3); 1H NMR (500 MHz, CDCl3): δ 6.61 (d, J = 10.1 Hz, 1H), 5.94 (d, J = 
10.1 Hz, 1H), 4.16 (t, J = 3.5 Hz, 1H), 2.42-2.31 (m, 4H), 1.96-1.93 (m, 2H), 
1.89 (d, J = 11.3 Hz, 1H), 1.76 (brs, 2H), 1.65 (d, J = 10.7 Hz, 1H), 1.44 (s, 
3H); 13C NMR (125 MHz, CDCl3): δ 199.0, 155.1, 128.9, 87.0, 79.0, 51.7, 
46.2, 44.2, 42.7, 42.3, 37.9, 37.5, 23.1; HRMS (IT-TOF): m/z calcd for 




Methylated tetracyclic enone 2-1: To a solution of tetracyclic enone (-)-1-
23 (14 mg, 0.0685 mmol) in THF (1.2 mL) and HMPA (0.24 mL) was added 
0.5M KHMDS in toluene (0.22 mL, 0.110 mmol) at -78 °C. The (bright) 
yellow solution was stirred at the same temperature for 20 min before the 
addition of MeI (35 µL, 0.562 mmol). The resulting mixture was stirred at -78 
°C and gradually warmed to -10 °C over 3 h before it was quenched with 
saturated aq. NaHCO3 and briefly stirred at room temperature. The mixture 
was diluted with water, and extracted with EtOAc (3x). The combined organic 
extracts were washed with water (1x), followed by brine, dried over Na2SO4, 
filtered, and concentrated in vacuo. Flash column chromatography of the crude 
product over silica gel (5% EtOAc/hexane → 20% EtOAc/hexane) afforded 
methylated tetracyclic enone 2-1 (11.9 mg, 80%) with almost complete C4-
diastereoselectivity, and as a white solid. 
2-1 (Appendix 5, p381): mp 79.1-81.0 °C; [α]D25 = -42.2 (c = 0.26, CHCl3); 
1H NMR (300 MHz, CDCl3): δ 6.53 (d, J = 10.0 Hz, 1H), 5.92 (d, J = 9.9 Hz, 
1H), 4.35 (brs, 1H), 2.40-2.31 (m, 2H), 2.09-2.05 (m, 1H), 1.97-1.73 (m, 5H), 
1.61 (d, J = 11.1 Hz, 1H), 1.43 (s, 3H), 1.13 (d, J = 6.7 Hz, 3H); 13C NMR (75 
MHz, CDCl3): δ 201.2, 154.1, 128.1, 77.6, 51.8, 48.5, 46.7, 44.4, 42.5, 41.2, 
37.1, 23.0, 10.9; HRMS (IT-TOF): m/z calcd for C14H18O2Na+ [M + Na]+ 




tert-Butyl platensinoate 5-56: To a solution of methylated tetracyclic 
enone 2-1 (12 mg, 0.0550 mmol) in THF (1 mL) was added 1M KOtBu in t-
BuOH (121 µL) at -10 °C. The resulting (bright) yellow solution was stirred at 
-10 °C for 10 min, followed by the addition of t-butyl acrylate 5-40 (36 µL, 
0.246 mmol). The resulting mixture was stirred at -10 °C for a further 1.5 h 
before it was quenched with saturated aq. NaHCO3, and briefly stirred at room 
temperature. The mixture was diluted with water, and extracted with EtOAc 
(4x). The combined organic extracts were washed with brine, dried over 
Na2SO4, filtered, and concentrated in vacuo. Flash column chromatography of 
the crude product over silica gel (10% EtOAc/hexane → 25% EtOAc/hexane) 
afforded an inseparable C4-diastereomeric mixture of tert-butyl platensinoate 
5-56 (6.5 mg, 34%) with 10:1 dr at C4, and as a colourless oil.  
5-56 (Appendix 5, p382): [α]D25 = -31.6 (c = 0.18, CHCl3); 1H NMR (500 
MHz, CDCl3): δ 6.45 (d, J = 10.1 Hz, 1H), 5.87 (d, J = 10.1 Hz, 1H), 4.39 (brs, 
1H), 2.41-2.38 (m, 1H), 2.34 (s, 1H), 2.24-2.21 (m, 2H), 2.14-2.06 (m, 2H), 
2.03-1.99 (m, 2H), 1.84 (dd, J = 3.1, 10.7 Hz, 1H), 1.77-1.73 (m, 1H), 1.69-
1.64 (m, 1H), 1.61-1.59 (m, 3H), 1.44 (s, 3H), 1.42 (s, 9H), 1.22 (s, 3H); 13C 
NMR (125 MHz, CDCl3): δ 203.3, 172.6, 153.4, 127.3, 87.0, 80.2, 76.5, 55.0, 
46.2, 46.02, 45.96, 44.7, 43.2, 40.6, 30.8, 30.3, 28.1, 24.6, 23.0; HRMS (EI): 




Platensic acid 1-14: To a solution of tert-butyl platensinoate 5-56 (6 mg, 
0.0173 mmol) in CH2Cl2 (0.6 mL) was added TFA (0.6 mL) at 0 °C. The 
resulting mixture was stirred at 0 °C for 12 h before it was concentrated in 
vacuo. The crude platensic acid 1-14 was placed under high vacuum pull for 12 
h to afford a white solid (5 mg, 100%), and it was used in the subsequent step 
without further purification. 
1-14: 1H NMR (500 MHz, CDCl3): δ 6.47 (d, J = 10.1 Hz, 1H), 5.89 (d, J = 
10.1 Hz, 1H), 4.41 (brs, 1H), 2.42-2.40 (t, 1H), 2.36-2.24 (m, 4H), 2.13-1.99 
(m, 3H), 1.87 (dd, J = 3.1, 11.3 Hz, 1H), 1.79-1.75 (m, 2H), 1.61 (d, J = 10.7 
Hz, 1H), 1.44 (s, 3H), 1.24 (s, 3H); HRMS (IT-TOF): m/z calcd for C17H23O4+ 
[M + H]+ 291.1596, found 291.1591.  
6-Methoxyplatensic acid 5-43: To a solution of 
tert-butyl 6-methoxyplatensinoate 5-37 (7.4 mg, 
0.0197 mmol) in CH2Cl2 (1 mL) was added TMSCN 
(10 µL, 0.0799 mmol), Et3N (20 mol%, 1 drop), and 
TMSOTf (18 µL, 0.0995 mmol) at 0 °C. The resulting mixture was stirred at 0 
°C to room temperature over 4 h before 1M HCl (2 mL) and THF (2 mL) were 
added, and stirred for a further 3 h. The mixture was diluted with water before 
it was extracted with EtOAc (3x). The combined organic extracts were washed 
with brine, dried over Na2SO4, filtered, and concentrated in vacuo. Flash 
column chromatography of the crude product over a short pad of silica gel 
(50% EtOAc/hexane → EtOAc) afforded the by-product 6-methoxyplatensic 
acid 5-43 (6.2 mg, 98%) as a white solid. 5-43: 1H NMR (300 MHz, CDCl3): δ 
5.36 (s, 1H), 4.39 (brs, 1H), 3.58 (s, 3H), 2.41-2.26 (m, 5H), 2.09-1.95 (m, 









1H), 1.43 (s, 3H), 1.25 (s, 3H); HRMS (IT-TOF): m/z calcd for C18H25O5+ [M 
+ H]+ 321.1702, found 321.1713.     
 
2,4-Dihydroxy-3-nitroacetophenone 5-57: Polyphosphoric acid (PPA, 11 
g/ 100 mg) was heated at 50 °C until it became less viscous, followed by the 
addition of glacial AcOH (0.51 mL, 8.86 mmol) and 2-nitroresorcinol 1-27 
(0.55 g, 3.58 mmol) at the same temperature. The temperature was raised to 
75-80 °C and the resulting mixture was stirred for 2 h before it was cooled to 
room temperature, and quenched with cold water (180 mL). The resulting 
mixture was extracted with EtOAc (4x), and the combined organic layers were 
washed with H2O (1x), followed by brine, dried over Na2SO4, filtered, and 
concentrated in vacuo. Flash column chromatography of the crude product over 
silica gel (CH2Cl2, then 5% MeOH/CH2Cl2 to eventually flush out the tailing) 
afforded 2,4-dihydroxy-3-nitroacetophenone 5-57 (0.482 g, 69%) as a yellow 
crystalline solid. 
5-57: mp 123.4-125.8 °C; 1H NMR (300 MHz, CDCl3): δ 14.84 (s, 1H), 
11.34 (s, 1H), 7.90 (d, J = 9.0 Hz, 1H), 6.64 (d, J = 9.0 Hz, 1H), 2.62 (s, 3H); 
13C NMR (75 MHz, CDCl3): δ 202.9, 161.9, 161.4, 137.6, 125.1, 113.5, 108.9, 















2,4-Dibenzyloxy-3-nitroacetophenone 5-58: To a solution of 
acetophenone 5-57 (0.356 g, 1.81 mmol) in anhydrous DMF (12 mL) was 
added anhydrous K2CO3 (1.50 g, 10.8 mmol), TBAI (0.133 g, 0.361 mmol) and 
BnBr (644 µL, 5.42 mmol) at room temperature. The resulting mixture was 
warmed to 55 °C and stirred for 12 h before it was cooled to room temperature, 
and quenched with cold water. Vigorous stirring was maintained for 5-10 min 
until a homogenous layer was obtained, and extracted with Et2O (3x). The 
combined organic extracts were washed with water (1x), followed by brine, 
dried over Na2SO4, filtered, and concentrated in vacuo. Flash column 
chromatography of the crude product over silica gel (5% EtOAc/hexane → 
25% EtOAc/hexane) afforded bis-benzyl ether 5-58 (0.647 g, 95%) as a pale 
yellow oil.  
5-58 (Appendix 5, p383): 1H NMR (500 MHz, CDCl3): δ 7.76 (d, J = 9.4 
Hz, 1H), 7.39-7.35 (m, 10H), 6.89 (d, J = 9.5 Hz, 1H), 5.25 (s, 2H), 5.03 (s, 
2H), 2.54 (s, 3H); 13C NMR (125 MHz, CDCl3): δ 196.8, 153.6, 151.0, 135.0, 
134.7, 132.5, 128.88, 128.85, 128.7, 128.62, 128.59, 127.1, 126.9, 109.3, 79.5, 
71.4, 30.1; HRMS (IT-TOF): m/z calcd for C22H19O5NNa+ [M + Na]+ 





Preparation of Methyl Benzoate 5-59 via a Lieben-Haloform Reaction 
 
Method 1: To a stirring solution of bis-benzyl ether 5-58 (0.226 g, 0.599 
mmol) in MeOH (5 mL) was added 10% NaOH solution (1.4 mL), followed by 
dropwise addition of 10% NaOCl solution (3.6 mL) at room temperature. The 
resulting mixture was stirred at room temperature for 30 min before acetone 
was added to decompose the excess NaOCl. The resulting mixture was 
concentrated in vacuo, and the remaining aqueous layer was acidified with 2M 
HCl and extracted with EtOAc (3x). The combined organic extracts were 
washed with water (1x), followed by brine, dried over Na2SO4, filtered, and 
concentrated in vacuo.  
To this crude benzoic acid in MeOH (15 mL) were added SOCl2 (88 µL, 
1.20 mmol) at room temperature. The resulting mixture was heated at 60 °C for 
3 h, before the solvent was concentrated in vacuo. Water was added to the 
residue and extracted with EtOAc (3x). The combined organic extracts were 
washed with water (1x), followed by brine, dried over Na2SO4, filtered, and 
concentrated in vacuo. Flash column chromatography of the crude product over 
silica gel (5% EtOAc/hexane → 23% EtOAc/hexane) afforded methyl 
benzoate 5-59 (0.165 g, 70% over two steps) as a white crystalline solid. 
Method 2: The preparation of tert-butyl hypochlorite (t-BuOCl) was carried 
out with minimal exposure to light. To a vigorously stirring 14% NaOCl 
solution placed in a conical flask wrapped with aluminum foil and immersed in 
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an ice-bath, a solution of t-BuOH (5 mL) and glacial AcOH (3 mL) was added 
in a single portion at 0 °C. The resulting mixture was stirred for 3-4 min before 
it was transferred to a separatory funnel, and the aqueous layer was separated. 
The yellow organic layer was washed with saturated aq. NaHCO3 (1x), 
followed by water, dried over Na2SO4, filtered, and used in the following 
reaction immediately. 
To a stirring solution of bis-benzyl ether 5-58 (0.166 g, 0.440 mmol) in 
MeOH (HPLC grade, 14 mL) was added 25% NaOMe in MeOH (0.6 mL), 
followed by dropwise addition of t-BuOCl (0.6 mL) at 5 °C with minimal 
exposure to light. The resulting mixture was stirred at room temperature for 1 h 
before acetone was added to decompose the excess t-BuOCl. The resulting 
mixture was concentrated in vacuo, and the residue was partitioned between 
1M HCl and EtOAc. The organic layer was separated, and the aqueous layer 
was extracted with EtOAc (2x). The combined organic layers were washed 
with brine, dried over Na2SO4, filtered, and concentrated in vacuo. Flash 
column chromatography of the crude product over silica gel (5% 
EtOAc/hexane → 23% EtOAc/hexane) afforded methyl benzoate 5-59 (0.164 
g, 95%) as a white crystalline solid.  
       5-59 (Appendix 5, p384): mp 101.2-102.6 °C; 1H NMR (500 MHz, 
CDCl3): δ 8.00 (d, J = 9.0 Hz, 1H), 7.48-7.33 (m, 10H), 6.87 (d, J = 8.9 Hz, 
1H), 5.21 (s, 2H), 5.15 (s, 2H), 3.88 (s, 3H); 13C NMR (125 MHz, CDCl3): δ 
164.2, 153.7, 151.9, 138.2, 135.8, 134.7, 134.2, 128.7, 128.43, 128.42, 127.0, 
117.8, 108.9, 78.7, 71.2, 52.2; ESI-MS: m/z calcd for C22H19O6NNa+ [M + 




Methyl 3-amino-2,4-dihydroxybenzoate 1-151: To a solution of methyl 
benzoate 5-59 (10.6 mg, 26.9 µmol) in MeOH (2 mL) was added 10% Pd on 
carbon (5 mg) at room temperature. The resulting mixture was stirred under a 
hydrogen atmosphere (balloon) for 16 h before it was filtered through a pad of 
Celite, eluted with 5% MeOH/EtOAc and concentrated in vacuo to afford 
aniline methyl benzoate 1-151 (4.5 mg, 92%) as a white crystalline solid. 
Crude aniline methyl benzoate 1-151 was carried forward to the amide 
coupling step without further purification. 
1-151 (Appendix 5, p385): 1H NMR (500 MHz, CD3OD): δ 7.19 (d, J = 8.8 
Hz, 1H), 6.35 (d, J = 8.8 Hz, 1H), 3.87 (s, 3H); ESI-MS: m/z calcd for 
C8H8O4N- [M – H]- 182.0, found 182.1; m/z calcd for C8H10O4N- [M + H]- 
184.1, found 184.0.  
 
(-)-Platensimycin methyl ester 5-62: To a solution of platensic acid 1-14 
(5 mg, 17.3 µmol) in anhydrous DMF (1 mL) was added Et3N (14.5 µL, 0.104 
mmol) and HATU (26.3 mg, 69.2 µmol) at room temperature. The resulting 
mixture was stirred at room temperature for 10-15 min before the addition of a 
solution of aniline methyl benzoate 1-151 (9.5 mg, 51.9 µmol) in anhydrous 
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DMF (1 mL). The resulting mixture was stirred at room temperature for 25 h 
before it was poured into brine, and extracted with EtOAc (4x). The combined 
organic extracts were back-washed with brine (1x), dried over Na2SO4, filtered, 
and concentrated in vacuo. Flash column chromatography of the crude product 
over silica gel (5% acetone/hexane → 24% acetone/hexane → 100% acetone), 
followed by prep. TLC (25% acetone/hexane x 02 elution) spread over 20 cm x 
10 cm glass plate afforded (-)-platensimycin methyl ester 5-62 (6.1 mg, 71%, 
single epimer at C4 with HPLC analysis) as a pale yellow viscous oil. 
5-62 (Appendix 5, p386): [α]D24 = -39.3 (c = 0.21, CHCl3); 1H NMR (500 
MHz, CDCl3): δ 11.64 (s, 1H), 11.07 (brs, 1H), 8.10 (s, 1H), 7.56 (d, J = 8.8 
Hz, 1H), 6.52-6.50 (m, 2H), 5.93 (d, J = 10.0 Hz, 1H), 4.44 (brs, 1H), 3.92 (s, 
3H), 2.56-2.49 (m, 1H), 2.44-2.36 (m, 4H), 2.12-2.00 (m, 3H), 1.93-1.86 (m, 2 
H), 1.81-1.77 (m, 1H), 1.63 (d, J = 11.3 Hz, 1H), 1.45 (s, 3H), 1.27 (s, 3H); 13C 
NMR (125 MHz, CDCl3): δ 203.6, 173.6, 170.7, 154.9, 153.9, 153.8, 127.37, 
127.15, 114.4, 111.3, 104.1, 87.0, 76.4, 54.9, 52.2, 46.7, 46.2, 46.1, 44.7, 43.1, 
40.6, 32.1, 31.6, 29.7, 24.2, 23.0; HRMS (EI): m/z calcd for C25H29O7N+ [M]+ 
455.1944, found 455.1946.  
6-Methoxyplatensimycin methyl ester 
5-60: Procedure was repeated with 6-
methoxyplatensic acid 5-43 (5.6 mg, 17.5 
µmol) and aniline methyl benzoate 1-151 
(12.8 mg, 69.9 µmol), followed by purification with prep. TLC (30% 
acetone/hexane x 03 elution) spread over 20 cm x 10 cm glass plate to afford 6-
methoxyplatensimycin methyl ester 5-60 (6.5 mg) as a pale yellow viscous oil 













NMR (500 MHz, CDCl3): δ 11.60 (s, 1H), 11.05 (brs, 1H), 8.05 (s, 1H), 7.55 
(d, J = 8.8 Hz, 1H), 6.50 (d, J = 8.8 Hz, 1H), 5.39 (s, 1H), 4.42 (brs, 1H), 3.93 
(s, 3H), 3.61 (s, 3H), 2.56-2.49 (m, 1H), 2.42-2.36 (m, 4H), 2.10-2.01 (m, 3H), 
1.98-1.86 (m, 2 H), 1.78-1.74 (m, 1H), 1.62 (d, J = 11.3 Hz, 1H), 1.44 (s, 3H), 
1.27 (s, 3H); 13C NMR (125 MHz, CDCl3): δ 198.3, 173.5, 170.7, 154.8, 153.8, 
149.0, 127.4, 124.1, 120.5, 114.4, 111.2, 110.9, 104.1, 86.9, 76.4, 56.0, 55.1, 
52.2, 51.8, 47.4, 45.9, 44.6, 44.5, 44.2, 40.5, 37.8, 32.1, 32.0, 29.7, 24.6, 23.1; 
HRMS (IT-TOF): m/z calcd for C26H32O8N+ [M + H]+ 486.2128, found 
486.2142.  
 
(-)-Platensimycin 1-4: To a solution of (-)-platensimycin methyl ester 5-62 
(3.7 mg, 8.12 µmol) in 1,4-dioxane (0.2 mL) and MeOH (0.1 mL) was added 
2M aq. KOH (0.2 mL) at room temperature. The resulting mixture was tightly 
sealed, and stirred at 35 °C for 16 h before the solvents were concentrated in 
vacuo, and the residue was partitioned between water and CH2Cl2. The organic 
layer was separated, and the aqueous layer was extracted with CH2Cl2 (2x). 
The aqueous layer was acidified with 1M HCl to pH 1-2, and extracted with 
EtOAc (5x). The combined EtOAc extracts were washed with brine, dried over 
Na2SO4, filtered, and concentrated in vacuo. Prep. TLC of the crude product 
(60% EtOAc/hexane + 1% AcOH x 02 elution) spread over 16 cm x 10 cm 
glass plate, followed by flash column chromatography over silica gel (10% 
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acetone/hexane → 40% acetone/hexane → 70% acetone/hexane + 0.5% 
AcOH) afforded (-)-platensimycin 1-4 (2.5 mg, 60%) as a white solid. 
1-4 (Appendix 5, p387-388): [α]D23 = -48.2 (c = 0.11, MeOH); 1H NMR 
(500 MHz, C5D5N): δ 10.5 (s, 1H), 8.11 (d, J = 8.8 Hz, 1H), 6.87 (d, J = 8.8 
Hz, 1H), 6.36 (d, J = 10.0 Hz, 1H), 5.93 (d, J = 9.4 Hz, 1H), 4.48 (brs, 1H), 
2.86-2.65 (m, 3H), 2.44 (s, 1H), 2.20-2.18 (m, 1H), 2.07-2.00 (m, 1H), 1.91-
1.89 (m, 1H), 1.80 (d, J = 11.9 Hz, 1H), 1.72 (d, J = 10.0 Hz, 1H), 1.58-1.54 
(m, 1H), 1.47 (d, J = 10.7 Hz, 1H), 1.39 (s, 3H), 1.14 (s, 3H); 13C NMR (125 
MHz, C5D5N): δ 203.2, 174.7, 158.2, 153.9, 129.4, 127.2, 115.3, 110.0, 107.1, 
86.8, 76.4, 54.9, 46.7, 46.6, 46.1, 45.0, 43.0, 40.8, 32.1, 31.8, 30.5, 24.4, 
23.2; HRMS (EI): m/z calcd for C24H27O7N+ [M]+ 441.1788, found 441.1784. 
Representative Procedure for the Preparation of TFA Salt of 1,n-diphenyl 
isopropylamine (n = 1, 3): 
 
TFA salt of 1,3-diphenyl isopropylamine 5-63: To a solution of 1,3-
diphenyl acetone (100 mg, 0.476 mmol)  in MeOH (5 mL) was added NH4OAc 
(0.147 g, 1.91 mmol) and NaBH3CN (0.179 g, 2.85 mmol) at room 
temperature. The resulting mixture was stirred at room temperature for 40 h 
before it was concentrated in vacuo, and the residue was partitioned between 
1M HCl and Et2O. The organic layer was separated, and the aqueous layer was 
extracted with Et2O (2x). The aqueous layer was basified with 2M NaOH to pH 
10-11 before it was extracted with EtOAc (3x). The combined organic extracts 
341 
 
were washed with brine, dried over Na2SO4, filtered, and concentrated in 
vacuo.  
To this crude amine in a mixture of hexane (AR, 2 mL) and CH2Cl2 (AR, 2 
mL) was added TFA (36 µL, 0.485 mmol) at 0 °C. The resulting mixture was 
stirred at room temperature for 3 h before it was concentrated in vacuo. The 
crude product was repeatedly washed with hexane, filtered, and dried in vacuo 
to obtain catalyst 5-63 (43.3 mg, 28% over two steps) as a white solid. 
5-63: Decomposed at 132.3-134.4 °C; 1H NMR (500 MHz, CDCl3): δ 7.79 
(hump, 2H), 7.33-7.19 (m, 10H), 3.62-3.56 (m, 1H), 3.02-2.92 (m, 4H); ESI-
MS: m/z calcd for C15H18N+ [M]+ 212.1, found 212.3, and m/z calcd for 
C2F3O2- [M]- 113.0, found 113.0.  
TFA salt of 1,1-diphenyl isopropylamine (±)-5-64: 
Procedure was repeated with 1,1-diphenyl acetone (50 
mg, 0.238 mmol) to afford catalyst (±)-5-64 (14.7 mg, 
19% over two steps) as a white solid. (±)-5-64: mp 148.1-148.9 °C; 1H NMR 
(500 MHz, CDCl3): δ 7.78 (hump, 2H), 7.38-7.20 (m, 10H), 4.08-3.99 (m, 1H), 
1.28 (d, J = 5.7 Hz, 3H); ESI-MS: m/z calcd for C15H18N+ [M]+ 212.1, found 
212.3, and m/z calcd for C2F3O2- [M]- 113.0, found 113.0. 
     
Di-tert-butyl Cbz-protected aminomalonate 5-70: To a stirring solution of 








in CH2Cl2 (5 mL) was slowly added a solution of di-tert-butyl diazomalonate 
5-69 (40 mg, 0.165 mmol) in CH2Cl2 (3 mL) at gentle reflux over a period of 
5-10 min. The resulting mixture was gently refluxed at 50 °C for 16 h before it 
was concentrated in vacuo. Flash column chromatography of the crude product 
over silica gel (hexane → 8% EtOAc/hexane) afforded Cbz-protected 
aminomalonate 5-70 (41.5 mg, 69%) as a colourless oil.  
5-70: 1H NMR (500 MHz, CDCl3): δ 7.33-7.29 (m, 5H), 5.73 (d, J = 7.0 Hz, 
1H), 5.12 (s, 2H), 4.79 (d, J = 7.5 Hz, 1H), 1.51 + 1.49 (s each, 18H); 13C 
NMR (125 MHz, CDCl3): δ 167.8, 165.5, 155.4, 136.1, 128.6, 128.12, 128.1, 
83.21, 83.17, 67.1, 59.1, 27.83, 27.29; ESI-MS: m/z calcd for C19H28O6N+ [M 
+ H]+ 366.2, found 366.1. 
Representative Procedure for the Preparation of TFA Salt of α-Amino-
1,n-Di-tert-Butyl Esters (n = 1-3): 
 
Cbz-protected DL-aspartate di-tert-Butyl ester (±)-5-81 (n = 2): To a 
mixture of DL-aspartic acid (500 mg, 3.76 mmol) and Na2CO3 (1.59 g, 15.0 
mmol) were added 1,4-dioxane (12 mL) and H2O (12 mL) at room 
temperature. The resulting mixture was cooled to 0 ºC before it was added 
CbzCl (1.15 mL, 7.52 mmol), and the reaction was stirred at room temperature 
for 16 h. Water was added and the aqueous mixture was extracted with Et2O 
(2x). The aqueous layer was acidified with 1 N HCl to pH 1-2 before it was 
extracted with EtOAc (3x). The combined EtOAc extracts were washed with 
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water (1x), followed by brine, dried over Na2SO4, filtered, and concentrated in 
vacuo to give crude Cbz-protected DL-aspartate (1.121 g) as a colourless oil.  
To a suspension of anhydrous MgSO4 (2.65 g, 22.0 mmol) in CH2Cl2 (6 
mL) was added conc. H2SO4 (0.54 mL, 9.72 mmol) at room temperature, and 
stirred under Ar for 15 min. To this mixture was added a solution of crude Cbz-
protected DL-aspartate (0.587 g, 2.20 mmol) in CH2Cl2 (6 mL) before 
anhydrous t-BuOH (2.5 mL, 26.1 mmol) was added at the same temperature. 
The resulting mixture was tightly stoppered, and stirred at room temperature 
for 40 h before it was carefully quenched with sat. aq. NaHCO3 to dissolve the 
MgSO4, and basified the solution. Diluted with water, the organic layer was 
separated, and the aqueous layer was extracted with Et2O (3x). The combined 
organic layers were washed with brine, dried over Na2SO4, filtered, and 
concentrated in vacuo.  Flash column chromatography of the crude product 
over silica gel (10% EtOAc/hexane) afforded di-tert-butyl ester (±)-5-81 (76.2 
mg, 11% over two steps) as a colourless oil. 
(±)-5-81: 1H NMR (500 MHz, CDCl3): δ 7.35-7.29 (m, 5H), 5.75 (d, J = 8.2 
Hz, 1H), 5.11 (s, 2H), 4.47-4.44 (m, 1H), 2.86 (dd, J = 4.4, 16.4 Hz, 1H), 2.71 
(dd, J = 4.4, 17.0 Hz, 1H), 1.44 + 1.42 (s each, 18H); 13C NMR (125 MHz, 
CDCl3): δ 170.0, 169.7, 156.0, 136.4, 128.4, 128.0, 127.9, 82.1, 81.4, 66.8, 
51.0, 37.8, 28.0, 27.8; ESI-MS: m/z calcd for C20H30O6N+ [M + H]+ 380.2, 
found 380.2. 
Cbz-protected DL-glutamate di-tert-butyl ester 
(±)-5-82 (n = 3): Procedure was repeated with DL-
glutamic acid (500 mg, 3.40 mmol) to provide crude 









di-tert-butyl ester (±)-5-82 (67.2 mg, 9% over two steps) as a colourless oil. 
(±)-5-82: 1H NMR (500 MHz, CDCl3): δ 7.35-7.27 (m, 5H), 5.40 (d, J = 6.9 
Hz, 1H), 5.09 (s, 2H), 4.26-4.25 (m, 1H), 2.36-2.22 (m, 2H), 2.15-2.11 (m, 
1H), 1.93-1.85 (m, 1H), 1.45 + 1.43 (s each, 18H); 13C NMR (125 MHz, 
CDCl3): δ 172.0, 171.0, 155.9, 136.3, 128.4, 128.0, 128.0, 82.2, 80.6, 66.8, 
53.9, 31.4, 28.0, 27.9; ESI-MS: m/z calcd for C21H32O6N+ [M + H]+ 394.2, 
found 394.2. 
 
TFA salt of DL-aspartate di-tert-butyl ester (±)-5-67 (n = 2): To a 
solution of di-t-butyl ester (±)-5-81 (76.2 mg, 0.236 mmol) in THF (freshly 
distilled over Na/benzophenone, 10 mL) was added 10% Pd on carbon (10 mg) 
at room temperature. The resulting mixture was stirred under a hydrogen 
atmosphere (balloon) for 4 h before it was filtered through a pad of Celite, 
eluted with CH2Cl2 and concentrated in vacuo at 28 °C.  
To this crude amine in hexane (AR, 10 mL) was added TFA (18 µL, 0.242 
mmol) at 0 °C. White precipitate was immediately observed upon addition of 
TFA. The resulting mixture was stirred at room temperature for 3 h before it 
was filtered, repeated washed with hexane, and dried in vacuo to obtain 
catalyst (±)-5-67 (60.7 mg, 85% over two steps) as a white solid. 
(±)-5-67: mp 157.0-158.4 °C; 1H NMR (500 MHz, CDCl3): δ 4.14-4.12 (m, 
1H), 3.06-2.96 (m, 2H), 1.48 + 1.46 (s each, 18H); ESI-MS: m/z calcd for 
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C12H24O4N+ [M]+ 246.2, found 246.3, and m/z calcd for C2F3O2- [M]- 113.0, 
found 113.0. 
TFA salt of DL-glutamate di-tert-butyl ester (±)-
5-68 (n = 3): Procedure was repeated with Cbz-
protected DL-glutamate di-t-butyl ester (±)-5-82 
(67.2 mg, 0.199 mmol) to afford catalyst (±)-5-68 (49.9 mg, 79% over two 
steps) as a white solid. (±)-5-68: mp 136.8-138.1 °C; 1H NMR (500 MHz, 
CDCl3): δ 4.04-4.02 (m, 1H), 2.52-2.49 (m, 2H), 2.23-2.16 (m, 2H), 1.49 + 
1.44 (s each, 18H); ESI-MS: m/z calcd for C13H26O4N+ [M]+ 260.2, found 
260.3, and m/z calcd for C2F3O2- [M]- 113.0, found 113.0. 
TFA salt of aminomalonate di-tert-butyl ester 5-66 
(n = 1): Procedure was repeated with Cbz-protected 
aminomalonate di-t-butyl ester 5-70 (41.5 mg, 0.114 
mmol) to afford catalyst 5-65 (33.3 mg, 85% over two steps) as a white fluffy 
solid. 5-66: mp 141.0-143.2 °C; 1H NMR (500 MHz, CD3OD): δ 4.68 (s, 1H), 
1.55 (s, 18H); ESI-MS: m/z calcd for C11H22O4N+ [M]+ 232.2, found 232.3, and 
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1H NMR spectrum 
(300 MHz, CDCl3) 
13C NMR spectrum of 2-6 










1H NMR spectrum 
(300 MHz, CDCl3) 
13C NMR spectrum of 2-4 












1H NMR spectrum 
(300 MHz, CDCl3) 
13C NMR spectrum of 2-40 












1H NMR spectrum 
(300 MHz, CDCl3) 
13C NMR spectrum of 2-59 












1H NMR spectrum 
(500 MHz, CDCl3) 
13C NMR spectrum of 2-39 










1H NMR spectrum 
(300 MHz, CDCl3) 
13C NMR spectrum of 3-7 












1H NMR spectrum 
(500 MHz, CDCl3) 
13C NMR spectrum of 3-12 















1H NMR spectrum 
(500 MHz, CDCl3) 
13C NMR spectrum of 3-17 












1H NMR spectrum 
(500 MHz, CDCl3) 
13C NMR spectrum of 3-21 

















1H NMR spectrum 
(500 MHz, CDCl3) 
13C NMR spectrum of 3-22 



































































































































































































































































































































































1H NMR spectrum 
(500 MHz, CDCl3) 
13C NMR spectrum of 5-8 














































































































































































































































































1H NMR spectrum 
(500 MHz, CDCl3) 
 
13C NMR spectrum of 4-1 










































































































































































































1H NMR spectrum 
(500 MHz, CDCl3) 
13C NMR spectrum of 1-23 






























































































































































































































1H NMR spectrum 
(300 MHz, CDCl3) 
13C NMR spectrum of 2-1 




















































































































































































































































































































1H NMR spectrum 
(500 MHz, CDCl3) 
13C NMR spectrum of 5-56 

















































































































































































































































1H NMR spectrum 
(500 MHz, CDCl3) 
13C NMR spectrum of 5-58 








































































































































































1H NMR spectrum 
(500 MHz, CDCl3) 
13C NMR spectrum of 5-59 



































































1H NMR spectrum 


































































































































































































































































































































































1H NMR spectrum 
(500 MHz, CDCl3) 
13C NMR spectrum of 5-62 

























































































































































































































1H NMR spectrum of synthetic platensimycin 
(500 MHz, C5D5N) 
1H NMR spectrum of natural platensimycin[17] 






































































































































































































































































13C NMR spectrum of synthetic platensimycin 
(125 MHz, C5D5N) 
13C NMR spectrum of natural platensimycin[17] 
(125 MHz, C5D5N) 
